

Effectiveness of Antipsychotic Drugs in Patients with C

New England Journal of Medicine

353, 1209-1223

DOI: [10.1056/nejmoa051688](https://doi.org/10.1056/nejmoa051688)

Citation Report

#	ARTICLE	IF	CITATIONS
2	And finally â€ the salutary tale of â€~atypicalityâ€™. , 0, , 304-319.		0
3	Technological and Price Uncertainty in a Ricardian Model of International Trade. <i>Review of Economic Studies</i> , 1974, 41, 201.	2.9	64
4	The triad of neurologic manifestations of Lyme disease. <i>Neurology</i> , 1985, 35, 47-47.	1.5	622
5	Drug attitude and subjective well-being in antipsychotic treatment monotherapy in real-world settings. <i>Epidemiologia E Psichiatria Sociale</i> , 1999, 18, 114-118.	1.0	5
6	From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone. <i>CNS Spectrums</i> , 2005, 10, 1-20.	0.7	36
7	The Risk of Unintended Consequences. <i>Journal of Psychiatric Practice</i> , 2005, 11, 359.	0.3	0
8	Introduction: Methods, Commentary, and Summary. <i>Journal of Psychiatric Practice</i> , 2005, 11, 5-25.	0.3	208
9	Strategies for Improving Adherence to Second-Generation Antipsychotics in Patients with Schizophrenia by Increasing Ease of Use. <i>Journal of Psychiatric Practice</i> , 2005, 11, 369-378.	0.3	55
10	A Case of "Ifufunyane": A Xhosa Culture-Bound Syndrome. <i>Journal of Psychiatric Practice</i> , 2005, 11, 411-413.	0.3	3
11	Study shows newer schizophrenia treatments no more effective than old. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 872-872.	21.5	2
12	Understanding human diversity. <i>Nature</i> , 2005, 437, 1241-1242.	13.7	103
13	Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. <i>BMC Medicine</i> , 2005, 3, 21.	2.3	128
15	The Choice of Antipsychotic Drugs for Schizophrenia. <i>New England Journal of Medicine</i> , 2005, 353, 1286-1288.	13.9	66
16	Medication Adherence in Schizophrenia: Exploring Patients', Carers' and Professionals' Views. <i>Schizophrenia Bulletin</i> , 2005, 32, 786-794.	2.3	118
18	Scientific and Consumer Models of Recovery in Schizophrenia: Concordance, Contrasts, and Implications. <i>Schizophrenia Bulletin</i> , 2005, 32, 432-442.	2.3	451
19	Incorporating pharmacoeconomic and health outcomes into randomized clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 695-703.	0.7	2
20	Treatment challenges in the acute hospital setting. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 210-211.	1.3	2
21	Head-To-Head Comparison of the Costs of Atypical Antipsychotics. <i>CNS Drugs</i> , 2005, 19, 935-950.	2.7	14

#	ARTICLE	IF	CITATIONS
22	The CATIE schizophrenia effectiveness trial. <i>Schizophrenia Research</i> , 2005, 80, v-vi.	1.1	7
23	Management of Schizophrenia. <i>Disease Management and Health Outcomes</i> , 2006, 14, 107-125.	0.3	11
24	Quetiapine: efficacy, tolerability and safety in schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 983-992.	1.4	8
25	Association of Co-Morbidities with Prescribing Patterns and Cost Savings. <i>Pharmacoeconomics</i> , 2006, 24, 1233-1248.	1.7	1
26	The SOHO (Schizophrenia Outpatient Health Outcome) Study. <i>CNS Drugs</i> , 2006, 20, 293-301.	2.7	74
27	Ziprasidone. <i>CNS Drugs</i> , 2006, 20, 1027-1052.	2.7	14
28	Whose Trial Is It Anyway? Reflections on Morality, Double Standards, Uncertainty and Criticism in International Collaborative Health Research. <i>Monash Bioethics Review</i> , 2006, 25, S51-S66.	0.4	3
29	Olanzapine/fluoxetine combination for bipolar depression. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 33-39.	1.4	10
30	Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. <i>Current Medical Research and Opinion</i> , 2006, 22, 2345-2353.	0.9	38
31	British Association for Psychopharmacology Summer Meeting. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2007-2010.	0.9	2
32	Antipsychotic drug action: targets for drug discovery with neurochemical imaging. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 57-64.	1.4	21
33	Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19. <i>Psychosomatics</i> , 2006, 47, 75-85.	2.5	270
34	S.14.04 CATIE trial results. <i>European Neuropsychopharmacology</i> , 2006, 16, S184-S185.	0.3	6
36	S.15.01 Atypical antipsychotics: a possible treatment for anxiety?. <i>European Neuropsychopharmacology</i> , 2006, 16, S185.	0.3	0
37	P.3.c.012 Discontinuation rate of antipsychotic drugs in the treatment of first treated schizophrenia. <i>European Neuropsychopharmacology</i> , 2006, 16, S402-S403.	0.3	0
39	P.3.c.054 Olanzapine, quetiapine, and risperidone in the treatment of first-episode psychosis: effectiveness and factors influencing adherence to treatment. <i>European Neuropsychopharmacology</i> , 2006, 16, S425-S426.	0.3	3
40	P.3.c.055 Dopamine D3 receptor polymorphism associated with amisulpride response on negative symptoms of schizophrenia. <i>European Neuropsychopharmacology</i> , 2006, 16, S426.	0.3	0
41	C.02.02 Understanding the complexities of treatment informed by new research. <i>European Neuropsychopharmacology</i> , 2006, 16, S572-S573.	0.3	0

#	ARTICLE	IF	CITATIONS
46	Meeting everyday challenges: Antipsychotic therapy in the real world. <i>European Neuropsychopharmacology</i> , 2006, 16, S156-S162.	0.3	26
47	Differential metabolic effects of antipsychotic treatments. <i>European Neuropsychopharmacology</i> , 2006, 16, S149-S155.	0.3	101
48	Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms. <i>European Neuropsychopharmacology</i> , 2006, 16, S135-S141.	0.3	19
49	Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. <i>European Psychiatry</i> , 2006, 21, 41-47.	0.1	41
50	Population Pharmacokinetics in Geriatric Psychiatry. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 993-1003.	0.6	23
51	Sleep in Schizophrenia: Impairments, Correlates, and Treatment. <i>Psychiatric Clinics of North America</i> , 2006, 29, 1033-1045.	0.7	89
52	SZ1 EFFECTIVENESS AND COSTS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA IN ROUTINE CARE. <i>Value in Health</i> , 2006, 9, A196.	0.1	4
53	Long-Term Treatment with Atypical Antipsychotics and the Risk of Weight Gain. <i>Drug Safety</i> , 2006, 29, 303-319.	1.4	99
54	Long-Term Treatment with Atypical Antipsychotics and Risk of Weight Gain. <i>Drug Safety</i> , 2006, 29, 550-552.	1.4	8
55	Extended-Release Intramuscular Naltrexone. <i>Drugs</i> , 2006, 66, 1752-1754.	4.9	2
56	Cost-Effectiveness Analysis of Schizophrenia Relapse Prevention. <i>Clinical Drug Investigation</i> , 2006, 26, 447-457.	1.1	22
59	Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. <i>BMJ: British Medical Journal</i> , 2006, 333, 224.	2.4	317
60	Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials. <i>Current Medical Research and Opinion</i> , 2006, 22, 2233-2242.	0.9	17
61	AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 277-286.	1.5	99
62	Food Intake and Reward Mechanisms in Patients with Schizophrenia: Implications for Metabolic Disturbances and Treatment with Second-Generation Antipsychotic Agents. <i>Neuropsychopharmacology</i> , 2006, 31, 2091-2120.	2.8	127
63	Making the Case for a Candidate Vulnerability Gene in Schizophrenia: Convergent Evidence for Regulator of G-Protein Signaling 4 (RGS4). <i>Biological Psychiatry</i> , 2006, 60, 534-537.	0.7	88
64	Higher Fasting Serum Insulin Is Associated with Increased Resting Energy Expenditure in Nondiabetic Schizophrenia Patients. <i>Biological Psychiatry</i> , 2006, 60, 1372-1377.	0.7	10
65	Response to Kujawa et al. letter-to-the-editor. <i>Schizophrenia Research</i> , 2006, 84, 172-173.	1.1	1

#	ARTICLE	IF	CITATIONS
66	A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). <i>Schizophrenia Research</i> , 2006, 84, 77-89.	1.1	85
67	Effect of initial ziprasidone dose on length of therapy in schizophrenia. <i>Schizophrenia Research</i> , 2006, 83, 285-292.	1.1	23
68	Effect of initial ziprasidone dose on treatment persistence in schizophrenia. <i>Schizophrenia Research</i> , 2006, 83, 277-284.	1.1	14
69	The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial. <i>Schizophrenia Research</i> , 2006, 84, 112-120.	1.1	83
70	A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. <i>Schizophrenia Research</i> , 2006, 85, 254-265.	1.1	81
71	Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. <i>Schizophrenia Research</i> , 2006, 86, 99-109.	1.1	32
72	Characteristics of two alternative schizophrenia remission definitions: Relationship to clinical and quality of life outcomes. <i>Schizophrenia Research</i> , 2006, 86, 300-308.	1.1	38
73	Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. <i>Schizophrenia Research</i> , 2006, 86, 15-22.	1.1	473
74	Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: Retrospective comparison of first generation and second generation antipsychotics. <i>Schizophrenia Research</i> , 2006, 88, 127-134.	1.1	18
75	Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2006, 88, 5-25.	1.1	180
76	A model of anticholinergic activity of atypical antipsychotic medications. <i>Schizophrenia Research</i> , 2006, 88, 63-72.	1.1	121
77	Genetics of antipsychotic treatment emergent weight gain in schizophrenia. <i>Pharmacogenomics</i> , 2006, 7, 863-887.	0.6	139
78	Une dimension de l'absence de traitement et l'absence de traitement chez les patients hospitalisés. <i>Annales Medico-Psychologiques</i> , 2006, 164, 750-755.	0.2	0
79	Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with Schizophrenia in Quebec and Saskatchewan: A retrospective database study. <i>Clinical Therapeutics</i> , 2006, 28, 1912-1921.	1.1	67
80	Behavioural effects of chronic haloperidol and risperidone treatment in rats. <i>Behavioural Brain Research</i> , 2006, 171, 286-294.	1.2	57
81	Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. <i>Psychiatry Research</i> , 2006, 144, 177-189.	1.7	39
82	Advances in psychotropic formulations. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 996-1008.	2.5	59
83	Neurobiology of Schizophrenia. <i>Neuron</i> , 2006, 52, 139-153.	3.8	617

#	ARTICLE	IF	CITATIONS
84	Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends in Pharmacological Sciences, 2006, 27, 391-398.	4.0	62
85	Outcomes, Costs, and Policy Caution. Archives of General Psychiatry, 2006, 63, 1074.	13.8	25
86	The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. British Journal of Psychiatry, 2006, 189, 391-392.	1.7	23
87	Increased Cardiovascular Risk with Second-Generation Antipsychotic Agent Switches. Journal of the American Pharmacists Association: JAPhA, 2006, 46, 491-501.	0.7	4
89	Efeitos adversos metabólic ³ licos de antipsic ³ ticos e estabilizadores de humor. Revista De Psiquiatria Do Rio Grande Do Sul, 2006, 28, 186-196.	0.3	8
90	Commentary on Wong, Wyatt and Midkiff. Behavior and Social Issues, 2006, 15, 178-180.	0.8	1
91	Six-to-One Gets the Job Done: Comments on the Reviews. Behavior and Social Issues, 2006, 15, 222-231.	0.8	5
92	Response to the Commentaries. Behavior and Social Issues, 2006, 15, 232-244.	0.8	5
93	Are We Treating Schizophrenia Effectively? Understanding the Primary Outcomes of the CATIE Study. CNS Spectrums, 2006, 11, 1-16.	0.7	6
95	Biological treatment of schizoaffective disorders. , 0, , 248-263.		0
97	Jose de Leon, MD. CNS Spectrums, 2006, 11, 8-12.	0.7	8
98	Spezielle Arzneimitteltherapie in der Schwangerschaft. , 2006, , 33-557.		0
100	The Metabolic Effects of Antipsychotic Medications. Canadian Journal of Psychiatry, 2006, 51, 480-491.	0.9	242
101	Pharmacologic and Nonpharmacologic Strategies for Weight Gain and Metabolic Disturbance in Patients Treated with Antipsychotic Medications. Canadian Journal of Psychiatry, 2006, 51, 502-511.	0.9	71
102	Beyond efficacy and effectiveness: A multifaceted approach to treatment evaluation.. Professional Psychology: Research and Practice, 2006, 37, 389-397.	0.6	40
103	Behavioral rehabilitation of the "treatment-refractory" schizophrenia patient: Conceptual foundations, interventions, and outcome data.. Psychological Services, 2006, 3, 145-169.	0.9	32
104	Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Dosesâ€”Reply. Archives of General Psychiatry, 2006, 63, 937.	13.8	3
105	Introduction: An Overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. CNS Spectrums, 2006, 11, 4-8.	0.7	8

#	ARTICLE	IF	CITATIONS
106	Clinical Trials in Schizophrenia with Results for the Real World. <i>CNS Spectrums</i> , 2006, 11, 9-13.	0.7	8
107	Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know. <i>CNS Spectrums</i> , 2006, 11, 14-24.	0.7	39
108	Distinguishing Current From Remitted Posttraumatic Stress Disorder. <i>Archives of General Psychiatry</i> , 2006, 63, 940.	13.8	3
110	Metabolic Findings From the CATIE Trial and Their Relation to Tolerability. <i>CNS Spectrums</i> , 2006, 11, 32-39.	0.7	49
111	Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses. <i>Archives of General Psychiatry</i> , 2006, 63, 935.	13.8	14
112	Effectiveness of Antipsychotic Drugs in Patients With Chronic Schizophrenia. <i>Yearbook of Endocrinology</i> , 2006, 2006, 25-27.	0.0	0
113	Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. <i>International Clinical Psychopharmacology</i> , 2006, 21, 233-240.	0.9	63
114	Atypical Antipsychotics: A Case Study in New Era Risk Management. <i>Journal of Psychiatric Practice</i> , 2006, 12, 253-258.	0.3	1
115	Comparing Antipsychotic Efficacy. <i>American Journal of Psychiatry</i> , 2006, 163, 1645-1645.	4.0	1
116	Letters. <i>Psychiatric Services</i> , 2006, 57, 723-724.	1.1	0
117	Letters. <i>Psychiatric Services</i> , 2006, 57, 722-722.	1.1	0
118	Rethinking Schizophrenia: Its Original Nature, Its Drug-Altered Character, and Thoughts About Its Treatment. <i>Ethical Human Psychology and Psychiatry</i> , 2006, 8, 69-76.	0.5	0
119	High Medication Discontinuation Rates in Psychiatry. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 109-112.	0.7	27
120	Differential Rates of Treatment Discontinuation in Clinical Trials as a Measure of Treatment Effectiveness for Olanzapine and Comparator Atypical Antipsychotics for Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 632-637.	0.7	26
121	Predicting Medication-Free Treatment Response in Acute Psychosis. <i>Journal of Nervous and Mental Disease</i> , 2006, 194, 732-739.	0.5	13
122	Early Intervention for psychosis. , 2006, , CD004718.		62
123	Risperidone versus olanzapine for schizophrenia. <i>The Cochrane Library</i> , 2006, , CD005237.	1.5	42
125	Utilization of Long-Acting Antipsychotic Medication in Patient Care. <i>CNS Spectrums</i> , 2006, 11, 1-8.	0.7	29

#	ARTICLE	IF	CITATIONS
126	The PDE-5 Inhibitors and Psychiatry. <i>Journal of Psychiatric Practice</i> , 2006, 12, 46-49.	0.3	1
127	Remission of Positive and Negative Symptoms in Refractory Schizophrenia with a Combination of Haloperidol and Quetiapine: Two Case Studies. <i>Journal of Psychiatric Practice</i> , 2006, 12, 332-336.	0.3	2
128	Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. <i>International Clinical Psychopharmacology</i> , 2006, 21, 261-266.	0.9	6
129	Strategies for Maximizing Clinical Effectiveness in the Treatment of Schizophrenia. <i>Journal of Psychiatric Practice</i> , 2006, 12, 348-363.	0.3	59
130	The Psychological Effects of Leech Therapy After Penile Auto-Amputation. <i>Journal of Psychiatric Practice</i> , 2006, 12, 119-123.	0.3	4
131	Orally Versus Intramuscularly Administered Antipsychotic Drugs in Psychiatric Emergencies. <i>Journal of Psychiatric Practice</i> , 2006, 12, 30-40.	0.3	45
132	Neuroleptic Malignant Syndrome: A Case Report. <i>Journal of Psychiatric Practice</i> , 2006, 12, 259-262.	0.3	1
133	Practical Treatment Information for Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 563-565.	4.0	21
134	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611-622.	4.0	312
135	Keeping Our Eyes on STAR*D. <i>American Journal of Psychiatry</i> , 2006, 163, 1484-1486.	4.0	10
136	Dr. Juurlink Replies. <i>American Journal of Psychiatry</i> , 2006, 163, 1644-1645.	4.0	2
137	Letters. <i>Psychiatric Services</i> , 2006, 57, 722-723.	1.1	1
138	Promoting Treatment Adherence in Assertive Community Treatment. <i>Social Service Review</i> , 2006, 80, 485-526.	0.3	31
139	Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 1697-1704.	4.0	39
140	The Costs of Drugs for Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 2029-2031.	4.0	17
141	Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 2080-2089.	4.0	247
142	Letters. <i>Psychiatric Services</i> , 2006, 57, 724-725.	1.1	11
143	Remission and Relapse in the Outpatient Care of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 571-578.	0.7	112

#	ARTICLE	IF	CITATIONS
144	Electroconvulsive Therapy as an Alternative Treatment for Obese Patients With Mood Disorders. <i>Journal of ECT</i> , 2006, 22, 223-225.	0.3	5
145	Early changes of plasma lipids during treatment with atypical antipsychotics. <i>International Clinical Psychopharmacology</i> , 2006, 21, 369-372.	0.9	31
146	Nontricyclic Antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 643-647.	0.7	59
147	Dissociative Disorder Underdiagnosed Due to Undescriptive Criteria?. <i>American Journal of Psychiatry</i> , 2006, 163, 1645-1645.	4.0	1
148	Agreement Between Patients With Schizophrenia and Providers on Factors of Antipsychotic Medication Adherence. <i>Psychiatric Services</i> , 2006, 57, 1170-1178.	1.1	27
149	Antipsychotic Treatment Discontinuation Among Individuals With Schizophrenia and Co-occurring Substance Use. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 666-667.	0.7	14
150	A Randomized, 1-Year Follow-up Study of Olanzapine and Risperidone in the Treatment of Negative Symptoms in Outpatients with Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 238-249.	0.7	50
151	Translating research into clinical practice: critical interpretation of clinical trials in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2006, 21, S1-S10.	0.9	5
152	Tardive Dyskinesia Circa 2006. <i>American Journal of Psychiatry</i> , 2006, 163, 1316-1318.	4.0	50
153	Psychiatric Decision Making in the Adoption of a New Antipsychotic in Germany. <i>Psychiatric Services</i> , 2006, 57, 700-703.	1.1	14
154	Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other. <i>Current Opinion in Internal Medicine</i> , 2006, 5, 232-238.	1.5	3
155	A 24-Week Randomized Study of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia or Schizoaffective Disorder in Patients with Prominent Depressive Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 157-162.	0.7	75
156	Hospitalization Risks in the Treatment of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 401-404.	0.7	12
157	Sex Selection Bias in Schizophrenia Antipsychotic Trials. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 489-494.	0.7	27
158	Randomized, Double-blind 6-Month Comparison of Olanzapine and Quetiapine in Patients With Schizophrenia or Schizoaffective Disorder With Prominent Negative Symptoms and Poor Functioning. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 453-461.	0.7	59
159	Polypharmacy in oligopopulations: what psychiatric genetics can teach biological psychiatry. <i>Psychiatric Genetics</i> , 2006, 16, 241-244.	0.6	21
160	Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms. <i>CNS Spectrums</i> , 2006, 11, 25-31.	0.7	57
162	Understanding the Results of CATIE in the Context of the Field. <i>CNS Spectrums</i> , 2006, 11, 40-47.	0.7	12

#	ARTICLE	IF	CITATIONS
163	Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo. Revista De Psiquiatria Clinica, 2006, 33, 65-100.	0.6	2
164	Treatment of Bipolar Disorder During Pregnancy. CNS Spectrums, 2006, 11, 11-12.	0.7	0
166	Comparison of second generation antipsychotics: are there any differences in efficacy?. Annals of General Psychiatry, 2006, 5, 1.	1.2	0
167	The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. European Journal of Neuroscience, 2006, 24, 2075-2083.	1.2	27
168	Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. Psychiatry and Clinical Neurosciences, 2006, 60, 751-757.	1.0	4
170	Risperidone long-acting injection in practice - more questions than answers?. Acta Psychiatrica Scandinavica, 2006, 114, 1-2.	2.2	17
171	CATIE for clinicians. International Journal of Clinical Practice, 2006, 60, 892-893.	0.8	1
172	Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. International Journal of Clinical Practice, 2006, 60, 933-940.	0.8	43
173	Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications. International Journal of Clinical Practice, 2006, 60, 1419-1424.	0.8	9
174	Treatment of psychosis: 30 years of progress. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 523-534.	0.7	47
175	Pathophysiologically based treatment interventions in schizophrenia. Nature Medicine, 2006, 12, 1016-1022.	15.2	307
176	Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Reviews Drug Discovery, 2006, 5, 133-146.	21.5	52
177	Is There an Anti-Fat Bias among Schizophrenia Patients?. Obesity, 2006, 14, 2305-2305.	1.5	0
178	Cure therapeutics and strategic prevention: raising the bar for mental health research. Molecular Psychiatry, 2006, 11, 11-17.	4.1	278
179	Lessons Learned in Implementing Evidence-Based Practices: Implications for Psychiatric Administrators. Psychiatric Quarterly, 2006, 77, 309-318.	1.1	10
180	Ethical Principles for Psychiatric Administrators: The Challenge of Formularies. Psychiatric Quarterly, 2006, 77, 319-327.	1.1	6
181	Point-Counterpoint: The Importance of Open Access to Psychotropics for our Patients. Psychiatric Quarterly, 2006, 77, 329-334.	1.1	0
183	Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis. Cellular and Molecular Neurobiology, 2006, 26, 363-382.	1.7	782

#	ARTICLE	IF	CITATIONS
184	SREBP Activation by Antipsychotic- and Antidepressant-Drugs in Cultured Human Liver Cells: Relevance for Metabolic Side-Effects?. <i>Molecular and Cellular Biochemistry</i> , 2006, 289, 167-173.	1.4	94
186	In the Aftermath of CATIE: How Should Administrators Value Atypical Antipsychotic Medications?. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2006, 33, 541-543.	1.2	8
187	Consumer Perspectives on Quality of Care in the Treatment of Schizophrenia. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2006, 33, 674-681.	1.2	23
188	Aligning Measurement-based Quality Improvement with Implementation of Evidence-based Practices. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2006, 33, 636-645.	1.2	26
189	CATIE and the Value of Atypical Antipsychotics in the Context of Creating a Recovery-Oriented Behavioral Health System. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2006, 33, 536-540.	1.2	4
190	Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. <i>European Child and Adolescent Psychiatry</i> , 2006, 15, 371-382.	2.8	34
193	Antipsychotic drugs and diabetes— an application of the Austin Bradford Hill criteria. <i>Diabetologia</i> , 2006, 49, 1467-1476.	2.9	57
194	Effects of typical and atypical antipsychotics on glucose—insulin homeostasis and lipid metabolism in first-episode schizophrenia. <i>Psychopharmacology</i> , 2006, 186, 572-578.	1.5	132
195	Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. <i>Psychopharmacology</i> , 2006, 188, 281-292.	1.5	109
196	Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. <i>Psychopharmacology</i> , 2006, 190, 201-211.	1.5	18
197	How antipsychotics work—From receptors to reality. <i>NeuroRx</i> , 2006, 3, 10-21.	6.0	77
198	Metabolic syndrome in patients with schizophrenia: CATIE results. <i>Current Psychiatry Reports</i> , 2006, 8, 213-214.	2.1	1
199	Guidelines for clinical treatment of early course schizophrenia. <i>Current Psychiatry Reports</i> , 2006, 8, 329-334.	2.1	11
200	Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms. <i>Neurotoxicity Research</i> , 2006, 10, 221-233.	1.3	68
202	Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist. <i>Current Psychosis & Therapeutics Reports</i> , 2006, 4, 5-11.	0.1	8
203	What have we learned from CATIE about the pharmacologic treatment of schizophrenia?. <i>Current Psychosis & Therapeutics Reports</i> , 2006, 4, 35-39.	0.1	0
204	Pharmacologic treatment of schizophrenia: Current status and future trends. <i>Current Psychosis & Therapeutics Reports</i> , 2006, 4, 40-49.	0.1	1
205	PLC or TLC: Is outpatient commitment the/an answer?. <i>International Journal of Law and Psychiatry</i> , 2006, 29, 451-468.	0.5	25

#	ARTICLE	IF	CITATIONS
206	Creating more effective antidepressants: clues from the clinic. <i>Drug Discovery Today</i> , 2006, 11, 623-631.	3.2	24
207	Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study. <i>Journal of Psychiatric Research</i> , 2006, 40, 669-676.	1.5	29
208	Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre. <i>BMC Psychiatry</i> , 2006, 6, 11.	1.1	23
209	Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report. <i>BMC Psychiatry</i> , 2006, 6, 37.	1.1	6
210	Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial. <i>BMC Psychiatry</i> , 2006, 6, 45.	1.1	43
211	Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. <i>BMC Psychiatry</i> , 2006, 6, 8.	1.1	93
212	Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study. <i>Pharmacotherapy</i> , 2006, 26, 748-758.	1.2	126
213	Psychological and social interventions for schizophrenia. <i>BMJ: British Medical Journal</i> , 2006, 333, 212-213.	2.4	9
214	Interpreting the Results of the CATIE Study. <i>Psychiatric Services</i> , 2006, 57, 139-139.	1.1	18
215	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 5-40.	1.3	194
216	Why are doctors still prescribing neuroleptics?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 417-420.	0.2	3
217	Are We Still Talking to Our Patients With Schizophrenia?. <i>American Journal of Psychiatry</i> , 2006, 163, 362-364.	4.0	11
218	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>Focus (American Journal of Psychiatry)</i> , 2006, 134, 107-110.	1.0	17
219	Bipolar Disorder Treatment: An Evidence-Based Reality Check. <i>American Journal of Psychiatry</i> , 2006, 163, 175-176.	4.0	16
220	A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents. <i>American Journal of Psychiatry</i> , 2006, 163, 2072-2079.	4.0	218
222	Beyond Efficacy: The STAR*D Trial. <i>American Journal of Psychiatry</i> , 2006, 163, 5-7.	4.0	96
223	The Concepts of Remission and Recovery in Schizophrenia. <i>Pharmacopsychiatry</i> , 2006, 39, 161-170.	1.7	123
225	Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone. <i>Schizophrenia Bulletin</i> , 2006, 33, 1379-1387.	2.3	53

#	ARTICLE	IF	CITATIONS
226	Are older antipsychotic drugs obsolete?. <i>BMJ: British Medical Journal</i> , 2006, 332, 1346-1347.	2.4	12
227	Antipsychotic Drugs and Schizophrenia. <i>New England Journal of Medicine</i> , 2006, 354, 298-300.	13.9	13
228	Is Hunger a Driver of the Cognitive Development?. <i>Neuropsychopharmacology</i> , 2006, 31, 2326-2327.	2.8	4
229	Is Mifepristone Useful in Psychotic Depression?. <i>Neuropsychopharmacology</i> , 2006, 31, 2793-2794.	2.8	14
230	Schizophrenia: Do the Genetics and Neurobiology of Neuregulin Provide a Pathogenesis Model?. <i>Harvard Review of Psychiatry</i> , 2006, 14, 64-77.	0.9	8
231	Estimation of Haplotypes at DRD2 May Have Produced Misleading Results. <i>Archives of General Psychiatry</i> , 2006, 63, 939.	13.8	0
232	Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?. <i>Schizophrenia Bulletin</i> , 2006, 32, 288-296.	2.3	39
233	Olanzapine led to fewer withdrawals than other antipsychotic drugs but increased weight gain, glucose, and lipids. <i>Evidence-Based Medicine</i> , 2006, 11, 81-81.	0.6	0
234	Essential fatty acids and mental illness. <i>International Review of Psychiatry</i> , 2006, 18, 81-84.	1.4	9
235	Psychosocial Acute Treatment in Early-Episode Schizophrenia Disorders. <i>Research on Social Work Practice</i> , 2006, 16, 263-275.	1.1	3
236	Metabolic Profiling of Patients with Schizophrenia. <i>PLoS Medicine</i> , 2006, 3, e363.	3.9	36
237	Meta-analysis in the assessment of treatment outcome. <i>Journal of Psychopharmacology</i> , 2006, 20, 67-71.	2.0	7
238	Divalproex and lithium are similarly cost effective for adults with bipolar disorder. <i>Evidence-Based Mental Health</i> , 2006, 9, 15-15.	2.2	1
239	Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. <i>Journal of Psychopharmacology</i> , 2006, 20, 20-37.	2.0	54
240	Improving patient outcomes in schizophrenia: achieving remission. <i>Journal of Psychopharmacology</i> , 2006, 20, 57-61.	2.0	61
241	Can Medication-Free Research Ever Be Ethical in Older People With Psychotic Disorders?. <i>Schizophrenia Bulletin</i> , 2006, 32, 303-304.	2.3	3
242	Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia. <i>American Journal of Epidemiology</i> , 2006, 164, 672-681.	1.6	105
243	Mental Health In The Medicare Part D Drug Benefit: A New Regulatory Model?. <i>Health Affairs</i> , 2006, 25, 707-719.	2.5	26

#	ARTICLE	IF	CITATIONS
244	Naturalistic Impact of Second-Generation Antipsychotics on Weight Gain. <i>Annals of Pharmacotherapy</i> , 2006, 40, 626-632.	0.9	41
245	Implications Of Part D For Mentally Ill Dual Eligibles: A Challenge For Medicare. <i>Health Affairs</i> , 2006, 25, 491-500.	2.5	19
246	Are atypical antipsychotics associated with a reduced risk of developing parkinsonism?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 132-133.	2.7	0
247	Allopurinol as Adjuvant Therapy in Poorly Responsive or Treatment Refractory Schizophrenia. <i>Annals of Pharmacotherapy</i> , 2006, 40, 2200-2204.	0.9	27
248	Review: higher rates of attrition in antipsychotic treatment arms of placebo controlled trials than in trials with active comparators. <i>Evidence-Based Mental Health</i> , 2006, 9, 70-70.	2.2	2
249	Side Effects of Atypical Antipsychotics: Extrapyramidal Symptoms and the Metabolic Syndrome. <i>Harvard Review of Psychiatry</i> , 2006, 14, 152-164.	0.9	98
250	Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia. <i>Archives of General Psychiatry</i> , 2006, 63, 1079.	13.8	1,031
251	Addressing Nonadherence in the Schizophrenic Population. <i>Journal of Pharmacy Practice</i> , 2006, 19, 361-368.	0.5	2
252	Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy. <i>Journal of Psychopharmacology</i> , 2006, 20, 3-5.	2.0	4
253	Prices, Profits, And Innovation: Examining Criticisms Of New Psychotropic Drugsâ€™ Value. <i>Health Affairs</i> , 2006, 25, 635-646.	2.5	28
254	Comparative Effectiveness of Antipsychotic Drugs. <i>Archives of General Psychiatry</i> , 2006, 63, 1069.	13.8	85
255	The Choice of Drugs for Schizophrenia. <i>New England Journal of Medicine</i> , 2006, 354, 518-520.	13.9	27
256	Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 199-204.	0.6	7
257	Complete Resolution of Olanzapine-Induced Diabetic Ketoacidosis. <i>Journal of Pharmacy Practice</i> , 2006, 19, 255-258.	0.5	5
258	Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. <i>Journal of Psychopharmacology</i> , 2006, 20, 33-40.	2.0	49
260	Shared Decision Making and Medication Management in the Recovery Process. <i>Psychiatric Services</i> , 2006, 57, 1636-1639.	1.1	394
261	Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. <i>British Journal of Ophthalmology</i> , 2006, 90, 1481-1485.	2.1	30
262	Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2006, 2, 14.	0.6	164

#	ARTICLE	IF	CITATIONS
263	Cognitive, Emotional, and Social Processes in Psychosis: Refining Cognitive Behavioral Therapy for Persistent Positive Symptoms. <i>Schizophrenia Bulletin</i> , 2006, 32, S24-S31.	2.3	122
264	Current schizophrenia drugs: efficacy and side effects. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1005-1016.	0.9	37
265	Sertindole: efficacy and safety in schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1825-1834.	0.9	27
266	Addressing the limitations of the CATIE study. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 126-127.	1.3	15
267	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600-610.	4.0	760
268	Olanzapine: a 5-year perspective. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 811-821.	1.4	11
269	Current and emerging somatic treatment strategies in psychotic major depression. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 73-80.	1.4	14
270	Collaborative Care for Bipolar Disorder: Part II. Impact on Clinical Outcome, Function, and Costs. <i>Psychiatric Services</i> , 2006, 57, 937-945.	1.1	272
271	A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1739-1748.	0.9	42
272	GABAergic Malfunction in the Limbic System Resulting from an Aboriginal Genetic Defect in Voltage-Gated Na ⁺ Channel SCN5A is Proposed to Give Rise to Susceptibility to Schizophrenia. <i>Advances in Pharmacology</i> , 2006, 54, 119-145.	1.2	9
273	A Perspective on the Emergence of Meditation Techniques for Medical Disorders. <i>Journal of Alternative and Complementary Medicine</i> , 2006, 12, 709-713.	2.1	3
274	Selecting antipsychotics in schizophrenia: lessons from CATIE. <i>Journal of Psychopharmacology</i> , 2006, 20, 332-334.	2.0	15
275	Can A Center For Comparative Effectiveness Information Succeed? Perspectives From A Health Care Company. <i>Health Affairs</i> , 2006, 25, W586-W588.	2.5	2
276	Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes. <i>American Journal of Psychiatry</i> , 2006, 163, 2096-2102.	4.0	98
277	Effectiveness of Switching Antipsychotic Medications. <i>American Journal of Psychiatry</i> , 2006, 163, 2090-2095.	4.0	153
278	Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3456-3459.	3.3	360
279	Cholinergic Circuits and Signaling in the Pathophysiology of Schizophrenia. <i>International Review of Neurobiology</i> , 2007, 78, 193-223.	0.9	37
280	Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects. <i>Evidence-Based Mental Health</i> , 2007, 10, 74-74.	2.2	0

#	ARTICLE	IF	CITATIONS
281	The use of antipsychotics in children and adolescents with bipolar disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2673-2687.	0.9	8
282	Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3019-3020.	3.3	21
283	Differentiation in the Preonset Phases of Schizophrenia and Mood Disorders: Evidence in Support of a Bipolar Mania Prodrome. <i>Schizophrenia Bulletin</i> , 2007, 33, 703-714.	2.3	175
284	A Meta-Analysis of Cognitive Remediation in Schizophrenia. <i>American Journal of Psychiatry</i> , 2007, 164, 1791-1802.	4.0	1,017
285	Remission and Recovery in Schizophrenia: Practitioner and Patient Perspectives. <i>Schizophrenia Bulletin</i> , 2007, 34, 5-8.	2.3	144
286	Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. <i>Journal of Psychopharmacology</i> , 2007, 21, 179-190.	2.0	27
287	Rationale for Emphasis on Management over Treatment of Schizophrenia in Clinical Practice. <i>Annals of Pharmacotherapy</i> , 2007, 41, 693-695.	0.9	4
288	Time-Dependent Cognitive Deficits Associated with First and Second Generation Antipsychotics: Cholinergic Dysregulation as a Potential Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 961-968.	1.3	62
289	Possible intranasal quetiapine misuse. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 723-725.	0.5	33
290	Schizophrenia: Multi-Attribute Utility Theory Approach to Selection of Atypical Antipsychotics. <i>Annals of Pharmacotherapy</i> , 2007, 41, 201-207.	0.9	13
291	How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs. <i>Current Medical Research and Opinion</i> , 2007, 23, 2567-2576.	0.9	25
293	Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals. <i>Schizophrenia Bulletin</i> , 2007, 34, 266-274.	2.3	12
294	Cessation of Medication for People With Schizophrenia Already Stable on Chlorpromazine. <i>Schizophrenia Bulletin</i> , 2007, 34, 13-14.	2.3	15
295	Unanswered Questions in Schizophrenia Clinical Trials. <i>Schizophrenia Bulletin</i> , 2007, 34, 302-309.	2.3	24
296	Antipsychotic use in a first episode psychosis program. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 151-156.	1.2	2
297	Partial compliance with antipsychotics and its impact on patient outcomes. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 102-111.	1.2	21
298	Management of acutely ill patients in the hospital setting: focus on quetiapine. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 61-72.	1.2	1
299	The "Seroquel" Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 222-232.	1.2	0

#	ARTICLE	IF	CITATIONS
300	Psychiatric Diagnosis and Clinical Trial Completion Rates: Analysis of the FDA SBA Reports. <i>Neuropsychopharmacology</i> , 2007, 32, 2422-2430.	2.8	21
301	Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia. <i>Evidence-Based Mental Health</i> , 2007, 10, 112-112.	2.2	2
302	Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 133-143.	0.6	13
303	Electroconvulsive Therapy for Schizophrenia. <i>Current Psychiatry Reviews</i> , 2007, 3, 15-24.	0.9	4
304	Psychopharmacologic Strategies and Associated Challenges in the Long-Term Treatment of Schizophrenia. <i>Journal of the American Psychiatric Nurses Association</i> , 2007, 13, S6-S15.	0.4	1
305	The role of second-generation antipsychotics in the treatment of psychotic disorders. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 815-815.	0.5	0
306	Editorial: Evidence-Based Therapeutics--Introducing the Cochrane Corner. <i>Schizophrenia Bulletin</i> , 2007, 33, 633-634.	2.3	5
307	Implications of Clinical Trial Design on Sample Size Requirements. <i>Schizophrenia Bulletin</i> , 2007, 34, 664-669.	2.3	28
308	PSYCHOPHARMACOLOGY UPDATE: WHY CHOOSE QUIETAPINE FOR BIPOLAR ILLNESS?. <i>Issues in Mental Health Nursing</i> , 2007, 28, 437-439.	0.6	1
309	Do effectiveness studies tell us the real truth?. <i>World Journal of Biological Psychiatry</i> , 2007, 8, 138-140.	1.3	3
310	Rethinking Antipsychotic Formulary Policy. <i>Schizophrenia Bulletin</i> , 2007, 34, 375-380.	2.3	15
311	New Paradigms for Treatment Development. <i>Schizophrenia Bulletin</i> , 2007, 33, 1093-1099.	2.3	18
312	Metabotropic Glutamate Receptor Genes as Candidates for Pharmacogenetic Studies of Current and Future Antipsychotic Agents in Schizophrenia. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007, 5, 21-30.	0.3	2
313	The lived experience of using psychiatric medication in the recovery process and a shared decision-making program to support it.. <i>Psychiatric Rehabilitation Journal</i> , 2007, 31, 62-69.	0.8	134
314	A Virtual Reality Apartment as a Measure of Medication Management Skills in Patients With Schizophrenia: A Pilot Study. <i>Schizophrenia Bulletin</i> , 2007, 33, 1162-1170.	2.3	59
315	Antipsychotics dosage and antiparkinsonian prescriptions. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2007, 3, 14.	0.6	5
316	Antipsychotic Medication Use in the Elderly Patient. <i>Journal of Pharmacy Practice</i> , 2007, 20, 318-326.	0.5	6
317	Differential pharmacology of atypical antipsychotics: Clinical implications. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, S3-S8.	0.5	22

#	ARTICLE	IF	CITATIONS
318	Has Research Informed Us on the Practical Drug Treatment of Schizophrenia?. Schizophrenia Bulletin, 2007, 34, 403-405.	2.3	3
319	The role of national public health institutes in health infrastructure development. BMJ: British Medical Journal, 2007, 335, 834-835.	2.4	16
320	Violence and gun crime. BMJ: British Medical Journal, 2007, 335, 837-837.	2.4	11
321	Providing care closer to home. BMJ: British Medical Journal, 2007, 335, 838-838.	2.4	4
322	Equitable access to health care. BMJ: British Medical Journal, 2007, 335, 833-834.	2.4	7
323	The Treatment of Psychotic Major Depression: Is There a Role for Adjunctive Psychotherapy?. Psychotherapy and Psychosomatics, 2007, 76, 271-277.	4.0	25
324	Psychotic Disorders, Eating Habits, and Physical Activity: Who Is Ready for Lifestyle Changes?. Psychiatric Services, 2007, 58, 233-239.	1.1	58
325	Towards an Automated Analysis of Neuroleptics' Impact on Human Hand Motor Skills. , 2007, , .		6
326	Dr. Keefe and Colleagues Reply. American Journal of Psychiatry, 2007, 164, 1911-1912.	4.0	1
327	Time Course of the Antipsychotic Effect and the Underlying Behavioral Mechanisms. Neuropsychopharmacology, 2007, 32, 263-272.	2.8	65
328	Chronic Restlessness With Antipsychotics. American Journal of Psychiatry, 2007, 164, 1648-1654.	4.0	37
329	Hyperammonemia and Valproic Acid-Induced Encephalopathy. American Journal of Psychiatry, 2007, 164, 1912-1913.	4.0	6
331	Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison. American Journal of Psychiatry, 2007, 164, 1050-1060.	4.0	329
332	Canâ€™t Get Enough of That Dopamine. American Journal of Psychiatry, 2007, 164, 543-546.	4.0	8
333	Understanding and Preventing Criminal Recidivism Among Adults With Psychotic Disorders. Psychiatric Services, 2007, 58, 773-781.	1.1	107
334	Second-generation antipsychotics: reviewing the costâ€™effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 103-111.	0.7	24
335	Effects of Topiramate. American Journal of Psychiatry, 2007, 164, 526-527.	4.0	3
336	Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. Archives of General Psychiatry, 2007, 64, 1259.	13.8	57

#	ARTICLE	IF	CITATIONS
337	Confounding by Indication and the Risk of Hyperlipidemia in Observational Studies of Antipsychotics. <i>American Journal of Psychiatry</i> , 2007, 164, 525-526.	4.0	2
338	Poison or Cure: Meanings of Medication in Schizophrenia. <i>Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry</i> , 2007, 35, 189-201.	0.3	8
339	Cognitive behavioural therapy group work with voice hearers. Part 1. <i>British Journal of Nursing</i> , 2007, 16, 248-252.	0.3	23
340	Memantine-associated Reversal of Clozapine-induced Weight Gain. <i>Pharmacopsychiatry</i> , 2007, 40, 149-151.	1.7	14
341	Psychiatric outcome studies (POS): Does treatment help the patients? A Popperian approach to research in clinical psychiatry. <i>Nordic Journal of Psychiatry</i> , 2007, 61, 4-34.	0.7	34
342	Making sense of evidence. <i>International Review of Psychiatry</i> , 2007, 19, 583-591.	1.4	10
343	Research for clinical practice: Focusing on the link. <i>International Review of Psychiatry</i> , 2007, 19, 469-471.	1.4	1
344	Cognitive Impairment in Schizophrenia: A Life Span Perspective. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2007, 22, 398-405.	0.9	15
345	Integrating Jungian and Self-Psychological Perspectives Within Cognitive-Behavior Therapy for a Young Man With a Fixed Religious Delusion. <i>Clinical Case Studies</i> , 2007, 6, 263-276.	0.5	18
346	The CATIE Schizophrenia Trial: Results, Impact, Controversy. <i>Harvard Review of Psychiatry</i> , 2007, 15, 245-258.	0.9	109
347	Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications. <i>American Journal of Psychiatry</i> , 2007, 164, 1568-1576.	4.0	215
348	Pharmacogenetics of risperidone response and induced side effects. <i>Personalized Medicine</i> , 2007, 4, 271-293.	0.8	13
349	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007, 64, 633.	13.8	928
350	The engineers of human souls & academia. <i>Epidemiologia E Psichiatria Sociale</i> , 2007, 16, 205-211.	1.0	5
351	Do findings from new trials for schizophrenia fit with existing evidence: not duped & not just beguiled?. <i>Epidemiologia E Psichiatria Sociale</i> , 2007, 16, 199-202.	1.0	8
352	Methodological Issues in Current Antipsychotic Drug Trials. <i>Schizophrenia Bulletin</i> , 2007, 34, 275-285.	2.3	76
353	ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 862-870.	1.3	54
354	Management of Antipsychotic-Induced Weight Gain: Prospective Naturalistic Study of the Effectiveness of a Supervised Exercise Programme. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 980-989.	1.3	111

#	ARTICLE	IF	CITATIONS
355	Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 34, 60-71.	2.3	149
356	Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia. <i>Evidence-Based Mental Health</i> , 2007, 10, 15-15.	2.2	1
357	Predictors of symptomatic remission in people with schizophrenia identified. <i>Evidence-Based Mental Health</i> , 2007, 10, 73-73.	2.2	0
358	Medicaid's Prior Authorization Program And Access To Atypical Antipsychotic Medications. <i>Health Affairs</i> , 2007, 26, 750-760.	2.5	46
359	Clinical Implications of the CATIE Schizophrenia Trials: Day-to-Day Management Lessons for Australasian Psychiatrists. <i>Australasian Psychiatry</i> , 2007, 15, 465-469.	0.4	9
360	Olanzapine-Induced Weight Gain and Increased Visceral Adiposity is Blocked by Melatonin Replacement Therapy in Rats. <i>Neuropsychopharmacology</i> , 2007, 32, 284-288.	2.8	96
361	The Neuropharmacology of Psychosis. <i>Schizophrenia Bulletin</i> , 2007, 33, 937-946.	2.3	22
362	Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 33, 1100-1119.	2.3	205
363	Evidence-based psychopharmacology: an agenda for the future. <i>Evidence-Based Mental Health</i> , 2007, 10, 4-6.	2.2	6
364	An introduction to sample size calculations in clinical trials. <i>Epidemiology and Psychiatric Sciences</i> , 2007, 16, 299-301.	1.8	8
365	Pharmacogenomics in Psychiatry. <i>Journal of Pharmacy Practice</i> , 2007, 20, 252-264.	0.5	2
366	Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. <i>Journal of Psychopharmacology</i> , 2007, 21, 357-373.	2.0	143
367	Acute Insulin Response and β -Cell Compensation in Normal Subjects Treated With Olanzapine or Risperidone for 2 Weeks: Response to Hardy et al.. <i>Diabetes Care</i> , 2007, 30, e69-e69.	4.3	2
368	The history of clozapine and its emergence in the US market. <i>History of Psychiatry</i> , 2007, 18, 39-60.	0.1	208
369	Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. <i>Evidence-Based Mental Health</i> , 2007, 10, 76-76.	2.2	4
370	Psychotropic drugs. , 2007, , 288-320.		2
371	A Systematic Review of Mortality in Schizophrenia. <i>Archives of General Psychiatry</i> , 2007, 64, 1123.	13.8	1,770
373	Explanatory and pragmatic trials. <i>Epidemiologia E Psichiatria Sociale</i> , 2007, 16, 124-125.	1.0	10

#	ARTICLE	IF	CITATIONS
374	First- and Second-Generation Antipsychotics: Learning From CUtLASS and CATIE. Archives of General Psychiatry, 2007, 64, 977.	13.8	18
375	Factors Involved in Outcome and Recovery in Schizophrenia Patients Not on Antipsychotic Medications: A 15-Year Multifollow-Up Study. Journal of Nervous and Mental Disease, 2007, 195, 406-414.	0.5	171
376	The Association of Dropout and Outcome in Trials of Antipsychotic Medication and Its Implications for Dealing With Missing Data. Schizophrenia Bulletin, 2007, 34, 286-291.	2.3	30
377	Comparing Adherence to and Persistence with Antipsychotic Therapy Among Patients with Bipolar Disorder. Annals of Pharmacotherapy, 2007, 41, 1812-1818.	0.9	22
378	Severe Mental Illness and Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2007, 298, 1794.	3.8	355
379	A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opinion on Pharmacotherapy, 2007, 8, 1211-1219.	0.9	55
380	Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics. Annals of Pharmacotherapy, 2007, 41, 1593-1603.	0.9	57
381	Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. Journal of Psychopharmacology, 2007, 21, 405-413.	2.0	95
382	Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. Journal of Psychopharmacology, 2007, 21, 768-773.	2.0	78
383	Weighing In: Emergent Diabetes Mellitus and Second-Generation Antipsychotics. Annals of Pharmacotherapy, 2007, 41, 1725-1727.	0.9	3
384	Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. American Journal of Psychiatry, 2007, 164, 428-436.	4.0	246
385	Association Between Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism and Progressive Brain Volume Changes in Schizophrenia. American Journal of Psychiatry, 2007, 164, 1890-1899.	4.0	152
386	Acute and Long-Term Adverse Effects of Antipsychotics. CNS Spectrums, 2007, 12, 10-14.	0.7	29
387	Balancing Efficacy and Safety in Treatment with Antipsychotics. CNS Spectrums, 2007, 12, 12-20.	0.7	64
388	Newer Antipsychotics and the Differences Between Clinical Experiences and Clinical Trials. CNS Spectrums, 2007, 12, 812-815.	0.7	1
389	Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. British Journal of Psychiatry, 2007, 191, 238-245.	1.7	33
390	Adverse effects of antipsychotics as outcome measures. British Journal of Psychiatry, 2007, 191, s64-s70.	1.7	49
391	Rapid tranquillisation in emergency psychiatric settings. BMJ: British Medical Journal, 2007, 335, 835-836.	2.4	11

#	ARTICLE	IF	CITATIONS
392	Managing the Acutely Agitated and Psychotic Patient. <i>CNS Spectrums</i> , 2007, 12, 5-11.	0.7	40
395	Cessation of medication for people with schizophrenia already stable on chlorpromazine. <i>The Cochrane Library</i> , 2007, , CD006329.	1.5	22
397	Evolution of outcome measures in schizophrenia. <i>British Journal of Psychiatry</i> , 2007, 191, s1-s6.	1.7	44
398	Imaging Mental Disorders in the 21st Century. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 133-134.	0.9	3
399	ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 863-876.	0.5	12
401	Impact of Medical Comorbidity on Medication Management of Schizophrenia. <i>CNS Spectrums</i> , 2007, 12, 15-17.	0.7	1
402	An Outcome Measure in Schizophrenia: Mortality. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 55-60.	0.9	27
406	Commentary on evidence-based psychological treatments for older adults.. <i>Psychology and Aging</i> , 2007, 22, 52-55.	1.4	30
407	Treatment Adherence and Long-Term Outcomes. <i>CNS Spectrums</i> , 2007, 12, 21-26.	0.7	83
408	Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. <i>British Journal of Psychiatry</i> , 2007, 191, 14-22.	1.7	97
409	Effect on lipid profiles of switching from olanzapine to another secondgeneration antipsychotic agent in veterans with schizophrenia. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2007, 47, 373-378.	0.7	20
410	Show Me the Evidence: Using Number Needed to Treat. <i>Southern Medical Journal</i> , 2007, 100, 881-884.	0.3	28
411	The many faces of psychosis in the elderly. <i>Current Opinion in Psychiatry</i> , 2007, 20, 551-558.	3.1	24
412	Factors That Affect Adherence to Bipolar Disorder Treatments. <i>Medical Care</i> , 2007, 45, 545-552.	1.1	124
413	Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. <i>International Clinical Psychopharmacology</i> , 2007, 22, 249-267.	0.9	46
414	Dysphagia: A Rare Form of Dyskinesia?. <i>Journal of Psychiatric Practice</i> , 2007, 13, 199-201.	0.3	8
415	Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. <i>International Clinical Psychopharmacology</i> , 2007, 22, 145-152.	0.9	29
416	Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. <i>International Clinical Psychopharmacology</i> , 2007, 22, 363-370.	0.9	44

#	ARTICLE	IF	CITATIONS
417	<i><i>Furor Therapeuticus</i></i> : Benjamin Rush and the Philadelphia Yellow Fever Epidemic of 1793. <i>American Journal of Psychiatry</i> , 2007, 164, 552-555.	4.0	10
418	Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications. <i>Psychiatric Services</i> , 2007, 58, 1187-1192.	1.1	209
419	Searching susceptibility genes for antipsychotic-induced weight gain: is the 5-HT _{2C} receptor gene a promising candidate?. <i>Personalized Medicine</i> , 2007, 4, 357-361.	0.8	2
422	Best Practices: Comparing Medication Treatments in Mental Health: Drug Class Reviews and Policy Challenges. <i>Psychiatric Services</i> , 2007, 58, 746-748.	1.1	2
423	Successful Monotherapy Treatment with Aripiprazole in a Patient with Schizophrenia and Prolactinoma. <i>Journal of Psychiatric Practice</i> , 2007, 13, 120-124.	0.3	14
424	Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats. <i>Behavioural Pharmacology</i> , 2007, 18, 9-17.	0.8	20
425	Pharmacological profiles in rats of novel antipsychotics with combined dopamine D ₂ /serotonin 5-HT _{1A} activity: comparison with typical and atypical conventional antipsychotics. <i>Behavioural Pharmacology</i> , 2007, 18, 103-118.	0.8	44
426	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 989-993.	0.7	35
427	Olanzapine Versus Chlorpromazine in the Treatment of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 329-337.	0.7	8
428	Oral Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2007, 30, 169-182.	0.2	17
429	A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2007, 22, 133-136.	0.9	4
430	Dose-dependent constipation with higher doses of quetiapine: a case series. <i>International Clinical Psychopharmacology</i> , 2007, 22, 244-246.	0.9	16
431	Paliperidone Extended-Release Tablets (Invega). <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2007, 42, 51-57.	0.1	4
432	Psychopharm Review: CME QUIZ. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2007, 42, 58.	0.1	0
433	Association of Acute Symptoms and Compliance Attitude in Noncompliant Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 392-394.	0.7	15
434	Discontinuation of Risperidone, Olanzapine, and Haloperidol in First-Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 400-401.	0.7	2
435	All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 252-258.	0.7	39
436	Experience of VA Psychiatrists With Pharmaceutical Detailing of Antipsychotic Medications. <i>Psychiatric Services</i> , 2007, 58, 1292-1296.	1.1	20

#	ARTICLE	IF	CITATIONS
437	Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 6-14.	0.7	180
438	Measuring Movement Disorders in Antipsychotic Drug Trials. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 423-430.	0.7	34
439	Lessons From Each Drug Trial. <i>American Journal of Psychiatry</i> , 2007, 164, 375-376.	4.0	7
440	Dr. Olfson and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2007, 164, 526-526.	4.0	4
441	Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. <i>International Clinical Psychopharmacology</i> , 2007, 22, 175-178.	0.9	6
442	The attitude of patients towards antipsychotic depot treatment. <i>International Clinical Psychopharmacology</i> , 2007, 22, 275-282.	0.9	87
443	Variation in Nursing Home Antipsychotic Prescribing Rates. <i>Archives of Internal Medicine</i> , 2007, 167, 676.	4.3	155
444	Psychiatrists' Failure to Inform: Is There Substantial Financial Exposure?. <i>Ethical Human Psychology and Psychiatry</i> , 2007, 9, 117-125.	0.5	3
445	Chapter 9.. <i>Journal of College Student Psychotherapy</i> , 2007, 21, 199-224.	0.6	2
446	Full Disclosure: Toward a Participatory and Risk-Limiting Approach to Neuroleptic Drugs. <i>Ethical Human Psychology and Psychiatry</i> , 2007, 9, 35-61.	0.5	5
447	CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6's serotonin-dopamine crosstalk revisited. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 339-347.	0.7	39
448	Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. <i>International Clinical Psychopharmacology</i> , 2007, 22, 356-362.	0.9	43
449	Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 415-427.	4.0	138
450	Olanzapine-Associated Bilateral Eyelid Edema. <i>Journal of Clinical Psychopharmacology</i> , 2007, 22, 214-215.	0.7	12
451	Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 639-661.	0.7	136
452	Long-acting injectable risperidone vs. olanzapine tablets for schizophrenia or schizoaffective disorder. <i>British Journal of Psychiatry</i> , 2007, 191, 131-139.	1.7	76
453	EPS Profiles: The Atypical Antipsychotics. <i>Journal of Psychiatric Practice</i> , 2007, 13, 13-24.	0.3	128
454	A Case-Control Study of Patients With Resistant Schizophrenia After Clozapine Discontinuation. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 90-91.	0.7	6

#	ARTICLE	IF	CITATIONS
455	Guideline Watch (November 2005): Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition. Focus (American Psychiatric Publishing), 2007, 5, 34-39.	0.4	6
456	Why don't patients take their medicine? Reasons and solutions in psychiatry. Advances in Psychiatric Treatment, 2007, 13, 336-346.	0.6	135
457	Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Research, 2007, 152, 165-172.	1.7	20
458	Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 32-40.	2.5	12
459	Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 703-712.	2.5	38
460	Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1012-1022.	2.5	23
461	Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: A 12-month, open-label, flexible-dose, naturalistic observational trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1401-1409.	2.5	15
462	The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: A 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1470-1477.	2.5	7
463	Schizophrenia in later life. Aging Health, 2007, 3, 383-396.	0.3	21
464	Heterogeneity of Treatment Effects in Schizophrenia. American Journal of Medicine, 2007, 120, S26-S31.	0.6	35
465	Appendectomy for appendicitis in patients with schizophrenia. American Journal of Surgery, 2007, 193, 41-48.	0.9	53
468	Antipsychotics inhibit TREK but not TRAAK channels. Biochemical and Biophysical Research Communications, 2007, 354, 284-289.	1.0	52
469	Role of patient experience in atypical antipsychotic adherence: A retrospective data analysis. Clinical Therapeutics, 2007, 29, 2768-2773.	1.1	11
470	Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes and Metabolism, 2007, 33, 169-175.	1.4	146
472	Adherence behaviour with psychotropic medication is a form of self-medication. Medical Hypotheses, 2007, 68, 12-21.	0.8	49
473	Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results. European Neuropsychopharmacology, 2007, 17, 235-244.	0.3	106
474	A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. European Neuropsychopharmacology, 2007, 17, 456-463.	0.3	12
475	Foreword: Improved understanding and treatment of schizophrenia. European Neuropsychopharmacology, 2007, 17, v-vi.	0.3	0

#	ARTICLE	IF	CITATIONS
476	The stable patient with schizophrenia â€” From antipsychotic effectiveness to adherence. <i>European Neuropsychopharmacology</i> , 2007, 17, S115-S122.	0.3	26
477	The long term â€” Maximising potential for rehabilitation in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2007, 17, S123-S129.	0.3	3
478	Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial. <i>European Psychiatry</i> , 2007, 22, 195-202.	0.1	18
479	Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy. <i>European Psychiatry</i> , 2007, 22, 267-275.	0.1	65
480	A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. <i>European Psychiatry</i> , 2007, 22, 433-443.	0.1	96
481	Physician observations and perceptions of positive and negative symptoms of schizophrenia: A multinational, cross-sectional survey. <i>European Psychiatry</i> , 2007, 22, 371-379.	0.1	22
482	AntipsicÃ³ticos tÃ©picos. AntipsicÃ³ticos atÃ©picos. FMC Formacion Medica Continuada En Atencion Primaria, 2007, 14, 637-647.	0.0	0
484	Le syndrome mÃ©tabolique : clinique, facteurs de risque, prise en charge. <i>L'Encephale</i> , 2007, 33, 23-26.	0.3	0
489	BÃ©nÃ©fices comparÃ©s des anti-psychotiques atypiques versus neuroleptiques classiques. <i>L'Encephale</i> , 2007, 33, 150-152.	0.3	1
490	Utilisation des antipsychotiques. <i>L'Encephale</i> , 2007, 33, 153-156.	0.3	1
491	Schizophrenia endophenotypes as treatment targets. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1189-1206.	1.5	42
492	Quality Toolbox: Evidence-Based Monitoring for Metabolic Syndrome in Clients with Chronic Schizophrenia. <i>Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality</i> , 2007, 29, 48-56.	0.3	3
494	P.3.c.078 Catechol-O-methyltransferase gene polymorphism in symptomatology of schizophrenia. <i>European Neuropsychopharmacology</i> , 2007, 17, S469-S470.	0.3	0
495	P.3.c.079 Negative impact of total antipsychotic dosage on cognition as assessed by the Brief Assessment of Cognition in Schizophrenia (BACS). <i>European Neuropsychopharmacology</i> , 2007, 17, S470.	0.3	0
497	C.01.03 Implications of sustained effectiveness in managing schizophrenia. <i>European Neuropsychopharmacology</i> , 2007, 17, S595-S596.	0.3	0
501	C.15.03 Bipolar disorder: optimal management strategies. <i>European Neuropsychopharmacology</i> , 2007, 17, S607-S608.	0.3	0
502	C.15.04 Acute schizophrenia and beyond: clinical case studies. <i>European Neuropsychopharmacology</i> , 2007, 17, S608.	0.3	0
505	C.17.02 The increasing relevance of drug-drug interactions (DDIs) in schizophrenic patients with polytherapy and comorbidities. <i>European Neuropsychopharmacology</i> , 2007, 17, S609.	0.3	0

#	ARTICLE	IF	CITATIONS
506	C.17.03 Can we reduce discontinuation rates in the treatment of schizophrenia?. European Neuropsychopharmacology, 2007, 17, S609.	0.3	0
507	C.17.04 Can we improve psychotic symptom control/ response in acute episodes of schizophrenia?. European Neuropsychopharmacology, 2007, 17, S609.	0.3	0
508	Clinical trials: Bridging the gap between efficacy and effectiveness. International Review of Psychiatry, 2007, 19, 531-539.	1.4	37
509	6 Antipsychotic drugs. Side Effects of Drugs Annual, 2007, , 60-86.	0.6	0
510	Psychoeducational Approaches to Medication Adherence in Patients with Bipolar Disorder. Disease Management and Health Outcomes, 2007, 15, 181-192.	0.3	31
511	Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia. Expert Opinion on Drug Discovery, 2007, 2, 1001-1009.	2.5	17
512	Reaching for Wellness in Schizophrenia. Psychiatric Clinics of North America, 2007, 30, 453-479.	0.7	16
513	Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?. Journal of Psychopharmacology, 2007, 21, 283-301.	2.0	91
515	The Evaluation and Management of Patients with First-Episode Schizophrenia: A Selective, Clinical Review of Diagnosis, Treatment, and Prognosis. Harvard Review of Psychiatry, 2007, 15, 189-211.	0.9	27
516	Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003â€“2004. Current Medical Research and Opinion, 2007, 23, 49-56.	0.9	57
517	Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Current Medical Research and Opinion, 2007, 23, 467-475.	0.9	37
518	A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed With Schizophrenia. Schizophrenia Bulletin, 2007, 34, 181-192.	2.3	88
519	Is antipsychotic medication stigmatizing for people with mental illness?. International Review of Psychiatry, 2007, 19, 107-112.	1.4	38
520	Maintenance treatment in bipolar disorder: a focus on aripiprazole. Expert Review of Neurotherapeutics, 2007, 7, 919-925.	1.4	10
521	Weight Gain Induced by Psychotropic Drugs. Obesity Management, 2007, 3, 165-169.	0.2	4
522	Restarting Clozapine after Neutropenia. CNS Drugs, 2007, 21, 25-35.	2.7	85
523	Extended-Release Intramuscular Naltrexone in Alcohol Dependence in Adults: Profile Report1. CNS Drugs, 2007, 21, 83-87.	2.7	0
524	When Should Clozapine Be Initiated in Schizophrenia?. CNS Drugs, 2007, 21, 267-278.	2.7	23

#	ARTICLE	IF	CITATIONS
525	Atypical Antipsychotics for the Treatment of Bipolar Disorder. <i>CNS Drugs</i> , 2007, 21, 367-387.	2.7	30
526	Conceptual and Methodological Issues in the Design of Clinical Trials of Antipsychotics for the Treatment of Schizophrenia. <i>CNS Drugs</i> , 2007, 21, 699-714.	2.7	28
527	Ziprasidone for the Treatment of Acute Manic or Mixed Episodes Associated with Bipolar Disorder. <i>CNS Drugs</i> , 2007, 21, 835-849.	2.7	22
528	Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. <i>Current Medical Research and Opinion</i> , 2007, 23, 2551-2557.	0.9	15
529	Cardiovascular effects of antipsychotics. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 829-839.	1.4	54
530	Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia. <i>Journal of Medical Economics</i> , 2007, 10, 427-442.	1.0	15
531	Cost analysis of a disease management programme for adult Medicaid clients with schizophrenia. <i>Journal of Medical Economics</i> , 2007, 10, 411-426.	1.0	0
532	Dementia syndromes: evaluation and treatment. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 407-422.	1.4	82
533	Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. <i>Current Medical Research and Opinion</i> , 2007, 23, 2805-2814.	0.9	14
534	Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. <i>Current Medical Research and Opinion</i> , 2007, 23, 2305-2312.	0.9	175
535	An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2007, 23, 97-104.	0.9	23
536	A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). <i>Current Medical Research and Opinion</i> , 2007, 23, 2313-2323.	0.9	25
537	Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. <i>Current Medical Research and Opinion</i> , 2007, 23, 1733-1744.	0.9	23
538	Atypical antipsychotics: new drugs, new challenges. <i>Cleveland Clinic Journal of Medicine</i> , 2007, 74, 597-606.	0.6	50
539	AKT1 and Neurocognition in Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 169-177.	1.3	12
540	Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects. <i>Neuropsychopharmacology</i> , 2007, 32, 289-297.	2.8	223
541	Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Demographic and Clinical Characteristics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 979-988.	0.3	91
542	Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. <i>Journal of Psychopharmacology</i> , 2007, 21, 774-782.	2.0	96

#	ARTICLE	IF	CITATIONS
543	Lack of Insight in Schizophrenia. <i>CNS Drugs</i> , 2007, 21, 129-141.	2.7	142
544	Drug treatment of hyperprolactinemia. <i>Annales D'Endocrinologie</i> , 2007, 68, 113-117.	0.6	26
545	Real-World Antipsychotic Treatment Practices. <i>Psychiatric Clinics of North America</i> , 2007, 30, 401-416.	0.7	34
546	Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 969-978.	0.3	64
547	Treatment-Resistant Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2007, 30, 511-533.	0.7	198
549	Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. <i>Schizophrenia Research</i> , 2007, 90, 147-161.	1.1	260
550	Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. <i>Schizophrenia Research</i> , 2007, 89, 129-139.	1.1	180
551	The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. <i>Schizophrenia Research</i> , 2007, 94, 99-106.	1.1	46
552	Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities. <i>Schizophrenia Research</i> , 2007, 92, 103-107.	1.1	17
553	A clinical study of the association of antipsychotics with hyperlipidemia. <i>Schizophrenia Research</i> , 2007, 92, 95-102.	1.1	72
554	Risperidone significantly inhibits interferon- β -induced microglial activation in vitro. <i>Schizophrenia Research</i> , 2007, 92, 108-115.	1.1	156
555	Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. <i>Schizophrenia Research</i> , 2007, 93, 117-130.	1.1	224
556	Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial. <i>Schizophrenia Research</i> , 2007, 93, 99-108.	1.1	129
557	Sexual functioning, psychopathology and quality of life in patients with schizophrenia. <i>Schizophrenia Research</i> , 2007, 94, 119-127.	1.1	60
558	Violence and schizophrenia: Commentary. <i>Schizophrenia Research</i> , 2007, 94, 377-378.	1.1	2
559	Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: The clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. <i>Schizophrenia Research</i> , 2007, 96, 185-197.	1.1	34
560	A pilot study of a weight management program with food provision in schizophrenia. <i>Schizophrenia Research</i> , 2007, 96, 198-205.	1.1	71
561	Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode. <i>Schizophrenia Research</i> , 2007, 95, 169-173.	1.1	15

#	ARTICLE	IF	CITATIONS
562	Neurotransmitter depleter tetrabenazine; potential candidate for schizophrenia treatment?. Schizophrenia Research, 2007, 96, 267-268.	1.1	2
563	Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research, 2007, 96, 146-155.	1.1	40
564	Schizophrenia. BMJ: British Medical Journal, 2007, 335, 91-95.	2.4	240
565	Long-Acting Injectable Risperidone for the Treatment of Schizophrenia. Drugs, 2007, 67, 1541-1566.	4.9	47
566	Aripiprazole in the Treatment of Schizophrenia. Clinical Drug Investigation, 2007, 27, 1-13.	1.1	22
567	Central Nervous System Drugs Overview. , 2007, , 1-16.		1
568	Paliperidone: a new extended-release oral atypical antipsychotic. Expert Opinion on Pharmacotherapy, 2007, 8, 2307-2313.	0.9	20
569	Mental health, antipsychotics and hyperglycaemia. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2007, 1, 209-224.	1.8	1
570	Fine-Tuning of Awake Prefrontal Cortex Neurons by Clozapine: Comparison With Haloperidol and N-Desmethylclozapine. Biological Psychiatry, 2007, 61, 679-687.	0.7	38
571	NCAM1 and Neurocognition in Schizophrenia. Biological Psychiatry, 2007, 61, 902-910.	0.7	80
572	Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study. Biological Psychiatry, 2007, 62, 1363-1370.	0.7	192
573	Neuroprotection and Enhancement of Neurite Outgrowth With Small Molecular Weight Compounds From Screens of Chemical Libraries. International Review of Neurobiology, 2007, 77, 247-289.	0.9	9
574	Schizophrenia: New Pathological Insights and Therapies. Annual Review of Medicine, 2007, 58, 49-61.	5.0	111
575	Adverse Effects of Atypical Antipsychotics. CNS Drugs, 2007, 21, 911-936.	2.7	364
576	Genomics and the future of pharmacotherapy in psychiatry. International Review of Psychiatry, 2007, 19, 523-530.	1.4	47
577	Prescribing psychotropic medication: what nurse prescribers need to know. NursePrescribing, 2007, 5, 148-152.	0.1	3
579	Anestesia e síndrome do QT longo. Revista Brasileira De Anestesiologia, 2007, 57, .	0.6	5
580	Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders. Journal of the American Pharmacists Association: JAPhA, 2007, 47, 156-164.	0.7	4

#	ARTICLE	IF	CITATIONS
581	Beyond management to cure: enhancing the positive dimensions of personality. , 2007, , 59-78.		0
582	First-Episode Psychosis: A Window of Opportunity for Best Practices. CNS Spectrums, 2007, 12, 1-16.	0.7	18
585	Which antipsychotics would mental health professionals take themselves?. Psychiatric Bulletin, 2007, 31, 94-96.	0.3	16
586	Measurement of long-term outcomes in observational and randomised controlled trials. British Journal of Psychiatry, 2007, 191, s78-s84.	1.7	25
587	Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evidence, 0, .	4.7	6
588	Dominance of second-generation antipsychotics â€“ time for reflection?. Psychiatric Bulletin, 2007, 31, 233-233.	0.3	3
589	Regulatory policies on medicines for psychiatric disorders: is Europe on target?. British Journal of Psychiatry, 2007, 190, 91-93.	1.7	9
590	Re: Community Treatment Orders: An Essential Therapeutic Tool in the Face of Continuing Deinstitutionalization. Canadian Journal of Psychiatry, 2007, 52, 542-542.	0.9	1
591	Rethinking Social Causes of Psychosis. Canadian Journal of Psychiatry, 2007, 52, 275-276.	0.9	3
592	Psychodynamic contributions to early intervention in psychosis. Advances in Psychiatric Treatment, 2007, 13, 34-42.	0.6	17
593	Supplementary prescribing and schizophrenia: a case study. Mental Health Practice, 2007, 10, 35-36.	0.1	2
594	Treatment adherence. South African Journal of Psychiatry, 2007, 13, 5.	0.2	1
598	Child psychiatry across cultures. , 2007, , 471-483.		3
599	Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Revista Brasileira De Psiquiatria, 2007, 29, 207-212.	0.9	28
600	Psychiatryâ€™s Thirty-Five-Year, Non-Empirical Reach For Biological Explanations. Behavior and Social Issues, 2007, 16, 197-213.	0.8	5
602	Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting. Human Psychopharmacology, 2007, 22, 515-528.	0.7	3
603	Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depression and Anxiety, 2007, 24, 522-526.	2.0	30
604	Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry, 2007, 7, 14.	1.1	42

#	ARTICLE	IF	CITATIONS
605	A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. <i>BMC Psychiatry</i> , 2007, 7, 28.	1.1	65
606	Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. <i>Synapse</i> , 2007, 61, 429-439.	0.6	34
607	Schizophrenia drug says goodbye to dopamine. <i>Nature Medicine</i> , 2007, 13, 1018-1019.	15.2	43
608	No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs. <i>International Journal of Obesity</i> , 2007, 31, 1014-1022.	1.6	10
609	Towards a muscarinic hypothesis of schizophrenia. <i>Molecular Psychiatry</i> , 2007, 12, 232-246.	4.1	242
610	Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. <i>Molecular Psychiatry</i> , 2007, 12, 474-482.	4.1	59
611	Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia?. <i>Molecular Psychiatry</i> , 2007, 12, 321-322.	4.1	16
612	Catechol-O-methyltransferase gene regulation in rat frontal cortex. <i>Molecular Psychiatry</i> , 2007, 12, 322-323.	4.1	14
613	Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. <i>Molecular Psychiatry</i> , 2007, 12, 572-580.	4.1	255
614	Metabolomic mapping of atypical antipsychotic effects in schizophrenia. <i>Molecular Psychiatry</i> , 2007, 12, 934-945.	4.1	241
615	Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. <i>Molecular Psychiatry</i> , 2007, 12, 707-747.	4.1	331
616	The pipeline and future of drug development in schizophrenia. <i>Molecular Psychiatry</i> , 2007, 12, 904-922.	4.1	173
617	Optimisation of anti-psychotic therapeutics: a balancing act?. <i>British Journal of Pharmacology</i> , 2007, 151, 161-162.	2.7	4
618	Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. <i>Diabetic Medicine</i> , 2007, 24, 481-485.	1.2	309
619	Mental health nurse supplementary prescribing: experiences of mental health nurses, psychiatrists and patients. <i>Journal of Advanced Nursing</i> , 2007, 59, 488-496.	1.5	63
620	Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. <i>Addiction</i> , 2007, 102, 16-32.	1.7	367
621	Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical Trials. <i>CNS Neuroscience & Therapeutics</i> , 2007, 13, 137-177.	4.0	74
622	Interictal Psychoses in Comparison with Schizophrenia—A Prospective Study. <i>Epilepsia</i> , 2007, 48, 2345-2351.	2.6	41

#	ARTICLE	IF	CITATIONS
623	Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT _{2A} receptors in human and monkey prefrontal cortex. <i>Journal of Neurochemistry</i> , 2007, 103, 475-486.	2.1	88
624	Novel $\alpha 7$ nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. <i>Genes, Brain and Behavior</i> , 2007, 7, 070514070132007-???	1.1	41
625	Weight development in patients treated with risperidone: a 5-year naturalistic study. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 277-285.	2.2	27
626	Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 36-46.	2.2	67
627	The case for long-acting antipsychotic agents in the post-CATIE era. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 260-267.	2.2	133
628	Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac?. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 93-100.	2.2	148
629	A prospective 6-month analysis of the naturalistic use of aripiprazole – factors predicting favourable outcome. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 461-466.	2.2	15
630	Paliperidone: quo vadis?. <i>International Journal of Clinical Practice</i> , 2007, 61, 653-662.	0.8	38
631	Metabolic side effects of antipsychotic medication. <i>International Journal of Clinical Practice</i> , 2007, 61, 1356-1370.	0.8	200
632	Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. <i>International Journal of Clinical Practice</i> , 2007, 61, 1979-1988.	0.8	29
633	Olanzapine: interpreting the label change. <i>International Journal of Clinical Practice</i> , 2007, 61, 1960-1962.	0.8	10
634	Effect of Antipsychotics on Creatine Kinase Activity in Rat Brain. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 101, 315-319.	1.2	20
635	Risk of Diabetes Mellitus Associated with Atypical Antipsychotic Use Among Medicaid Patients with Bipolar Disorder: A Nested Case-Control Study. <i>Pharmacotherapy</i> , 2007, 27, 27-35.	1.2	47
636	The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. <i>Brain Research Reviews</i> , 2007, 56, 427-442.	9.1	96
637	The impact of pharmacogenetics on the development and use of antipsychotic drugs. <i>Drug Discovery Today</i> , 2007, 12, 953-959.	3.2	39
638	Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities. <i>Journal of Intellectual Disability Research</i> , 2008, 52, 132-140.	1.2	20
639	Pharmacology of N-desmethylozapine†. , 2007, 115, 223-231.		94
640	How healers manage the pluralistic healing context: The perspective of indigenous, religious and allopathic healers in relation to psychosis in Uganda. <i>Social Science and Medicine</i> , 2007, 65, 1260-1273.	1.8	37

#	ARTICLE	IF	CITATIONS
641	Pharmacological strategies for relapse prevention in schizophrenia. <i>Psychiatry (Abingdon, England)</i> , 2007, 6, 351-356.	0.2	4
642	Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. <i>Journal of Psychiatric Research</i> , 2007, 41, 305-310.	1.5	18
643	BAP annual conference. <i>Progress in Neurology and Psychiatry</i> , 2007, 11, 15-18.	0.4	0
644	How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?â€”A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. <i>Psychopharmacology</i> , 2007, 195, 285-295.	1.5	49
645	Personalized treatment with atypical antipsychotic medications. <i>Advances in Therapy</i> , 2007, 24, 721-740.	1.3	6
646	Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. <i>Psychopharmacology</i> , 2007, 190, 479-484.	1.5	74
647	Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. <i>Psychopharmacology</i> , 2007, 191, 1015-1022.	1.5	33
648	Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. <i>Psychopharmacology</i> , 2007, 192, 27-38.	1.5	26
649	Risk of readmission in compulsorily and voluntarily admitted patients. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2007, 42, 916-922.	1.6	18
650	Patientsâ€™ perspectives on what works in psychoeducational groups for schizophrenia. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2007, 42, 909-915.	1.6	23
651	Bias in research and conflict of interest: why should we care?. <i>International Urogynecology Journal</i> , 2007, 18, 241-243.	0.7	4
653	The relationships between antipsychotic dose and efficacy, and the time to treatment response. <i>Psychiatrie Und Psychotherapie</i> , 2007, 3, 9-13.	0.0	0
654	Assessing Obesity and Other Related Health Problems of Mentally Ill Hispanic Patients in an Urban Outpatient Setting. <i>Psychiatric Quarterly</i> , 2007, 78, 171-181.	1.1	19
655	The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2007, 34, 307-314.	1.2	31
656	Distress with Medication Side Effects among Persons with Severe Mental Illness. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2007, 34, 435-442.	1.2	22
657	Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. <i>Journal of Neural Transmission</i> , 2007, 114, 1443-1454.	1.4	17
658	The EU-regulation on medicinal products for paediatric use. <i>European Child and Adolescent Psychiatry</i> , 2007, 16, 229-235.	2.8	24
659	Antipsychotic treatment of schizophrenia: Two steps forward, one step back. <i>Current Psychiatry Reports</i> , 2007, 9, 263-264.	2.1	2

#	ARTICLE	IF	CITATIONS
660	Individualizing antipsychotic drug therapy in schizophrenia: The promise of pharmacogenetics. <i>Current Psychiatry Reports</i> , 2007, 9, 313-318.	2.1	39
661	Reducing variation in the pharmacologic treatment of schizophrenia: Defining acceptable standards of treatment. <i>Current Psychiatry Reports</i> , 2007, 9, 319-324.	2.1	0
662	Early intervention in schizophrenia: Current and future perspectives. <i>Current Psychiatry Reports</i> , 2007, 9, 325-328.	2.1	26
663	Schizophrenia: From brain morphology to psychopathology. <i>Current Psychiatry Reports</i> , 2007, 9, 337-342.	2.1	0
664	STEP-BD and bipolar depression: What have we learned?. <i>Current Psychiatry Reports</i> , 2007, 9, 497-503.	2.1	50
665	Weight gain and metabolic issues of medicines used for bipolar disorder. <i>Current Psychiatry Reports</i> , 2007, 9, 521-528.	2.1	27
666	â€œReal Worldâ€™ Comparison of First- and Second-Generation Antipsychotics in Regard to Length of Inpatient Hospitalization and Number of Re-hospitalizations. <i>Psychiatric Quarterly</i> , 2008, 79, 55-64.	1.1	1
667	The Role of a Behavioral Health Medical Director in Medicaid Managed Care. <i>Psychiatric Quarterly</i> , 2008, 79, 33-42.	1.1	2
668	Subjectivity in the Perception and Measurement of Quality of Life: Conceptualization and Development of the Seville Questionnaire. <i>Psychiatric Quarterly</i> , 2008, 79, 321-330.	1.1	4
669	Subjective quality of life in outpatients with schizophrenia in Hong Kong and Beijing: relationship to socio-demographic and clinical factors. <i>Quality of Life Research</i> , 2008, 17, 27-36.	1.5	50
670	Pathways to care and treatment delays in first and multi episode psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2008, 43, 727-735.	1.6	45
671	Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. <i>Psychopharmacology</i> , 2008, 196, 255-267.	1.5	34
672	Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. <i>Psychopharmacology</i> , 2008, 197, 229-235.	1.5	99
673	Realistic expectations of prepulse inhibition in translational models for schizophrenia research. <i>Psychopharmacology</i> , 2008, 199, 331-388.	1.5	479
674	Cognitive performance in neurokinin 3 receptor knockout mice. <i>Psychopharmacology</i> , 2008, 198, 211-220.	1.5	24
675	Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. <i>Psychopharmacology</i> , 2008, 200, 317-331.	1.5	59
676	Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia. <i>Psychopharmacology</i> , 2008, 200, 157-165.	1.5	23
677	Do we learn the right things from clinical trials?. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 115-125.	0.8	3

#	ARTICLE	IF	CITATIONS
678	Clinical utility of drug measurement and pharmacokinetics " therapeutic drug monitoring in psychiatry. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 159-166.	0.8	55
679	Further evidence for the association between 5-HT _{2C} receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 477-482.	0.8	61
680	Predicting Time-to-Independent-Release from Current Level of Functioning for Psychiatric Inpatients: A "Survivor" Analysis. <i>Journal of Behavioral Health Services and Research</i> , 2008, 35, 315-333.	0.6	3
681	Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia. <i>Journal of Behavioral Health Services and Research</i> , 2008, 35, 215-225.	0.6	19
682	Pharmacokinetics in geriatric psychiatry. <i>Current Psychiatry Reports</i> , 2008, 10, 30-36.	2.1	3
683	Tactics and technologies to manage nonadherence in patients with schizophrenia. <i>Current Psychiatry Reports</i> , 2008, 10, 359-369.	2.1	8
685	Predisposing factors for early retirement in patients with Schizophrenia in Germany. <i>European Journal of Health Economics</i> , 2008, 9, 265-274.	1.4	6
686	Do effectiveness ("real world") studies on antipsychotics tell us the real truth?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 257-270.	1.8	33
687	Effectiveness of second generation antipsychotics: A systematic review of randomized trials. <i>BMC Psychiatry</i> , 2008, 8, 31.	1.1	67
688	Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. <i>BMC Psychiatry</i> , 2008, 8, 32.	1.1	232
689	The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe. <i>BMC Psychiatry</i> , 2008, 8, 57.	1.1	17
690	Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. <i>BMC Psychiatry</i> , 2008, 8, 78.	1.1	25
691	Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study. <i>Annals of General Psychiatry</i> , 2008, 7, 16.	1.2	23
692	Are changes in the pharmacokinetic (PK) and pharmacodynamic (PD) properties of antipsychotics able to improve efficacy and safety?. <i>Annals of General Psychiatry</i> , 2008, 7, .	1.2	0
693	Incorporating clinical guidelines through clinician decision-making. <i>Implementation Science</i> , 2008, 3, 13.	2.5	3
694	EQUIP: Implementing chronic care principles and applying formative evaluation methods to improve care for schizophrenia: QUERI Series. <i>Implementation Science</i> , 2008, 3, 9.	2.5	43
695	Sequential causal inference: Application to randomized trials of adaptive treatment strategies. <i>Statistics in Medicine</i> , 2008, 27, 1626-1645.	0.8	14
696	Identification of Novel CDK2 Inhibitors by QSAR and Virtual Screening Procedures. <i>QSAR and Combinatorial Science</i> , 2008, 27, 1362-1373.	1.5	8

#	ARTICLE	IF	CITATIONS
697	Somnolence effects of antipsychotic medications and the risk of unintentional injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 354-364.	0.9	9
698	Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 686-696.	0.9	69
699	Neurological complications of psychiatric drugs: clinical features and management. <i>Human Psychopharmacology</i> , 2008, 23, S15-S26.	0.7	175
700	Improving drug safety and tolerability in psychiatric clinical practice. <i>Human Psychopharmacology</i> , 2008, 23, S1-S2.	0.7	1
701	Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. <i>Human Psychopharmacology</i> , 2008, 23, 211-216.	0.7	16
702	Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. <i>Human Psychopharmacology</i> , 2008, 23, 275-281.	0.7	10
703	Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. <i>Human Psychopharmacology</i> , 2008, 23, 455-463.	0.7	43
704	Adjunct extended-release valproate semisodium in late life schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 142-147.	1.3	15
705	Treatment outcomes for female offenders: Relationship to number of Axis I diagnoses. <i>Behavioral Sciences and the Law</i> , 2008, 26, 413-434.	0.6	6
706	The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1298-1300.	1.1	25
707	Efficacy of Omega-3 Fatty Acid Supplementation on Improvement of Bipolar Symptoms: A Systematic Review. <i>Archives of Psychiatric Nursing</i> , 2008, 22, 305-311.	0.7	39
708	The Clinical Antipsychotic Trials of Intervention Effectiveness: What Did We Learn?. <i>Archives of Psychiatric Nursing</i> , 2008, 22, 56-58.	0.7	0
709	Symptomatic Treatment of Huntington Disease. <i>Neurotherapeutics</i> , 2008, 5, 181-197.	2.1	110
710	Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?. <i>Schizophrenia Bulletin</i> , 2008, 34, 1130-1144.	2.3	88
711	Cognitive behaviour therapy in patients with schizophrenia who are not prescribed antipsychotic medication: A case series. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2008, 81, 199-207.	1.3	19
713	Psychoses: current approaches to drug management. <i>The Prescriber</i> , 2008, 19, 29-46.	0.1	1
714	Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 342-347.	2.2	80
715	Compelling or irrelevant? Using number needed to treat can help decide. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 412-419.	2.2	140

#	ARTICLE	IF	CITATIONS
716	Antipsychotic-induced movement disorders – forgotten but not gone. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 401-402.	2.2	16
717	Antipsychotic use in the elderly: What doctors say they do, and what they do. <i>Australasian Journal on Ageing</i> , 2008, 27, 134-142.	0.4	8
718	Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. <i>International Journal of Clinical Practice</i> , 2008, 62, 837-840.	0.8	8
719	Heterogeneity of violence in schizophrenia and implications for long-term treatment. <i>International Journal of Clinical Practice</i> , 2008, 62, 1237-1245.	0.8	140
720	ITAREPS relapse prevention in schizophrenia. <i>International Journal of Clinical Practice</i> , 2008, 62, 1824-1825.	0.8	1
721	The Prescribing Pattern of a New Antipsychotic: A Descriptive Study of Aripiprazole for Psychiatric In-Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 75-81.	1.2	7
722	Caregiver Perceptions and Needs Regarding Symptom Attenuation in Severe and Persistent Mental Illness. <i>Perspectives in Psychiatric Care</i> , 2008, 44, 99-109.	0.9	5
723	Biological Perspectives – Incarcerated Care and Quetiapine Abuse. <i>Perspectives in Psychiatric Care</i> , 2008, 44, 202-206.	0.9	18
724	Genomewide association for schizophrenia in the CATIE study: results of stage 1. <i>Molecular Psychiatry</i> , 2008, 13, 570-584.	4.1	332
725	Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. <i>Molecular Psychiatry</i> , 2008, 13, 918-929.	4.1	95
726	Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. <i>British Journal of Pharmacology</i> , 2008, 153, S465-70.	2.7	136
727	Impact of Obesity on Health-related Quality of Life in Schizophrenia and Bipolar Disorder. <i>Obesity</i> , 2008, 16, 749-754.	1.5	87
728	Schizophrenia therapy: beyond atypical antipsychotics. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 471-472.	21.5	32
729	Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. <i>Molecular Psychiatry</i> , 2008, 13, 27-35.	4.1	635
730	Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. <i>Molecular Psychiatry</i> , 2008, 13, 544-556.	4.1	141
731	Duration of Antipsychotic Drug Therapy in Real-World Practice: A Comparison with CATIE Trial Results. <i>Value in Health</i> , 2008, 11, 487-496.	0.1	15
732	The Cost-Effectiveness of Atypicals in the UK. <i>Value in Health</i> , 2008, 11, 1007-1021.	0.1	20
733	Three cases of schizophrenia for which olanzapine was effective after early acute phase. <i>Psychiatry and Clinical Neurosciences</i> , 2008, 62, 93-97.	1.0	0

#	ARTICLE	IF	CITATIONS
734	A comparative study of antipsychotic medication taking in people with schizophrenia. <i>International Journal of Mental Health Nursing</i> , 2008, 17, 428-438.	2.1	8
735	The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment. <i>Bipolar Disorders</i> , 2008, 10, 900-906.	1.1	22
736	Choice as an intervention to promote well-being: the role of the nurse prescriber. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2008, 15, 75-81.	1.2	9
737	Time to wake up and smell the coffee: antipsychotic medication and schizophrenia. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2008, 15, 344-348.	1.2	11
738	Risk profiles for non-adherence to antipsychotic medications. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2008, 15, 622-629.	1.2	53
739	What are the nursing implications when using paliperidone prolonged release for people with schizophrenia. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2008, 15, 792-799.	1.2	2
740	Paliperidone Extended-Release for the Treatment of Schizophrenia. <i>Pharmacotherapy</i> , 2008, 28, 1283-1298.	1.2	31
741	Molecular profiles of schizophrenia in the CNS at different stages of illness. <i>Brain Research</i> , 2008, 1239, 235-248.	1.1	178
742	Mental health policy in the liberal state: The example of the United States. <i>International Journal of Law and Psychiatry</i> , 2008, 31, 89-100.	0.5	61
744	Mexiletine Therapy for Chronic Pain: Survival Analysis Identifies Factors Predicting Clinical Success. <i>Journal of Pain and Symptom Management</i> , 2008, 35, 321-326.	0.6	30
745	Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2008, 42, 1076-1085.	1.5	41
746	Effectiveness of lamotrigine in bipolar disorder in a clinical setting. <i>Journal of Psychiatric Research</i> , 2008, 43, 13-23.	1.5	21
748	New and old antipsychotics: what "effectiveness"™ trials tell us. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 443-446.	0.2	1
749	Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1077-1107.	2.9	51
750	Paliperidone for schizophrenia. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 403-413.	0.5	60
751	Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. <i>Schizophrenia Research</i> , 2008, 98, 8-15.	1.1	59
752	The course of tardive dystonia in Afro Caribbean patients, a population-based study. <i>Schizophrenia Research</i> , 2008, 98, 79-83.	1.1	13
753	A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: The QUERISOLA trial. <i>Schizophrenia Research</i> , 2008, 98, 55-65.	1.1	16

#	ARTICLE	IF	CITATIONS
754	A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: A five-year follow-up. <i>Schizophrenia Research</i> , 2008, 98, 1-7.	1.1	100
755	Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. <i>Schizophrenia Research</i> , 2008, 98, 47-54.	1.1	93
756	Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. <i>Schizophrenia Research</i> , 2008, 98, 40-46.	1.1	37
757	Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950-2005. <i>Schizophrenia Research</i> , 2008, 98, 287-294.	1.1	174
758	Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. <i>Schizophrenia Research</i> , 2008, 100, 97-107.	1.1	36
759	Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population. <i>Schizophrenia Research</i> , 2008, 99, 13-22.	1.1	102
760	Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. <i>Schizophrenia Research</i> , 2008, 100, 70-85.	1.1	133
761	World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. <i>Schizophrenia Research</i> , 2008, 100, 20-38.	1.1	240
762	The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. <i>Schizophrenia Research</i> , 2008, 100, 39-52.	1.1	53
763	Adjunctive psychosocial therapies for the treatment of schizophrenia. <i>Schizophrenia Research</i> , 2008, 100, 108-119.	1.1	97
764	Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia. <i>Schizophrenia Research</i> , 2008, 101, 304-311.	1.1	20
765	Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. <i>Schizophrenia Research</i> , 2008, 101, 287-294.	1.1	53
766	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. <i>Schizophrenia Research</i> , 2008, 101, 273-286.	1.1	258
767	Association of RGS2 and RGS5 variants with schizophrenia symptom severity. <i>Schizophrenia Research</i> , 2008, 101, 67-75.	1.1	35
768	Schizophrenia, "Just the Facts": What we know in 2008. <i>Schizophrenia Research</i> , 2008, 100, 4-19.	1.1	298
769	Factors affecting antipsychotic drug discontinuation in the treatment of schizophrenia: Evidence from a naturalistic, retrospective, 18-month follow-up study. <i>Schizophrenia Research</i> , 2008, 104, 302-304.	1.1	5
770	Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. <i>Schizophrenia Research</i> , 2008, 103, 83-93.	1.1	71
771	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , 2008, 103, 104-109.	1.1	64

#	ARTICLE	IF	CITATIONS
772	Attitudes of patients and family members towards implantable psychiatric medication. <i>Schizophrenia Research</i> , 2008, 105, 279-286.	1.1	9
773	Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , 2008, 105, 175-187.	1.1	195
774	Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment. <i>Schizophrenia Research</i> , 2008, 106, 315-319.	1.1	17
775	Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. <i>Schizophrenia Research</i> , 2008, 106, 300-307.	1.1	22
776	Upcoming Agents for the Treatment of Schizophrenia. <i>Drugs</i> , 2008, 68, 2269-2292.	4.9	75
777	Practical Issues with Amisulpride in the Management of Patients with Schizophrenia. <i>Clinical Drug Investigation</i> , 2008, 28, 465-477.	1.1	28
779	Metabolomics: A Global Biochemical Approach to Drug Response and Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 653-683.	4.2	599
780	Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. <i>Pharmacogenomics</i> , 2008, 9, 1055-1068.	0.6	25
781	Contribution of Cystine-Glutamate Antiporters to the Psychotomimetic Effects of Phencyclidine. <i>Neuropsychopharmacology</i> , 2008, 33, 1760-1772.	2.8	100
786	AMISULPRIDE IMPROVES OBSESSIVE-COMPULSIVE SYMPTOMS IN SCHIZOPHRENIA PATIENTS TAKING ATYPICAL ANTIPSYCHOTICS: AN OPEN-LABEL SWITCH STUDY. <i>Schizophrenia Research</i> , 2008, 102, 266.	1.1	0
787	Actitud respecto a la medicaci3n antipsic3tica como factor predictivo de la suspensi3n del tratamiento antipsic3tico en el per4odo inicial de la psicosis de inicio temprano. <i>Revista De Psiquiatr4a Y Salud Mental</i> , 2008, 1, 10-17.	1.0	8
788	Consenso Espa4ol de Salud F4sica del Paciente con Trastorno Bipolar. <i>Revista De Psiquiatr4a Y Salud Mental</i> , 2008, 1, 26-37.	1.0	33
789	Attitude Toward Antipsychotic Medication as a Predictor of Antipsychotic Treatment Discontinuation in First-Episode Early-Onset Psychosis. <i>Revista De Psiquiatr4a Y Salud Mental (English Edition)</i> , 2008, 1, 10-17.	0.2	5
790	Spanish Consensus on Physical Health of Patients With Bipolar Disorder. <i>Revista De Psiquiatr4a Y Salud Mental (English Edition)</i> , 2008, 1, 26-37.	0.2	5
791	Selection of Antipsychotic Agents in a Psychiatric Hospital Based on Results of CATIE Study. <i>Farmacia Hospitalaria (English Edition)</i> , 2008, 32, 83-90.	0.0	1
792	Antipsic3ticos at4picos: un factor de riesgo de s4ndrome metab4lico. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2008, 55, 61-63.	0.8	0
793	Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia. <i>Biological Psychiatry</i> , 2008, 63, 32-41.	0.7	57
794	Clozapine and 4High-Dose4 Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison. <i>Biological Psychiatry</i> , 2008, 63, 524-529.	0.7	194

#	ARTICLE	IF	CITATIONS
795	Early intervention in psychosis: concepts, evidence and future directions. <i>World Psychiatry</i> , 2008, 7, 148-156.	4.8	402
796	Clozapine use in children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 459-465.	0.9	49
798	Symptomatic Therapeutic Aspects in Alzheimer's Disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008, 89, 269-271.	1.0	0
799	Pimavanserin tartrate: a 5-HT _{2A} inverse agonist with potential for treating various neuropsychiatric disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 3251-3259.	0.9	74
800	Olanzapine: review of safety 2008. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 761-769.	1.0	56
802	Antipsychotic-induced extrapyramidal symptoms and their management. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1451-1462.	0.9	79
803	Antipsychotic Medicationâ€œInduced Weight Gain and Risk for Diabetes and Cardiovascular Disease. , 2007, , 223-245.		1
804	The Role of Phosphodiesterases in Schizophrenia. <i>CNS Drugs</i> , 2008, 22, 983-993.	2.7	91
805	Acceptance and Commitment Therapy Applied to Treatment of Auditory Hallucinations. <i>Clinical Case Studies</i> , 2008, 7, 118-135.	0.5	33
806	Substance abuse and schizophrenia: Pharmacotherapeutic intervention. <i>Journal of Substance Abuse Treatment</i> , 2008, 34, 61-71.	1.5	114
808	Antipsychotic drug use among elderly nursing home residents in the United States. <i>American Journal of Geriatric Pharmacotherapy</i> , 2008, 6, 187-197.	3.0	93
809	Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. <i>American Journal of Geriatric Pharmacotherapy</i> , 2008, 6, 198-204.	3.0	30
810	Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. <i>Neuropharmacology</i> , 2008, 54, 405-416.	2.0	62
811	Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. <i>Neuropharmacology</i> , 2008, 55, 743-754.	2.0	83
812	Preferential relocation of the N-methyl-d-aspartate receptor NR1 subunit in nucleus accumbens neurons that contain dopamine D1 receptors in rats showing an apomorphine-induced sensorimotor gating deficit. <i>Neuroscience</i> , 2008, 154, 965-977.	1.1	17
813	Partial compliance in schizophrenia and the impact on patient outcomes. <i>Psychiatry Research</i> , 2008, 161, 235-247.	1.7	147
814	Correlates of response to Olanzapine in a North Indian Schizophrenia sample. <i>Psychiatry Research</i> , 2008, 161, 275-283.	1.7	28
815	Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: A case report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 308-310.	2.5	3

#	ARTICLE	IF	CITATIONS
816	Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 428-436.	2.5	57
817	Antipsychotic prescriptions in a university hospital outpatient population in Turkey: A retrospective database analysis, 2005-2006. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 968-974.	2.5	6
818	Pharmacotherapy of schizophrenia with comorbid substance use disorder - Reviewing the evidence and clinical recommendations. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1375-1385.	2.5	53
819	Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1527-1532.	2.5	25
820	Comparative remission rates of schizophrenic patients using various remission criteria. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1643-1651.	2.5	37
821	Effect of antipsychotic drugs on brain morphometry. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1936-1943.	2.5	46
822	Antipsychotic drug action: antagonism, inverse agonism or partial agonism. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 314-321.	4.0	92
823	Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. <i>Clinical Therapeutics</i> , 2008, 30, 231-248.	1.1	31
824	Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications. <i>Clinical Therapeutics</i> , 2008, 30, 1524-1539.	1.1	30
825	Insulin sensitivity, adjusted β -cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective study. <i>Diabetes and Metabolism</i> , 2008, 34, 490-496.	1.4	52
827	P.1.g.006 Cognitive disorders in 6-hydroxydopamine-induced rat model of Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2008, 18, S276.	0.3	0
829	C.03.02 Early predictors - a review of current knowledge. <i>European Neuropsychopharmacology</i> , 2008, 18, S590-S591.	0.3	0
832	C.04.02 Innovation translates into antidepressant effectiveness. <i>European Neuropsychopharmacology</i> , 2008, 18, S591-S592.	0.3	0
833	C.23.02 Remission: the expectations of both doctors and patients. <i>European Neuropsychopharmacology</i> , 2008, 18, S613-S614.	0.3	0
835	C.24.01 Clinical strategies when switching antipsychotics. <i>European Neuropsychopharmacology</i> , 2008, 18, S614.	0.3	0
836	Pharmacogenetic Testing in Psychiatry: A Review of Features and Clinical Realities. <i>Clinics in Laboratory Medicine</i> , 2008, 28, 599-617.	0.7	69
837	Evidence of Exacerbated Cognitive Deficits in Schizophrenia Patients With Comorbid Diabetes. <i>Psychosomatics</i> , 2008, 49, 123-131.	2.5	51
838	Evidence that lithium protects against tardive dyskinesia: The Curaçao Extrapyramidal Syndromes study VI. <i>European Neuropsychopharmacology</i> , 2008, 18, 152-155.	0.3	19

#	ARTICLE	IF	CITATIONS
839	Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. <i>European Neuropsychopharmacology</i> , 2008, 18, 170-180.	0.3	22
840	Psychosocial and economic issues related to physical health in psychiatric illness. <i>European Neuropsychopharmacology</i> , 2008, 18, S115-S120.	0.3	1
841	Limitations of current therapies: Why do patients switch therapies?. <i>European Neuropsychopharmacology</i> , 2008, 18, S135-S139.	0.3	10
842	Do we need another atypical antipsychotic?. <i>European Neuropsychopharmacology</i> , 2008, 18, S146-S152.	0.3	7
843	Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology. <i>European Neuropsychopharmacology</i> , 2008, 18, 773-786.	0.3	114
844	The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. <i>European Psychiatry</i> , 2008, 23, 1-7.	0.1	28
845	Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: Results from the STAR study. <i>European Psychiatry</i> , 2008, 23, 336-343.	0.1	15
846	Remission in the outpatient care of schizophrenia: 3-Year results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study in France. <i>European Psychiatry</i> , 2008, 23, 491-496.	0.1	21
847	Time and humanity on psychiatric wards. <i>Lancet, The</i> , 2008, 371, 285-286.	6.3	4
848	Pharmacotherapy of first-episode schizophrenia. <i>Lancet, The</i> , 2008, 371, 1048-1049.	6.3	7
849	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. <i>Lancet, The</i> , 2008, 371, 1085-1097.	6.3	964
850	Risk of discontinuation of risperidone after exposure to potentially interacting drugs: A nested case-control study in patients with schizophrenia. <i>Clinical Therapeutics</i> , 2008, 30, 1251-1263.	1.1	4
851	Antipsychotics and Diabetes: An Age-Related Association. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1316-1322.	0.9	73
852	In vitro and in vivo demonstration of risperidone implants in mice. <i>Schizophrenia Research</i> , 2008, 98, 66-78.	1.1	59
853	Quid des schizophr�nies r�sistantes ?. <i>L'Encephale</i> , 2008, 34, S223-S225.	0.3	3
854	Traitements neuroleptiques et troubles m�taboliques. <i>Medecine Des Maladies Metaboliques</i> , 2008, 2, 593-599.	0.1	4
855	Medications Prescribed by Specialists in Nursing Homes. <i>Journal of the American Medical Directors Association</i> , 2008, 9, 137-138.	1.2	8
856	Sleep in Schizophrenia. <i>Sleep Medicine Clinics</i> , 2008, 3, 251-260.	1.2	32

#	ARTICLE	IF	CITATIONS
858	Managing Persons with Dementia in the Nursing Home: High Touch Trumps High Tech. Journal of the American Medical Directors Association, 2008, 9, 139-146.	1.2	52
859	Pharmacogenetic Testing in Schizophrenia and Posttraumatic Stress Disorder. Clinics in Laboratory Medicine, 2008, 28, 627-643.	0.7	2
860	Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. International Journal of Psychiatry in Clinical Practice, 2008, 12, 215-227.	1.2	0
861	A Pharmacoeconomic analysis of compliance gains on antipsychotic medications. Applied Health Economics and Health Policy, 2008, 6, 189-197.	1.0	16
862	Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study. Pharmacoeconomics, 2008, 26, 341-358.	1.7	25
863	Modelling Approaches. Pharmacoeconomics, 2008, 26, 633-648.	1.7	38
864	Quetiapine. CNS Drugs, 2008, 22, 49-68.	2.7	39
865	Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain. CNS Drugs, 2008, 22, 477-495.	2.7	97
866	Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders. CNS Drugs, 2008, 22, 547-562.	2.7	229
867	There are important differences between atypical antipsychotics in the relative risk of adverse effects. Drugs and Therapy Perspectives, 2008, 24, 19-22.	0.3	0
868	Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia. Applied Health Economics and Health Policy, 2008, 6, 41-53.	1.0	62
869	Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection. Pharmacological Reviews, 2008, 60, 358-403.	7.1	213
870	Olanzapine in the treatment of depression with psychotic features: A prospective open-label study. International Journal of Psychiatry in Clinical Practice, 2008, 12, 202-209.	1.2	2
871	Oral paliperidone for schizophrenia. The Cochrane Library, 2008, , CD006369.	1.5	22
872	Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 187 T Targets, 2008, 12, 1097-1108.	1.5	11
873	Clozapine Versus "High-Dose" Olanzapine in Refractory Early-Onset Schizophrenia: An Open-Label Extension Study. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 307-316.	0.7	48
874	Analisi costo-efficacia dello switch da un trattamento antipsicotico a risperidone iniettabile a rilascio prolungato in pazienti con schizofrenia. Giornale Italiano Di Health Technology Assessment, 2008, 1, 39-48.	0.1	0
875	One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Current Medical Research and Opinion, 2008, 24, 3341-3355.	0.9	25

#	ARTICLE	IF	CITATIONS
876	Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 629-638.	1.5	180
877	CNS Disordersâ€™ Current Treatment Options and the Prospects for Advanced Therapies. <i>Drug Development and Industrial Pharmacy</i> , 2008, 34, 1141-1167.	0.9	36
879	Relationship between adherence, symptoms, treatment attitudes, satisfaction, and side effects in prisoners taking antipsychotic medication. <i>Journal of Forensic Psychiatry and Psychology</i> , 2008, 19, 335-351.	0.6	21
880	Disrupted small-world networks in schizophrenia. <i>Brain</i> , 2008, 131, 945-961.	3.7	944
881	Rehabilitation: New term for or further development of social psychiatry? A Dutch perspective. <i>International Review of Psychiatry</i> , 2008, 20, 540-545.	1.4	1
882	Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2008, 193, 37-43.	1.7	171
883	Brain-Derived Neurotrophic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of Schizophrenia. <i>NeuroSignals</i> , 2008, 16, 183-193.	0.5	113
884	Sex, Race, and Smoking Impact Olanzapine Exposure. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 157-165.	1.0	146
885	Feasibility of Reducing the Duration of Placebo-Controlled Trials in Schizophrenia Research. <i>Schizophrenia Bulletin</i> , 2008, 34, 292-301.	2.3	26
886	Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence. <i>Journal of Psychiatric Practice</i> , 2008, 14, 345-367.	0.3	49
887	Antipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and Management. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 369-381.	1.3	64
888	Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 817-829.	1.1	139
889	Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes. <i>Psychotherapy and Psychosomatics</i> , 2008, 77, 69-77.	4.0	150
890	Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. <i>Journal of Psychopharmacology</i> , 2008, 22, 576-580.	2.0	23
892	To See or Not To See â€™Schizophreniaâ€™ and The Possibility of Full â€™Recoveryâ€™. <i>Journal of Humanistic Psychology</i> , 2008, 48, 489-504.	1.4	11
893	Emerging drugs for schizophrenia. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 479-495.	1.0	45
894	Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. <i>Journal of Psychopharmacology</i> , 2008, 22, 56-62.	2.0	40
895	A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications. <i>Schizophrenia Bulletin</i> , 2008, 34, 1145-1150.	2.3	15

#	ARTICLE	IF	CITATIONS
896	Interventions to Address Violence Associated with Mental Illness. <i>Australasian Psychiatry</i> , 2008, 16, 405-411.	0.4	3
897	Time to Discontinuation of Depot and Oral First-Generation Antipsychotics in the Usual Care of Schizophrenia. <i>Psychiatric Services</i> , 2008, 59, 315-317.	1.1	60
898	Critical Thinking about Adverse Drug Effects: Lessons from the Psychology of Risk and Medical Decision-Making for Clinical Psychopharmacology. <i>Psychotherapy and Psychosomatics</i> , 2008, 77, 201-208.	4.0	13
899	Ingenuity Pathway Analysis of Clozapine-Induced Obesity. <i>Obesity Facts</i> , 2008, 1, 93-102.	1.6	7
900	Possible dose–side effect relationship of antipsychotic drugs: relevance to cognitive function in schizophrenia. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 791-802.	1.3	13
901	Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. <i>American Journal of Psychiatry</i> , 2008, 165, 1420-1431.	4.0	414
902	Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 491-499.	0.7	47
903	Mood and Anxiety Symptoms in Psychiatric Inpatients with Autism Spectrum Disorder and Depression. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 2008, 1, 238-253.	1.3	24
904	A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. <i>Journal of Psychopharmacology</i> , 2008, 22, 238-243.	2.0	116
905	Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. <i>Current Medical Research and Opinion</i> , 2008, 24, 3275-3285.	0.9	24
906	Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. <i>Pharmacogenomics</i> , 2008, 9, 1285-1306.	0.6	45
907	A review of the association between antipsychotic use and hyperprolactinaemia. <i>Journal of Psychopharmacology</i> , 2008, 22, 46-55. S33138	2.0	122
908	A Preferential Dopamine D ₃ versus D ₂ Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 587-599.	1.3	61
909	Messing Up with Traffic: Different Effects of Antipsychotic Agents on Glutamate Receptor Complexes in Vivo. <i>Molecular Pharmacology</i> , 2008, 73, 1339-1342.	1.0	16
910	Special Section on Implications of CATIE: Lessons to Take Home From CATIE. <i>Psychiatric Services</i> , 2008, 59, 523-525.	1.1	37
911	Clozapine, Olanzapine, or Typical Antipsychotics for Alcohol Use Disorder in Patients With Schizophrenia. <i>Journal of Dual Diagnosis</i> , 2008, 4, 344-354.	0.7	6
912	Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1079-1091.	1.4	38
913	Issues that May Determine the Outcome of Antipsychotic Trials: Industry Sponsorship and Extrapyramidal Side Effect. <i>Neuropsychopharmacology</i> , 2008, 33, 971-975.	2.8	25

#	ARTICLE	IF	CITATIONS
914	Dopamine Depletion of the Prefrontal Cortex Induces Dendritic Spine Loss: Reversal by Atypical Antipsychotic Drug Treatment. <i>Neuropsychopharmacology</i> , 2008, 33, 1276-1286.	2.8	77
915	Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2008, 33, 1633-1641.	2.8	91
916	The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. <i>Neuropsychopharmacology</i> , 2008, 33, 2061-2079.	2.8	183
917	Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. <i>Journal of Psychopharmacology</i> , 2008, 22, 323-329.	2.0	34
918	Pharmacotherapy for schizophrenic inpatients in East Asia – Changes and challenges. <i>International Review of Psychiatry</i> , 2008, 20, 460-468.	1.4	43
919	Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats. <i>Neuropsychopharmacology</i> , 2008, 33, 2922-2933.	2.8	40
920	Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone. <i>Neuropsychopharmacology</i> , 2008, 33, 985-994.	2.8	68
921	Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. <i>Pharmacogenomics Journal</i> , 2008, 8, 228-236.	0.9	35
922	Issues in co-morbid severe mental illnesses in HIV infected individuals. <i>International Review of Psychiatry</i> , 2008, 20, 95-101.	1.4	22
923	Supplement Issue. <i>Annals of Clinical Psychiatry</i> , 2008, 20 Suppl 1, 1-32.	0.6	1
924	Accessing Health Care Professionals About Antipsychotic Medication Related Concerns. <i>Issues in Mental Health Nursing</i> , 2008, 29, 739-754.	0.6	4
925	The persistence of stigma and discrimination.. <i>Psychiatric Rehabilitation Journal</i> , 2008, 31, 183-184.	0.8	1
926	Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications. <i>Journal of Psychopharmacology</i> , 2008, 22, 815-817.	2.0	17
927	Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study. <i>Neuropsychopharmacology</i> , 2008, 33, 2467-2473.	2.8	107
928	Effect of Prior Authorization of Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements. <i>Psychiatric Services</i> , 2008, 59, 540-546.	1.1	59
929	Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: Randomised controlled trial. <i>British Journal of Psychiatry</i> , 2008, 192, 412-423.	1.7	251
930	So careless of the single trial. <i>Evidence-Based Mental Health</i> , 2008, 11, 65-66.	2.2	5
931	Neuropsychiatric Evaluation in Dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 53-61.	1.0	0

#	ARTICLE	IF	CITATIONS
932	A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial). <i>PLoS Medicine</i> , 2008, 5, e76.	3.9	183
933	Patterns of Quetiapine Use in Psychiatric Inpatients: An Examination of Off-Label Use. <i>Annals of Clinical Psychiatry</i> , 2008, 20, 15-20.	0.6	59
934	Review: Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness. <i>Evidence-Based Mental Health</i> , 2008, 11, 114-114.	2.2	0
935	Increased cortical inhibition in persons with schizophrenia treated with clozapine. <i>Journal of Psychopharmacology</i> , 2008, 22, 203-209.	2.0	79
936	ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia. <i>Neuropsychopharmacology</i> , 2008, 33, 957-970.	2.8	334
937	Epilepsy and Dementia in the Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 293-300.	0.7	74
938	Promoting recovery of schizophrenic patients: discrepancy between routine practice and evidence. The SIEP-DIRECT's Project. <i>Epidemiology and Psychiatric Sciences</i> , 2008, 17, 331-348.	1.8	29
939	Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 185-93.	3.8	316
940	The treatment of acute psychotic episode: discrepancy between routine practice and evidence. The project SIEP-DIRECT's. <i>Epidemiology and Psychiatric Sciences</i> , 2008, 17, 319-330.	1.8	6
941	Clinical questions and uncertainty " prolactin measurement in patients with schizophrenia and bipolar disorder. <i>Journal of Psychopharmacology</i> , 2008, 22, 82-89.	2.0	32
942	Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S20-S28.	0.7	94
943	Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. <i>Journal of Psychopharmacology</i> , 2008, 22, 778-783.	2.0	13
944	A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1046-1056.	1.1	109
945	Safety Profile of Iloperidone. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S12-S19.	0.7	87
946	High Initial Dosing of Olanzapine for Stabilization of Acute Agitation: A Retrospective Case Series. <i>Journal of Pharmacy Technology</i> , 2008, 24, 7-11.	0.5	0
947	Haloperidol versus chlorpromazine for treatment of schizophrenia. <i>Schizophrenia Bulletin</i> , 2008, 34, 813-815.	2.3	9
948	Antipsychotic-Like Properties of Phosphodiesterase 4 Inhibitors: Evaluation of 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with Auditory Event-Related Potentials and Prepulse Inhibition of Startle. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 230-239.	1.3	55
949	Antipsychotic Medication Utilization Trends Among Texas Veterans: 1997-2002. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1229-1238.	0.9	26

#	ARTICLE	IF	CITATIONS
950	Tolerability of antipsychotic drugs: does patients perspective deserve consideration?. <i>Epidemiologia E Psichiatria Sociale</i> , 2008, 17, 182-185.	1.0	3
951	A Mathematical Model of Presynaptic Dopamine Homeostasis: Implications for Schizophrenia. <i>Pharmacopsychiatry</i> , 2008, 41, S89-S98.	1.7	35
953	What Explains the Diffusion of Treatments for Mental Illness?. <i>American Journal of Psychiatry</i> , 2008, 165, 1385-1392.	4.0	32
954	lloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 61-75.	1.9	19
955	Overview of the findings from the European SOHO study. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 873-880.	1.4	18
956	Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2008, 165, 978-987.	4.0	182
957	Mental Health in the Mainstream of Public Policy: Research Issues and Opportunities. <i>American Journal of Psychiatry</i> , 2008, 165, 1099-1101.	4.0	6
958	Bringing a research base to psychiatry. <i>Cmaj</i> , 2008, 178, 1257-1258.	0.9	1
959	D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2008, 33, 298-304.	2.8	65
960	Effectiveness of selective serotonin reuptake inhibitors. <i>Cmaj</i> , 2008, 178, 1185-1186.	0.9	0
961	Normal Pressure Hydrocephalus Presenting as Othello Syndrome: Case Presentation and Review of the Literature. <i>American Journal of Psychiatry</i> , 2008, 165, 1119-1125.	4.0	29
962	Drug discovery based on genetic and metabolic findings in schizophrenia. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 773-789.	1.3	8
963	Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer's Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial. <i>American Journal of Psychiatry</i> , 2008, 165, 844-854.	4.0	274
964	Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. <i>Current Medical Research and Opinion</i> , 2008, 24, 2271-2282.	0.9	13
965	Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. <i>Genetics in Medicine</i> , 2008, 10, 720-729.	1.1	48
966	Special Section on Implications of CATIE: Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making. <i>Psychiatric Services</i> , 2008, 59, 515-520.	1.1	32
967	Schizophrenia, Obesity, and Antipsychotic Medications: What Can We Do?. <i>Postgraduate Medicine</i> , 2008, 120, 18-33.	0.9	56
968	Aripiprazole: 6-month outcomes in a retrospective naturalistic study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2008, 12, 243-246.	1.2	1

#	ARTICLE	IF	CITATIONS
969	Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. <i>Current Medical Research and Opinion</i> , 2008, 24, 709-716.	0.9	22
970	Antipsychotic Treatment in Child and Adolescent First-Episode Psychosis: A Longitudinal Naturalistic Approach. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 327-336.	0.7	58
971	Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. <i>Current Medical Research and Opinion</i> , 2008, 24, 1399-1405.	0.9	11
972	Etablir une base de recherche en psychiatrie. <i>Cmaj</i> , 2008, 178, 1259-1260.	0.9	0
973	Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 42-48.	0.5	6
974	A Comparative Pilot Study of Second-Generation Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 317-326.	0.7	41
975	Staging intervention and meeting needs in early psychosis. <i>World Psychiatry</i> , 2008, 7, 160-162.	4.8	1
976	Side effects of atypical antipsychotics: a brief overview. <i>World Psychiatry</i> , 2008, 7, 58-62.	4.8	166
977	A Review of Second-Generation Antipsychotic Discontinuation in First-Episode Psychosis. <i>Journal of Psychiatric Practice</i> , 2008, 14, 289-300.	0.3	38
978	Extrapyramidal side-effects of antipsychotics in a randomised trial. <i>British Journal of Psychiatry</i> , 2008, 193, 279-288.	1.7	228
979	Editor's Introduction: Why Are the Mentally Ill Dying?. <i>International Journal of Mental Health</i> , 2008, 37, 3-12.	0.5	2
980	The EPISODE II trial of cognitive and family therapy for relapse prevention in early psychosis: Rationale and sample characteristics. <i>Journal of Mental Health</i> , 2008, 17, 19-32.	1.0	21
981	COMPARISONS BETWEEN PSYCHOTROPIC DRUGS: MUST THE RISK OF SIDE EFFECTS DICTATE OUR PRACTICES?. <i>Acta Clinica Belgica</i> , 2008, 63, 235-241.	0.5	3
982	Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial. <i>Psychiatric Services</i> , 2008, 59, 500-506.	1.1	110
983	The Quest for Optimal Health: Can Education and Training Cure What Ails Us?. <i>International Journal of Mental Health</i> , 2008, 37, 69-88.	0.5	12
984	Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 172-179.	0.4	3
985	Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 172-179.	0.4	0
986	Dosing Atypical Antipsychotics. <i>CNS Spectrums</i> , 2008, 13, 3-14.	0.7	15

#	ARTICLE	IF	CITATIONS
987	Ziprasidone: clinical properties and therapeutic promise. <i>Future Neurology</i> , 2008, 3, 19-27.	0.9	0
988	New-Onset Schizophrenia: Pharmacologic Treatment. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 167-171.	0.4	0
989	Neurocognition as a Treatment Target in Schizophrenia. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 180-183.	0.4	2
990	Update on the Etiology and Treatment of Schizophrenia and Bipolar Disorder. <i>CNS Spectrums</i> , 2008, 13, 1-12.	0.7	25
991	When Is Antipsychotic Polypharmacy Supported by Research Evidence? Implications for QI. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2008, 34, 571-582.	0.4	41
992	The Urgent Need for Monitoring and Intervention to Reduce Metabolic Risk Factors in Patients with Schizophrenia. <i>CNS Spectrums</i> , 2008, 13, 5-6.	0.7	1
993	Antipsychotic drugs. <i>Side Effects of Drugs Annual</i> , 2008, 30, 56-77.	0.6	0
994	Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: Findings from a Veterans Affairs-based population. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2008, 48, 393-400.	0.7	20
995	How Long Can We Treat a Patient With the Same Antipsychotic Drug? Results from an Outpatient Psychiatric Practice in Prague. <i>Activitas Nervosa Superior</i> , 2008, 50, 118-120.	0.4	0
998	Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 599-609.	0.7	38
999	Possible Varenicline-Induced Paranoia and Irritability in a Patient With Major Depressive Disorder, Borderline Personality Disorder, and Methamphetamine Abuse in Remission. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 720-721.	0.7	22
1000	Insomnia, Night Terror, and Depression Related to Clonidine in Attention-Deficit/Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 725-726.	0.7	11
1001	CATIE and CUTLASS: can we handle the truth?. <i>British Journal of Psychiatry</i> , 2008, 192, 161-163.	1.7	130
1002	Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 985-97.	1.0	55
1003	Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 392-400.	0.7	89
1004	Restless Legs Syndrome Caused by Quetiapine Successfully Treated With Ropinirole in 2 Patients With Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 704-705.	0.7	21
1005	Special Section on Implications of CATIE: What CATIE Did: Some Thoughts on Implications Deep and Wide. <i>Psychiatric Services</i> , 2008, 59, 530-533.	1.1	12
1006	Antipsychotic Use in the Treatment of Outpatients With Schizophrenia in the VA From Fiscal Years 1999 to 2006. <i>Psychiatric Services</i> , 2008, 59, 567-569.	1.1	32

#	ARTICLE	IF	CITATIONS
1007	Reply to Dr Baldessarini's Comments on "Efficacy of Imipramine in Psychotic Versus Nonpsychotic Depression". Journal of Clinical Psychopharmacology, 2008, 28, 717-718.	0.7	0
1008	Utilization and Costs of Antipsychotic Agents: A Canadian Population-Based Study, 1996â€“2006. Psychiatric Services, 2008, 59, 547-553.	1.1	41
1009	Long-Term Improvement in Efficacy and Safety After Switching to Ziprasidone in Stable Outpatients with Schizophrenia. CNS Spectrums, 2008, 13, 898-905.	0.7	20
1010	Cognitive-behavioural therapy for severe mental disorders: Back to the future?. British Journal of Psychiatry, 2008, 192, 401-403.	1.7	41
1011	Integrating theory, practice and economics in psychopharmacology. , 2008, , 158-168.		0
1012	Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. International Clinical Psychopharmacology, 2008, 23, 216-222.	0.9	29
1013	Model-based gene selection shows engrailed 1 is associated with antipsychotic response. Pharmacogenetics and Genomics, 2008, 18, 751-759.	0.7	14
1014	Efficacy of Iloperidone in the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology, 2008, 28, S4-S11.	0.7	80
1015	Reply to Comments by Dr Peng et al for "Pharmacokinetics Study for Hyperprolactinemia Among Schizophrenics Switched from Risperidone to Risperidone Long-Acting Injection". Journal of Clinical Psychopharmacology, 2008, 28, 727-728.	0.7	2
1017	Special Section on Implications of CATIE: Policy Toward Second-Generation Antipsychotic Drugs: A Cautionary Note. Psychiatric Services, 2008, 59, 521-522.	1.1	6
1018	Datapoints: Did CATIE Influence Antipsychotic Use?. Psychiatric Services, 2008, 59, 476-476.	1.1	5
1019	Special Section on Implications of CATIE: Introduction to the CATIE Special Section. Psychiatric Services, 2008, 59, 497-499.	1.1	5
1020	Special Section on Implications of CATIE: Impact of the CATIE Findings on State Mental Health Policy. Psychiatric Services, 2008, 59, 534-536.	1.1	10
1021	Curidium Medica, plc. Personalized Medicine, 2008, 5, 219-223.	0.8	1
1022	Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry, 2008, 21, 151-156.	3.1	331
1023	Long-Term Efficacy and Safety of Iloperidone. Journal of Clinical Psychopharmacology, 2008, 28, S29-S35.	0.7	239
1024	Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis. Journal of Clinical Psychopharmacology, 2008, 28, 210-213.	0.7	87
1025	High-Dose Ziprasidone Monotherapy in Bipolar I Disorder Patients With Depressed or Mixed Episodes. Journal of Clinical Psychopharmacology, 2008, 28, 240-241.	0.7	8

#	ARTICLE	IF	CITATIONS
1026	Antipsychotic Withdrawal-Induced Relapse Predicts Future Relapses in Institutionalized Adults With Severe Intellectual Disability. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 401-405.	0.7	8
1027	Shared Decision Making in Antipsychotic Management. <i>Journal of Psychiatric Practice</i> , 2008, 14, 333-344.	0.3	39
1028	The Temporal Relationship Between Symptom Change and Treatment Discontinuation in a Pooled Analysis of 4 Schizophrenia Trials. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 544-549.	0.7	20
1029	Tactile and Visual Hallucinations in a Child With Methylphenidate and Fluoxetine Combination. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 723-725.	0.7	24
1030	New generation antipsychotic drugs and compliance behaviour. <i>Current Opinion in Psychiatry</i> , 2008, 21, 133-139.	3.1	56
1031	Leukopenia During Therapy With Risperidone Long-Acting Injectable. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 713-714.	0.7	9
1032	Dosing Frequency and Adherence to Antipsychotic Medications. <i>Psychiatric Services</i> , 2008, 59, 1207-1210.	1.1	32
1033	Special Section on Implications of CATIE: Who Are the New Users of Antipsychotic Medications?. <i>Psychiatric Services</i> , 2008, 59, 507-514.	1.1	109
1034	Safety Evaluation of the Concomitant Use of Clozapine and Benzodiazepines: A Retrospective, Cross-Sectional Chart Review. <i>Journal of Psychiatric Practice</i> , 2008, 14, 265-270.	0.3	12
1035	Time to Discontinuation and Self-Discontinuation of Olanzapine and Risperidone in Patients With Schizophrenia in a Naturalistic Outpatient Setting. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 74-77.	0.7	20
1036	Long-Acting Risperidone-Induced Periorbital Edema. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 709-710.	0.7	12
1037	The Effectiveness of Guideline Implementation Strategies on Improving Antipsychotic Medication Management for Schizophrenia. <i>Medical Care</i> , 2008, 46, 686-691.	1.1	24
1038	Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. <i>International Clinical Psychopharmacology</i> , 2008, 23, 343-356.	0.9	75
1039	Atypical Antipsychotics and Metabolic Outcomes in Chinese Patients. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 707-709.	0.7	7
1040	Variability of the In Vivo Metabolism of Clozapine. <i>Clinical Neuropharmacology</i> , 2008, 31, 347-352.	0.2	14
1041	Psychotropic prescription practices in east Asia: looking back and peering ahead. <i>Current Opinion in Psychiatry</i> , 2008, 21, 645-650.	3.1	25
1042	Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. <i>International Clinical Psychopharmacology</i> , 2008, 23, 209-215.	0.9	45
1043	Special Section on Implications of CATIE: Implications of CATIE for Mental Health Services Researchers. <i>Psychiatric Services</i> , 2008, 59, 526-529.	1.1	12

#	ARTICLE	IF	CITATIONS
1044	Brief Reports: Psychiatric Opinion and Antipsychotic Selection in the Management of Schizophrenia. <i>Psychiatric Services</i> , 2008, 59, 561-565.	1.1	11
1045	Utility of biomarkers to improve the diagnosis and treatment of schizophrenia. <i>Future Neurology</i> , 2008, 3, 619-622.	0.9	0
1046	Are Second Generation Antipsychotics a Distinct Class?. <i>Journal of Psychiatric Practice</i> , 2008, 14, 225-231.	0.3	7
1047	Quetiapine Versus Trazodone in Reducing Rehospitalization for Alcohol Dependence: A Large Data-Base Study. <i>Journal of Addiction Medicine</i> , 2008, 2, 128-134.	1.4	8
1048	Comparison Between Lithium and Valproate in the Treatment of Acute Mania. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 718-720.	0.7	8
1049	A Comparison of the Effects of Olanzapine and Risperidone Versus Placebo on Ghrelin Plasma Levels. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 21-26.	0.7	12
1050	Introduction. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S1-S3.	0.7	3
1051	Second-Generation Antipsychotics in Primary and Secondary Delusional Parasitosis. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 500-508.	0.7	97
1052	Ziprasidone-Associated Mania in Korean Schizophrenic Patient. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 711-712.	0.7	3
1053	Recent Trends in Selective Serotonin Reuptake Inhibitor Use in Pregnancy. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 714-716.	0.7	28
1054	Oropharyngeal and Facial Dyskinesia After Discontinuation of Quetiapine. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 705-706.	0.7	1
1055	Five Female Cases of Prolonged Depression in Chronic Anorexia Nervosa Treated With Selective Estrogen Receptor Modulator Raloxifene-Augmented Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 721-722.	0.7	6
1056	Comments on Article by Dr Birkenhager et al. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 716.	0.7	0
1057	Antidepressant-Induced Sweating Alleviated by Aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 710-711.	0.7	13
1058	Alleviation of Both Binge Eating and Sexual Dysfunction With Naltrexone. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 722-723.	0.7	10
1059	The Disparity of Pharmacokinetics and Prolactin Study for Risperidone Long-Acting Injection. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 726-727.	0.7	10
1060	Leukopenia and Neutropenia After Intoxication With Diphenhydramine (Nytol) During Clozapine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 706-707.	0.7	5
1062	A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2008, 23, 138-149.	0.9	11

#	ARTICLE	IF	CITATIONS
1063	Pharmacological treatments for schizophrenia. , 0, , 459-468.		2
1064	Biological treatments for psychotic disorders. , 2008, , 586-621.		0
1065	Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Preference and Adherence, 2008, 2, 67.	0.8	54
1067	How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia. Advances in Psychiatric Treatment, 2008, 14, 17-28.	0.6	19
1068	Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder. Neuropsychiatric Disease and Treatment, 2008, 4, 311.	1.0	29
1071	Ziprasidone in the treatment of mania in bipolar disorder. Neuropsychiatric Disease and Treatment, 2007, Volume 3, 823-834.	1.0	1
1072	Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatric Disease and Treatment, 2008, 4, 919.	1.0	56
1073	Clinical Experiences and Clinical Trials. CNS Spectrums, 2008, 13, 461-463.	0.7	0
1074	Factors associated with relapse in schizophrenia. South African Journal of Psychiatry, 2008, 14, 7.	0.2	29
1075	First-episode psychosis: An update. South African Journal of Psychiatry, 2008, 14, 6.	0.2	1
1076	Medication-Induced Movement Disorders. , 2008, , 1773-1793.		4
1077	PSYCHIATRIC MEDICATIONS AND METABOLIC SYNDROME. , 2008, , 73-91.		1
1078	Issues in the Design and Conductance of Clinical Trials. , 2008, , 75-95.		4
1079	Schizophrenia and related disorders. , 2008, , 284-319.		4
1080	Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Preference and Adherence, 2008, 2, 233.	0.8	18
1081	Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians. Neuropsychiatric Disease and Treatment, 2008, Volume 3, 965-973.	1.0	12
1082	Is There A Role For "Older" Agents in Child Psychopharmacology?. Child and Adolescent Psychopharmacology News, 2009, 14, 1-6.	0.1	0
1083	Religion/Spirituality and Psychosis. , 2009, , 65-80.		8

#	ARTICLE	IF	CITATIONS
1084	Treatment Adherence. , 0, , 114-132.		6
1087	Electroconvulsive therapy or antipsychotic drugs (or benzodiazepines for catatonia). , 0, , 362-383.		1
1088	Screening for and monitoring of cardio-metabolic risk factors in outpatients with severe mental illness in a primary care setting. African Journal of Psychiatry, 2009, 12, 287-92.	0.1	4
1089	Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics. Revista Brasileira De Psiquiatria, 2009, 31, 52-56.	0.9	8
1090	Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Preference and Adherence, 2009, 3, 345.	0.8	17
1091	Alteraciones metabólicas asociadas al uso de terapia antipsicótica. Revista Medica De Chile, 2009, 137, .	0.1	4
1092	Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period. Arquivos De Neuro-Psiquiatria, 2009, 67, 195-202.	0.3	10
1093	Suicide Risk in Schizophrenia - a follow-up study after 20 years. Part 2: Symptomatology and pharmacotherapy. South African Journal of Psychiatry, 2009, 15, 7.	0.2	0
1094	Disruptive insights in psychiatry: transforming a clinical discipline. Journal of Clinical Investigation, 2009, 119, 700-705.	3.9	131
1095	Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia. Clinical Interventions in Aging, 2009, 4, 351.	1.3	13
1097	Characterising novel pathways to schizophrenia. Medical Journal of Australia, 2009, 190, S5-6.	0.8	3
1098	Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics. Journal of the American Pharmacists Association: JAPhA, 2009, 49, 223-231.	0.7	3
1099	Does abnormal sleep impair memory consolidation in schizophrenia?. Frontiers in Human Neuroscience, 2009, 3, 21.	1.0	77
1100	Clinical significance of neurological abnormalities in psychosis. Advances in Psychiatric Treatment, 2009, 15, 419-427.	0.6	7
1101	Olanzapine depot for schizophrenia. The Cochrane Library, 0, , .	1.5	1
1102	Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia. Neuropsychiatric Disease and Treatment, 2009, 5, 491.	1.0	10
1103	Diagnosing and Treating Schizophrenia. AMA Journal of Ethics, 2009, 11, 43-48.	0.4	0
1104	Pharmacotherapy Update: Risperidone in the Treatment of Schizophrenia. Clinical Medicine Therapeutics, 2009, 1, CMT.S1123.	0.1	1

#	ARTICLE	IF	CITATIONS
1105	Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2009, 35, 443-457.	2.3	360
1106	A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. <i>American Journal of Psychiatry</i> , 2009, 166, 152-163.	4.0	453
1107	LETTER TO THE EDITOR. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 252-253.	1.3	0
1108	The quest for a meaningful evidence base in psychiatry. <i>World Psychiatry</i> , 2009, 8, 33-34.	4.8	4
1109	Effectiveness as an outcome measure for treatment trials in psychiatry. <i>World Psychiatry</i> , 2009, 8, 23-27.	4.8	17
1110	The assessment of dangerous and severe personality disorder: lessons from a randomised controlled trial linked to qualitative analysis. <i>Journal of Forensic Psychiatry and Psychology</i> , 2009, 20, 132-146.	0.6	46
1111	Clinical trial design: horses for courses. <i>World Psychiatry</i> , 2009, 8, 28-29.	4.8	4
1112	Evidence-based guidelines for treating bipolar disorder: revised second edition“ recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2009, 23, 346-388.	2.0	451
1113	Improving Quality And Diffusing Best Practices: The Case Of Schizophrenia. <i>Health Affairs</i> , 2009, 28, 701-712.	2.5	45
1114	Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. <i>Current Medical Research and Opinion</i> , 2009, 25, 2197-2206.	0.9	54
1115	Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: A 12-week open-label, multicentre clinical trial. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 710-718.	1.3	14
1116	Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first-episode psychosis: A review of the literature. <i>Psychosis</i> , 2009, 1, 4-18.	0.4	46
1117	Why and how people decide to stop taking prescribed psychiatric medication: Exploring the subjective process of choice.. <i>Psychiatric Rehabilitation Journal</i> , 2009, 33, 38-46.	0.8	77
1118	Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients. <i>Mental Illness</i> , 2009, 1, 4-9.	0.8	37
1119	Second-generation antipsychotics: a therapeutic downturn?. <i>Psychological Medicine</i> , 2009, 39, 1603.	2.7	3
1120	Medication Adherence: A Review of the Literature and Implications for Clinical Practice. <i>Journal of Psychiatric Practice</i> , 2009, 15, 34-44.	0.3	228
1121	First-generation antipsychotic long-acting injections <i>v</i>. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. <i>British Journal of Psychiatry</i> , 2009, 195, s20-s28.	1.7	89
1122	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). <i>American Journal of Psychiatry</i> , 2009, 166, 675-682.	4.0	284

#	ARTICLE	IF	CITATIONS
1123	Metabolic and Cardiac Side Effects of Second-generation Antipsychotics: What Every Clinician Should Know. <i>Journal of Pharmacy Practice</i> , 2009, 22, 478-488.	0.5	10
1124	Implications of Marked Weight Gain Associated With Atypical Antipsychotic Medications in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1811.	3.8	40
1125	Cardiovascular Effects of Noncardiovascular Drugs. <i>Circulation</i> , 2009, 120, 1123-1132.	1.6	27
1126	Comparative effectiveness research: Relevance and applications to pharmacy. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 1278-1286.	0.5	34
1127	Tense Prescriptions? Alzheimer Medications and the Anthropology of Uncertainty. <i>Transcultural Psychiatry</i> , 2009, 46, 180-206.	0.9	25
1128	Passive and Active Schizophrenia: Toward a New Descriptive Micropsychopathology. <i>Schizophrenia Bulletin</i> , 2009, 35, 1183-1196.	2.3	8
1129	Management of delirium. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2009, 70, 217-221.	0.2	3
1130	Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1917-1928.	0.9	69
1131	Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia. <i>American Journal of Psychiatry</i> , 2009, 166, 691-701.	4.0	66
1132	The role of antipsychotic agents in the development of diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2009, 5, 22-23.	2.9	1
1133	Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders. <i>Neuropsychopharmacology</i> , 2009, 34, 204-212.	2.8	16
1134	Clozapine Interaction with Phosphatidyl Inositol 3-Kinase (PI3K)/Insulin-Signaling Pathway in <i>Caenorhabditis elegans</i> . <i>Neuropsychopharmacology</i> , 2009, 34, 1968-1978.	2.8	33
1135	Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer's Disease Patients: The CATIE-AD Study. <i>American Journal of Psychiatry</i> , 2009, 166, 583-590.	4.0	76
1136	Clinical Trials Design Lessons From the CATIE Study. <i>American Journal of Psychiatry</i> , 2009, 166, 1222-1228.	4.0	45
1137	Antipsychotic Agents and Sudden Cardiac Death – How Should We Manage the Risk?. <i>New England Journal of Medicine</i> , 2009, 360, 294-296.	13.9	57
1138	Translation of Randomised Controlled Trial Findings into Clinical Practice: Comparison of Olanzapine and Valproate in the EMBLEM Study. <i>Pharmacopsychiatry</i> , 2009, 42, 145-152.	1.7	9
1140	Psychosocial Functioning in Patients with Schizophrenia Treated with Aripiprazole – an Office-based Real-world Setting. Results from the German Post-marketing Surveillance Study. <i>Pharmacopsychiatry</i> , 2009, 42, 101-108.	1.7	3
1141	Psychopharmacology for Neurologists. <i>Seminars in Neurology</i> , 2009, 29, 200-219.	0.5	1

#	ARTICLE	IF	CITATIONS
1142	Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial. <i>Pharmacopsychiatry</i> , 2009, 42, 14-19.	1.7	36
1143	Effects of Six Second Generation Antipsychotics on Body Weight and Metabolism – Risk Assessment and Results from a Prospective Study. <i>Pharmacopsychiatry</i> , 2009, 42, 29-34.	1.7	50
1144	Relationship between Neuroleptic Extrapyramidal Syndromes and Patients' All-Cause Mortality. <i>Pharmacopsychiatry</i> , 2009, 42, 57-60.	1.7	3
1146	Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review. <i>British Journal of Psychiatry</i> , 2009, 195, s13-s19.	1.7	98
1147	Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents. <i>American Journal of Psychiatry</i> , 2009, 166, 345-353.	4.0	166
1148	Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission. <i>Recent Patents on CNS Drug Discovery</i> , 2009, 4, 220-238.	0.9	12
1149	Drug Prescription Patterns in Schizophrenia Outpatients: Analysis of Data from a German Health Insurance Fund. <i>Pharmacopsychiatry</i> , 2009, 42, 66-71.	1.7	46
1150	Antipsychotic Drugs and Hyperglycemia in Older Patients With Diabetes. <i>Archives of Internal Medicine</i> , 2009, 169, 1282.	4.3	61
1151	Current perspectives in the treatment of resistant schizophrenia. <i>Indian Journal of Psychiatry</i> , 2009, 51, 254.	0.4	28
1152	Creation of a Metabolic Monitoring Program for Second-Generation (Atypical) Antipsychotics. <i>Journal of Correctional Health Care</i> , 2009, 15, 292-301.	0.2	7
1153	Risperidone long acting injection: Findings of a 2-year retrospective follow-up study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2009, 13, 298-302.	1.2	4
1154	Cognitive behaviour therapy for first episode psychosis: Good for nothing or fit for purpose?. <i>Psychosis</i> , 2009, 1, 103-112.	0.4	25
1155	Improving Mental Health Treatments Through Comparative Effectiveness Research. <i>Health Affairs</i> , 2009, 28, 783-791.	2.5	22
1156	Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. <i>Journal of Psychopharmacology</i> , 2009, 23, 915-922.	2.0	23
1157	A Psychiatric-Cardiac Case: Analysis for Education and Clinical Practice. <i>Issues in Mental Health Nursing</i> , 2009, 30, 392-398.	0.6	1
1158	Safety and Efficacy of Quetiapine in Bipolar Depression. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1848-1856.	0.9	22
1159	Translating Scientific Opportunity Into Public Health Impact. <i>Archives of General Psychiatry</i> , 2009, 66, 128.	13.8	411
1160	Trussed in Evidence? Ambiguities at the Interface between Clinical Evidence and Clinical Practice. <i>Transcultural Psychiatry</i> , 2009, 46, 16-37.	0.9	19

#	ARTICLE	IF	CITATIONS
1161	The choice of antipsychotics in schizophrenia. <i>Nature Reviews Neurology</i> , 2009, 5, 308-310.	4.9	2
1162	Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?. <i>Evidence-Based Mental Health</i> , 2009, 12, 101-104.	2.2	5
1163	Long-term treatment with flupentixol results of a post-marketing surveillance study. <i>Journal of Psychopharmacology</i> , 2009, 23, 805-813.	2.0	6
1164	Developing A Policy For Second-Generation Antipsychotic Drugs. <i>Health Affairs</i> , 2009, 28, w782-w793.	2.5	19
1165	Neuropsychiatric Disease and <i>Toxoplasma gondii</i>; Infection. <i>NeuroImmunoModulation</i> , 2009, 16, 122-133.	0.9	162
1166	Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment. <i>Schizophrenia Bulletin</i> , 2009, 35, 931-936.	2.3	36
1167	Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough?. <i>Health Affairs</i> , 2009, 28, w794-w808.	2.5	16
1168	STAR [®] -D: Has it Taught us Anything about the Management of Depression?. <i>Australasian Psychiatry</i> , 2009, 17, 360-364.	0.4	5
1169	Successful Identification of Glycine Transporter Inhibitors Using an Adaptation of a Functional Cell-Based Assay. <i>Journal of Biomolecular Screening</i> , 2009, 14, 1185-1194.	2.6	4
1170	Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features. <i>Schizophrenia Bulletin</i> , 2009, 35, 775-788.	2.3	58
1171	Using prepulse inhibition to detect functional D3 receptor antagonism: Effects of WC10 and WC44. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 93, 141-147.	1.3	16
1172	Antipsychotic drug actions on gene modulation and signaling mechanisms. , 2009, 124, 74-85.		75
1173	Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. <i>Journal of Psychiatric Research</i> , 2009, 43, 265-273.	1.5	36
1174	In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. <i>Journal of Psychiatric Research</i> , 2009, 43, 997-1002.	1.5	23
1175	Last [®] Observation [®] Carried [®] Forward Imputation Method in Clinical Efficacy Trials: Review of 352 Antidepressant Studies. <i>Pharmacotherapy</i> , 2009, 29, 1408-1416.	1.2	41
1176	Management of Atypical Antipsychotic Drug [®] Induced Weight Gain: Focus on Metformin. <i>Pharmacotherapy</i> , 2009, 29, 725-735.	1.2	31
1177	Comparative Effectiveness Research: An Approach to Avoiding [®] Overgeneralized Medicine [®] . <i>Clinical and Translational Science</i> , 2009, 2, 444-445.	1.5	1
1178	Results of a thematic analysis to explore the experiences of patients with schizophrenia taking antipsychotic medication. <i>Clinical Therapeutics</i> , 2009, 31, 1488-1496.	1.1	16

#	ARTICLE	IF	CITATIONS
1179	Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials. <i>Clinical Therapeutics</i> , 2009, 31, 1345-1359.	1.1	37
1180	The role of patient inexperience in medication discontinuation: A retrospective analysis of medication nonpersistence in seven chronic illnesses. <i>Clinical Therapeutics</i> , 2009, 31, 2628-2652.	1.1	53
1181	The association between class of antipsychotic and rates of hospitalization: Results of a retrospective analysis of data from the 2005 medicare current beneficiary survey. <i>Clinical Therapeutics</i> , 2009, 31, 2931-2939.	1.1	14
1182	Medicinal chemistry strategies in follow-on drug discovery. <i>Drug Discovery Today</i> , 2009, 14, 516-522.	3.2	40
1183	Commentary: Genome-based CNS drug discovery: d-Amino acid oxidase (DAAO) as a novel target for antipsychotic medications: Progress and challenges. <i>Biochemical Pharmacology</i> , 2009, 78, 1360-1365.	2.0	25
1184	Wards features associated with high rates of medication refusal by patients: a large multi-centred survey. <i>General Hospital Psychiatry</i> , 2009, 31, 80-89.	1.2	38
1185	The impact of obesity on health care costs among persons with schizophrenia. <i>General Hospital Psychiatry</i> , 2009, 31, 1-7.	1.2	34
1186	A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 336-340.	1.1	28
1187	Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. <i>Human Psychopharmacology</i> , 2009, 24, 574-583.	0.7	30
1188	Cognitive behavioral therapy of negative symptoms. <i>Journal of Clinical Psychology</i> , 2009, 65, 815-830.	1.0	33
1189	Atypical antipsychotic use and risk of fracture in persons with Parkinsonism. <i>Movement Disorders</i> , 2009, 24, 1941-1948.	2.2	24
1190	Olanzapine compared to quetiapine in adolescents with a first psychotic episode. <i>European Child and Adolescent Psychiatry</i> , 2009, 18, 418-428.	2.8	66
1191	Validity of the Movement Psychodiagnostic Inventory: A Pilot Study. <i>American Journal of Dance Therapy</i> , 2009, 31, 122-135.	0.7	9
1193	UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 239-247.	1.8	17
1195	Is evidence sufficient for evidence-based medicine?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 167-172.	1.8	9
1196	Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster. <i>Culture, Medicine and Psychiatry</i> , 2009, 33, 185-215.	0.7	54
1197	Oil and Water or Oil and Vinegar? Evidence-Based Medicine Meets Recovery. <i>Community Mental Health Journal</i> , 2009, 45, 323-332.	1.1	76
1198	Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia. <i>Psychiatric Quarterly</i> , 2009, 80, 241-249.	1.1	16

#	ARTICLE	IF	CITATIONS
1199	Clozapine-Induced ERK1 and ERK2 Signaling in Prefrontal Cortex Is Mediated by the EGF Receptor. <i>Journal of Molecular Neuroscience</i> , 2009, 39, 185-198.	1.1	24
1200	Metabolic risks in older adults receiving second-generation antipsychotic medication. <i>Current Psychiatry Reports</i> , 2009, 11, 33-40.	2.1	22
1201	Antipsychotic treatment of first-episode or early-onset schizophrenia. <i>Current Psychiatry Reports</i> , 2009, 11, 261-263.	2.1	5
1202	Using oral ziprasidone effectively: the food effect and dose-response. <i>Advances in Therapy</i> , 2009, 26, 739-748.	1.3	43
1203	Mifepristone treatment of olanzapine-induced weight gain in healthy men. <i>Advances in Therapy</i> , 2009, 26, 959-969.	1.3	44
1204	Potential of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 380, 383-397.	1.4	15
1205	Recent advances in treating cognitive impairment in schizophrenia. <i>Psychopharmacology</i> , 2009, 202, 259-273.	1.5	40
1206	Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. <i>Psychopharmacology</i> , 2009, 203, 723-735.	1.5	35
1207	WAY-163909, a 5-HT _{2C} agonist, enhances the preclinical potency of current antipsychotics. <i>Psychopharmacology</i> , 2009, 204, 37-48.	1.5	23
1208	Asenapine effects in animal models of psychosis and cognitive function. <i>Psychopharmacology</i> , 2009, 206, 699-714.	1.5	41
1209	A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naïve, newly diagnosed schizophrenia. <i>Psychopharmacology</i> , 2009, 206, 437-446.	1.5	52
1210	Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. <i>Psychopharmacology</i> , 2009, 206, 491-499.	1.5	61
1211	Age-dependent discrepancies between computerized and paper cognitive testing in patients with schizophrenia. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2009, 44, 73-77.	1.6	2
1212	Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2009, 44, 143-150.	1.6	11
1213	Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1229-1235.	0.8	6
1214	Dopaminergic synapses in the caudate of subjects with schizophrenia: Relationship to treatment response. <i>Synapse</i> , 2009, 63, 520-530.	0.6	55
1215	Atypical and typical antipsychotics in the schools. <i>Psychology in the Schools</i> , 2009, 46, 869-884.	1.1	2
1216	Sample size for two-stage studies with maintenance therapy. <i>Statistics in Medicine</i> , 2009, 28, 2028-2041.	0.8	21

#	ARTICLE	IF	CITATIONS
1217	The incidence of diabetes in atypical antipsychotic users differs according to agentâ€”results from a multisite epidemiologic study. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 791-799.	0.9	98
1218	Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. <i>BMC Psychiatry</i> , 2009, 9, 12.	1.1	19
1219	Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. <i>BMC Psychiatry</i> , 2009, 9, 13.	1.1	7
1220	Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. <i>BMC Psychiatry</i> , 2009, 9, 24.	1.1	119
1221	Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. <i>BMC Psychiatry</i> , 2009, 9, 46.	1.1	23
1222	Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. <i>BMC Psychiatry</i> , 2009, 9, 54.	1.1	37
1223	Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example. <i>Cost Effectiveness and Resource Allocation</i> , 2009, 7, 11.	0.6	17
1224	Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. <i>Cost Effectiveness and Resource Allocation</i> , 2009, 7, 4.	0.6	37
1225	Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. <i>Trials</i> , 2009, 10, 31.	0.7	21
1226	Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. <i>Journal of Advanced Nursing</i> , 2009, 65, 534-543.	1.5	36
1227	Misplaced epistemological certainty and pharmacoâ€”centrism in mental health nursing. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2009, 16, 199-205.	1.2	15
1228	Partial agonists and schizophrenia: theoretical developments for the development of mental health nursing. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2009, 16, 409-415.	1.2	3
1229	Highâ€”dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 110-117.	1.1	44
1230	Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?. <i>Molecular Psychiatry</i> , 2009, 14, 308-317.	4.1	96
1231	How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. <i>Molecular Psychiatry</i> , 2009, 14, 429-447.	4.1	428
1232	Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. <i>European Journal of Human Genetics</i> , 2009, 17, 946-957.	1.4	89
1233	Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. <i>Molecular Psychiatry</i> , 2009, 14, 804-819.	4.1	139
1234	The 'atypicality' of antipsychotics: a concept re-examined and re-defined. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 197-202.	21.5	125

#	ARTICLE	IF	CITATIONS
1235	Targeting the CNS to treat type 2 diabetes. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 386-398.	21.5	87
1236	Asenapine. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 843-844.	21.5	20
1237	Human freedom and the brain. <i>Acta Neuropsychiatrica</i> , 2009, 21, 1-6.	1.0	0
1238	Preface: Treatment optimization in schizophrenia through active patient management – proceedings from two European consensus meetings. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 5-6.	2.2	13
1239	Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 7-14.	2.2	173
1240	Schizophrenia and physical health problems. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 15-21.	2.2	196
1241	Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 22-28.	2.2	54
1242	Connecting patient needs with treatment management. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 33-39.	2.2	9
1243	The metabolic syndrome and schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 4-14.	2.2	216
1244	The subjective experience of taking antipsychotic medication: a content analysis of Internet data. <i>Acta Psychiatrica Scandinavica</i> , 2009, 120, 102-111.	2.2	111
1245	Achieving symptomatic remission in outpatients with schizophrenia – a naturalistic study with quetiapine. <i>Acta Psychiatrica Scandinavica</i> , 2009, 120, 120-128.	2.2	12
1246	Olanzapine pamoate: a stick in time?. <i>International Journal of Clinical Practice</i> , 2009, 63, 140-150.	0.8	63
1247	Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. <i>International Journal of Clinical Practice</i> , 2009, 63, 1743-1761.	0.8	52
1248	Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. <i>Obesity Reviews</i> , 2009, 10, 527-542.	3.1	52
1249	Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 440-448.	1.0	10
1250	Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. <i>Bipolar Disorders</i> , 2009, 11, 77-83.	1.1	56
1251	The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. <i>Bipolar Disorders</i> , 2009, 11, 559-595.	1.1	159
1252	Obesity, serious mental illness and antipsychotic drugs. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 665-679.	2.2	130

#	ARTICLE	IF	CITATIONS
1253	Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. <i>Microbial Biotechnology</i> , 2009, 3, 58-65.	0.9	21
1254	Impact of Patient Selection Criteria and Treatment History on Comparisons of Alternative Therapies: A Case Study of Atypical Antipsychotics. <i>Value in Health</i> , 2009, 12, 473-480.	0.1	4
1255	Health-Related Quality of Life (HRQL) and Continuous Antipsychotic Treatment: 3-year Results from the Schizophrenia Health Outcomes (SOHO) Study. <i>Value in Health</i> , 2009, 12, 536-543.	0.1	51
1256	Resource Utilization and Costs of Schizophrenia Patients Treated with Olanzapine versus Quetiapine in a Medicaid Population. <i>Value in Health</i> , 2009, 12, 708-715.	0.1	10
1257	Relapse and Long-Acting Injectable Risperidone: A 1-Year Mirror Image Study with a National Claims Database in Taiwan. <i>Value in Health</i> , 2009, 12, S118-S121.	0.1	17
1258	Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia?. <i>Neurotherapeutics</i> , 2009, 6, 86-93.	2.1	22
1260	Antipsychotics in the treatment of schizophrenia. <i>Progress in Neurology and Psychiatry</i> , 2009, 13, 22-29.	0.4	1
1261	Adherence to risperidone long-acting injection dosing recommendations. <i>Progress in Neurology and Psychiatry</i> , 2009, 13, 32-39.	0.4	0
1262	Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. <i>Psychological Medicine</i> , 2009, 39, 1591.	2.7	155
1263	Quetiapine: a new option in bipolar depression. <i>Future Prescriber</i> , 2009, 10, 9-14.	0.1	2
1264	A Comparative Proteomics Analysis of Rat Mitochondria from the Cerebral Cortex and Hippocampus in Response to Antipsychotic Medications. <i>Journal of Proteome Research</i> , 2009, 8, 3633-3641.	1.8	69
1265	What We Know: Findings That Every Theory of Schizophrenia Should Explain. <i>Schizophrenia Bulletin</i> , 2009, 35, 493-508.	2.3	117
1266	Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases. <i>Neuropsychopharmacology</i> , 2009, 34, 173-186.	2.8	255
1267	Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. <i>Pharmacogenomics Journal</i> , 2009, 9, 168-174.	0.9	29
1268	Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 837-856.	2.5	26
1269	Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 9-31.	1.4	35
1270	Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. <i>Comprehensive Psychiatry</i> , 2009, 50, 437-442.	1.5	54
1273	Improving psychological adjustment following a first episode of psychosis: A randomised controlled trial of cognitive therapy to reduce post psychotic trauma symptoms. <i>Behaviour Research and Therapy</i> , 2009, 47, 454-462.	1.6	69

#	ARTICLE	IF	CITATIONS
1274	Animal models of geneâ€environment interactions in schizophrenia. <i>Behavioural Brain Research</i> , 2009, 204, 274-281.	1.2	88
1275	Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412). <i>Neuropharmacology</i> , 2009, 56, 342-349.	2.0	12
1276	N-methyl-d-aspartic acid receptor antagonistâ€induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. <i>Neuroscience</i> , 2009, 158, 705-712.	1.1	161
1277	Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean?. <i>Psychiatry Research</i> , 2009, 170, 172-176.	1.7	45
1278	Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. <i>Research in Developmental Disabilities</i> , 2009, 30, 613-669.	1.2	61
1279	Ethics in clinical research. <i>Journal of Hepatology</i> , 2009, 51, 792-797.	1.8	28
1280	Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. <i>Neurochemistry International</i> , 2009, 55, 85-97.	1.9	87
1283	Les antipsychotiques lors dâ€™un premier Ã©pisode psychotique. <i>Annales Medico-Psychologiques</i> , 2009, 167, 86-92.	0.2	0
1285	Perioperative Nursing Care of Patients with Schizophrenia. <i>AORN Journal</i> , 2009, 89, 893-897.	0.2	0
1286	An Exploration of the Effect of Modafinil on Olanzapine Associated Weight Gain in Normal Human Subjects. <i>Biological Psychiatry</i> , 2009, 65, 607-613.	0.7	14
1287	Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. <i>Biological Psychiatry</i> , 2009, 66, 1013-1022.	0.7	91
1288	Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile?. <i>Pharmacological Research</i> , 2009, 59, 1-12.	3.1	93
1289	A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. <i>Schizophrenia Research</i> , 2009, 107, 13-21.	1.1	34
1290	Weight effects associated with antipsychotics: A comprehensive database analysis. <i>Schizophrenia Research</i> , 2009, 110, 103-110.	1.1	174
1291	Does switching to a new antipsychotic improve outcomes?. <i>Schizophrenia Research</i> , 2009, 107, 22-29.	1.1	232
1292	Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function. <i>Schizophrenia Research</i> , 2009, 107, 275-285.	1.1	40
1293	Results of phase 3 of the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009, 107, 1-12.	1.1	129
1294	Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients. <i>Schizophrenia Research</i> , 2009, 108, 122-126.	1.1	29

#	ARTICLE	IF	CITATIONS
1295	Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophrenia Research, 2009, 108, 223-230.	1.1	111
1296	Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophrenia Research, 2009, 108, 134-142.	1.1	74
1297	Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial. Schizophrenia Research, 2009, 108, 245-251.	1.1	56
1298	Remission in schizophrenia: Results from a 1-year follow-up observational study. Schizophrenia Research, 2009, 108, 214-222.	1.1	50
1299	Reduction of functional disability with atypical antipsychotic treatment: A randomized long term comparison of ziprasidone and haloperidol. Schizophrenia Research, 2009, 115, 24-29.	1.1	11
1300	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophrenia Research, 2009, 110, 80-89.	1.1	38
1301	Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophrenia Research, 2009, 111, 39-45.	1.1	15
1302	Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research, 2009, 111, 9-16.	1.1	144
1303	Effects and side effects of antipsychotic treatment in schizophrenia: Pros and cons of available self-rating scales. Schizophrenia Research, 2009, 112, 114-118.	1.1	29
1304	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophrenia Research, 2009, 113, 112-121.	1.1	34
1305	Influence of antipsychotics on mortality in schizophrenia: Systematic review. Schizophrenia Research, 2009, 113, 1-11.	1.1	202
1306	A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study. Schizophrenia Research, 2009, 113, 41-48.	1.1	29
1307	Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Research, 2009, 113, 49-55.	1.1	42
1308	Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research, 2009, 113, 12-18.	1.1	10
1309	Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: Implications for glucose metabolism and food choice behaviour. Schizophrenia Research, 2009, 115, 30-40.	1.1	47
1310	The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research, 2009, 115, 17-23.	1.1	85
1311	Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Schizophrenia Research, 2009, 115, 115-120.	1.1	19
1312	Biochemical risk factors for development of obesity in first-episode schizophrenia. Schizophrenia Research, 2009, 115, 141-145.	1.1	13

#	ARTICLE	IF	CITATIONS
1313	From mice to men: What can animal models tell us about the relationship between mental health and physical activity?. <i>Mental Health and Physical Activity</i> , 2009, 2, 10-15.	0.9	22
1314	Lurasidone: a new drug in development for schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1715-1726.	1.9	115
1316	Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 164-172.	0.7	50
1317	Análisis de simulación de coste-efectividad en el tratamiento de la esquizofrenia en el Instituto Mexicano del Seguro Social. Evaluación de antipsicóticos típicos y atípicos. <i>Revista De Psiquiatría Y Salud Mental</i> , 2009, 2, 108-118.	1.0	2
1318	Uso de antipsicóticos durante el embarazo y la lactancia. <i>Revista De Psiquiatría Y Salud Mental</i> , 2009, 2, 138-145.	1.0	5
1319	Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social. Assessment of typical and atypical antipsychotics. <i>Revista De Psiquiatría Y Salud Mental (English)</i> Tj ETQq1 1 0.78#314 rgBTi/Overload	0.7	31
1320	Use of antipsychotics during pregnancy and breastfeeding. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2009, 2, 138-145.	0.2	2
1321	Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 319-331.	2.4	23
1322	Prefrontal cognitive systems in schizophrenia : Towards human genetic brain mechanisms. <i>Cognitive Neuropsychiatry</i> , 2009, 14, 277-298.	0.7	80
1323	The CATIE and CUtLASS Studies in Schizophrenia. <i>CNS Drugs</i> , 2009, PAP, 649-59.	2.7	92
1324	Utilizing VA Information Technology to Develop Psychiatric Resident Prescription Profiles. <i>Academic Psychiatry</i> , 2009, 33, 27-30.	0.4	5
1325	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 85-116.	1.3	302
1326	Polypharmacy in the Nursing Home. <i>Journal of the American Medical Directors Association</i> , 2009, 10, 289-291.	1.2	52
1327	Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 1137.	1.0	114
1328	Drugs in development for the treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1103-1118.	1.9	27
1329	Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2009, 25, 2121-2132.	0.9	16
1330	Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 336-346.	2.3	228
1331	Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population. <i>Current Medical Research and Opinion</i> , 2009, 25, 755-764.	0.9	17

#	ARTICLE	IF	CITATIONS
1332	Delusional Infestation. <i>Clinical Microbiology Reviews</i> , 2009, 22, 690-732.	5.7	235
1333	Comparative utility of aripiprazole and haloperidol in schizophrenia. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 109-119.	1.0	15
1334	Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia. <i>CNS Drugs</i> , 2009, 23, 193-212.	2.7	34
1335	GABAB Receptors, Schizophrenia and Sleep Dysfunction. <i>CNS Drugs</i> , 2009, 23, 681-691.	2.7	62
1336	Asenapine. <i>CNS Drugs</i> , 2009, 23, 781-792.	2.7	49
1337	Antipsychotic Drugs for First-Episode Schizophrenia. <i>CNS Drugs</i> , 2009, 23, 837-855.	2.7	60
1338	lloperidone: a new option for the treatment of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1727-1741.	1.4	7
1340	ADME pharmacogenetics: current practices and future outlook. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 449-462.	1.5	25
1341	Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1045-1058.	1.4	30
1342	Pharmacotherapy of patients with schizophrenia and substance abuse. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 353-367.	0.9	18
1343	Analisi di costo-efficacia dello switch da un antipsicotico orale a risperidone a rilascio prolungato nel trattamento dei pazienti affetti da schizofrenia. <i>Giornale Italiano Di Health Technology Assessment</i> , 2009, 2, 1-8.	0.1	2
1344	BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. <i>European Neuropsychopharmacology</i> , 2009, 19, 1-13.	0.3	32
1345	Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. <i>European Neuropsychopharmacology</i> , 2009, 19, 317-328.	0.3	45
1346	Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. <i>European Neuropsychopharmacology</i> , 2009, 19, 542-550.	0.3	33
1347	BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans. <i>European Neuropsychopharmacology</i> , 2009, 19, 841-850.	0.3	10
1348	The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. <i>European Psychiatry</i> , 2009, 24, 143-148.	0.1	17
1349	Belgian Schizophrenia Outcome Survey â€œ Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. <i>European Psychiatry</i> , 2009, 24, 154-163.	0.1	8
1350	Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). <i>European Psychiatry</i> , 2009, 24, 287-296.	0.1	133

#	ARTICLE	IF	CITATIONS
1351	Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). <i>European Psychiatry</i> , 2009, 24, 412-424.	0.1	751
1354	<i>CYP2D6</i> genotyping for psychiatric patients treated with risperidone: considerations for effectiveness studies. <i>Pharmacogenomics</i> , 2009, 10, 685-699.	0.6	34
1355	Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. <i>Lancet</i> , The, 2009, 373, 31-41.	6.3	1,663
1356	The spurious advance of antipsychotic drug therapy. <i>Lancet</i> , The, 2009, 373, 4-5.	6.3	96
1357	Assessing bleeds clinically: what's the score?. <i>Lancet</i> , The, 2009, 373, 5-7.	6.3	5
1358	Antidepressants are not all created equal. <i>Lancet</i> , The, 2009, 373, 700-701.	6.3	11
1359	11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11). <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	6.3	1,179
1360	Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. <i>European Neuropsychopharmacology</i> , 2009, 19, 629-635.	0.3	184
1361	Inducible and conditional transgenic mouse models of schizophrenia. <i>Progress in Brain Research</i> , 2009, 179, 35-47.	0.9	18
1362	Neurological Disorders in Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2009, 32, 719-757.	0.7	23
1364	Management of Schizophrenia with Obesity, Metabolic, and Endocrinological Disorders. <i>Psychiatric Clinics of North America</i> , 2009, 32, 775-794.	0.7	44
1365	Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. <i>Schizophrenia Research</i> , 2009, 110, 95-102.	1.1	62
1366	Schizophrenia with Impulsive and Aggressive Behaviors. <i>Psychiatric Clinics of North America</i> , 2009, 32, 885-902.	0.7	6
1368	Contrasting Measures of Adherence with Simple Drug Use, Medication Switching, and Therapeutic Duplication. <i>Annals of Pharmacotherapy</i> , 2009, 43, 36-44.	0.9	191
1369	Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 373-382.	0.7	78
1370	Innovative Therapeutics for Schizophrenia. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2009, 44, 17-23.	0.1	0
1371	Psychopharm Review. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2009, 44, 88.	0.1	0
1372	Systematic Overview of Cochrane Reviews for Anticholinergic Effects of Antipsychotic Drugs. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 141-146.	0.7	52

#	ARTICLE	IF	CITATIONS
1373	Akathisia and second-generation antipsychotic drugs. <i>Current Opinion in Psychiatry</i> , 2009, 22, 293-299.	3.1	73
1374	Innovative Therapeutics for Schizophrenia. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2009, 44, 24.	0.1	0
1375	Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. <i>International Clinical Psychopharmacology</i> , 2009, 24, 204-213.	0.9	29
1376	First- and Second-Generation Antipsychotics and the Concept of "Atypicality". <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2009, 44, 81-88.	0.1	3
1378	An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm. <i>Behavioural Pharmacology</i> , 2009, 20, 184-194.	0.8	22
1379	Improved Body Weight and Metabolic Outcomes in Overweight or Obese Psychiatric Patients Switched to Amisulpride From Other Atypical Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 529-536.	0.7	21
1380	Americans' Attitudes Toward Psychiatric Medications: 1998-2006. <i>Psychiatric Services</i> , 2009, 60, 1015-1023.	1.1	50
1381	Number Needed to Treat or Harm Analyses of Olanzapine for Maintenance Treatment of Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 520-528.	0.7	6
1382	Denial and Acceptance Coping Styles and Medication Adherence in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2009, 197, 580-584.	0.5	24
1384	A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. <i>International Clinical Psychopharmacology</i> , 2009, 24, 181-188.	0.9	19
1385	Clinical Antipsychotic Trials of Intervention Effectiveness Study. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 410-411.	0.7	0
1386	Antipsychotic long-acting injections: Mind the gap. <i>British Journal of Psychiatry</i> , 2009, 195, s1-s4.	1.7	61
1387	Sulpiride versus other antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	5
1388	Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1501-1513.	1.1	45
1389	Minimal-medication approaches to treating schizophrenia. <i>Advances in Psychiatric Treatment</i> , 2009, 15, 209-217.	0.6	17
1390	Ziprasidone in Black Patients with Schizophrenia: Analysis of Four Short-term, Double-blind Studies. <i>CNS Spectrums</i> , 2009, 14, 478-486.	0.7	10
1392	Mortality and tardive dyskinesia: long-term study using the US National Death Index. <i>British Journal of Psychiatry</i> , 2009, 194, 360-364.	1.7	32
1393	Identifying patient-relevant endpoints among individuals with schizophrenia: An application of patient-centered health technology assessment. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 35-41.	0.2	45

#	ARTICLE	IF	CITATIONS
1394	Treatment choice in psychiatry? Would trainees choose similar treatments to those prescribed, and what influences decision-making? A survey of the European Federation of Trainees' (EFPT) Research Group. <i>Acta Neuropsychiatrica</i> , 2009, 21, 64-65.	1.0	0
1395	Decision making under uncertainty and mood induction: further evidence for liberal acceptance in schizophrenia. <i>Psychological Medicine</i> , 2009, 39, 1821-1829.	2.7	57
1396	Current approaches to the management of schizophrenia. <i>Irish Journal of Psychological Medicine</i> , 2009, 26, i-vii.	0.7	2
1397	Public-Academic Partnerships: The Thresholds-Dartmouth Partnership and Research on Shared Decision Making. <i>Psychiatric Services</i> , 2009, 60, 142-144.	1.1	11
1398	Dropout From Outpatient Mental Health Care in the United States. <i>Psychiatric Services</i> , 2009, 60, 898-907.	1.1	225
1399	Ziprasidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2009, , CD006627.	1.5	45
1400	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2009, , CD006569.		57
1401	Sertindole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2009, , CD006752.	1.5	13
1402	Antipsychotic Drug Treatment for Patients with Schizophrenia: Theoretical Background, Clinical Considerations and Patient Preferences. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2175.	0.1	4
1403	Glucose Abnormalities in Schizophrenia, Bipolar and Major Depressive Disorders. <i>Modern Problems of Pharmacopsychiatry</i> , 2009, , 47-65.	2.5	3
1404	Duration of untreated psychosis in LAMI countries. <i>British Journal of Psychiatry</i> , 2009, 194, 188-188.	1.7	3
1405	Behavior Analysis in the Era of Medicalization: The State of the Science and Recommendations for Practitioners. <i>Behavior Analysis in Practice</i> , 2009, 2, 49-57.	1.5	6
1406	An Epidemiologic Study of Psychotropic Medication and Obesity-Related Chronic Illnesses in Older Psychiatric Patients. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 269-274.	0.9	23
1407	Antipsychotics and risk of diabetes in schizophrenia. <i>British Journal of Psychiatry</i> , 2009, 194, 186-187.	1.7	2
1408	Homicide due to mental disorder. <i>British Journal of Psychiatry</i> , 2009, 194, 185-185.	1.7	3
1409	Obesity and Mental Illness. <i>Modern Problems of Pharmacopsychiatry</i> , 2009, , 25-46.	2.5	12
1410	The Sequence of Recovery in Long-Term Dynamic Psychotherapy. <i>Journal of Nervous and Mental Disease</i> , 2009, 197, 930-937.	0.5	26
1411	Medicaid Prescription Drug Policies and Medication Access and Continuity: Findings From Ten States. <i>Psychiatric Services</i> , 2009, 60, 601-610.	1.1	34

#	ARTICLE	IF	CITATIONS
1412	Low doses of antipsychotic drugs for hospitalized schizophrenia patients in East Asia: 2004 vs. 2001. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 117.	1.0	9
1413	Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 1233.	1.0	34
1414	Mortality Rates Among Patients With Schizophrenia and Tardive Dyskinesia. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 5-8.	0.7	45
1415	Association Between HTR2C and HTR2A Polymorphisms and Metabolic Abnormalities in Patients Treated With Olanzapine or Clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 65-68.	0.7	73
1416	A Comparison of Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia: A 44-Week, Double-Blind, Continuation Study. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 46-54.	0.9	22
1417	A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression. <i>Archives of General Psychiatry</i> , 2009, 66, 838.	13.8	188
1418	A New Kind of Homelessness for Individuals With Serious Mental Illness? The Need for a "Mental Health Home". <i>Psychiatric Services</i> , 2009, 60, 528-533.	1.1	56
1419	Biases in Medication Prescribing: The Case of Second-Generation Antipsychotics. <i>Journal of Psychiatric Practice</i> , 2010, 16, 15-21.	0.3	12
1420	Lipid profile screening in second-generation antipsychotic users: the gap between policy and practice. <i>Clinical Lipidology</i> , 2010, 5, 299-303.	0.4	2
1421	Conditioned Avoidance Response in the Development of New Antipsychotics. <i>Current Pharmaceutical Design</i> , 2010, 16, 358-370.	0.9	69
1422	Unraveling Monoamine Receptors Involved in the Action of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission in Prefrontal Cortex. <i>Current Pharmaceutical Design</i> , 2010, 16, 502-515.	0.9	66
1423	Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 117-125.	0.9	45
1424	Treatment Response Trajectories and Their Antecedents in Recent-Onset Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 446-449.	0.7	35
1425	Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients. <i>Psychiatric Services</i> , 2010, 61, 892-898.	1.1	87
1426	Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia. <i>Current Pharmaceutical Design</i> , 2010, 16, 344-357.	0.9	28
1427	Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 433.	1.0	25
1428	Higher Motor Activity in Schizophrenia Patients Treated With Olanzapine Versus Risperidone. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 181-184.	0.7	19
1429	Esquire Trial. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 600-606.	0.7	21

#	ARTICLE	IF	CITATIONS
1430	Metabolic syndrome with the atypical antipsychotics. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 460-466.	1.2	149
1431	Detecting and defusing cognitive traps: metacognitive intervention in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2010, 23, 561-569.	3.1	164
1432	Schizophrenia in a worldwide perspective: explaining similarities and differences. <i>Future Neurology</i> , 2010, 5, 345-348.	0.9	0
1433	Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia. <i>Clinical Neuropharmacology</i> , 2010, 33, 169-175.	0.2	211
1434	The Adjunctive Use of Metformin to Treat or Prevent Atypical Antipsychotic-Induced Weight Gain: A Review. <i>Journal of Psychiatric Practice</i> , 2010, 16, 289-296.	0.3	13
1435	Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats. <i>Behavioural Pharmacology</i> , 2010, 21, 668-675.	0.8	16
1436	Assessment of Clinician Awareness of Nonadherence Using a New Structured Rating Scale. <i>Journal of Psychiatric Practice</i> , 2010, 16, 164-169.	0.3	16
1437	Genetic Studies of Schizophrenia and Bipolar Disorder. <i>Focus (American Psychiatric Publishing)</i> , 2010, 8, 323-338.	0.4	2
1438	A Post Hoc Analysis of Negative Symptoms and Psychosocial Function in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 425-430.	0.7	25
1439	A Randomized, Double-Blind Comparison of Risperidone Versus Low-Dose Risperidone Plus Low-Dose Haloperidol in Treating Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 518-525.	0.7	26
1440	Medicaid Prescription Cost Containment and Schizophrenia. <i>Medical Care</i> , 2010, 48, 440-447.	1.1	19
1441	Cardiovascular aspects of antipsychotics. <i>Current Opinion in Psychiatry</i> , 2010, 23, 574-581.	3.1	72
1442	A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. <i>International Clinical Psychopharmacology</i> , 2010, 25, 1-6.	0.9	46
1443	Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. <i>International Clinical Psychopharmacology</i> , 2010, 25, 155-164.	0.9	28
1444	Repetitive transcranial magnetic stimulation for refractory symptoms in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2010, 23, 85-90.	3.1	23
1445	Containing Cost Despite the Cost. <i>Medical Care</i> , 2010, 48, 1-3.	1.1	13
1446	A Longitudinal Study on the Impact of Antipsychotic Treatment on Serum Leptin in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2010, 33, 288-292.	0.2	37
1447	Off-Label Use of Second-Generation Antipsychotic Agents Among Elderly Nursing Home Residents. <i>Psychiatric Services</i> , 2010, 61, 130-136.	1.1	56

#	ARTICLE	IF	CITATIONS
1448	Simplifying Adherence in Schizophrenia. <i>Psychiatric Services</i> , 2010, 61, 405-408.	1.1	21
1450	An Open-Label Tolerability Study of BL-1020 Antipsychotic. <i>Clinical Neuropharmacology</i> , 2010, 33, 297-302.	0.2	6
1451	Prise en charge des États dangereux des pathologies mentales graves. , 2010, , 97-152.		0
1452	Quetiapine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006625.		122
1453	Treatment with antipsychotics and the risk of diabetes in clinical practice. <i>British Journal of Psychiatry</i> , 2010, 197, 266-271.	1.7	131
1455	Where to Position Clozapine: Re-Examining the Evidence. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 677-684.	0.9	52
1457	Zotepine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006628.		10
1458	Unexplained Variation Across US Nursing Homes in Antipsychotic Prescribing Rates. <i>Archives of Internal Medicine</i> , 2010, 170, 89.	4.3	169
1459	Polypharmacy and high-dose antipsychotic regimes in the community. <i>The Psychiatrist</i> , 2010, 34, 44-46.	0.3	17
1460	Adherence to Treatment and Therapeutic Strategies in Schizophrenic Patients: The ADHERE Study. <i>CNS Spectrums</i> , 2010, 15, 327-338.	0.7	21
1461	Zotepine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006628.	1.5	7
1463	Patterns and prevalence of metabolic syndrome among psychiatric inpatients receiving antipsychotic medications: Implications for the practicing psychologist.. <i>Professional Psychology: Research and Practice</i> , 2010, 41, 244-252.	0.6	4
1464	A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients.. <i>Experimental and Clinical Psychopharmacology</i> , 2010, 18, 445-450.	1.3	5
1466	Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial. <i>Focus (American J Psychiatry)</i> , 2010, 116, 1040-1044.	0.4	0
1468	Maintenance Strategies in Schizophrenia. <i>CNS Spectrums</i> , 2010, 15, 12-14.	0.7	0
1469	Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2010, 49, 583-594.	0.3	2
1470	A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia. <i>Neuropsychopharmacology</i> , 2010, 35, 2072-2082.	2.8	131
1471	Discovery of N-Aryl Piperazines as Selective mGluR ₅ Potentiators with Improved In Vivo Utility. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 433-438.	1.3	35

#	ARTICLE	IF	CITATIONS
1474	Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposureâ€”an impact similar to male gender or smoking in schizophrenic patients. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 465-474.	0.8	58
1475	The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2010, 45, 461-468.	1.6	78
1476	Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 25-39.	1.8	33
1477	Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 3-16.	1.8	27
1479	Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients. <i>Neurotoxicity Research</i> , 2010, 18, 229-243.	1.3	11
1481	Cognitive Behavioral Therapy and Schizophrenia: A Survey of Clinical Practices and Views on Efficacy in the United States and United Kingdom. <i>Community Mental Health Journal</i> , 2010, 46, 2-9.	1.1	22
1482	In Vitroâ€”In Vivo Correlations of Scalable PLGA-Risperidone Implants for the Treatment of Schizophrenia. <i>Pharmaceutical Research</i> , 2010, 27, 1730-1737.	1.7	82
1483	Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages. <i>Journal of Psychiatric Research</i> , 2010, 44, 112-120.	1.5	145
1484	Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. <i>Journal of Psychiatric Research</i> , 2010, 44, 493-498.	1.5	22
1485	Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting. <i>Journal of Psychiatric Research</i> , 2010, 44, 921-929.	1.5	8
1486	Olanzapine affects locomotor activity and meal size in male rats. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 97, 130-137.	1.3	37
1487	Metabolic side effects of antipsychotic drug treatment â€” pharmacological mechanisms. , 2010, 125, 169-179.		327
1488	A comparison of the clinical effectiveness and costs of mental health nurse supplementary prescribing and independent medical prescribing: a post-test control group study. <i>BMC Health Services Research</i> , 2010, 10, 4.	0.9	25
1489	Statistically Significant Increase in Weight Caused by Lowâ€”Dose Quetiapine. <i>Pharmacotherapy</i> , 2010, 30, 1011-1015.	1.2	28
1490	Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder. <i>Pharmacotherapy</i> , 2010, 30, 127-135.	1.2	37
1491	Patterns of discontinuation of atypical antipsychotics in the province of QuÃ©bec: A retrospective prescription claims database analysis. <i>Clinical Therapeutics</i> , 2010, 32, S21-S31.	1.1	21
1492	Aripiprazole in schizophrenia and schizoaffective disorder: A review. <i>Clinical Therapeutics</i> , 2010, 32, S3-S20.	1.1	86
1493	Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: A randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. <i>Clinical Therapeutics</i> , 2010, 32, 472-491.	1.1	37

#	ARTICLE	IF	CITATIONS
1494	Is It the Symptom or the Relation to It? Investigating Potential Mediators of Change in Acceptance and Commitment Therapy for Psychosis. <i>Behavior Therapy</i> , 2010, 41, 543-554.	1.3	78
1495	Medicaid medication access problems and increased psychiatric hospital and emergency care. <i>General Hospital Psychiatry</i> , 2010, 32, 615-622.	1.2	9
1496	Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. <i>Journal of Affective Disorders</i> , 2010, 122, 27-38.	2.0	153
1497	A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2010, 127, 19-30.	2.0	81
1498	Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3½ years duration. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 411-418.	1.3	18
1499	Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. <i>Human Psychopharmacology</i> , 2010, 25, 37-46.	0.7	16
1500	Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. <i>Human Psychopharmacology</i> , 2010, 25, 133-138.	0.7	28
1501	Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients. <i>Human Psychopharmacology</i> , 2010, 25, 230-235.	0.7	9
1502	Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. <i>Human Psychopharmacology</i> , 2010, 25, 243-252.	0.7	29
1503	Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. <i>Human Psychopharmacology</i> , 2010, 25, 253-259.	0.7	30
1504	More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. <i>Human Psychopharmacology</i> , 2010, 25, 431-438.	0.7	21
1505	Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: a post hoc analysis from a 3-year observational study. <i>Human Psychopharmacology</i> , 2010, 25, 439-447.	0.7	29
1506	The Buccal Mucosa as an Alternative Route for the Systemic Delivery of Risperidone. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 4584-4592.	1.6	21
1507	Evidence for association of the <i>GLI2</i> gene with tardive dyskinesia in patients with chronic schizophrenia. <i>Movement Disorders</i> , 2010, 25, 2809-2817.	2.2	43
1508	3-Aryl-5-phenoxyethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3129-3133.	1.0	41
1509	Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. <i>BMC Psychiatry</i> , 2010, 10, 26.	1.1	53
1510	Predictors of switching antipsychotic medications in the treatment of schizophrenia. <i>BMC Psychiatry</i> , 2010, 10, 75.	1.1	38
1511	Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. <i>BMC Psychiatry</i> , 2010, 10, 89.	1.1	19

#	ARTICLE	IF	CITATIONS
1512	The cross-sectional GRAS sample: A comprehensive phenotypical data collection of schizophrenic patients. <i>BMC Psychiatry</i> , 2010, 10, 91.	1.1	53
1513	A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. <i>Annals of General Psychiatry</i> , 2010, 9, 35.	1.2	13
1514	Diabetes and cardiovascular risk in severe mental illness: a missed opportunity and challenge for the future. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2010, 27, 79.	0.2	32
1515	Elucidation of <i>CYP2D6</i> Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population. <i>Annals of Human Genetics</i> , 2010, 74, 340-350.	0.3	53
1516	Antipsychotic-induced gene regulation in multiple brain regions. <i>Journal of Neurochemistry</i> , 2010, 113, 175-187.	2.1	23
1517	The prefrontal cortex: a target for antipsychotic drugs. <i>Acta Psychiatrica Scandinavica</i> , 2010, 121, 11-21.	2.2	55
1518	Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study. <i>International Journal of Clinical Practice</i> , 2010, 64, 697-706.	0.8	7
1519	Adherence According to Mary Poppins: Strategies to Make the Medicine Go Down. <i>Perspectives in Psychiatric Care</i> , 2010, 46, 3-13.	0.9	3
1520	Incorporating Evidence From Pharmacologic and Pharmacogenetic Studies of Atypical Antipsychotic Drugs Into Advanced Psychiatric Nursing Practice. <i>Perspectives in Psychiatric Care</i> , 2010, 46, 98-107.	0.9	4
1521	Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 744-755.	0.9	23
1522	Health professionals' attitudes to depot injection antipsychotic medication: a systematic review. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2010, 17, 452-462.	1.2	20
1523	Does psychopharmacology training enhance the knowledge of mental health nurses who prescribe?. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2010, 17, 804-812.	1.2	16
1524	Walking a fine line: managing the tensions associated with medication non-adherence in an acute inpatient psychiatric setting. <i>Journal of Clinical Nursing</i> , 2010, 19, 1378-1386.	1.4	10
1525	Mifepristone Reduces Weight Gain and Improves Metabolic Abnormalities Associated With Risperidone Treatment in Normal Men. <i>Obesity</i> , 2010, 18, 2295-2300.	1.5	43
1526	Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men. <i>Obesity</i> , 2010, 18, 1646-1651.	1.5	93
1527	Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole. <i>International Journal of Obesity</i> , 2010, 34, 970-979.	1.6	32
1528	Rethinking schizophrenia. <i>Nature</i> , 2010, 468, 187-193.	13.7	1,482
1529	Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. <i>Microbial Biotechnology</i> , 2010, 4, 64-78.	0.9	16

#	ARTICLE	IF	CITATIONS
1530	Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD. <i>Bipolar Disorders</i> , 2010, 12, 56-67.	1.1	31
1532	Targeted Care Plans for Schizophrenia. <i>CNS Spectrums</i> , 2010, 15, 6-9.	0.7	0
1533	Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. , 0, , 80-96.		0
1534	Family outcomes. , 2010, , 133-155.		0
1535	Study design and protocol development process. , 2010, , 1-21.		1
1536	Statistical considerations. , 2010, , 22-38.		0
1537	Neurocognition. , 0, , 97-119.		2
1538	Metabolic side effects and risk of cardiovascular disease. , 0, , 173-188.		0
1539	Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome. , 0, , 189-206.		4
1540	Genetic investigations in the CATIE sample. , 0, , 237-254.		0
1541	Conclusion and implications for practice and policy. , 0, , 288-306.		0
1542	When Symptoms and Treatments Hinder Vocational Recovery. , 0, , 173-186.		0
1543	Patient perspectives on antipsychotic treatments and their association with clinical outcomes. <i>Patient Preference and Adherence</i> , 2010, 4, 369.	0.8	13
1544	Confounding placebo response in clinical trials: Analysing the little we know and current strategies to address the crisis. <i>South African Journal of Psychiatry</i> , 2010, 16, 3.	0.2	0
1545	Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. <i>Patient Preference and Adherence</i> , 2010, 4, 263.	0.8	13
1546	Identifying Phronotypes in Psychiatry. <i>Frontiers in Psychiatry</i> , 2010, 1, 141.	1.3	4
1547	Psychotic Patients. , 2010, , 119-132.		0
1548	Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics. <i>Psychiatry Investigation</i> , 2010, 7, 189.	0.7	4

#	ARTICLE	IF	CITATIONS
1549	Schizophrenia and related disorders. , 2010, , 391-426.		1
1550	Effectiveness and efficacy: staying on treatment and symptom reduction. , 2010, , 39-56.		0
1551	Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence. Patient Preference and Adherence, 2010, 4, 301.	0.8	7
1552	Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatric Disease and Treatment, 2010, 6, 573.	1.0	23
1553	Asenapine versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2010, , .	1.5	2
1554	Dysbindin Regulates the Transcriptional Level of Myristoylated Alanine-Rich Protein Kinase C Substrate via the Interaction with NF-YB in Mice Brain. PLoS ONE, 2010, 5, e8773.	1.1	15
1555	Modulation of Central Nitric Oxide as a Therapeutic Strategy for Schizophrenia. Journal of Microbiology and Biotechnology, 2010, 20, 115-119.	0.9	7
1556	Future of Personalized Prescription in Psychiatry. Advances in Biological Psychiatry, 2010, , 118-134.	0.2	1
1558	New atypical antipsychotics for schizophrenia: iloperidone. Drug Design, Development and Therapy, 2010, 4, 33.	2.0	39
1559	Safety and tolerability of antipsychotics: focus on amisulpride. Drug, Healthcare and Patient Safety, 2010, 2, 205.	1.0	27
1560	Incidence of Tardive Dyskinesia With Atypical Versus Conventional Antipsychotic Medications. Journal of Clinical Psychiatry, 2010, 71, 463-474.	1.1	170
1562	Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf schizophrenia: overview of systematic reviews. Sao Paulo Medical Journal, 2010, 128, 141-166.	0.4	18
1563	Emerging treatments in the management of schizophrenia – focus on sertindole. Drug Design, Development and Therapy, 2010, 4, 187.	2.0	13
1564	Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schizophrenia in Thailand. Patient Preference and Adherence, 2010, 4, 363.	0.8	5
1565	Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. Journal of Clinical Psychiatry, 2010, 71, 1115-1124.	1.1	188
1566	Adjunctive Atypical Antipsychotics in Medication-Resistant Depression. CNS Spectrums, 2010, 15, 10-13.	0.7	0
1567	Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatric Disease and Treatment, 2010, 6, 749.	1.0	14
1568	Population pharmacokinetics of antipsychotics. , 2010, , 267-280.		4

#	ARTICLE	IF	CITATIONS
1569	Risperidone for Individuals with Refractory Schizophrenia. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S3567.	0.4	0
1570	Drug treatment of secondary schizophrenia. , 2010, , 393-405.		0
1571	Vocational outcomes. , 0, , 120-132.		0
1572	A correlation of haloperidol-induced cognitive deficit with dysfunctional dopamine receptor activity in nonhuman primate. <i>Open Access Animal Physiology</i> , 2010, , 1.	0.3	0
1573	Development and Delivery of a Quality Improvement Program to Reduce Antipsychotic Polytherapy. <i>Journal of Managed Care Pharmacy</i> , 2010, 16, 393-401.	2.2	7
1574	First- and Second-Generation Antipsychotics. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 144-149.	0.9	4
1576	Antipsychotics and Metabolics in the Post-CATIE Era. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 4, 23-42.	0.8	32
1577	Extrapyramidal side effects. , 2010, , 156-172.		1
1579	Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. <i>Journal of Psychopharmacology</i> , 2010, 24, 1001-1009.	2.0	26
1580	A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?. <i>Annals of Clinical Biochemistry</i> , 2010, 47, 292-300.	0.8	48
1581	Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation. <i>Schizophrenia Bulletin</i> , 2010, 36, 410-418.	2.3	69
1582	Dyskinesia and Parkinsonism in Antipsychotic-Naive Patients With Schizophrenia, First-Degree Relatives and Healthy Controls: A Meta-analysis. <i>Schizophrenia Bulletin</i> , 2010, 36, 723-731.	2.3	100
1583	Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia. <i>Archives of General Psychiatry</i> , 2010, 67, 895.	13.8	124
1584	Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia. <i>Archives of General Psychiatry</i> , 2010, 67, 231.	13.8	468
1585	Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. <i>Current Medical Research and Opinion</i> , 2010, 26, 2403-2410.	0.9	44
1586	Specialty Care Medical Homes For People With Severe, Persistent Mental Disorders. <i>Health Affairs</i> , 2010, 29, 867-873.	2.5	110
1587	Lost in Translation: Neuropsychiatric Drug Development. <i>Science Translational Medicine</i> , 2010, 2, 61rv6.	5.8	54
1588	Appraising Evidence for Intervention Effectiveness in Early Psychosis: Conceptual Framework and Review of Evaluation Approaches. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 195-219.	1.3	16

#	ARTICLE	IF	CITATIONS
1589	Insular Hypoperfusion Correlates with the Severity of Delusions in Individuals with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 287-293.	0.7	25
1590	Designing Comparative Effectiveness Research On Prescription Drugs: Lessons From The Clinical Trial Literature. <i>Health Affairs</i> , 2010, 29, 1842-1848.	2.5	27
1591	Negative Symptoms in Schizophrenia: Avolition and Occam's Razor. <i>Schizophrenia Bulletin</i> , 2010, 36, 359-369.	2.3	504
1592	The Role of Rodent Models in The Discovery of New Treatments for Schizophrenia: Updating Our Strategy. <i>Schizophrenia Bulletin</i> , 2010, 36, 1066-1072.	2.3	40
1593	Psicofarmacología de la Psicosis: Elección del Fármaco, Adherencia al Tratamiento y Nuevos Horizontes. <i>Clinica Y Salud</i> , 2010, 21, 271-283.	0.3	1
1594	Bases Clínicas para un Nuevo Modelo de Atención a las Psicosis. <i>Clinica Y Salud</i> , 2010, 21, 299-318.	0.3	1
1595	Computational Modeling of Synaptic Neurotransmission as a Tool for Assessing Dopamine Hypotheses of Schizophrenia. <i>Pharmacopsychiatry</i> , 2010, 43, S50-S60.	1.7	23
1596	Amisulpride Versus Olanzapine in the Treatment of Schizophrenia in Indian Patients: Randomized Controlled Trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 237-242.	1.3	14
1597	Polymorphisms of the <i>HTR2C</i> gene and antipsychotic-induced weight gain: an update and meta-analysis. <i>Pharmacogenomics</i> , 2010, 11, 1561-1571.	0.6	99
1598	Modified Therapeutic Community for Co-Occurring Disorders: Single Investigator Meta Analysis. <i>Substance Abuse</i> , 2010, 31, 146-161.	1.1	27
1599	Association Study of Energy Homeostasis Genes and Antipsychotic-Induced Weight Gain in Patients with Schizophrenia. <i>Pharmacopsychiatry</i> , 2010, 44, 15-20.	1.7	23
1600	Shadow science: Zyprexa, Eli Lilly and the globalization of pharmaceutical damage control. <i>BioSocieties</i> , 2010, 5, 236-255.	0.8	9
1601	Weight gain in antipsychotic-naive patients: a review and meta-analysis. <i>Psychological Medicine</i> , 2010, 40, 187-200.	2.7	94
1602	Effects of Rivastigmine Transdermal Patch and Capsule on Aspects of Clinical Global Impression of Change in Alzheimer's Disease: A Retrospective Analysis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 406-412.	0.7	9
1603	lloperidone: A Second-Generation Antipsychotic for the Treatment of Acute Schizophrenia. <i>Journal of Pharmacy Technology</i> , 2010, 26, 193-202.	0.5	3
1604	Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 894-903.	1.3	28
1605	Population Pharmacokinetics of Perphenazine in Schizophrenia Patients From CATIE: Impact of Race and Smoking. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 73-80.	1.0	27
1606	Are psychiatrists an endangered species? Observations on internal and external challenges to the profession. <i>World Psychiatry</i> , 2010, 9, 21-28.	4.8	149

#	ARTICLE	IF	CITATIONS
1607	The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1217-1233.	1.9	32
1608	Cognitive Behavioral Therapy With a Paranoid Schizophrenic Patient. <i>Clinical Case Studies</i> , 2010, 9, 311-327.	0.5	11
1609	Economic Impact of Prior Authorization Policies for Atypical Antipsychotics in the Treatment of Schizophrenia. <i>Population Health Management</i> , 2010, 13, 247-254.	0.8	16
1610	Advances in the Management of Treatment- Resistant Schizophrenia. <i>Focus (American Psychiatric) Tj ETQq1 1 0.784314 rgBTg/Overlo</i>	0.4	0
1611	Weight gain related to treatment with atypical antipsychotics is due to activation of PKC- β . <i>Pharmacogenomics Journal</i> , 2010, 10, 408-417.	0.9	25
1612	Opportunities for Research and NIH. <i>Science</i> , 2010, 327, 36-37.	6.0	91
1613	Effect of medication-related factors on adherence in people with schizophrenia: A European multi-centre study. <i>Epidemiologia E Psichiatria Sociale</i> , 2010, 19, 251-259.	1.0	19
1614	Comparative Effectiveness Research In Mental Health: An Advocate's Perspective. <i>Health Affairs</i> , 2010, 29, 1857-1862.	2.5	1
1615	A Decade of Progress in the Discovery and Development of "Atypical" Antipsychotics. <i>Progress in Medicinal Chemistry</i> , 2010, 49, 37-80.	4.1	20
1616	Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia. <i>Neuropsychopharmacology</i> , 2010, 35, 581-590.	2.8	165
1617	Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance. <i>Diabetes</i> , 2010, 59, 2418-2425.	0.3	79
1618	Antipsychotic Therapy During Early and Late Pregnancy. A Systematic Review. <i>Schizophrenia Bulletin</i> , 2010, 36, 518-544.	2.3	221
1619	Sertindole for the treatment of schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 3053-3064.	0.9	9
1620	Acute antipsychotic-induced akathisia revisited. <i>British Journal of Psychiatry</i> , 2010, 196, 89-91.	1.7	62
1621	Impact of FDA Black Box Advisory on Antipsychotic Medication Use. <i>Archives of Internal Medicine</i> , 2010, 170, 96.	4.3	211
1622	Second generation antipsychotics reduce dropout rates compared with first generation antipsychotics. <i>Evidence-Based Mental Health</i> , 2010, 13, 24-24.	2.2	0
1623	Haplotype-Based Pharmacogenetic Analysis for Longitudinal Quantitative Traits in the Presence of Dropout. <i>Journal of Biopharmaceutical Statistics</i> , 2010, 20, 334-350.	0.4	3
1624	Clinical use of aripiprazole in patients with schizophrenia: A real-life setting results from the German Postmarketing Surveillance Study. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 231-238.	1.3	6

#	ARTICLE	IF	CITATIONS
1625	The safety and tolerability of clozapine in aged patients: A retrospective clinical file review. World Journal of Biological Psychiatry, 2010, 11, 788-791.	1.3	20
1626	The Appropriateness of Routine Medication Treatment for Schizophrenia. Schizophrenia Bulletin, 2010, 36, 732-739.	2.3	18
1627	The Catatonia Conundrum: Evidence of Psychomotor Phenomena as a Symptom Dimension in Psychotic Disorders. Schizophrenia Bulletin, 2010, 36, 231-238.	2.3	107
1628	Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine. International Review of Psychiatry, 2010, 22, 138-147.	1.4	13
1629	Pharmacological Interventions. Key Issues in Mental Health, 2010, , 145-157.	0.6	1
1630	Review: Mortality in schizophrenia: a measurable clinical endpoint. Journal of Psychopharmacology, 2010, 24, 17-25.	2.0	163
1631	Clozapine: a distinct, poorly understood and under-used molecule. Journal of Psychiatry and Neuroscience, 2010, 35, 147-149.	1.4	46
1632	Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data. American Journal of Health-System Pharmacy, 2010, 67, 27-37.	0.5	14
1633	Pharmacogenetics of Schizophrenia: Bringing 'Order to Chaos' in the Psychopharmacology of Schizophrenia?. Advances in Biological Psychiatry, 2010, , 46-57.	0.2	1
1634	Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology, 2010, 13, 1115-1125.	1.0	153
1635	Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia. Evidence-Based Mental Health, 2010, 13, 53-53.	2.2	0
1636	Designing outcome studies to determine efficacy and safety of antipsychotics for 'real world'™ treatment of schizophrenia. International Journal of Neuropsychopharmacology, 2010, 13, 971-973.	1.0	14
1637	The Application of PET Technique for the Development and Evaluation of Novel Antipsychotics. Current Pharmaceutical Design, 2010, 16, 371-377.	0.9	17
1638	Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder. Pharmacopsychiatry, 2010, 43, 138-146.	1.7	79
1640	The Number Needed to Treat for All-Cause Medication Discontinuation in the Treatment of Schizophrenia: Consistency Across World Geographies and Study Designs. Pharmacopsychiatry, 2010, 43, 81-85.	1.7	3
1641	Effect of Early Dysphoric Response and Cannabis Use on Discontinuation of Olanzapine or Risperidone in Patients With Early Psychosis. Pharmacopsychiatry, 2010, 43, 281-281.	1.7	5
1642	D ₂ Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis. American Journal of Psychiatry, 2010, 167, 763-772.	4.0	192
1643	What Have We Learned about Trial Design From NIMH-Funded Pragmatic Trials?. Neuropsychopharmacology, 2010, 35, 2491-2501.	2.8	24

#	ARTICLE	IF	CITATIONS
1644	Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2010, 341, c4024-c4024.	2.4	125
1645	Cross-Disorder Genomewide Analysis of Schizophrenia, Bipolar Disorder, and Depression. <i>American Journal of Psychiatry</i> , 2010, 167, 1254-1263.	4.0	190
1646	Schizophrenia: The drug deadlock. <i>Nature</i> , 2010, 468, 158-159.	13.7	82
1647	Efficacy of atypical v. atypical antipsychotics in the treatment of early psychosis: meta-analysis. <i>British Journal of Psychiatry</i> , 2010, 196, 434-439.	1.7	126
1648	Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients. <i>Pharmacopsychiatry</i> , 2010, 43, 66-72.	1.7	13
1649	Does Oral Antipsychotic Pre-Treatment Influence Outcome of a Switch to Long-Acting Injectable Risperidone in Patients with Schizophrenia?. <i>Pharmacopsychiatry</i> , 2010, 43, 73-80.	1.7	7
1650	Risperidone Maintenance Treatment in Schizophrenia: A Randomized, Controlled Trial. <i>American Journal of Psychiatry</i> , 2010, 167, 676-685.	4.0	61
1651	Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. <i>British Journal of Psychiatry</i> , 2010, 197, 67-72.	1.7	46
1652	Psychotropic drug safety issues: continuing vigilance is needed. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 427-432.	1.3	0
1653	Pharmacogenetics of antipsychotic treatment response and side effects. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 191-198.	0.2	14
1654	Integrative Circuit Models and Their Implications for the Pathophysiologies and Treatments of the Schizophrenias. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 4, 555-583.	0.8	35
1655	Cognitive Behavioral Therapy for Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2010, 33, 527-536.	0.7	25
1656	Clinical Update on Nursing Home Medicine: 2010. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 543-566.	1.2	6
1658	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 81-109.	1.3	322
1659	lloperidone for the Treatment of Schizophrenia. <i>Annals of Pharmacotherapy</i> , 2010, 44, 863-870.	0.9	25
1660	Antipsychotic Dosing and Drug Delivery. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 4, 141-177.	0.8	5
1661	Delirium. A Swedish perspective. <i>European Geriatric Medicine</i> , 2010, 1, 374-376.	1.2	0
1662	Practicing evidence-based psychiatry: 1. Applying a study's findings: The threats to validity approach. <i>Asian Journal of Psychiatry</i> , 2010, 3, 35-40.	0.9	8

#	ARTICLE	IF	CITATIONS
1663	Health outcomes of schizophrenia in Thailand: Health care provider and patient perspectives. <i>Asian Journal of Psychiatry</i> , 2010, 3, 200-205.	0.9	3
1664	Treating depression and achieving remission. <i>Asian Journal of Psychiatry</i> , 2010, 3, 163-168.	0.9	1
1665	Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects. <i>Biological Psychiatry</i> , 2010, 67, 279-282.	0.7	122
1666	Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs. <i>Biological Psychiatry</i> , 2010, 67, 255-262.	0.7	852
1667	Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action: Treatment Response Trajectories. <i>Biological Psychiatry</i> , 2010, 68, 86-92.	0.7	55
1670	Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial. <i>Schizophrenia Research</i> , 2010, 116, 118-125.	1.1	16
1671	Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. <i>Schizophrenia Research</i> , 2010, 116, 44-48.	1.1	38
1672	Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. <i>Schizophrenia Research</i> , 2010, 118, 271-278.	1.1	62
1673	Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial. <i>Schizophrenia Research</i> , 2010, 118, 218-223.	1.1	102
1674	Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. <i>Schizophrenia Research</i> , 2010, 119, 1-10.	1.1	97
1675	Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study. <i>Schizophrenia Research</i> , 2010, 120, 204-209.	1.1	30
1676	Schizophrenia, "Just the Facts" 5. Treatment and prevention Past, present, and future. <i>Schizophrenia Research</i> , 2010, 122, 1-23.	1.1	323
1677	Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2010, 123, 225-233.	1.1	577
1678	The contributions of disease and genetic factors towards regional cortical thinning in schizophrenia: The UCLA family study. <i>Schizophrenia Research</i> , 2010, 123, 116-125.	1.1	33
1679	Amisulpride versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006624.	1.5	26
1680	Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2010, 49, 583-594.	0.3	86
1681	Olanzapine Long-Acting Injection. <i>Drugs</i> , 2010, 70, 2289-2313.	4.9	35
1683	Psychotherapygenetic: Do Genes Influence Psychotherapy Adherence?. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2010, 3, 68-71.	0.2	1

#	ARTICLE	IF	CITATIONS
1684	Quetiapine treatment in adolescents: a 6-month naturalistic study. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2010, 3, 106-110.	0.2	0
1685	From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. <i>European Psychiatry</i> , 2010, 25, S12-S21.	0.1	215
1686	Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. <i>Journal of Psychopharmacology</i> , 2010, 24, 1037-1044.	2.0	118
1687	Social Work Education on Mental Health: Postmodern Discourse and the Medical Model. <i>Journal of Teaching in Social Work</i> , 2010, 30, 385-398.	0.3	10
1688	The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. <i>Schizophrenia Bulletin</i> , 2010, 36, 71-93.	2.3	822
1689	The catechol- <i>O</i> -methyl-transferase gene in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 803-812.	1.3	25
1690	Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. <i>Pharmacogenomics Journal</i> , 2010, 10, 200-218.	0.9	64
1691	Progress in Defining Optimal Treatment Outcome in Schizophrenia. <i>CNS Drugs</i> , 2010, 24, 9-20.	2.7	74
1692	Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders. <i>Journal of Psychopharmacology</i> , 2010, 24, 973-980.	2.0	7
1694	Olanzapine increases cell mitotic activity and oligodendrocyte-lineage cells in the hypothalamus. <i>Neurochemistry International</i> , 2010, 57, 565-571.	1.9	18
1697	Quetiapine XR: Current status for the treatment of major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1165-1173.	2.5	44
1698	Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1243-1249.	2.5	31
1699	Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1484-1490.	2.5	18
1700	Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. <i>Psychiatry Research</i> , 2010, 179, 12-18.	1.7	15
1701	Absence of weight gain association with the HTR2C $\hat{7}59C/T$ polymorphism in patients with schizophrenia treated with iloperidone. <i>Psychiatry Research</i> , 2010, 175, 271-273.	1.7	22
1702	Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. <i>Psychiatry Research</i> , 2010, 180, 16-19.	1.7	5
1703	A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. <i>Psychiatry Research</i> , 2010, 177, 286-293.	1.7	24
1704	Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. <i>Psychosis</i> , 2010, 2, 50-69.	0.4	16

#	ARTICLE	IF	CITATIONS
1705	Pregnenolone, Dehydroepiandrosterone, and Schizophrenia: Alterations and Clinical Trials. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 32-44.	1.9	43
1706	Replication of association between schizophrenia and ZNF804A in the Irish Caseâ€“Control Study of Schizophrenia sample. <i>Molecular Psychiatry</i> , 2010, 15, 29-37.	4.1	191
1707	Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 277-291.	21.5	127
1708	Antipsychotic-Induced Movement Disorders. , 2010, , 115-115.		0
1709	P.3.c.031 Risk of metabolic, cardiologic, and endocrinologic abnormalities in patients under long-term antipsychotic treatment. <i>European Neuropsychopharmacology</i> , 2010, 20, S475-S476.	0.3	0
1710	P.3.c.032 Long-acting risperidone injection versus conventional depots in chronic psychotic patients: a 54 months study. <i>European Neuropsychopharmacology</i> , 2010, 20, S476.	0.3	0
1711	Tackling the Global Mental Health Challenge: A Psychosomatic Medicine/Consultationâ€“Liaison Psychiatry Perspective. <i>Psychosomatics</i> , 2010, 51, 185-193.	2.5	2
1712	Management of Psychosis Associated With a Prolactinoma: Case Report and Review of the Literature. <i>Psychosomatics</i> , 2010, 51, 370-376.	2.5	33
1713	MicroRNA dysregulation in psychiatric disease. <i>Brain Research</i> , 2010, 1338, 89-99.	1.1	184
1714	The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia11The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the EMEA or one of its committees or working parties or the BfArM., <i>European Neuropsychopharmacology</i> , 2010, 20, 139-145.	0.3	11
1715	Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). <i>European Neuropsychopharmacology</i> , 2010, 20, 310-316.	0.3	53
1717	The Future of Psychiatric Research: Genomes and Neural Circuits. <i>Science</i> , 2010, 327, 1580-1581.	6.0	164
1718	Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. <i>Current Medical Research and Opinion</i> , 2010, 26, 501-509.	0.9	62
1719	Levomepromazine for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD007779.	1.5	11
1720	The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. <i>Schizophrenia Bulletin</i> , 2010, 36, 94-103.	2.3	401
1721	Management of Neuropsychiatric Symptoms in People with Dementia. <i>CNS Drugs</i> , 2010, 24, 1.	2.7	102
1722	Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2301-2317.	0.9	69
1723	An Assigned Teaching Resident Rotation. <i>Academic Psychiatry</i> , 2010, 34, 263-268.	0.4	16

#	ARTICLE	IF	CITATIONS
1724	The Promise and Reality of Pharmacogenetics in Psychiatry. <i>Clinics in Laboratory Medicine</i> , 2010, 30, 931-974.	0.7	22
1725	The Promise and Reality of Pharmacogenetics in Psychiatry. <i>Psychiatric Clinics of North America</i> , 2010, 33, 181-224.	0.7	32
1726	Development of animal models for schizophrenia. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 22-26.	1.2	32
1728	Discovery of Oxazolobenzimidazoles as Positive Allosteric Modulators for the mGluR2 Receptor. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 406-410.	1.3	22
1729	Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism Dysregulation. <i>CNS Drugs</i> , 2010, 24, 193-206.	2.7	33
1730	Area Under the Curve. , 2010, , 151-151.		1
1731	Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 53-62.	1.2	17
1732	Olanzapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006654.	1.5	120
1733	Perceptions on efficacy and side effects of conventional depot antipsychotics (CDA) and atypical depot antipsychotics (ADA): Psychiatrists versus patients in Hong Kong. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 23-32.	1.2	3
1734	Optimizing treatment of schizophrenia to minimize relapse. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 147-150.	1.4	7
1735	Efficacy of Metformin and Topiramate in Prevention and Treatment of Second-Generation Antipsychotic-Induced Weight Gain. <i>Annals of Pharmacotherapy</i> , 2010, 44, 668-679.	0.9	38
1736	Pharmacogenetic considerations in the treatment of psychiatric disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 423-439.	0.9	36
1737	Management of antipsychotic-related weight gain. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1175-1200.	1.4	95
1738	Consider endocrine and metabolic effects when selecting an antipsychotic, then monitor and manage accordingly. <i>Drugs and Therapy Perspectives</i> , 2010, 26, 24-26.	0.3	0
1739	Cost Effectiveness of Long-Acting Risperidone in Sweden. <i>Applied Health Economics and Health Policy</i> , 2010, 8, 327-341.	1.0	18
1740	Evaluation of Benefit-Risk. <i>Pharmacoeconomics</i> , 2010, 28, 981-986.	1.7	14
1741	The Economics of Comparative Effectiveness Studies. <i>Pharmacoeconomics</i> , 2010, 28, 843-853.	1.7	25
1742	DSM-5 and the "Psychosis Risk Syndrome": Eight reasons to reject it. <i>Psychosis</i> , 2010, 2, 107-110.	0.4	9

#	ARTICLE	IF	CITATIONS
1743	Strategies for successful clinical management of schizophrenia with ziprasidone. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2199-2220.	0.9	15
1745	A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 403-413.	0.7	15
1746	¿Estamos estudiando y tratando correctamente la esquizofrenia?. <i>Psiquiatria Biologica</i> , 2011, 18, 168-178.	0.0	1
1748	Antipsychotic Pharmacotherapy and Orthostatic Hypotension. <i>CNS Drugs</i> , 2011, 25, 659-671.	2.7	77
1749	Pharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings. <i>CNS Drugs</i> , 2011, 25, 1009-1021.	2.7	40
1750	Drug safety evaluation of ziprasidone. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 437-448.	1.0	22
1751	Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). <i>Current Medical Research and Opinion</i> , 2011, 27, 1603-1611.	0.9	37
1752	A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia. <i>American Journal of Psychiatry</i> , 2011, 168, 603-609.	4.0	552
1753	Pharmacokinetics and metabolism update for some recent antipsychotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 829-846.	1.5	29
1754	Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 9-37.	1.5	173
1755	Pathways to Aggression in Schizophrenia Affect Results of Treatment. <i>Schizophrenia Bulletin</i> , 2011, 37, 921-929.	2.3	154
1756	Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial. <i>Neurologic Clinics</i> , 2011, 29, 127-148.	0.8	140
1757	Interview: In search of the pathophysiology and prevention of schizophrenia. <i>Neuropsychiatry</i> , 2011, 1, 225-231.	0.4	0
1758	Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. <i>Current Medical Research and Opinion</i> , 2011, 27, 713-730.	0.9	46
1759	Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2011, 25, 567-620.	2.0	332
1760	Paliperidone ER: efficacia nella gestione in acuto e nel mantenimento per la schizofrenia?. <i>Quaderni Italiani Di Psichiatria</i> , 2011, 30, 33-42.	0.1	0
1761	Alzheimer's Disease: Future Treatments. <i>Journal of the American Medical Directors Association</i> , 2011, 12, 1-7.	1.2	31
1762	The rise and fall of the atypical antipsychotics. <i>British Journal of Psychiatry</i> , 2011, 199, 266-268.	1.7	45

#	ARTICLE	IF	CITATIONS
1763	Obesity, Psychiatric Status, and Psychiatric Medications. <i>Psychiatric Clinics of North America</i> , 2011, 34, 747-764.	0.7	70
1764	Prevention of Metabolic Syndrome in Serious Mental Illness. <i>Psychiatric Clinics of North America</i> , 2011, 34, 109-125.	0.7	17
1765	Eligibility of the patients admitted to psychiatric inpatient units for participation in catie clinical trial. <i>European Psychiatry</i> , 2011, 26, 1368-1368.	0.1	0
1766	PKC- β activation and pharmacologically induced weight gain during antipsychotic treatment. <i>Pharmacogenomics</i> , 2011, 12, 453-455.	0.6	4
1767	Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. <i>European Psychiatry</i> , 2011, 26, 3-16.	0.1	19
1768	Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe. <i>European Psychiatry</i> , 2011, 26, 17-28.	0.1	20
1769	Use of ziprasidone in patients with schizophrenia in four European countries. <i>European Psychiatry</i> , 2011, 26, 29-37.	0.1	2
1770	Practicing evidence-based psychiatry- 2. Interpreting integrative literature: Systematic reviews and meta-analyses. <i>Asian Journal of Psychiatry</i> , 2011, 4, 80-85.	0.9	4
1771	Atypical Antipsychotic-Induced Weight Gain. <i>CNS Drugs</i> , 2011, 25, 1035-1059.	2.7	142
1772	Evidence-based pharmacotherapy of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 269-284.	1.0	87
1773	Serotonin 2A receptor antagonists for treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1211-1223.	1.9	72
1775	Effect of Antipsychotic Medications on Glucose and Lipid Levels. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 631-638.	1.0	52
1776	Schizophrenia: Treatment Targets Beyond Monoamine Systems. <i>Annual Review of Pharmacology and Toxicology</i> , 2011, 51, 189-209.	4.2	56
1777	Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 517-535.	0.7	221
1778	Psychopharmacology of Schizophrenia in Children and Adolescents. <i>Pediatric Clinics of North America</i> , 2011, 58, 205-218.	0.9	11
1779	Recomendaciones para el cambio de antipsicóticos. Posicionamiento de la Sociedad Española de Psiquiatría y Sociedad Española de Psiquiatría Biológica. <i>Revista De Psiquiatría Y Salud Mental</i> , 2011, 4, 150-168.	1.0	26
1780	Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2011, 4, 150-168.	0.2	7
1781	Trajectories of the course of schizophrenia: From progressive deterioration to amelioration over three decades. <i>Schizophrenia Research</i> , 2011, 126, 184-191.	1.1	72

#	ARTICLE	IF	CITATIONS
1782	Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: A population-based study. Schizophrenia Research, 2011, 126, 110-116.	1.1	69
1783	Cardiovascular risk in a first-episode psychosis sample: A "critical period"™ for prevention?. Schizophrenia Research, 2011, 127, 257-261.	1.1	46
1784	Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophrenia Research, 2011, 128, 61-65.	1.1	82
1785	The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia Research, 2011, 128, 166-170.	1.1	73
1786	Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophrenia Research, 2011, 131, 127-132.	1.1	56
1787	Adherence to antipsychotic drug treatment in early-episode schizophrenia: A six-month naturalistic follow-up study. Schizophrenia Research, 2011, 130, 176-181.	1.1	57
1788	Are we studying and treating schizophrenia correctly?. Schizophrenia Research, 2011, 130, 1-10.	1.1	71
1789	Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophrenia Research, 2011, 132, 28-34.	1.1	17
1790	Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophrenia Research, 2011, 132, 18-23.	1.1	88
1791	Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits. Schizophrenia Research, 2011, 132, 24-27.	1.1	128
1792	Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophrenia Research, 2011, 132, 114-120.	1.1	18
1793	Substance use and schizophrenia: Adverse correlates in the CATIE study sample. Schizophrenia Research, 2011, 132, 177-182.	1.1	56
1794	Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. Schizophrenia Research, 2011, 133, 42-46.	1.1	35
1795	Impact of Drug Treatment History on Comparative Effectiveness Research in Schizophrenia. Value in Health, 2011, 14, 679-686.	0.1	2
1796	PMH56 Negative Symptoms Have Greater Impact on Functioning Than Positive Symptoms in Schizophrenia: Analysis of Catie Data. Value in Health, 2011, 14, A296-A297.	0.1	1
1797	Management of Schizophrenia in Children and Adolescents. Drugs, 2011, 71, 179-208.	4.9	78
1798	Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?. Clinical Pharmacokinetics, 2011, 50, 415-428.	1.6	17
1799	Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder. Clinical Drug Investigation, 2011, 31, 455-482.	1.1	93

#	ARTICLE	IF	CITATIONS
1801	Brain tissue changes and antipsychotic medication. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 943-946.	1.4	11
1802	Handbook of Child and Adolescent Anxiety Disorders. , 2011, , .		17
1803	Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu ₅). <i>ACS Chemical Neuroscience</i> , 2011, 2, 450-470.	1.7	56
1804	Antipsychotic Medications and Brain Volume. <i>Archives of General Psychiatry</i> , 2011, 68, 126.	13.8	38
1805	The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy. <i>Neuropsychopharmacology</i> , 2011, 36, 638-651.	2.8	63
1806	Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 53-68.	1.0	64
1807	Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1509-1523.	1.4	128
1808	Toward Useful Services for Elderly and People with Disabilities. <i>Lecture Notes in Computer Science</i> , 2011, , .	1.0	15
1809	Early intervention for psychosis. <i>The Cochrane Library</i> , 2011, , CD004718.	1.5	235
1810	Medications in Long-Term Care: When Less is More. <i>Clinics in Geriatric Medicine</i> , 2011, 27, 171-191.	1.0	10
1811	Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 120-132.	3.0	20
1812	The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. <i>Contemporary Clinical Trials</i> , 2011, 32, 675-684.	0.8	2
1813	Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs. <i>Cell</i> , 2011, 147, 1011-1023.	13.5	271
1814	The role of serotonin receptors in the action of atypical antipsychotic drugs. <i>Current Opinion in Pharmacology</i> , 2011, 11, 59-67.	1.7	304
1816	Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. <i>Behavioural Brain Research</i> , 2011, 217, 337-346.	1.2	94
1817	Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. <i>Archives of Physiology and Biochemistry</i> , 2011, 117, 241-249.	1.0	40
1818	Use of instrumental variable in prescription drug research with observational data: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 687-700.	2.4	72
1819	Reliance on credibility to prioritise interventions can lead to sub-optimal management strategies. <i>Medical Hypotheses</i> , 2011, 77, 541-543.	0.8	0

#	ARTICLE	IF	CITATIONS
1820	Antipsychotic drugs and obesity. Trends in Molecular Medicine, 2011, 17, 97-107.	3.5	256
1821	Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: A naturalistic 12-month follow-up study. Neuroscience Letters, 2011, 503, 141-146.	1.0	34
1822	The impact of comparative effectiveness research on health and health care spending. Journal of Health Economics, 2011, 30, 695-706.	1.3	36
1823	Controversies Surrounding Pediatric Psychopharmacology. Advances in Pediatrics, 2011, 58, 153-179.	0.5	7
1824	Application of cement as new electrode material and solid-phase microextraction material demonstrated by electrochemiluminescent detection of perphenazine. Talanta, 2011, 84, 49-52.	2.9	23
1825	Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends in Pharmacological Sciences, 2011, 32, 507-513.	4.0	283
1826	Psychopharmacology: A house divided. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1-10.	2.5	11
1827	Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 78-83.	2.5	49
1828	Straight gyrus morphology in first-episode schizophrenia-spectrum patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 84-90.	2.5	4
1829	A pilot study of antipsychotic prescribing decisions for acutely-ill hospitalized patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 246-251.	2.5	3
1830	Antipsychotic dose and diminished neural modulation: A multi-site fMRI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 473-482.	2.5	46
1831	Gray matter volume deficits are associated with motor and attentional impairments in adolescents with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 939-943.	2.5	4
1832	A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 965-969.	2.5	11
1833	More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1080-1086.	2.5	21
1834	Metabolic profile of first and second generation antipsychotics among Chinese patients. Psychiatry Research, 2011, 185, 456-458.	1.7	12
1835	Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. Psychiatry Research, 2011, 187, 49-54.	1.7	18
1836	Use of antipsychotics â€” An analysis of lifetime treatment in 66 patients with psychoses. Psychiatry Research, 2011, 187, 80-88.	1.7	7
1837	Recommendations to improve the Positive and Negative Syndrome Scale (PANSS) based on item response theory. Psychiatry Research, 2011, 188, 446-452.	1.7	40

#	ARTICLE	IF	CITATIONS
1838	Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison. <i>Psychiatry Research</i> , 2011, 189, 349-356.	1.7	18
1839	Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. <i>Psychiatry Research</i> , 2011, 188, 315-319.	1.7	24
1840	Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation. <i>Psychiatry Research</i> , 2011, 189, 463-468.	1.7	7
1841	The impact of atypical antipsychotic use on obstructive sleep apnea: A pilot study and literature review. <i>Sleep Medicine</i> , 2011, 12, 591-597.	0.8	44
1844	Therapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 58-65.	1.9	92
1847	P.3.c.030 Combination of electroconvulsive therapy and clozapine in treatment resistant schizophrenia: about two cases. <i>European Neuropsychopharmacology</i> , 2011, 21, S485.	0.3	0
1848	Second-generation antipsychotics and constipation: A review of the literature. <i>European Psychiatry</i> , 2011, 26, 34-44.	0.1	113
1849	Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. <i>European Psychiatry</i> , 2011, 26, 313-319.	0.1	14
1850	Prescribing practices in psychiatric hospitals in Eastern Europe. <i>European Psychiatry</i> , 2011, 26, 414-418.	0.1	18
1851	The impact of the social network, stigma and empowerment on the quality of life in patients with schizophrenia. <i>European Psychiatry</i> , 2011, 26, 28-33.	0.1	161
1854	Clinical potential of lurasidone in the management of schizophrenia. <i>Therapeutics and Clinical Risk Management</i> , 2011, 7, 239.	0.9	32
1855	Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNSD.S4091.	0.7	9
1856	Prolactin and Schizophrenia, an Evolving Relationship. , 0, , .		0
1860	Psychotropics and Fertility. <i>Current Women's Health Reviews</i> , 2011, 7, 4-9.	0.1	1
1861	Sertindole in the Management of Schizophrenia. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNSD.S5729.	0.7	11
1866	Does mental illness have a place alongside social and recovery models of mental health in service users' lived experiences? Issues and implications for mental health education. <i>Journal of Mental Health Training, Education and Practice</i> , 2011, 6, 65-75.	0.3	3
1867	Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNSD.S4125.	0.7	2
1868	Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. <i>Patient Preference and Adherence</i> , 2011, 5, 547.	0.8	5

#	ARTICLE	IF	CITATIONS
1869	The Impact of Cardiometabolic Risk in Patients with Severe Mental Illness: From Evidence to Clinical Management. , 0, , .		0
1870	Comparative Effectiveness Research under the Patient Protection and Affordable Care Act: Can New Bottles Accommodate Old Wine?. American Journal of Law and Medicine, 2011, 37, 522-566.	0.5	13
1871	Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo. Revista De Saude Publica, 2011, 45, 14-23.	0.7	11
1872	Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability. Journal of Receptor, Ligand and Channel Research, 2011, , 49.	0.7	1
1873	Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan. Patient Preference and Adherence, 2011, 5, 611.	0.8	7
1874	Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia. Neuropsychiatric Disease and Treatment, 2011, 7, 391.	1.0	8
1875	Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Preference and Adherence, 2011, 5, 213.	0.8	18
1876	Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. Neuropsychiatric Disease and Treatment, 2011, 7, 77.	1.0	9
1877	Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. Patient Preference and Adherence, 2011, 5, 601.	0.8	4
1878	Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder. Neuropsychiatric Disease and Treatment, 2011, 7, 691.	1.0	10
1879	Psychiatric genetics in South Africa: cutting a rough diamond. African Journal of Psychiatry, 2011, 14, 355-66.	0.1	1
1880	QTc Prolongation by Psychotropic Drugs and the Risk of Torsade de Pointes. Deutsches Ärzteblatt International, 2011, 108, 687-93.	0.6	187
1881	Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case“Control Trial with Quetiapine. Frontiers in Psychiatry, 2011, 2, 22.	1.3	12
1882	Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). Frontiers in Genetics, 2011, 2, 56.	1.1	19
1884	Numbers-needed-to-treat analysis: an explanation using antipsychotic trials in schizophrenia. Advances in Psychiatric Treatment, 2011, 17, 63-71.	0.6	6
1885	Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia. Journal of Central Nervous System Disease, 2011, 3, JCNSD.S1607.	0.7	12
1886	Monitoring and Prevalence Rates of Metabolic Syndrome in Military Veterans with Serious Mental Illness. PLoS ONE, 2011, 6, e19298.	1.1	32
1887	Antiepileptic and antipsychotic drugs. , 0, , 589-607.		0

#	ARTICLE	IF	CITATIONS
1889	Long-Term Safety and Tolerability of Open-Label Olanzapine Long-Acting Injection in the Treatment of Schizophrenia: 190-Week Interim Results. <i>Clinical Medicine Insights Psychiatry</i> , 2011, 3, CMPsy.S6659.	0.4	12
1892	Outcome Assessment of an Antipsychotic Drug Algorithm: Effects of the Mississippi State Hospital Algorithm Project. <i>Psychiatric Services</i> , 2011, 62, 963-965.	1.1	3
1893	Bromization. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 736-737.	0.5	0
1895	Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 337-340.	0.7	4
1896	Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. <i>International Clinical Psychopharmacology</i> , 2011, 26, 96-106.	0.9	54
1897	A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. <i>International Clinical Psychopharmacology</i> , 2011, 26, 130-140.	0.9	148
1898	Antipsychotic Polypharmacy Among Patients Admitted to a Geriatric Psychiatry Unit. <i>Journal of Psychiatric Practice</i> , 2011, 17, 368-374.	0.3	24
1899	Interview: Pursuing the rational pharmacological treatment of schizophrenia. <i>Neuropsychiatry</i> , 2011, 1, 425-430.	0.4	0
1900	Aripiprazole Versus Haloperidol in Combination With Clozapine for Treatment-Resistant Schizophrenia in Routine Clinical Care. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 266-273.	0.7	33
1901	Predictors of the Discharge Dosage of an Atypical Antipsychotic Agent Among Hospitalized, Treatment-Naive, First-Episode Psychosis Patients in Naturalistic, Public-Sector Settings. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 10-15.	0.7	2
1902	The Effectiveness of the Combination Therapy of Amisulpride and Quetiapine for Managing Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 240-242.	0.7	3
1903	The METEOR study. <i>International Clinical Psychopharmacology</i> , 2011, 26, 291-302.	0.9	54
1904	Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications. <i>International Clinical Psychopharmacology</i> , 2011, 26, 43-47.	0.9	11
1905	Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2011, 26, 303-310.	0.9	34
1906	Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 539-551.	0.7	46
1907	The Relationship between Body Mass Index, the Use of Second-Generation Antipsychotics, and Dental Caries among Hospitalized Patients with Schizophrenia. <i>International Journal of Psychiatry in Medicine</i> , 2011, 41, 343-353.	0.8	14
1908	Association between the ROBO1 gene and body mass index in patients using antipsychotics. <i>Psychiatric Genetics</i> , 2011, 21, 202-207.	0.6	8
1909	Predicting Psychiatric Hospital Admission Among Adults With Schizophrenia. <i>Psychiatric Services</i> , 2011, 62, 1138-1145.	1.1	51

#	ARTICLE	IF	CITATIONS
1910	An Evaluation of the Impact of a Social Inclusion Programme on Occupational Functioning for Forensic Service Users. <i>British Journal of Occupational Therapy</i> , 2011, 74, 465-472.	0.5	16
1912	The Impact of Evidence-Based Education on Prescribing in a Psychiatry Residency. <i>Journal of Psychiatric Practice</i> , 2011, 17, 110-117.	0.3	9
1914	Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 1327-1339.	1.0	46
1915	Pharmacogenomic testing to guide treatment using antipsychotic medications. <i>Clinical Investigation</i> , 2011, 1, 1513-1521.	0.0	0
1916	Risperidone Long-Acting Injection (RLAI) – real world outcomes from the United Kingdom high-security hospitals. <i>British Journal of Forensic Practice</i> , 2011, 13, 264-269.	0.6	6
1917	Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis. <i>Archives of Neurology</i> , 2011, 68, 899.	4.9	105
1918	Jumping to conclusions: the psychology of delusional reasoning. <i>Advances in Psychiatric Treatment</i> , 2011, 17, 332-339.	0.6	35
1921	Therapeutic Drug Monitoring for Drugs Used in the Treatment of Substance-Related Disorders: Literature Review Using a Therapeutic Drug Monitoring Appropriateness Rating Scale. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 561-572.	1.0	25
1922	Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). <i>British Journal of Psychiatry</i> , 2011, 199, 467-472.	1.7	67
1923	Economic Approaches to Improving Access to Evidence-Based and Recovery-Oriented Services for People with Severe Mental Illness. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 523-529.	0.9	17
1924	Ziprasidone Hydrochloride: What Role in the Management of Schizophrenia?. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNSD.S4138.	0.7	13
1925	Sleep abnormalities in schizophrenia may suggest impaired trans-thalamic cortico-cortical communication: towards a dynamic model of the illness. <i>European Journal of Neuroscience</i> , 2011, 34, 1031-1039.	1.2	54
1926	Large-bowel obstruction secondary to urinary retention. <i>Colorectal Disease</i> , 2011, 13, e160-e161.	0.7	6
1927	Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics. <i>International Journal of Mental Health Nursing</i> , 2011, 20, 428-437.	2.1	54
1928	A systematic review of metformin to limit weight-gain with atypical antipsychotics. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 537-545.	0.7	11
1929	Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 377-382.	1.1	82
1930	The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and desmethyl olanzapine. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 611-615.	1.1	14
1931	Vanishing clinical psychopharmacology. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 1-5.	1.1	22

#	ARTICLE	IF	CITATIONS
1932	Medication-taking behaviours in young adults with schizophrenia: a pilot study. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2011, 18, 418-424.	1.2	8
1933	Antipsychotic prescribing: old wine in new bottles?. <i>Child and Adolescent Mental Health</i> , 2011, 16, 218-221.	1.8	2
1934	Impact of species variability and probe-dependence™ on the detection and <i>in vivo</i> validation of allosteric modulation at the M ₄ muscarinic acetylcholine receptor. <i>British Journal of Pharmacology</i> , 2011, 162, 1659-1670.	2.7	60
1935	Animal models of schizophrenia. <i>British Journal of Pharmacology</i> , 2011, 164, 1162-1194.	2.7	613
1936	Psychotic disorders in learning disabilities—outcome of an audit across community teams. <i>British Journal of Learning Disabilities</i> , 2011, 39, 148-153.	0.8	3
1937	Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study. <i>International Journal of Clinical Practice</i> , 2011, 65, 945-953.	0.8	25
1938	Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 175-189.	2.2	42
1939	Psychiatry and the scientific fallacy. <i>Acta Psychiatrica Scandinavica</i> , 2011, 124, 70-72.	2.2	7
1940	Treatment of psychosis during pregnancy—a case report and a mini-review. <i>Acta Neuropsychiatrica</i> , 2011, 23, 210-214.	1.0	8
1941	Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis. <i>Neuropsychopharmacology</i> , 2011, 36, 1781-1791.	2.8	214
1942	A Concise Display of Multiple End Points for Benefit-Risk Assessment. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 56-59.	2.3	11
1943	A behavioral weight-loss intervention for persons with serious mental illness in psychiatric rehabilitation centers. <i>International Journal of Obesity</i> , 2011, 35, 1114-1123.	1.6	59
1944	Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. <i>Molecular Psychiatry</i> , 2011, 16, 76-85.	4.1	141
1945	Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. <i>Molecular Psychiatry</i> , 2011, 16, 321-332.	4.1	141
1946	Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. <i>Molecular Psychiatry</i> , 2011, 16, 620-625.	4.1	61
1947	Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. <i>Pharmacogenomics Journal</i> , 2011, 11, 35-44.	0.9	38
1948	Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. <i>Pharmacogenomics Journal</i> , 2011, 11, 1-14.	0.9	99
1949	Group cognitive behavioural therapy as a treatment for negative symptoms in first-episode psychosis. <i>Microbial Biotechnology</i> , 2011, 5, 168-173.	0.9	13

#	ARTICLE	IF	CITATIONS
1950	National mental health registry for schizophrenia in Malaysia: A preliminary assessment on service utilization. <i>Asia-Pacific Psychiatry</i> , 2011, 3, 151-156.	1.2	0
1951	Non-ψpsychiatric health problems among psychiatric inpatients with intellectual disabilities. <i>Journal of Intellectual Disability Research</i> , 2011, 55, 199-209.	1.2	69
1952	Schizophrenia: Current Therapy and Review. <i>Journal of Oral and Maxillofacial Surgery</i> , 2011, 69, 192-198.	0.5	7
1953	Antipsychotics. <i>Journal of Pain and Symptom Management</i> , 2011, 41, 956-965.	0.6	9
1954	Adjunct Mirtazapine for Negative Symptoms of Schizophrenia. <i>Pharmacotherapy</i> , 2011, 31, 1017-1030.	1.2	16
1955	Factors Associated with the Prescribing of Olanzapine, Quetiapine, and Risperidone in Patients with Bipolar and Related Affective Disorders. <i>Pharmacotherapy</i> , 2011, 31, 806-812.	1.2	12
1956	Improving the clinical effectiveness of antidepressant treatment. <i>Journal of Affective Disorders</i> , 2011, 132, S1-S2.	2.0	0
1957	Clinical effectiveness, construct and assessment. <i>Journal of Affective Disorders</i> , 2011, 132, S3-S8.	2.0	3
1958	lloperidone for the Management of Adults with Schizophrenia. <i>Clinical Therapeutics</i> , 2011, 33, 330-345.	1.1	19
1959	Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile. <i>Clinical Therapeutics</i> , 2011, 33, 1853-1867.	1.1	14
1960	Communication of Potential Benefits and Harm to Patients and Payers in Psychiatry: A Review and Commentary. <i>Clinical Therapeutics</i> , 2011, 33, B62-B76.	1.1	7
1961	Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. <i>Clinical Nutrition</i> , 2011, 30, 616-623.	2.3	32
1962	Risperidone in Schizophrenia: Is There a Role for Therapeutic Drug Monitoring?. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 275-283.	1.0	29
1963	Tetrabenazine for the Treatment of Tardive Dyskinesia. <i>Annals of Pharmacotherapy</i> , 2011, 45, 525-531.	0.9	51
1964	Predictors of clozapine discontinuation in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2011, 26, 311-315.	0.9	38
1965	Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications. <i>Pharmacogenomics</i> , 2011, 12, 999-1016.	0.6	33
1966	Overcoming splits in our understanding of schizophrenia and its management. <i>Progress in Neurology and Psychiatry</i> , 2011, 15, 6-7.	0.4	0
1967	Psychoses: an evidence-based approach to drug treatment. <i>The Prescriber</i> , 2011, 22, 16-32.	0.1	1

#	ARTICLE	IF	CITATIONS
1968	Antipsychotics: is it time to end the generation game?. <i>The Prescriber</i> , 2011, 22, 48-50.	0.1	3
1969	The use of atypical antipsychotics and the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 541-548.	1.1	25
1970	A Role for Hypothalamic AMP-Activated Protein Kinase in the Mediation of Hyperphagia and Weight Gain Induced by Chronic Treatment with Olanzapine in Female Rats. <i>Cellular and Molecular Neurobiology</i> , 2011, 31, 985-989.	1.7	27
1971	Criminal Justice System Involvement Among People with Schizophrenia. <i>Community Mental Health Journal</i> , 2011, 47, 727-736.	1.1	10
1972	Recovery from Schizophrenia: A Four-year Study of an Inner City Cohort. <i>Community Mental Health Journal</i> , 2011, 47, 660-667.	1.1	5
1973	Hypothalamic control of energy and glucose metabolism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2011, 12, 219-233.	2.6	38
1974	The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 173-177.	1.8	7
1975	EEG alterations during treatment with olanzapine. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 483-8.	1.8	12
1979	Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine. <i>Psychopharmacology</i> , 2011, 213, 1-9.	1.5	7
1980	Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. <i>Psychopharmacology</i> , 2011, 214, 729-736.	1.5	19
1981	Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. <i>Psychopharmacology</i> , 2011, 216, 257-265.	1.5	40
1982	Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. <i>Psychopharmacology</i> , 2011, 216, 475-484.	1.5	24
1983	Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia. <i>Psychopharmacology</i> , 2011, 216, 579-587.	1.5	6
1984	Dipyridamole monotherapy in schizophrenia. <i>Psychopharmacology</i> , 2011, 218, 341-345.	1.5	16
1985	Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia. <i>BMC Psychiatry</i> , 2011, 11, 126.	1.1	14
1986	Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study. <i>BMC Psychiatry</i> , 2011, 11, 143.	1.1	21
1987	Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. <i>BMC Psychiatry</i> , 2011, 11, 145.	1.1	26
1988	Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. <i>BMC Psychiatry</i> , 2011, 11, 87.	1.1	11

#	ARTICLE	IF	CITATIONS
1989	Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. <i>Annals of General Psychiatry</i> , 2011, 10, 10.	1.2	39
1990	Estimating cost offsets of new medications: Use of new antipsychotics and mental health costs for schizophrenia. <i>Statistics in Medicine</i> , 2011, 30, 1971-1988.	0.8	27
1991	Alternative methods for testing treatment effects on the basis of multiple outcomes: Simulation and case study. <i>Statistics in Medicine</i> , 2011, 30, 1917-1932.	0.8	19
1992	Mitochondria in the striatum of subjects with schizophrenia: Relationship to treatment response. <i>Synapse</i> , 2011, 65, 215-224.	0.6	27
1993	The predictive validity of subjective adherence measures in patients with schizophrenia. <i>International Journal of Methods in Psychiatric Research</i> , 2011, 20, 73-81.	1.1	18
1994	How to assess the clinical impact of treatments on patients, rather than the statistical impact of treatments on measures. <i>International Journal of Methods in Psychiatric Research</i> , 2011, 20, 63-72.	1.1	41
1995	An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. <i>Human Psychopharmacology</i> , 2011, 26, 81-85.	0.7	4
1996	Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study. <i>Journal of Community Psychology</i> , 2011, 39, 76-88.	1.0	22
1997	Evidence for a <i>SULT4A1</i> haplotype correlating with baseline psychopathology and atypical antipsychotic response. <i>Pharmacogenomics</i> , 2011, 12, 471-480.	0.6	20
1999	Challenges of Introducing New Biomarker Products for Neuropsychiatric Disorders into the Market. <i>International Review of Neurobiology</i> , 2011, 101, 299-327.	0.9	18
2000	A Randomized Experimental Investigation of Reasoning Training for People With Delusions. <i>Schizophrenia Bulletin</i> , 2011, 37, 324-333.	2.3	124
2001	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. <i>Pharmacopsychiatry</i> , 2011, 44, 195-235.	1.7	774
2003	Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone. <i>Postgraduate Medicine</i> , 2011, 123, 135-159.	0.9	11
2004	The NIMH-CATIE Schizophrenia Study: What Did We Learn?. <i>American Journal of Psychiatry</i> , 2011, 168, 770-775.	4.0	84
2005	Atypical antipsychotic drugs. <i>BMJ: British Medical Journal</i> , 2011, 342, d1126-d1126.	2.4	25
2006	Impact of Patients' Preexisting Metabolic Risk Factors on the Choice of Antipsychotics by Office-Based Physicians. <i>Psychiatric Services</i> , 2011, 62, 1477-1484.	1.1	10
2007	From "classical" antipsychotics to "multidimensional stabilizers": do we need a new classification for novel drugs used in schizophrenia?. <i>Neuropsychiatry</i> , 2011, 1, 541-552.	0.4	1
2009	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011, 10, 52-77.	4.8	1,767

#	ARTICLE	IF	CITATIONS
2010	Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1587-1591.	1.0	21
2011	Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia. <i>Journal of Psychopharmacology</i> , 2011, 25, 1207-1225.	2.0	22
2012	Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 143-148.	1.3	15
2013	Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 589-607.	1.4	32
2014	The safety of atypical antipsychotics: does QTc provide all the answers?. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 341-344.	1.0	11
2015	Schizophrenia Treatment Guidelines in the United States. <i>Clinical Schizophrenia and Related Psychoses</i> , 2011, 5, 40-49.	1.4	20
2016	Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. <i>Journal of Psychopharmacology</i> , 2011, 25, 630-638.	2.0	11
2017	Identifying an optimal treatment for schizophrenia: A 2-year randomized controlled trial comparing integrated care to a high-quality routine treatment. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 118-127.	1.2	21
2018	Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia. <i>Neuropsychopharmacology</i> , 2011, 36, 616-626.	2.8	103
2019	Evolution of Psychopharmacology Trial Design and Analysis. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 331-340.	1.1	16
2020	Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E624-E632.	1.8	54
2021	Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy. <i>American Journal of Psychiatry</i> , 2011, 168, 702-708.	4.0	149
2022	What Can Large Simple Trials Do for Psychiatry?. <i>American Journal of Psychiatry</i> , 2011, 168, 117-119.	4.0	11
2023	GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia. <i>Neural Plasticity</i> , 2011, 2011, 1-24.	1.0	193
2024	Early Intervention for Schizophrenia: The Risk-Benefit Ratio of Antipsychotic Treatment in the Prodromal Phase. <i>American Journal of Psychiatry</i> , 2011, 168, 761-763.	4.0	19
2026	Clozapine Plasma Level Monitoring for Prediction of Rehospitalization Schizophrenic Outpatients. <i>Pharmacopsychiatry</i> , 2011, 44, 55-59.	1.7	18
2027	Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 286-295.	1.2	12
2028	Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine. <i>Evidence-Based Mental Health</i> , 2011, 13, 84-84.	2.2	0

#	ARTICLE	IF	CITATIONS
2029	Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. <i>Journal of Psychopharmacology</i> , 2011, 25, 646-666.	2.0	49
2030	Does Assertive Community Treatment Increase Medication Adherence for People With Co-occurring Psychotic and Substance Use Disorders?. <i>Journal of the American Psychiatric Nurses Association</i> , 2011, 17, 51-56.	0.4	25
2031	Rational Antipsychotic Choice: Weighing the Risk of Tardive Dyskinesia and Metabolic Syndrome. <i>Harvard Review of Psychiatry</i> , 2011, 19, 271-276.	0.9	5
2032	Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials. <i>Journal of Psychopharmacology</i> , 2011, 25, 639-645.	2.0	18
2033	Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis. <i>Journal of Psychopharmacology</i> , 2011, 25, 675-684.	2.0	5
2034	Are all antipsychotic drugs the same?. <i>British Journal of Psychiatry</i> , 2011, 199, 269-271.	1.7	11
2035	The tardive syndromes. , 2011, , 415-446.		7
2036	Letter to the Editor: The need for drug-naïve research in first-episode psychosis: a response to Moncrieff & Leo (). <i>Psychological Medicine</i> , 2011, 41, 1117-1118.	2.7	1
2037	The heterogeneity of antipsychotic response in the treatment of schizophrenia. <i>Psychological Medicine</i> , 2011, 41, 1291-1300.	2.7	54
2039	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression. <i>Focus (American Psychiatric Publishing)</i> , 2011, 9, 500-525.	0.4	1
2040	Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia. <i>Current Pharmaceutical Design</i> , 2011, 17, 94-102.	0.9	35
2041	Commentary: Psychiatric Training for Physicians: A Call to Modernize. <i>Academic Medicine</i> , 2011, 86, 285-287.	0.8	18
2042	Psychotropic Drug Prescribing in the United States. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 1-3.	0.7	32
2043	Clozapine Safety, 35 Years Later. <i>Current Drug Safety</i> , 2011, 6, 164-184.	0.3	35
2044	Clozapine vs. chlorpromazine in treatment-naïve, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. <i>British Journal of Psychiatry</i> , 2011, 199, 281-288.	1.7	69
2045	lloperidone: A new drug for the treatment of schizophrenia. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 301-308.	0.5	29
2046	Functional SNPs in Genes Encoding the 5-HT _{2A} Receptor Modify the Affinity and Potency of Several Atypical Antipsychotic Drugs. <i>Biological Research for Nursing</i> , 2011, 13, 55-60.	1.0	12
2047	Schizophrenia guidelines across the world: A selective review and comparison. <i>International Review of Psychiatry</i> , 2011, 23, 379-387.	1.4	56

#	ARTICLE	IF	CITATIONS
2048	Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. <i>Schizophrenia Bulletin</i> , 2011, 37, 352-361.	2.3	46
2049	Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2011, 100, 601-616.	1.0	71
2050	Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 989-1006.	1.4	6
2051	Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 40-46.	0.7	11
2052	Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 389-405.	1.3	13
2053	Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. <i>Cmaj</i> , 2011, 183, E411-9.	0.9	59
2054	Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. <i>Current Medical Research and Opinion</i> , 2011, 27, 115-122.	0.9	14
2055	A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2011, 24, 619-26.	0.4	7
2056	A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). <i>American Journal of Psychiatry</i> , 2011, 168, 947-956.	4.0	158
2057	Safety of antipsychotics in people with intellectual disability. <i>British Journal of Psychiatry</i> , 2011, 199, 289-295.	1.7	39
2058	Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. <i>Statistics in Biopharmaceutical Research</i> , 2011, 3, 253-265.	0.6	16
2059	Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population. <i>Schizophrenia Bulletin</i> , 2011, 37, 94-100.	2.3	135
2060	How to read a research paper: Reading between and beyond the lines. <i>Indian Journal of Psychiatry</i> , 2011, 53, 362.	0.4	5
2061	Encyclopedia of Schizophrenia. , 2011, , .		2
2062	Augmentation Treatment with Amisulpride in Schizophrenic Patients Partially Responsive to Olanzapine. <i>Pharmacopsychiatry</i> , 2011, 44, 142-147.	1.7	11
2063	Many people show poor adherence to their initial antipsychotic after first hospitalisation with schizophrenia. <i>Evidence-Based Mental Health</i> , 2011, 14, 96-96.	2.2	3
2064	Sample size formulae for two-stage randomized trials with survival outcomes. <i>Biometrika</i> , 2011, 98, 503-518.	1.3	32
2065	Sexual self-perception in schizophrenic and depressive patients. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 306-310.	0.7	6

#	ARTICLE	IF	CITATIONS
2066	The Relevance of <i>Caenorhabditis elegans</i> Genetics for Understanding Human Psychiatric Disease. <i>Harvard Review of Psychiatry</i> , 2011, 19, 210-218.	0.9	8
2067	Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. <i>Clinical Trials</i> , 2011, 8, 196-204.	0.7	9
2068	Tardive Dyskinesia: Clinical Presentation and Treatment. <i>International Review of Neurobiology</i> , 2011, 98, 187-210.	0.9	32
2069	Trends in Antipsychotic Use in Dementia 1999-2007. <i>Archives of General Psychiatry</i> , 2011, 68, 190.	13.8	153
2070	Stigma Resistance in Patients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 316-323.	2.3	167
2071	Presynaptic Regulation of Dopamine Transmission in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 108-117.	2.3	56
2072	Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. <i>Schizophrenia Bulletin</i> , 2011, 37, 788-799.	2.3	94
2073	Alstonine as an Antipsychotic: Effects on Brain Amines and Metabolic Changes. <i>Evidence-based Complementary and Alternative Medicine</i> , 2011, 2011, 1-7.	0.5	8
2074	Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 1057-1065.	2.3	76
2075	Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. <i>Journal of Psychopharmacology</i> , 2012, 26, 1194-1200.	2.0	10
2076	Examining the effectiveness of antipsychotic medication in first-episode psychosis. <i>Journal of Psychopharmacology</i> , 2012, 26, 27-32.	2.0	19
2077	Meet the relatives: a reintroduction to the clinical pharmacology of "atypical" antipsychotics (Part 1). <i>Advances in Psychiatric Treatment</i> , 2012, 18, 323-336.	0.6	9
2078	Efficacy and Tolerability of Switching to Ziprasidone in Italian Patients with Acute Exacerbation of Schizophrenia: An Open-Label Trial. <i>Pharmacopsychiatry</i> , 2012, 45, 236-240.	1.7	7
2079	The use of antipsychotics in a medium-long stay psychiatric hospital from 1998 to 2010. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 143-147.	1.2	4
2080	Psychotherapy for Schizophrenia: A Review of Modalities and Their Evidence Base. <i>Psychodynamic Psychiatry</i> , 2012, 40, 609-616.	0.1	12
2081	Two Centuries of Neurology and Psychiatry in the <i>Journal</i> . <i>New England Journal of Medicine</i> , 2012, 367, 58-65.	13.9	5
2082	"I want the one that will heal me completely so it won't come back again" The limits of antipsychotic medication in rural Ghana. <i>Transcultural Psychiatry</i> , 2012, 49, 438-460.	0.9	91
2083	Adherence and Long-Acting Injectable Antipsychotics in Schizophrenia: An Update. <i>Dusunen Adam</i> , 2012, , .	0.0	1

#	ARTICLE	IF	CITATIONS
2084	Sleep dysfunctions in schizophrenia: A practical review. <i>Open Journal of Psychiatry</i> , 2012, 02, 384-392.	0.2	21
2085	Psychosis in Patients with Systemic Lupus Erythematosus. <i>Indian Journal of Psychological Medicine</i> , 2012, 34, 90-93.	0.6	10
2086	Clozapine-Induced Locomotor Suppression is Mediated by 5-HT2A Receptors in the Forebrain. <i>Neuropsychopharmacology</i> , 2012, 37, 2747-2755.	2.8	49
2087	The ties that bind: Using ethnographic methods to understand service engagement. <i>Qualitative Social Work</i> , 2012, 11, 412-430.	0.9	18
2088	Antipsychotic drug treatment for elderly people with late-onset schizophrenia. <i>The Cochrane Library</i> , 2012, , CD004162.	1.5	23
2089	Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of headâ€“head comparisons. <i>Journal of Psychopharmacology</i> , 2012, 26, 15-26.	2.0	60
2090	INRICH: interval-based enrichment analysis for genome-wide association studies. <i>Bioinformatics</i> , 2012, 28, 1797-1799.	1.8	218
2091	Comparing Retrospective Reports to Real-Time/Real-Place Mobile Assessments in Individuals With Schizophrenia and a Nonclinical Comparison Group. <i>Schizophrenia Bulletin</i> , 2012, 38, 396-404.	2.3	87
2092	Guideline, Education, and Peer Comparison to Reduce Prescriptions of Benzodiazepines and Low-Dose Quetiapine in Prison. <i>Journal of Correctional Health Care</i> , 2012, 18, 45-52.	0.2	27
2093	Next-Generation Treatments for Mental Disorders. <i>Science Translational Medicine</i> , 2012, 4, 155ps19.	5.8	136
2094	Revolution Stalled. <i>Science Translational Medicine</i> , 2012, 4, 155cm11.	5.8	207
2095	Effectiveness and Cost of Atypical Versus Typical Antipsychotic Treatment in a Nationwide Cohort of Patients With Schizophrenia in Germany. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 602-607.	0.7	15
2096	Long-Term Effect of Haloperidol, Olanzapine, and Risperidone on Plasma Prolactin Levels in Patients With First-Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 804-808.	0.7	24
2097	Rethinking the role of long-acting atypical antipsychotics in the community setting. <i>International Clinical Psychopharmacology</i> , 2012, 27, 1.	0.9	27
2098	Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications. <i>International Clinical Psychopharmacology</i> , 2012, 27, 275-282.	0.9	14
2099	Valproic Acid Significantly Lowers Serum Concentrations of Olanzapineâ€“An Interaction Effect Comparable With Smoking. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 512-517.	1.0	36
2100	Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable. <i>International Clinical Psychopharmacology</i> , 2012, 27, 283-290.	0.9	8
2101	Management of Acute Agitation in the Emergency Department. <i>Advanced Emergency Nursing Journal</i> , 2012, 34, 306-318.	0.2	15

#	ARTICLE	IF	CITATIONS
2102	Ziprasidone Versus Clozapine in the Treatment of Psychotic Symptoms in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 61-66.	0.2	44
2103	Is Psychiatry Ignoring Suicide?. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 307-308.	0.7	10
2104	Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients. <i>International Clinical Psychopharmacology</i> , 2012, 27, 159-164.	0.9	7
2105	Schizophrenia and the Efficacy of qEEG-Guided Neurofeedback Treatment. <i>Clinical EEG and Neuroscience</i> , 2012, 43, 133-144.	0.9	73
2106	Medicare Part D's Impact on Antipsychotic Drug Use and Costs Among Elderly Patients Without Prior Drug Insurance. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 3-10.	0.7	6
2107	Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. <i>Psychological Medicine</i> , 2012, 42, 1049-1056.	2.7	58
2108	Randomized Trial to Evaluate the Efficacy of Cognitive Therapy for Low-Functioning Patients With Schizophrenia. <i>Archives of General Psychiatry</i> , 2012, 69, 121.	13.8	292
2109	A regulator's view of comparative effectiveness research. <i>Clinical Trials</i> , 2012, 9, 56-65.	0.7	22
2110	Update on the Adverse Effects of Clozapine: Focus on Myocarditis. <i>Current Drug Safety</i> , 2012, 7, 55-62.	0.3	56
2111	Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 287-300.	1.1	11
2112	Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants: A Review for Primary Care Physicians. <i>Postgraduate Medicine</i> , 2012, 124, 154-167.	0.9	81
2113	A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 589-600.	1.0	181
2114	Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study. <i>Pharmacogenomics</i> , 2012, 13, 1227-1237.	0.6	12
2115	Genetic Variation in KCNH2 and a Unique hERG Isoform in Patients With Schizophrenia: Efficacy-Safety Link. <i>American Journal of Psychiatry</i> , 2012, 169, 1318-1318.	4.0	0
2116	Response to Warner Letter. <i>American Journal of Psychiatry</i> , 2012, 169, 1318-1319.	4.0	0
2117	Exposure to Potentially Dangerous Drug-Drug Interactions Involving Antipsychotics. <i>Psychiatric Services</i> , 2012, 63, 1080-1088.	1.1	31
2119	Identifying Priorities for Patient-Centered Outcomes Research for Serious Mental Illness. <i>Psychiatric Services</i> , 2012, 63, 1125-1130.	1.1	15
2120	Comparative Effectiveness of Second-Generation Antipsychotic Medications in Early-Onset Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 845-853.	2.3	20

#	ARTICLE	IF	CITATIONS
2121	Lurasidone: An Atypical Antipsychotic for Schizophrenia. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1033-1046.	0.9	16
2122	Investigation of a Possible Interaction Between Quetiapine and Armodafinil in Patients With Schizophrenia: An Open-Label, Multiple-Dose Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1399-1409.	1.0	12
2123	The influence of therapeutic alliance and insight on medication adherence in schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2012, 66, 49-54.	0.7	64
2124	The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving. <i>Journal of Medical Economics</i> , 2012, 15, 623-634.	1.0	11
2125	Les traitements psychotropes. , 2012, , 571-630.		0
2126	Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. <i>Journal of Psychopharmacology</i> , 2012, 26, 42-51.	2.0	77
2127	A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 107-118.	1.0	87
2128	Another view of the history of antipsychotic drug discovery and development. <i>Molecular Psychiatry</i> , 2012, 17, 1168-1173.	4.1	57
2129	Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 171-180.	0.6	3
2130	Genome-wide association study of antipsychotic-induced QTc interval prolongation. <i>Pharmacogenomics Journal</i> , 2012, 12, 165-172.	0.9	78
2131	Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. <i>Pharmacogenomics Journal</i> , 2012, 12, 147-155.	0.9	31
2132	Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. <i>Psychological Medicine</i> , 2012, 42, 2145-2155.	2.7	166
2133	Comprehension and companionship in the emergency department as predictors of treatment adherence. <i>Australasian Psychiatry</i> , 2012, 20, 112-116.	0.4	11
2134	The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 259-269.	0.7	12
2135	Guide to Assessment Scales in Schizophrenia. , 2012, , .		5
2136	Development and implementation of an integrated care pathway for managing compliance problems in patients with schizophrenia. <i>International Journal of Care Pathways</i> , 2012, 16, 139-145.	0.5	1
2137	Metabolic Consequences of Antipsychotic Therapy: Preclinical and Clinical Perspectives on Diabetes, Diabetic Ketoacidosis, and Obesity. <i>Handbook of Experimental Pharmacology</i> , 2012, , 135-164.	0.9	21
2138	Beyond Dopamine: Glutamate as a Target for Future Antipsychotics. <i>ISRN Pharmacology</i> , 2012, 2012, 1-9.	1.6	25

#	ARTICLE	IF	CITATIONS
2139	Risperidone and Olanzapine versus Another First Generation Antipsychotic in Patients with Schizophrenia Inadequately Responsive to First Generation Antipsychotics. <i>Pharmacopsychiatry</i> , 2012, 45, 64-71.	1.7	10
2140	Comparative Effectiveness Research: The Experience of the National Institute for Health and Clinical Excellence. <i>Journal of Clinical Oncology</i> , 2012, 30, 4267-4274.	0.8	10
2141	Antipsychotic agents: efficacy and safety in schizophrenia. <i>Drug, Healthcare and Patient Safety</i> , 2012, 4, 173.	1.0	18
2142	Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-5.	0.7	17
2143	Where Does Evidence from New Trials for Schizophrenia Fit with the Existing Evidence: A Case of the Emperor's New Clothes?. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-4.	0.7	1
2144	Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-7.	0.7	20
2145	The Differential Effect of Risperidone and Olanzapine on Insulin Sensitivity after 3 Weeks of Treatment: A HOMA Pilot Study. <i>Pharmacopsychiatry</i> , 2012, 45, 96-99.	1.7	3
2146	Insulin Secretion and Sensitivity after Single-Dose Amisulpride, Olanzapine or Placebo in Young Male Subjects: Double Blind, Cross-Over Glucose Clamp Study. <i>Pharmacopsychiatry</i> , 2012, 45, 223-228.	1.7	13
2147	Recent Approaches to the Synthesis of Aripiprazole – A New Generation Antipsychotic Drug. <i>Mini-Reviews in Organic Chemistry</i> , 2012, 9, 374-380.	0.6	5
2148	Physical health of patients with severe mental illness. <i>International Journal of Health Care Quality Assurance</i> , 2012, 25, 363-370.	0.2	14
2149	Adherence to Antipsychotics and Cardiometabolic Medication: Association With Health Care Utilization and Costs. <i>Psychiatric Services</i> , 2012, 63, 920-928.	1.1	31
2150	Glutamate and Psychosis Risk. <i>Current Pharmaceutical Design</i> , 2012, 18, 466-478.	0.9	34
2151	Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. <i>Aids</i> , 2012, 26, S39-S53.	1.0	90
2152	Leveraging disruptive technologies to drive innovation in CNS clinical drug development. , 0, , 192-199.		0
2153	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). , 2012, 11, CD009377.		50
2154	Recent Advances in Targeting the Ionotropic Glutamate Receptors in Treating Schizophrenia. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1535-1542.	0.9	12
2155	Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1149-1160.	1.0	27
2156	Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 2357-2374.	1.0	26

#	ARTICLE	IF	CITATIONS
2157	Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. <i>Current Psychiatry Reviews</i> , 2012, 8, 25-36.	0.9	63
2158	Safety, Efficacy, and Patient Acceptability of Aripiprazole in the Maintenance Treatment of Bipolar Disorder. <i>Clinical Medicine Insights Therapeutics</i> , 2012, 4, CMT.S7388.	0.4	0
2160	Reporting Bias in Industry-Supported Medication Trials Presented at the American Psychiatric Association Meeting. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 435.	0.7	2
2162	Sulpiride dose for schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	1
2163	Biases in the Evaluation of Psychiatric Clinical Evidence. <i>Journal of Nervous and Mental Disease</i> , 2012, 200, 76-82.	0.5	10
2164	Rater Evaluations for Psychiatric Instruments and Cultural Differences. <i>Journal of Nervous and Mental Disease</i> , 2012, 200, 814-820.	0.5	6
2165	How Do People Taking Psychiatric Drugs Explain Their "Chemical Imbalance"? <i>Ethical Human Psychology and Psychiatry</i> , 2012, 13, 176-189.	0.5	12
2166	Optimizing Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment. <i>CNS Spectrums</i> , 2012, 17, 10-21.	0.7	14
2167	Strategies for optimizing medication adherence in schizophrenia. <i>CNS Spectrums</i> , 2012, 17, 31-41.	0.7	2
2168	Clozapine is gold standard, but questions remain. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1201-1204.	1.0	7
2169	The NIMH-CATIE Schizophrenia Study: What Did We Learn?. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 226-230.	0.4	1
2170	Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications. <i>Annals of Internal Medicine</i> , 2012, 157, 498.	2.0	121
2171	Decision making in recovery-oriented mental health care.. <i>Psychiatric Rehabilitation Journal</i> , 2012, 35, 305-314.	0.8	83
2172	Performance in Practice. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 157-171.	0.4	4
2173	The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 194-216.	0.4	7
2175	UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 221-227.	2.3	29
2176	Assessing the Outcome of Compulsory Treatment Orders on Management of Psychiatric Patients at 2 McGill University- Associated Hospitals. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 359-365.	0.9	31
2177	Delivery Systems and Dosing for Antipsychotics. <i>Handbook of Experimental Pharmacology</i> , 2012, , 267-298.	0.9	6

#	ARTICLE	IF	CITATIONS
2178	Using a pharmacogenomic algorithm to guide the treatment of depression. <i>Translational Psychiatry</i> , 2012, 2, e172-e172.	2.4	149
2179	HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. <i>Nature Neuroscience</i> , 2012, 15, 1245-1254.	7.1	247
2180	Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks. <i>Neuron</i> , 2012, 75, 963-980.	3.8	446
2181	Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nature Reviews Endocrinology</i> , 2012, 8, 114-126.	4.3	832
2182	Paliperidone Palmitate for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 1124-1127.	2.3	40
2183	Deletion of GSK3 β in D2R-expressing neurons reveals distinct roles for β -arrestin signaling in antipsychotic and lithium action. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 20732-20737.	3.3	78
2184	Antipsychotic medicines in Australian community practice: Effectiveness, adverse effects and quality of life for people with schizophrenia. <i>Asia-Pacific Psychiatry</i> , 2012, 4, 48-58.	1.2	0
2185	The Pharmacogenetics of Antipsychotic Treatment. <i>Handbook of Experimental Pharmacology</i> , 2012, , 213-239.	0.9	5
2186	Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 589-598.	1.8	14
2187	Pimavanserin, a selective serotonin (5-HT) _{2A} -inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day. <i>Schizophrenia Research</i> , 2012, 141, 144-152.	1.1	87
2191	Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. <i>Human Psychopharmacology</i> , 2012, 27, 605-614.	0.7	19
2192	Patient-centered or "central" patient: Raising the veil of ignorance over randomization. <i>Statistics in Medicine</i> , 2012, 31, 3057-3059.	0.8	2
2193	Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders. <i>Drug Safety</i> , 2012, 35, 819-836.	1.4	28
2194	Schizophrenia for Primary Care Providers: How to Contribute to the Care of a Vulnerable Patient Population. <i>American Journal of Medicine</i> , 2012, 125, 223-230.	0.6	34
2195	Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study. <i>European Neuropsychopharmacology</i> , 2012, 22, 17-26.	0.3	37
2196	Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles. <i>European Neuropsychopharmacology</i> , 2012, 22, 123-131.	0.3	15
2197	Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. <i>European Neuropsychopharmacology</i> , 2012, 22, 364-373.	0.3	70
2198	Head to head comparisons as an alternative to placebo-controlled trials. <i>European Neuropsychopharmacology</i> , 2012, 22, 800-803.	0.3	35

#	ARTICLE	IF	CITATIONS
2199	DAI-10 is as good as DAI-30 in schizophrenia. <i>European Neuropsychopharmacology</i> , 2012, 22, 747-750.	0.3	68
2200	Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. <i>European Neuropsychopharmacology</i> , 2012, 22, 812-817.	0.3	10
2201	Geographical and temporal variations in clozapine prescription for schizophrenia. <i>European Neuropsychopharmacology</i> , 2012, 22, 818-824.	0.3	71
2202	Electrocardiographic signs of autonomic imbalance in medicated patients with first-episode schizophrenia spectrum disorders – relations to first treatment discontinuation and five-year remission status. <i>European Psychiatry</i> , 2012, 27, 213-218.	0.1	3
2203	Time-dependent effect analysis of antipsychotic treatment in a naturalistic cohort study of patients with schizophrenia. <i>European Psychiatry</i> , 2012, 27, 489-495.	0.1	10
2204	Effects of the putative antipsychotic alstonine on glutamate uptake in acute hippocampal slices. <i>Neurochemistry International</i> , 2012, 61, 1144-1150.	1.9	17
2205	Genome-wide association study identifies genetic loci associated with body mass index and high density lipoprotein-cholesterol levels during psychopharmacological treatment – a cross-sectional naturalistic study. <i>Psychiatry Research</i> , 2012, 197, 327-336.	1.7	9
2206	Impaired plasmalogens in patients with schizophrenia. <i>Psychiatry Research</i> , 2012, 198, 347-352.	1.7	63
2207	Predictors of antipsychotic dose changes in the CATIE schizophrenia trial. <i>Psychiatry Research</i> , 2012, 199, 1-7.	1.7	9
2208	Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. <i>Psychiatry Research</i> , 2012, 200, 835-842.	1.7	10
2209	The Patient Assessment Questionnaire: Initial validation of a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder. <i>Psychiatry Research</i> , 2012, 200, 857-866.	1.7	17
2210	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naïve patients with a first-episode psychosis. <i>Psychiatry Research</i> , 2012, 200, 693-701.	1.7	29
2211	Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: A naturalistic 18-month follow-up study. <i>Psychiatry Research</i> , 2012, 200, 96-101.	1.7	6
2213	Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea. <i>Value in Health Regional Issues</i> , 2012, 1, 59-65.	0.5	7
2214	Evidencias disponibles y criterios para la retirada de fármacos en las demencias. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2012, 19, 547-551.	0.0	2
2215	Pharmacological treatment of schizophrenia. <i>International Review of Psychiatry</i> , 2012, 24, 489-498.	1.4	10
2216	Five Reasons That Many Comparative Effectiveness Studies Fail To Change Patient Care And Clinical Practice. <i>Health Affairs</i> , 2012, 31, 2168-2175.	2.5	66
2217	Flexible Analytical Methods for Adding a Treatment Arm Mid-Study to an Ongoing Clinical Trial. <i>Journal of Biopharmaceutical Statistics</i> , 2012, 22, 758-772.	0.4	16

#	ARTICLE	IF	CITATIONS
2218	Prevalence of the Metabolic Syndrome in Schizophrenic Patients Receiving Second-Generation Antipsychotic Agents—A Cross-Sectional Study. <i>Journal of Pharmacy Practice</i> , 2012, 25, 368-373.	0.5	28
2220	Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. <i>Journal of Medical Economics</i> , 2012, 15, 531-547.	1.0	31
2221	A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1545-1573.	0.9	52
2222	The Voices Go, But the Song Remains the Same: How Can We Rescue Cognition in Early-Onset Schizophrenia?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2012, 51, 464-466.	0.3	4
2223	Lurasidone for schizophrenia: what's different?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 265-273.	1.4	11
2224	Systematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain. <i>Pharmacogenomics Journal</i> , 2012, 12, 156-164.	0.9	54
2225	Farmacogenética de las reacciones adversas a los antipsicóticos en pacientes con esquizofrenia. <i>Psiquiatría Biológica</i> , 2012, 19, 15-20.	0.0	0
2226	Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. <i>Pharmacogenomics Journal</i> , 2012, 12, 513-520.	0.9	33
2227	A framework to avoid irrational polypharmacy in psychiatry. <i>Journal of Psychopharmacology</i> , 2012, 26, 1507-1511.	2.0	10
2228	Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials. <i>Therapeutic Advances in Psychopharmacology</i> , 2012, 2, 151-156.	1.2	10
2229	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. <i>Psychiatry Research</i> , 2012, 197, 1-6.	1.7	148
2230	T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. <i>Neuropharmacology</i> , 2012, 62, 1413-1421.	2.0	31
2231	Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. <i>Neuropharmacology</i> , 2012, 62, 1391-1400.	2.0	43
2232	Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?. <i>Neuropharmacology</i> , 2012, 62, 1371-1380.	2.0	42
2233	5-HT _{2A/C} receptors mediate the antipsychotic-like effects of alstonine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 29-33.	2.5	15
2234	Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 245-250.	2.5	16
2235	Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 300-306.	2.5	31
2236	Dopamine D ₄ and D ₅ receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 62-75.	2.5	34

#	ARTICLE	IF	CITATIONS
2237	Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns. <i>American Journal of Psychiatry</i> , 2012, 169, 900-906.	4.0	171
2238	Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. <i>British Journal of Psychiatry</i> , 2012, 200, 387-392.	1.7	157
2239	Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. <i>Journal of Psychopharmacology</i> , 2012, 26, 1271-1279.	2.0	66
2240	Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2012, 53, 107-115.	1.5	32
2241	Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. <i>Comprehensive Psychiatry</i> , 2012, 53, 145-151.	1.5	90
2242	Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications. <i>Handbook of Experimental Pharmacology</i> , 2012, , 267-295.	0.9	149
2243	Multivariate Phenotype Association Analysis by Marker-Set Kernel Machine Regression. <i>Genetic Epidemiology</i> , 2012, 36, 686-695.	0.6	76
2244	Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population. <i>BMC Clinical Pharmacology</i> , 2012, 12, 10.	2.5	21
2245	Mortality and guideline-concordant care for older patients with schizophrenia: a retrospective longitudinal study. <i>BMC Medicine</i> , 2012, 10, 147.	2.3	10
2246	Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model. <i>Annals of General Psychiatry</i> , 2012, 11, 29.	1.2	5
2247	A pilot study on community-based outpatient treatment for patients with chronic psychotic disorders in Somalia: Change in symptoms, functioning and co-morbid khat use. <i>International Journal of Mental Health Systems</i> , 2012, 6, 8.	1.1	19
2248	Effects of group metacognitive training (MCT) on mental capacity and functioning in patients with psychosis in a secure forensic psychiatric hospital: a prospective-cohort waiting list controlled study. <i>BMC Research Notes</i> , 2012, 5, 302.	0.6	39
2249	From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment. <i>Neuropsychopharmacology</i> , 2012, 37, 4-15.	2.8	829
2250	Extended-Release Intramuscular Paliperidone Palmitate. <i>Drugs</i> , 2012, 72, 1137-1160.	4.9	32
2251	Effect of Quetiapine and Norquetiapine on Anxiety and Depression in Major Psychoses Using a Pharmacokinetic Approach. <i>Clinical Drug Investigation</i> , 2012, 32, 213-219.	1.1	26
2252	Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. <i>CNS Drugs</i> , 2012, 26, 733-759.	2.7	136
2253	Pharmacogenetics in psychiatry: translating research into clinical practice. <i>Molecular Psychiatry</i> , 2012, 17, 760-769.	4.1	76
2254	Medical Needs in the Treatment of Psychotic Disorders. <i>Handbook of Experimental Pharmacology</i> , 2012, , 165-185.	0.9	9

#	ARTICLE	IF	CITATIONS
2256	CHAPTER 3. Monoaminergic Approaches for Treatment of Schizophrenia. RSC Drug Discovery Series, 2012, , 35-55.	0.2	0
2257	CHAPTER 4. Glutamatergic Approaches for the Treatment of Schizophrenia. RSC Drug Discovery Series, 2012, , 56-98.	0.2	1
2258	Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert Opinion on Drug Safety, 2012, 11, 713-732.	1.0	20
2259	Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics, 2012, 13, 1773-1782.	0.6	17
2260	Comparative Effectiveness of Atypical Antipsychotics in Schizophrenia. CNS Drugs, 2012, 26, 491-508.	2.7	38
2261	Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety, 2012, 11, 527-542.	1.0	163
2263	Atypical Antipsychotic Use and Parkinsonism in Dementia: Effects of Drug, Dose, and Sex. American Journal of Geriatric Pharmacotherapy, 2012, 10, 381-389.e3.	3.0	11
2265	Reduced Sleep Spindles and Spindle Coherence in Schizophrenia: Mechanisms of Impaired Memory Consolidation?. Biological Psychiatry, 2012, 71, 154-161.	0.7	406
2266	MRI-targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimulation, 2012, 5, 577-585.	0.7	48
2267	Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study. Comprehensive Psychiatry, 2012, 53, 1006-1012.	1.5	13
2268	Clinician Education Improves Lipid Monitoring in Patients Taking Second-Generation Antipsychotic Agents, Nationally and Locally. Health Outcomes Research in Medicine, 2012, 3, e121-e137.	0.6	2
2270	Eligibility of schizophrenia inpatients to participate in clinical trials. Revista De Psiquiatria Y Salud Mental (English Edition), 2012, 5, 71-78.	0.2	0
2271	Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophrenia Research, 2012, 134, 16-19.	1.1	74
2272	Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophrenia Research, 2012, 134, 187-194.	1.1	87
2273	SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: Data from the CATIE study. Schizophrenia Research, 2012, 135, 200-201.	1.1	47
2274	Treatment response trajectories and antipsychotic medications: Examination of up to 18months of treatment in the CATIE chronic schizophrenia trial. Schizophrenia Research, 2012, 137, 141-146.	1.1	42
2275	Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophrenia Research, 2012, 137, 147-150.	1.1	305
2276	Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility. Schizophrenia Research, 2012, 137, 137-140.	1.1	7

#	ARTICLE	IF	CITATIONS
2277	Meeting report: The Schizophrenia International Research Society (SIRS) South America Conference (August 5-7, 2011). Schizophrenia Research, 2012, 137, 1-6.	1.1	0
2278	Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophrenia Research, 2012, 140, 159-168.	1.1	161
2279	Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research, 2012, 138, 18-28.	1.1	255
2280	Heritability of functioning in families with schizophrenia in relation to neurocognition. Schizophrenia Research, 2012, 139, 105-109.	1.1	5
2281	Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: A meta-analysis. Schizophrenia Research, 2012, 140, 214-220.	1.1	46
2282	Early symptom response to antipsychotic medication as a marker of subsequent symptom change: An eighteen-month follow-up study of recent episode schizophrenia. Schizophrenia Research, 2012, 141, 168-172.	1.1	21
2283	Updating and Confirming an Industry-Sponsored Pharmacoeconomic Model: Comparing Two Antipsychotics in the Treatment of Schizophrenia. Value in Health, 2012, 15, 55-64.	0.1	11
2286	Neural Correlates of Weight Gain With Olanzapine. Archives of General Psychiatry, 2012, 69, 1226.	13.8	42
2287	Schizophrenia and Its Associated Sleep Disorders. , 2012, , 705-713.		0
2288	Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. International Journal of Neuropsychopharmacology, 2012, 15, 163-179.	1.0	69
2289	Drug safety and efficacy evaluation of sertindole for schizophrenia. Expert Opinion on Drug Safety, 2012, 11, 1047-1062.	1.0	13
2290	Metabotropic Glutamate Receptors for New Treatments in Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 297-365.	0.9	33
2291	Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 81-111.	0.9	18
2292	Role of Dopamine D2 Receptors for Antipsychotic Activity. Handbook of Experimental Pharmacology, 2012, , 27-52.	0.9	106
2293	A Tail with a Thorn in it: Second-Generation Antipsychotics Hand in Hand with Statins. Current Atherosclerosis Reports, 2012, 14, 391-393.	2.0	1
2294	PMH5 Does Participation in a Weight Control Program Also Improve Clinical and Functional Outcomes for Chinese Patients with Schizophrenia Treated with Olanzapine?. Value in Health, 2012, 15, A669.	0.1	1
2295	Target practice: HDAC inhibitors for schizophrenia. Nature Neuroscience, 2012, 15, 1180-1181.	7.1	15
2297	Aripiprazole. CNS Drugs, 2012, 26, 155-183.	2.7	58

#	ARTICLE	IF	CITATIONS
2298	Comparative Effectiveness Research in the Regulatory Setting. <i>Pharmaceutical Medicine</i> , 2012, 26, 5-11.	1.0	3
2299	Paliperidone palmitate for schizophrenia. <i>The Cochrane Library</i> , 2012, , CD008296.	1.5	28
2300	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 318-378.	1.3	498
2301	lloperidone, asenapine and lurasidone: a primer on their current status. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1911-1922.	0.9	189
2302	Current Antipsychotics. <i>Handbook of Experimental Pharmacology</i> , 2012, , .	0.9	6
2303	Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. <i>Journal of Medical Economics</i> , 2012, 15, 844-861.	1.0	32
2304	Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patientsâ€™ and cliniciansâ€™ perspectives in a clinical trial. <i>BMC Medical Research Methodology</i> , 2012, 12, 142.	1.4	3
2305	Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study. <i>BMC Psychiatry</i> , 2012, 12, 218.	1.1	8
2306	Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study. <i>BMC Psychiatry</i> , 2012, 12, 99.	1.1	27
2307	The effect of clinician-patient alliance and communication on treatment adherence in mental health care: a systematic review. <i>BMC Psychiatry</i> , 2012, 12, 87.	1.1	182
2308	Antipsychotic polypharmacy in a regional health service: a population-based study. <i>BMC Psychiatry</i> , 2012, 12, 42.	1.1	32
2309	Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?. <i>BMC Psychiatry</i> , 2012, 12, 27.	1.1	29
2310	A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. <i>BMC Psychiatry</i> , 2012, 12, 20.	1.1	225
2311	Changes in Body Weight and Psychotropic Drugs: A Systematic Synthesis of the Literature. <i>PLoS ONE</i> , 2012, 7, e36889.	1.1	81
2312	Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 113.	1.0	6
2313	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. <i>Frontiers in Psychiatry</i> , 2012, 3, 62.	1.3	25
2314	Antipsychotic Drugs Alter Functional Connectivity between the Medial Frontal Cortex, Hippocampus, and Nucleus Accumbens as Measured by H215O PET. <i>Frontiers in Psychiatry</i> , 2012, 3, 105.	1.3	33
2315	Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia. <i>Reviews on Recent Clinical Trials</i> , 2012, 7, 2-9.	0.4	31

#	ARTICLE	IF	CITATIONS
2316	Section summary and perspectives: Translational medicine in psychiatry. , 0, , 118-128.		0
2317	Olanzapine discontinuation for schizophrenia. The Cochrane Library, 0, , .	1.5	1
2318	Aripiprazole dose for schizophrenia. The Cochrane Library, 0, , .	1.5	0
2319	Evidence-based pharmacotherapy of schizophrenia. , 0, , 18-38.		1
2320	Pharmacogenetics of Antipsychotic Drugs in Schizophrenia Treatment. Current Psychopharmacology, 2012, 1, 47-60.	0.1	1
2321	Ziprasidone versus Olanzapine in the weight gain associated with the treatment of schizophrenia: A six-month double-blind randomized parallel group study. European Journal of Psychiatry, 2012, 26, 248-259.	0.7	4
2322	Schizophrenia Outpatient Health Outcomes study: twelve-month findings. Journal of Pragmatic and Observational Research, 2012, 3, 27.	1.1	4
2323	Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness. Pharmaceuticals Policy and Law, 2012, 14, 27-35.	0.1	0
2324	Psychotropic drugs. , 2012, , 311-348.		3
2325	Integration of Pharmacological and Psychosocial Treatment for Schizophrenia in Mexico: The Case of a Developing Country Proposal. , 0, , .		3
2326	The cardiovascular health of young people with severe mental illness: addressing an epidemic within an epidemic. The Psychiatrist, 2012, 36, 375-378.	0.3	21
2327	Attitude Toward Antipsychotic Treatment According to Patients' Awareness of the Name of Their Illness in Patients with Schizophrenia. Korean Journal of Schizophrenia Research, 2012, 15, 106.	0.3	2
2330	Pharmacogenetics in psychiatry. , 0, , 53-68.		2
2331	Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatric Disease and Treatment, 2012, 8, 155.	1.0	29
2332	Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature. Current Psychopharmacology, 2012, 2, 18-28.	0.1	1
2333	Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. International Journal of General Medicine, 2012, 5, 391.	0.8	10
2334	Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation. Patient Preference and Adherence, 2012, 6, 521.	0.8	7
2335	One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study. Journal of Pragmatic and Observational Research, 2012, 3, 41.	1.1	1

#	ARTICLE	IF	CITATIONS
2336	Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 247.	1.0	13
2337	Comparison of facial expression in patients with obsessive-compulsive disorder and schizophrenia using the Facial Action Coding System: a preliminary study. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 537.	1.0	13
2338	Prescription patterns of patients diagnosed with schizophrenia in mental hospitals in Tashkent/Uzbekistan and in four German cities. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 145-151.	0.9	8
2339	Antipsychotic drugs and risk of pulmonary embolism. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 42-48.	0.9	57
2340	National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 161-169.	0.9	27
2341	Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. <i>Molecular Psychiatry</i> , 2012, 17, 1206-1227.	4.1	479
2342	Levomepromazine for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 219-220.	2.3	7
2343	Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1251-1260.	0.9	8
2344	Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study. <i>Human Psychopharmacology</i> , 2012, 27, 284-294.	0.7	5
2345	A global measure to assess switching antipsychotic medications in the treatment of schizophrenia. <i>Human Psychopharmacology</i> , 2012, 27, 455-463.	0.7	7
2346	Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. <i>Treatments and Ongoing Management. Pediatrics</i> , 2012, 129, e1577-e1586.	1.0	117
2347	Perphenazine Suspension: A New, Old Treatment, Side Effects and Continuous Use. <i>Psychiatric Quarterly</i> , 2012, 83, 335-341.	1.1	1
2348	Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine. <i>Pharmacogenomics Journal</i> , 2012, 12, 507-512.	0.9	14
2349	Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?. <i>Journal of Psychopharmacology</i> , 2012, 26, 1167-1174.	2.0	49
2350	Role of aripiprazole in treatment-resistant schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 235.	1.0	16
2351	Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. <i>Psychopharmacology</i> , 2012, 220, 519-528.	1.5	20
2352	How close is evidence to truth in evidence-based treatment of mental disorders?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 277-289.	1.8	7
2353	Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. <i>Journal of Neurochemistry</i> , 2012, 120, 371-384.	2.1	59

#	ARTICLE	IF	CITATIONS
2354	Prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index hospitalization: a retrospective cohort study. <i>General Hospital Psychiatry</i> , 2012, 34, 380-384.	1.2	5
2355	Asenapine: A Clinical Review of a Second-Generation Antipsychotic. <i>Clinical Therapeutics</i> , 2012, 34, 1023-1040.	1.1	36
2356	Solid lipid nanoparticles (SLN) - based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: Preparation and characterization studies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2012, 93, 241-248.	2.5	79
2357	Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients. <i>Journal of Affective Disorders</i> , 2012, 137, 139-145.	2.0	3
2358	Effects of the selective kainate receptor antagonist ACET on altered sensorimotor gating in a genetic model of reduced NMDA receptor function. <i>Brain Research</i> , 2012, 1443, 98-105.	1.1	6
2359	Efficacy and tolerability of blonanserin in 48 patients with intractable schizophrenia. <i>Acta Neuropsychiatrica</i> , 2012, 24, 380-383.	1.0	9
2360	Pharmacotherapy and clinical characteristics of ultra-high-risk for psychosis according to conversion status: a naturalistic observational study. <i>Microbial Biotechnology</i> , 2012, 6, 30-37.	0.9	20
2361	Effects of dropout on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2012, 126, 1-11.	2.2	18
2362	A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: A one-year mirror-image study with national claim-based database in Taiwan. <i>Journal of Psychiatric Research</i> , 2012, 46, 751-756.	1.5	19
2363	Abnormalities in thalamic neurophysiology in schizophrenia: Could psychosis be a result of potassium channel dysfunction?. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 960-968.	2.9	36
2364	Glutamate signaling in the pathophysiology and therapy of schizophrenia. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 665-677.	1.3	132
2365	Overview of glutamatergic neurotransmission in the nervous system. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 656-664.	1.3	224
2366	Joint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2012, 175, 417-433.	0.6	27
2367	Estimating the Optimal Dynamic Antipsychotic Treatment Regime: Evidence from the Sequential Multiple-Assignment Randomized Clinical Antipsychotic Trials of Intervention and Effectiveness Schizophrenia Study. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2012, 61, 577-599.	0.5	36
2368	Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. <i>Psychiatry and Clinical Neurosciences</i> , 2012, 66, 313-321.	1.0	6
2369	Evolving role of mental health nurses in the physical health care of people with serious mental health illness. <i>International Journal of Mental Health Nursing</i> , 2012, 21, 266-273.	2.1	71
2370	Side-effects of antipsychotics is not apocryphal. <i>International Journal of Mental Health Nursing</i> , 2012, 21, 396-397.	2.1	2
2371	Customization in prescribing for bipolar disorder. <i>Health Economics (United Kingdom)</i> , 2012, 21, 653-668.	0.8	8

#	ARTICLE	IF	CITATIONS
2372	Adverse effects of antipsychotic drugs: survey of doctorsâ€™ versus patientsâ€™ perspective. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 157-164.	1.6	15
2373	Discovery of potential antipsychotic agents possessing pro-cognitive properties. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 313-323.	1.4	7
2374	Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. <i>Psychopharmacology</i> , 2012, 219, 783-794.	1.5	67
2375	Variability in the Efficacy of Psychopharmaceuticals: Contributions from Pharmacogenomics, Ethnopsychopharmacology, and Psychological and Psychiatric Anthropologies. <i>Culture, Medicine and Psychiatry</i> , 2012, 36, 10-25.	0.7	20
2376	Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders. <i>Molecular Biology Reports</i> , 2012, 39, 2003-2010.	1.0	10
2377	Evidence review and clinical guidance for the use of ziprasidone in Canada. <i>Annals of General Psychiatry</i> , 2013, 12, 1.	1.2	11
2378	Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc ⁻ activity in the medial prefrontal cortex. <i>Psychopharmacology</i> , 2013, 226, 531-540.	1.5	12
2379	Atypical antipsychotics and diabetic ketoacidosis: a review. <i>Psychopharmacology</i> , 2013, 226, 1-12.	1.5	45
2380	Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. <i>Psychopharmacology</i> , 2013, 225, 519-530.	1.5	104
2381	The association between CYP2D6 genotype and switching antipsychotic medication to clozapine. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1927-1932.	0.8	3
2382	Polypharmacy in Psychiatry Practice, Volume II. , 2013, , .		2
2383	A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and Î²-cell function in schizophrenic patients. <i>Psychopharmacology</i> , 2013, 230, 3-13.	1.5	23
2384	Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: Results after one year. <i>Schizophrenia Research</i> , 2013, 149, 156-161.	1.1	33
2385	Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 104, 113-118.	1.3	16
2386	A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness. <i>New England Journal of Medicine</i> , 2013, 368, 1594-1602.	13.9	452
2387	Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. <i>European Neuropsychopharmacology</i> , 2013, 23, 1017-1022.	0.3	37
2388	Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. <i>Psychopharmacology</i> , 2013, 230, 49-55.	1.5	53
2389	The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 95-106.	1.0	47

#	ARTICLE	IF	CITATIONS
2390	Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 737-744.	1.9	44
2391	Cognitive remediation improves cognition and good cognitive performance increases time to relapse – results of a 5 year catamnestic study in schizophrenia patients. <i>BMC Psychiatry</i> , 2013, 13, 184.	1.1	38
2392	Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy. <i>BMC Psychiatry</i> , 2013, 13, 179.	1.1	8
2393	The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. <i>BMC Psychiatry</i> , 2013, 13, 109.	1.1	43
2394	Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. <i>BMC Psychiatry</i> , 2013, 13, 98.	1.1	19
2395	Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses. <i>BMC Psychiatry</i> , 2013, 13, 58.	1.1	34
2396	Personalized medicine in psychiatry: problems and promises. <i>BMC Medicine</i> , 2013, 11, 132.	2.3	192
2397	Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1203-1214.	0.6	9
2398	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2013, , CD006569.		18
2399	Behavioral Interventions for Antipsychotic Induced Appetite Changes. <i>Current Psychiatry Reports</i> , 2013, 15, 347.	2.1	20
2400	Impact of Early Nonadherence to Oral Antipsychotics on Clinical and Economic Outcomes Among Patients with Schizophrenia. <i>Advances in Therapy</i> , 2013, 30, 286-297.	1.3	60
2401	Polypharmacy in Psychiatry Practice, Volume I. , 2013, , .		5
2402	Novel approaches to drug design for the treatment of schizophrenia. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1285-1296.	2.5	20
2403	A Medicaid and Commercial Insured Claims-Based Study to Estimate Improved Antipsychotic Medication Adherence Among Patients with Schizophrenia. <i>Journal of Behavioral Health Services and Research</i> , 2013, 40, 222-233.	0.6	3
2404	Quetiapine versus typical antipsychotic medications for schizophrenia. <i>The Cochrane Library</i> , 2013, , CD007815.	1.5	23
2405	Drugs for Neuropsychiatric Disorders. , 2013, , 180-207.		0
2408	Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2013, 47, 670-677.	1.5	129
2409	The Association between Cataract Surgery and Atypical Antipsychotic Use: A Nested Case-Control Study. <i>American Journal of Ophthalmology</i> , 2013, 156, 1141-1146.e1.	1.7	12

#	ARTICLE	IF	CITATIONS
2410	P.1.j.026 Cognitive deficits caused by hippocampal disinhibition: attentional and memory deficits. <i>European Neuropsychopharmacology</i> , 2013, 23, S296-S297.	0.3	1
2411	Age-related cortical thickness differences in adolescents with early-onset schizophrenia compared with healthy adolescents. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 190-196.	0.9	30
2413	The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. <i>Psychiatry Research</i> , 2013, 210, 396-401.	1.7	7
2414	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 328-333.	1.1	46
2415	Pharmacogenetics of olanzapine metabolism. <i>Pharmacogenomics</i> , 2013, 14, 1319-1336.	0.6	39
2416	Diab�ete et sant� mentale. <i>Canadian Journal of Diabetes</i> , 2013, 37, S459-S465.	0.4	1
2417	Repetitive Transcranial Magnetic Stimulation Treatment for Depressive Disorders. , 2013, , .		14
2418	Kami-ondam-tang, a traditional herbal prescription, attenuates the prepulse inhibition deficits and cognitive impairments induced by MK-801 in mice. <i>Journal of Ethnopharmacology</i> , 2013, 146, 600-607.	2.0	17
2419	The use of clinical trials in comparative effectiveness research on mental health. <i>Journal of Clinical Epidemiology</i> , 2013, 66, S29-S36.	2.4	5
2420	Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: Potential utility as antipsychotic medications. <i>Neuropharmacology</i> , 2013, 72, 274-281.	2.0	18
2422	Detection of Metabolic Syndrome in Schizophrenia and Implications for Antipsychotic Therapy. <i>Molecular Diagnosis and Therapy</i> , 2013, 17, 21-30.	1.6	25
2423	Ethik psychiatrischer Forschung. , 2013, , .		5
2424	Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia. <i>BMC Psychiatry</i> , 2013, 13, 243.	1.1	1
2425	Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 976-990.	0.3	213
2426	Genetic predictors of risk and resilience in psychiatric disorders: A cross-disorder genome-wide association study of functional impairment in major depressive disorder, bipolar disorder, and schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 779-788.	1.1	36
2427	Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 146, 285-288.	1.1	58
2428	Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 961-969.	0.9	55
2429	Design of a dual nanostructured lipid carrier formulation based on physicochemical, rheological, and mechanical properties. <i>Journal of Nanoparticle Research</i> , 2013, 15, 1.	0.8	24

#	ARTICLE	IF	CITATIONS
2430	Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2013, 7, 31.	1.2	19
2431	Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. <i>BMC Psychiatry</i> , 2013, 13, 221.	1.1	69
2432	Implementation of a Weight Loss Program for Latino Outpatients with Severe Mental Illness. <i>Community Mental Health Journal</i> , 2013, 49, 150-156.	1.1	8
2433	Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study. <i>Annals of General Psychiatry</i> , 2013, 12, 42.	1.2	18
2434	Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor. <i>CNS Drugs</i> , 2013, 27, 1069-1080.	2.7	89
2436	Statistical Methods for Dynamic Treatment Regimes. <i>Statistics in the Health Sciences</i> , 2013, , .	0.2	196
2437	Effects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 545-563.	1.2	130
2438	Pimavanserin for the treatment of Parkinson's disease psychosis. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1969-1975.	0.9	35
2439	Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2013, 91, 1119-1126.	0.7	21
2440	Improving Treatment Adherence in Your Patients with Schizophrenia. <i>Clinical Drug Investigation</i> , 2013, 33, 97-107.	1.1	38
2441	Sleep in Schizophrenia and Substance Use Disorders: A Review of the Literature. <i>Journal of Dual Diagnosis</i> , 2013, 9, 228-238.	0.7	4
2442	Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. <i>Psychosis</i> , 2013, 5, 82-92.	0.4	10
2443	HDAC2 as a new target to improve schizophrenia treatment. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1-3.	1.4	21
2444	What is the role of pharmacogenetics in clinical psychiatry?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1-4.	1.5	9
2445	Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 489-504.	0.9	8
2446	Neuroimaging as a potential biomarker to optimize psychiatric research and treatment. <i>International Review of Psychiatry</i> , 2013, 25, 619-631.	1.4	13
2447	Psychosis in Children and Youth: Focus on Early-Onset Schizophrenia. <i>Pediatrics in Review</i> , 2013, 34, 296-306.	0.2	12
2448	Pharmacogenetics of antipsychotics: recent progress and methodological issues. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 183-191.	1.5	45

#	ARTICLE	IF	CITATIONS
2449	The Alabama Coalition for a Healthier Black Belt: A Proof of Concept Project. <i>Community Mental Health Journal</i> , 2013, 49, 79-85.	1.1	5
2450	Genetic Variation Throughout the Folate Metabolic Pathway Influences Negative Symptom Severity in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2013, 39, 330-338.	2.3	66
2452	The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. <i>Psychopharmacology</i> , 2013, 228, 31-42.	1.5	31
2453	Changes in QT interval after switching to quetiapine in Japanese patients with schizophrenia. <i>Human Psychopharmacology</i> , 2013, 28, 94-96.	0.7	5
2454	Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1). <i>Schizophrenia Research</i> , 2013, 144, 80-86.	1.1	9
2455	Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect?. <i>Neuropharmacology</i> , 2013, 72, 179-186.	2.0	39
2457	Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysis. <i>Schizophrenia Research</i> , 2013, 150, 339-342.	1.1	86
2458	Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE Study. <i>Schizophrenia Research</i> , 2013, 149, 21-25.	1.1	20
2459	Clinical determinants of life satisfaction in chronic schizophrenia: Data from the CATIE study. <i>Schizophrenia Research</i> , 2013, 151, 203-208.	1.1	35
2461	Criterios de valoración clínicos y de funcionamiento en un estudio de interacción gen-ambiente en primeros episodios psicóticos (PEPs). <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 4-16.	1.0	99
2462	Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data. <i>Schizophrenia Research</i> , 2013, 150, 373-379.	1.1	8
2463	Acute antipsychotic treatments induce distinct c-Fos expression patterns in appetite-related neuronal structures of the rat brain. <i>Brain Research</i> , 2013, 1508, 34-43.	1.1	18
2464	Shared understanding in psychiatrist-patient communication: Association with treatment adherence in schizophrenia. <i>Patient Education and Counseling</i> , 2013, 93, 73-79.	1.0	60
2465	Insomnia Comorbid to Severe Psychiatric Illness. <i>Sleep Medicine Clinics</i> , 2013, 8, 361-371.	1.2	60
2467	The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. <i>Psychoneuroendocrinology</i> , 2013, 38, 2423-2438.	1.3	50
2468	Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. <i>Journal of Chromatography A</i> , 2013, 1292, 160-172.	1.8	69
2469	Deep brain stimulation of the ventral hippocampus restores deficits in processing of auditory evoked potentials in a rodent developmental disruption model of schizophrenia. <i>Schizophrenia Research</i> , 2013, 143, 377-383.	1.1	29
2470	Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: A review of the literature. <i>Schizophrenia Research</i> , 2013, 147, 368-374.	1.1	37

#	ARTICLE	IF	CITATIONS
2471	Validation of an abbreviated quality of life scale for schizophrenia. <i>European Neuropsychopharmacology</i> , 2013, 23, 1072-1077.	0.3	14
2472	Patterns and predictors of antipsychotic medication use among the U.S. population: Findings from the Medical Expenditure Panel Survey. <i>Research in Social and Administrative Pharmacy</i> , 2013, 9, 263-275.	1.5	17
2473	Attaining and sustaining remission of predominant negative symptoms. <i>Schizophrenia Research</i> , 2013, 143, 60-64.	1.1	13
2474	A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials. <i>European Neuropsychopharmacology</i> , 2013, 23, 1570-1576.	0.3	14
2476	The interaction of subjective experience and attitudes towards specific antipsychotic-related adverse effects in schizophrenia patients. <i>European Psychiatry</i> , 2013, 28, 340-343.	0.1	5
2477	Intermittent drug techniques for schizophrenia. <i>The Cochrane Library</i> , 2013, , CD006196.	1.5	32
2478	Medication and suicide risk in schizophrenia: A nested case-control study. <i>Schizophrenia Research</i> , 2013, 150, 416-420.	1.1	37
2479	The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 1886-1892.	1.5	23
2480	Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 45, 178-182.	2.5	25
2481	Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: A nationwide study in Hungary. <i>European Neuropsychopharmacology</i> , 2013, 23, 1383-1390.	0.3	29
2482	Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. <i>Schizophrenia Research</i> , 2013, 145, 116-119.	1.1	18
2483	Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia. <i>Contemporary Clinical Trials</i> , 2013, 34, 239-247.	0.8	7
2484	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2013, 6, 4-16.	0.2	24
2485	Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms. <i>European Neuropsychopharmacology</i> , 2013, 23, 1051-1056.	0.3	18
2486	Diabetes and Mental Health. <i>Canadian Journal of Diabetes</i> , 2013, 37, S87-S92.	0.4	75
2487	Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness. <i>Psychosomatics</i> , 2013, 54, 67-73.	2.5	59
2488	Early prediction of clinical and functional outcome in schizophrenia. <i>European Neuropsychopharmacology</i> , 2013, 23, 842-851.	0.3	21
2489	Impact of the Pharma Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007-2010). <i>Value in Health Regional Issues</i> , 2013, 2, 290-299.	0.5	4

#	ARTICLE	IF	CITATIONS
2490	Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: An approach using generalised estimating equations. <i>Psychiatry Research</i> , 2013, 210, 745-750.	1.7	9
2491	Psychiatric comorbidity among adults with schizophrenia: A latent class analysis. <i>Psychiatry Research</i> , 2013, 210, 16-20.	1.7	67
2492	Short-term remission in schizophrenia as a combination of several outcome measures. <i>Psychiatry Research</i> , 2013, 209, 401-405.	1.7	5
2493	An acute rat in vivo screening model to predict compounds that alter blood glucose and/or insulin regulation. <i>Journal of Pharmacological and Toxicological Methods</i> , 2013, 68, 190-196.	0.3	3
2494	Psychosocial Treatments for Schizophrenia. <i>Annual Review of Clinical Psychology</i> , 2013, 9, 465-497.	6.3	284
2495	Are immediate and extended release drugs interchangeable?. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 78-80.	2.2	6
2496	Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. <i>International Journal of Clinical Practice</i> , 2013, 67, 170-180.	0.8	12
2497	Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-7.	0.7	6
2498	Co-encapsulating nanostructured lipid carriers for transdermal application: From experimental design to the molecular detail. <i>Journal of Controlled Release</i> , 2013, 167, 301-314.	4.8	113
2499	Predictors of medication adherence in patients with schizophrenia and bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 23-33.	2.2	123
2500	The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2013, 29, 227-239.	0.9	9
2501	Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. <i>Pharmacogenomics Journal</i> , 2013, 13, 544-550.	0.9	26
2502	Pharmacogenetics of Risperidone: A Systematic Review of the Clinical Effects of CYP2D6 Polymorphisms. <i>Annals of Pharmacotherapy</i> , 2013, 47, 350-360.	0.9	19
2503	Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. <i>Psychopharmacology</i> , 2013, 225, 627-635.	1.5	31
2504	Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules. <i>Neurobiology of Disease</i> , 2013, 53, 61-74.	2.1	29
2505	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 2-44.	1.3	343
2506	Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2013, 23, 118-125.	0.3	19
2507	Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. <i>Human Psychopharmacology</i> , 2013, 28, 205-214.	0.7	43

#	ARTICLE	IF	CITATIONS
2508	Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 273-284.	1.8	44
2509	The biomedical model of mental disorder: A critical analysis of its validity, utility, and effects on psychotherapy research. <i>Clinical Psychology Review</i> , 2013, 33, 846-861.	6.0	377
2510	Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia. <i>Human Psychopharmacology</i> , 2013, 28, 215-219.	0.7	16
2511	The Use of rTMS in Other Psychiatric Disorders. , 2013, , 103-116.		0
2512	Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. <i>European Journal of Medicinal Chemistry</i> , 2013, 66, 122-134.	2.6	25
2513	Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. <i>Lancet, The</i> , 2013, 382, 951-962.	6.3	2,094
2514	<i>Prunella vulgaris</i> Attenuates Prepulse Inhibition Deficit and Attention Disruption induced by MK801 in Mice. <i>Phytotherapy Research</i> , 2013, 27, 1763-1769.	2.8	9
2515	Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents. <i>Paediatric Drugs</i> , 2013, 15, 217-233.	1.3	76
2516	Quetiapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2013, , CD006625.	1.5	44
2517	An In Vitro Analysis of Disintegration Times of Different Formulations of Olanzapine Orodispersible Tablet: A Preliminary Report. <i>Drugs in R and D</i> , 2013, 13, 281-288.	1.1	7
2518	Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 61-91.	1.3	22
2519	Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. <i>Journal of Medical Economics</i> , 2013, 16, 951-961.	1.0	12
2520	Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 347-356.	0.8	34
2521	Pharmacological and Psychosocial Management of Mental, Neurological and Substance Use Disorders in Low- and Middle-Income Countries: Issues and Current Strategies. <i>Drugs</i> , 2013, 73, 1549-1568.	4.9	13
2523	Teaching All the Evidence Bases: Reintegrating Psychodynamic Aspects of Prescribing into Psychopharmacology Training. <i>Psychodynamic Psychiatry</i> , 2013, 41, 13-37.	0.1	7
2524	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. <i>Molecular Psychiatry</i> , 2013, 18, 53-66.	4.1	136
2525	Subjective Quality of Life and Sexual Dysfunction in Outpatients With Schizophrenia or Schizoaffective Disorder. <i>Journal of Sex and Marital Therapy</i> , 2013, 39, 336-346.	1.0	22
2526	Update on Typical and Atypical Antipsychotic Drugs. <i>Annual Review of Medicine</i> , 2013, 64, 393-406.	5.0	337

#	ARTICLE	IF	CITATIONS
2527	Antipsychotic Agents. , 2013, , 31-88.		0
2528	Modern Psychopharmacology and Psychiatric Treatment. , 2013, , 1-29.		0
2529	Research Policies for Schizophrenia in the Global Health Context. International Journal of Mental Health, 2013, 42, 51-76.	0.5	1
2530	Diffusion of Antipsychotics in the U.S. and French Markets, 1998â€“2008. Psychiatric Services, 2013, 64, 680-687.	1.1	24
2531	Measuring mental illness stigma with diminished social desirability effects. Journal of Mental Health, 2013, 22, 218-226.	1.0	44
2532	How Quickly Do Physicians Adopt New Drugs? The Case of Second-Generation Antipsychotics. Psychiatric Services, 2013, 64, 324-330.	1.1	31
2533	Relationship Between Relapse and Hospitalization in First-Episode Psychosis. Psychiatric Services, 2013, 64, 796-799.	1.1	38
2534	The LORS-Enabled Dialogue: A Collaborative Intervention to Promote Recovery From Psychotic Disorders. Psychiatric Services, 2013, 64, 58-64.	1.1	4
2535	Antipsychotic Formulation and One-Year Rehospitalization of Schizophrenia Patients: A Population-Based Cohort Study. Psychiatric Services, 2013, 64, 1259-1262.	1.1	15
2536	Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design. Epidemiology and Psychiatric Sciences, 2013, 22, 223-233.	1.8	9
2537	First and second generation antipsychotics: translating the results from pragmatic trials into clinical practice. Epidemiology and Psychiatric Sciences, 2013, 22, 239-240.	1.8	2
2538	Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. Current Medical Research and Opinion, 2013, 29, 1231-1240.	0.9	13
2539	The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation. Epigenomics, 2013, 5, 317-329.	1.0	26
2540	Pharmacological Treatment of Schizophrenia. Fortschritte Der Neurologie Psychiatrie, 2013, 81, e1-e13.	0.3	14
2541	Leverage, the Treatment Relationship, and Treatment Participation. Psychiatric Services, 2013, 64, 431-436.	1.1	15
2542	Monitoring Veterans for Metabolic Side Effects When Prescribing Antipsychotics. Psychiatric Services, 2013, 64, 28-35.	1.1	14
2543	The Effect of Race-Ethnicity on the Comparative Effectiveness of Clozapine Among Medicaid Beneficiaries. Psychiatric Services, 2013, 64, 230-237.	1.1	22
2544	Comparison of Outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE Study. Psychiatric Services, 2013, 64, 570-578.	1.1	12

#	ARTICLE	IF	CITATIONS
2545	Racial-Ethnic Differences in Incident Olanzapine Use After an FDA Advisory for Patients With Schizophrenia. <i>Psychiatric Services</i> , 2013, 64, 83-87.	1.1	5
2546	Prescription of Second-Generation Antipsychotics: Responding to Treatment Risk in Real-World Practice. <i>Psychiatric Services</i> , 2013, 64, 238-244.	1.1	9
2547	Antipsychotic Prescribing Pathways, Polypharmacy, and Clozapine Use in Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2013, 64, 527-533.	1.1	59
2548	Generic atypical antipsychotic drugs in Belgium: their influence and implications. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 551-561.	0.6	14
2549	Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2013, 170, 1032-1040.	4.0	118
2550	Weight Considerations in Psychotropic Drug Prescribing and Switching. <i>Postgraduate Medicine</i> , 2013, 125, 117-129.	0.9	73
2551	Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 987-995.	1.0	69
2552	Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1205-1218.	1.0	257
2553	The Long-Term Effects of Conventional and Atypical Antipsychotics in Patients With Probable Alzheimer's Disease. <i>American Journal of Psychiatry</i> , 2013, 170, 1051-1058.	4.0	110
2554	PS1-16: Directions for Future Patient-Centered and Comparative Effectiveness Research for People with Serious Mental Illness. <i>Clinical Medicine and Research</i> , 2013, 11, 166-166.	0.4	0
2555	A Genome-Wide RNAi Screen in <i>Caenorhabditis elegans</i> Identifies the Nicotinic Acetylcholine Receptor Subunit ACR-7 as an Antipsychotic Drug Target. <i>PLoS Genetics</i> , 2013, 9, e1003313.	1.5	21
2556	Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, 176.	0.2	66
2557	The Cognitive Assessment Interview (CAI): Reliability and Validity of a Brief Interview-Based Measure of Cognition. <i>Schizophrenia Bulletin</i> , 2013, 39, 583-591.	2.3	50
2558	Peripubertal Diazepam Administration Prevents the Emergence of Dopamine System Hyperresponsivity in the MAM Developmental Disruption Model of Schizophrenia. <i>Neuropsychopharmacology</i> , 2013, 38, 1881-1888.	2.8	86
2559	Management of Antipsychotic-Induced Weight Gain. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2013, 48, 48.	0.1	0
2560	The Prevalence of Glucose Intolerance in Japanese Schizophrenic Patients With a Normal Fasting Glucose Level. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 525-527.	0.7	2
2561	Aripiprazole Versus Haloperidol in Combination With Clozapine for Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 533-537.	0.7	26
2562	Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 329-335.	0.7	56

#	ARTICLE	IF	CITATIONS
2563	Efficacy and safety of second-generation long-acting injections in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2013, 28, 57-66.	0.9	83
2564	Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. <i>Journal of Lipid Research</i> , 2013, 54, 310-324.	2.0	87
2565	Second-Generation Antipsychotic Medications and Risk of Pneumonia in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2013, 39, 648-657.	2.3	124
2566	Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 80-83.	0.7	62
2567	Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 535-548.	0.7	170
2568	A Pilot Study Investigating Tumor Necrosis Factor- α as a Potential Intervening Variable of Atypical Antipsychotic-Associated Metabolic Syndrome in Bipolar Disorder. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 194-202.	1.0	11
2569	Neurological and Psychiatric Diseases and Their Unique Cognitive Profiles. <i>Journal of Neuroscience Nursing</i> , 2013, 45, 77-87.	0.7	10
2570	Management of Antipsychotic-Induced Weight Gain. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2013, 48, 41-47.	0.1	1
2571	Effect of Topiramate on Weight Gain in Patients Receiving Atypical Antipsychotic Agents. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 90-94.	0.7	30
2572	Can Repetitive Transcranial Magnetic Stimulation Be Considered Effective Treatment Option for Negative Symptoms of Schizophrenia?. <i>Journal of ECT</i> , 2013, 29, 67-74.	0.3	24
2573	High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 485-490.	0.7	19
2574	A Randomized Clinical Trial of Histamine 2 Receptor Antagonism in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 472-478.	0.7	52
2575	Antipsychotic combinations. <i>Middle East Current Psychiatry</i> , 2013, 20, 60-72.	0.5	0
2576	Dichotomizing rating scale scores in psychiatry: a bad idea?. <i>Epidemiology and Psychiatric Sciences</i> , 2013, 22, 17-19.	1.8	13
2577	The advance of research governance in psychiatry: one step forward, two steps back. <i>Epidemiology and Psychiatric Sciences</i> , 2013, 22, 313-320.	1.8	12
2578	Personalized Medicine in the Context of Comparative Effectiveness Research. <i>Forum for Health Economics and Policy</i> , 2013, 16, S73-S86.	0.2	2
2579	Add-on Treatment of Benzoate for Schizophrenia. <i>JAMA Psychiatry</i> , 2013, 70, 1267.	6.0	194
2580	Guideline-Concordant Antipsychotic Use and Mortality in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2013, 39, 1159-1168.	2.3	64

#	ARTICLE	IF	CITATIONS
2581	The Psychopharmacology Algorithm Project at the Harvard South Shore Program. <i>Harvard Review of Psychiatry</i> , 2013, 21, 18-40.	0.9	38
2582	Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 11-17.	0.7	44
2583	Polypharmacy for schizophrenia. <i>Current Opinion in Psychiatry</i> , 2013, 26, 208-213.	3.1	53
2584	Understanding depot antipsychotics: an illustrated guide to kinetics. <i>CNS Spectrums</i> , 2013, 18, 55-68.	0.7	24
2585	N-3 Fatty Acids for Hypertriglyceridemia in Patients Taking Second-Generation Antipsychotics. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 7, 73-77A.	1.4	5
2586	Effectiveness of Sulpiride in Adult Patients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2013, 39, 673-683.	2.3	29
2587	Treatment Engagement of Psychotic Patients with a Mobile Mental Health Unit in Rural Areas in Greece: A Five-Year Study. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-6.	0.7	19
2588	Reply. <i>Psychotherapy and Psychosomatics</i> , 2013, 82, 259-259.	4.0	0
2589	Extended-release intramuscular aripiprazole for maintenance pharmacotherapy in schizophrenia and related disorders. <i>Neuropsychiatry</i> , 2013, 3, 345-354.	0.4	1
2590	Antipsychotics in the treatment of schizophrenia. <i>Progress in Neurology and Psychiatry</i> , 2013, 17, 6-18.	0.4	3
2591	Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia. <i>Human Psychopharmacology</i> , 2013, 28, 124-133.	0.7	32
2592	Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia. <i>Human Psychopharmacology</i> , 2013, 28, 438-446.	0.7	5
2593	Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement. <i>Human Psychopharmacology</i> , 2013, 28, 107-116.	0.7	12
2594	Glycogen synthase kinase-3 substrates in mood disorders and schizophrenia. <i>FEBS Journal</i> , 2013, 280, 5213-5227.	2.2	58
2595	Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. <i>Nordic Journal of Psychiatry</i> , 2013, 67, 22-29.	0.7	22
2596	The effects of an adherence therapy approach in a secure forensic hospital: a randomised controlled trial. <i>Journal of Forensic Psychiatry and Psychology</i> , 2013, 24, 458-478.	0.6	10
2597	Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. <i>Journal of Pharmaceutical Health Services Research</i> , 2013, 4, 139-150.	0.3	8
2598	Exploring service users perceptions of recovery from psychosis: A methodological approach. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2013, 86, 245-261.	1.3	20

#	ARTICLE	IF	CITATIONS
2599	Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. <i>Journal of Pharmaceutical Health Services Research</i> , 2013, 4, 29-39.	0.3	19
2600	Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 200-218.	1.2	400
2601	Risk of Pneumonia in Elderly Nursing Home Residents Using Typical Versus Atypical Antipsychotics. <i>Annals of Pharmacotherapy</i> , 2013, 47, 464-474.	0.9	21
2602	The mental health social worker as a transitional participant: actively listening to "voices" and getting into the recovery position. <i>Journal of Social Work Practice</i> , 2013, 27, 21-32.	0.6	27
2603	The Challenge of Adherence in Schizophrenia. , 2013, , .		0
2604	Pharmacological approaches to the management of schizophrenia: 10 years on. <i>Australasian Psychiatry</i> , 2013, 21, 329-334.	0.4	7
2605	Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. <i>Pharmacogenomics Journal</i> , 2013, 13, 197-204.	0.9	20
2606	DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. <i>Journal of Psychopharmacology</i> , 2013, 27, 343-348.	2.0	19
2607	Synaptic synopsis. <i>Science-Business EXchange</i> , 2013, 6, 1153-1153.	0.0	0
2608	Cognitive behavioral therapy for psychosis " training practices and dissemination in the United States. <i>Psychosis</i> , 2013, 5, 296-305.	0.4	31
2609	Atypical antipsychotics for psychosis in adolescents. <i>The Cochrane Library</i> , 2013, , CD009582.	1.5	37
2610	A Critical Perspective on the Role of Psychotropic Medications in Mental Health Courts. <i>American Behavioral Scientist</i> , 2013, 57, 244-265.	2.3	7
2611	Differential Long-Term Effects of Haloperidol and Risperidone on the Acquisition and Performance of Tasks of Spatial Working and Short-Term Memory and Sustained Attention in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 547-556.	1.3	17
2612	Should the training of clinical psychologists require competence in the treatment and rehabilitation of individuals with a serious mental illness?. <i>Psychiatric Rehabilitation Journal</i> , 2013, 36, 54-59.	0.8	14
2614	The Adequacy of Pharmaceutical Treatment of Schizophrenia in Quebec Varies with Age, but is Not Influenced by Sex or Neighbourhood Deprivation. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 456-465.	0.9	7
2615	Predicting Psychiatric Hospital Admission Among Adults With Schizophrenia. <i>Yearbook of Psychiatry and Applied Mental Health</i> , 2013, 2013, 258-259.	0.1	0
2617	Switching to Ziprasidone in the Clinical Practice Setting: An Open-Label Study. <i>International Journal of Psychiatry in Medicine</i> , 2013, 45, 125-142.	0.8	8
2618	Do Low- and Middle-Income Countries Learn from the Experience of High-Income Countries?. <i>International Journal of Mental Health</i> , 2013, 42, 33-50.	0.5	4

#	ARTICLE	IF	CITATIONS
2619	Prevalence of Metabolic Syndrome and Associated Risk Factors in Hospitalized Patients with Schizophrenia in Mexico. <i>International Journal of Mental Health</i> , 2013, 42, 95-104.	0.5	3
2620	Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. <i>CNS Spectrums</i> , 2013, 18, 43-54.	0.7	27
2621	Genetics of Schizophrenia. <i>International Journal of Mental Health</i> , 2013, 42, 5-22.	0.5	4
2622	Comparing Symptom Response Among Antipsychotic Medications in CATIE. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 123-126.	0.7	2
2623	Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 69-77.	0.7	43
2624	Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 5-13.	0.9	47
2625	NMDA Receptor Activity in Neuropsychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2013, 4, 52.	1.3	111
2626	Antipsychotic treatments; focus on lurasidone. <i>Frontiers in Pharmacology</i> , 2013, 4, 102.	1.6	9
2627	Comparative Safety of Antipsychotics: Another Look at the Risk of Diabetes. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 218-224.	0.9	10
2628	Social Network Intervention in Patients with Schizophrenia and Marked Social Withdrawal: A Randomized Controlled Study. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 622-631.	0.9	29
2629	Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 133.	1.0	8
2630	Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome. <i>The Open Neurology Journal</i> , 2013, 7, 23-31.	0.4	15
2631	The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 407.	0.7	29
2632	An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1553.	1.0	2
2633	Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 815.	1.0	4
2634	Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1311.	1.0	55
2635	Gaining Autonomy & Medication Management (GAM): new perspectives on well-being, quality of life and psychiatric medication. <i>Ciencia E Saude Coletiva</i> , 2013, 18, 2879-2887.	0.1	14
2636	New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 753.	1.0	5

#	ARTICLE	IF	CITATIONS
2637	The prevalence of metabolic syndrome and its associated factors in long-term patients in a specialist psychiatric hospital in South Africa. <i>African Journal of Psychiatry</i> , 2013, 16, .	0.1	14
2638	Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1163.	1.0	14
2641	Genotype-Based Ancestral Background Consistently Predicts Efficacy and Side Effects across Treatments in CATIE and STAR*D. <i>PLoS ONE</i> , 2013, 8, e55239.	1.1	6
2642	Profile of blonanserin for the treatment of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 587.	1.0	55
2643	Pharmacogenetics in schizophrenia: a review of clozapine studies. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, 305-317.	0.9	21
2644	Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future. <i>Frontiers in Pharmacology</i> , 2012, 3, 198.	1.6	13
2645	Yoga on Our Minds: A Systematic Review of Yoga for Neuropsychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2012, 3, 117.	1.3	257
2646	Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, 295-304.	0.9	22
2647	BIPOLAR DISORDER IN ADULTS. <i>International Research Journal of Pharmacy</i> , 2013, 4, 34-38.	0.0	4
2648	Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1737.	1.0	1
2649	Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. <i>Patient Preference and Adherence</i> , 2013, 7, 1171.	0.8	137
2650	Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 459.	0.7	16
2651	Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 341.	1.0	23
2652	Participants With Schizophrenia Retain the Information Necessary for Informed Consent During Clinical Trials. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 622-627.	1.1	8
2653	Recovery and Mental Health. , 2013, , .		41
2654	The South African Society of Psychiatrists (SASOP) Treatment Guidelines for Psychiatric Disorders. <i>South African Journal of Psychiatry</i> , 2013, 19, 2.	0.2	13
2655	Drug information update: paliperidone palmitate for schizophrenia. <i>The Psychiatrist</i> , 2013, 37, 164-166.	0.3	2
2656	The Preference Survey for Long-Acting Injectable Antipsychotics of Community-Dwelling Patients with Schizophrenia and their Caregivers. <i>Korean Journal of Schizophrenia Research</i> , 2013, 16, 14.	0.3	4

#	ARTICLE	IF	CITATIONS
2657	Ambulatory Clinical Pharmacy Specialty Services: The Kaiser Permanente Colorado Experience. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 245-253.	2.2	8
2658	Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 869.	1.0	3
2659	Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1287.	1.0	1
2660	History and Therapeutic Rationale of Long Acting Antipsychotics. <i>Current Clinical Pharmacology</i> , 2014, 9, 39-52.	0.2	21
2661	Dopamine Signaling Regulates Fat Content through β^2 -Oxidation in <i>Caenorhabditis elegans</i> . <i>PLoS ONE</i> , 2014, 9, e85874.	1.1	20
2662	Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment. <i>PLoS ONE</i> , 2014, 9, e104160.	1.1	65
2663	The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse. <i>PLoS ONE</i> , 2014, 9, e115225.	1.1	147
2664	Aggression in Psychoses. <i>Advances in Psychiatry</i> , 2014, 2014, 1-20.	0.4	10
2665	Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 841.	1.0	7
2666	Targeting Neural Synchrony Deficits is Sufficient to Improve Cognition in a Schizophrenia-Related Neurodevelopmental Model. <i>Frontiers in Psychiatry</i> , 2014, 5, 15.	1.3	40
2667	Sleep spindle deficits in antipsychotic-naïve early course schizophrenia and in non-psychotic first-degree relatives. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 762.	1.0	126
2668	Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample. <i>Journal of Korean Medical Science</i> , 2014, 29, 719.	1.1	28
2669	Recent advances in understanding schizophrenia. <i>F1000prime Reports</i> , 2014, 6, 57.	5.9	42
2670	Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach. <i>Journal of Multidisciplinary Healthcare</i> , 2014, 7, 489.	1.1	23
2671	Neuroleptic Drugs Affect Sympathetic and Thermogenic Reactions to Orexin A. <i>African Journal of Psychiatry</i> , 2014, 17, .	0.1	2
2672	Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 417.	1.0	7
2673	Long-term efficacy and safety of iloperidone: an update. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 409.	1.0	6
2674	Towards a framework for treatment effectiveness in schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1867.	1.0	18

#	ARTICLE	IF	CITATIONS
2675	Yokukansan and its ingredients as possible treatment options for schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1629.	1.0	9
2676	Prescribing for personality disorder: qualitative study of interviews with general and forensic consultant psychiatrists. <i>Psychiatric Bulletin</i> (2014), 2014, 38, 116-121.	0.4	13
2679	Management of the Psychotic Substance Using Patient. <i>Canadian Journal of Addiction</i> , 2014, 5, 5-9.	0.2	3
2680	Safety profile of iloperidone in the treatment of schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 241-246.	1.0	165
2681	New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. <i>Autophagy</i> , 2014, 10, 2324-2332.	4.3	64
2682	Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 67-73.	1.4	4
2683	Metacognitive Therapy in Treatment-Resistant Psychosis: A Multiple-Baseline Study. <i>Behavioural and Cognitive Psychotherapy</i> , 2014, 42, 166-185.	0.9	39
2684	Lack of Insight in Psychosis: Theoretical Concepts and Clinical Aspects. <i>Behavioural and Cognitive Psychotherapy</i> , 2014, 42, 327-338.	0.9	9
2685	Cognitive-Behavioral Therapy for Medication-Resistant Psychosis: A Meta-Analytic Review. <i>Psychiatric Services</i> , 2014, 65, 874-880.	1.1	178
2686	Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. <i>Journal of Medical Economics</i> , 2014, 17, 296-304.	1.0	6
2687	Development of a Patient-Centered Antipsychotic Medication Adherence Intervention. <i>Health Education and Behavior</i> , 2014, 41, 315-324.	1.3	7
2688	5-HT _{2A} receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 823-832.	1.0	34
2689	Vagal Nerve Stimulation Reverses Aberrant Dopamine System Function in the Methylazoxymethanol Acetate Rodent Model of Schizophrenia. <i>Journal of Neuroscience</i> , 2014, 34, 9261-9267.	1.7	49
2690	Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. <i>Behavioral and Brain Functions</i> , 2014, 10, 35.	1.4	25
2691	Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 30-36.	1.2	21
2692	Ventral Tegmental Area/Midbrain Functional Connectivity and Response to Antipsychotic Medication in Schizophrenia. <i>Neuropsychopharmacology</i> , 2014, 39, 1020-1030.	2.8	145
2693	A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia. <i>Neuropsychopharmacology</i> , 2014, 39, 1347-1354.	2.8	26
2694	Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014, 2014, CD009268.	1.5	31

#	ARTICLE	IF	CITATIONS
2695	GWAS, Cytomegalovirus Infection, and Schizophrenia. <i>Current Behavioral Neuroscience Reports</i> , 2014, 1, 215-223.	0.6	9
2696	Antipsychotics and the Dopamine-Serotonin Connection. <i>Topics in Medicinal Chemistry</i> , 2014, , 1-49.	0.4	1
2697	The use of antipsychotics in preschoolers: A veto or a sensible last option?. <i>Journal of Psychopharmacology</i> , 2014, 28, 303-319.	2.0	14
2698	Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 723-737.	1.0	43
2699	Clinical Features of Schizophrenia With Enhanced Carbonyl Stress. <i>Schizophrenia Bulletin</i> , 2014, 40, 1040-1046.	2.3	56
2700	A Synaptic Function Approach to Investigating Complex Psychiatric Diseases. <i>Neuroscientist</i> , 2014, 20, 257-271.	2.6	22
2701	More People Than Ever Before Are Receiving Behavioral Health Care In The United States, But Gaps And Challenges Remain. <i>Health Affairs</i> , 2014, 33, 1416-1424.	2.5	73
2702	The Ethics Of "Fail First": Guidelines And Practical Scenarios For Step Therapy Coverage Policies. <i>Health Affairs</i> , 2014, 33, 1779-1785.	2.5	24
2703	A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents. <i>Clinical Therapeutics</i> , 2014, 36, 1372-1388.e1.	1.1	35
2704	History, background, concepts and current use of comedication and polypharmacy in psychiatry. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 983-996.	1.0	40
2705	Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	64
2707	Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia. <i>Biomarkers in Medicine</i> , 2014, 8, 5-8.	0.6	9
2708	Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group. <i>Pharmacogenomics</i> , 2014, 15, 933-939.	0.6	9
2709	Second-Generation Antipsychotics and Extrapyramidal Adverse Effects. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	202
2710	Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia. <i>Indian Journal of Psychological Medicine</i> , 2014, 36, 33-39.	0.6	10
2711	The rational patient and beyond: Implications for treatment adherence in people with psychiatric disabilities.. <i>Rehabilitation Psychology</i> , 2014, 59, 85-98.	0.7	19
2712	Role of Atypical Antipsychotics in the Development of Metabolic Syndrome. <i>Current Approaches in Psychiatry</i> , 2014, , 1.	0.2	1
2713	Genetics of Adverse Reactions to Haloperidol in a Mouse Diallel: A Drug-Placebo Experiment and Bayesian Causal Analysis. <i>Genetics</i> , 2014, 196, 321-347.	1.2	30

#	ARTICLE	IF	CITATIONS
2714	Human rights and the use of psychiatric medication. <i>Journal of Public Mental Health</i> , 2014, 13, 179-188.	0.8	11
2715	Modelling olanzapine-induced weight gain in rats. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 169-186.	1.0	32
2716	The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study. <i>Current Medical Research and Opinion</i> , 2014, 30, 997-1005.	0.9	4
2717	Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , 2014, 12, 192-204.	0.4	1
2718	Treating Thought Disorders. , 2014, , 213-251.		2
2719	Risk of Hospitalization and Use of First- Versus Second-Generation Antipsychotics Among Nursing Home Residents. <i>Psychiatric Services</i> , 2014, 65, 781-788.	1.1	11
2721	Changes in Physician Antipsychotic Prescribing Preferences, 2002â€“2007. <i>Psychiatric Services</i> , 2014, 65, 315-322.	1.1	25
2722	Monitoring for Metabolic Side Effects Among Outpatients With Dementia Receiving Antipsychotics. <i>Psychiatric Services</i> , 2014, 65, 1147-1153.	1.1	3
2723	Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 807-818.	1.0	49
2724	Management of New Hyperglycemia in Patients Prescribed Antipsychotics. <i>Psychiatric Services</i> , 2014, 65, 1502-1505.	1.1	6
2726	Service Usersâ€™ Priorities and Preferences for Treatment of Psychosis: A User-Led Delphi Study. <i>Psychiatric Services</i> , 2014, 65, 1167-1169.	1.1	33
2727	Electrophysiology and Psychophysiology in Psychiatry and Psychopharmacology. <i>Current Topics in Behavioral Neurosciences</i> , 2014, , .	0.8	2
2728	Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. <i>European Psychiatry</i> , 2014, 29, 1409-1413.	0.1	70
2729	Cumulative sojourn time in longitudinal studies: a sequential imputation method to handle missing health state data due to dropout. <i>Statistics in Medicine</i> , 2014, 33, 2030-2047.	0.8	0
2730	A Dopamine D2 Receptor-DISC1 Protein Complex may Contribute to Antipsychotic-Like Effects. <i>Neuron</i> , 2014, 84, 1302-1316.	3.8	91
2731	Prediction of outcome in schizophrenia depends on the sample. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 241-242.	2.2	1
2732	Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. <i>Human Psychopharmacology</i> , 2014, 29, 459-469.	0.7	33
2733	Paliperidone palmitate long-acting injection â€“ prospective year-long follow-up of use in clinical practice. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 46-51.	2.2	51

#	ARTICLE	IF	CITATIONS
2734	HETEROGENEITY IN ACTION: THE ROLE OF <i>PASSIVE</i> PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH. Health Economics (United Kingdom), 2014, 23, 359-373.	0.8	22
2735	IS THERE A PHYSICIAN PEER EFFECT? EVIDENCE FROM NEW DRUG PRESCRIPTIONS. Economic Inquiry, 2014, 52, 116-137.	1.0	8
2736	Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed <sc>B</sc>elgian schizophrenic patients: results from electronic <sc>S</sc>chizophrenia <sc>T</sc>reatment <sc>A</sc>dherence <sc>R</sc>egistry (<sc>e</sc> STAR</sc>) and <sc>T</sc>rial for the <sc>I</sc>nitiation and <sc>M</sc>aintenance Of <sc>RE</sc>mission in <sc>S</sc>chizophrenia with risperidone (<sc>TIMORES</sc>). Microbial Biotechnology, 2014, 8, 39-49.	0.9	15
2737	The politics of knowledge: implications for understanding and addressing mental health and illness. Nursing Inquiry, 2014, 21, 3-10.	1.1	5
2738	Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Human Psychopharmacology, 2014, 29, 183-189.	0.7	38
2739	Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatrica Scandinavica, 2014, 130, 290-299.	2.2	190
2740	Antipsychotic discontinuation syndromes: A narrative review of the evidence and its integration into <sc>A</sc>ustralian mental health nursing textbooks. International Journal of Mental Health Nursing, 2014, 23, 69-78.	2.1	10
2741	PSYCHIATRIC GENETICS AND THE FUTURE OF PERSONALIZED TREATMENT. Depression and Anxiety, 2014, 31, 893-898.	2.0	16
2742	The Rights of Children and Parents In Regard to Children Receiving Psychiatric Diagnoses and Drugs. Children and Society, 2014, 28, 231-241.	1.0	18
2743	Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial. Schizophrenia Research, 2014, 160, 73-79.	1.1	21
2744	Antipsychotic treatment discontinuation in clinical practice. Lancet Psychiatry, the, 2014, 1, 500-501.	3.7	0
2745	CAN WE MAKE SMART CHOICES BETWEEN OLS AND CONTAMINATED IV METHODS?. Health Economics (United Kingdom), 2014, 23, 462-472.	0.8	13
2746	A multiple imputation strategy for sequential multiple assignment randomized trials. Statistics in Medicine, 2014, 33, 4202-4214.	0.8	38
2747	Validation of a claims-based antipsychotic polypharmacy measure. Pharmacoepidemiology and Drug Safety, 2014, 23, 628-635.	0.9	17
2748	New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways. Drug Design, Development and Therapy, 2014, 8, 887.	2.0	28
2749	Kinetics of Drug Interaction with the Kv11.1 Potassium Channel. Molecular Pharmacology, 2014, 85, 769-776.	1.0	26
2750	We need to talk about depot: effect of Community Treatment Order on depot antipsychotic medication compliance. Australasian Psychiatry, 2014, 22, 357-359.	0.4	7
2751	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectrums, 2014, 19, 374-381.	0.7	33

#	ARTICLE	IF	CITATIONS
2752	Schizophrenia--Time to Commit to Policy Change. <i>Schizophrenia Bulletin</i> , 2014, 40, S165-S194.	2.3	153
2753	Psychiatric tertiary referral and clinical decision making. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 219-223.	1.3	3
2754	Psychotic disorder is an independent risk factor for increased fasting glucose and waist circumference. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 251-258.	0.7	11
2755	Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. <i>BMC Medicine</i> , 2014, 12, 98.	2.3	35
2756	Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 322-331.	0.9	25
2757	Extrapyramidal symptoms following administration of oral perphenazine 4 or 8 mg. <i>European Journal of Anaesthesiology</i> , 2014, 31, 231-235.	0.7	14
2758	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. <i>JAMA Psychiatry</i> , 2014, 71, 1350.	6.0	318
2759	Schizophrenia-negative symptoms. <i>Middle East Current Psychiatry</i> , 2014, 21, 11-21.	0.5	0
2760	Statistics Commentary Series. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 423-425.	0.7	11
2761	Multifactorial Determinants of the Neurocognitive Effects of Electroconvulsive Therapy. <i>Journal of ECT</i> , 2014, 30, 165-176.	0.3	98
2762	Effect of S-ketamine as an Anesthetic Adjuvant to Propofol on Treatment Response to Electroconvulsive Therapy in Treatment-Resistant Depression. <i>Journal of ECT</i> , 2014, 30, 176.	0.3	1
2763	Noninferiority of Perphenazine vs. Three Second-Generation Antipsychotics in Chronic Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2014, 202, 18-24.	0.5	10
2764	Self-disorders and Schizophrenia: A Phenomenological Reappraisal of Poor Insight and Noncompliance. <i>Schizophrenia Bulletin</i> , 2014, 40, 542-547.	2.3	103
2765	Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 52-60.	1.3	51
2766	Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 257-267.	1.2	32
2767	Postmortem Brain: An Underutilized Substrate for Studying Severe Mental Illness. <i>Neuropsychopharmacology</i> , 2014, 39, 65-87.	2.8	96
2768	Motivational Deficits and Cognitive Test Performance in Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 1058.	6.0	122
2769	Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. <i>Psychological Medicine</i> , 2014, 44, 61-69.	2.7	41

#	ARTICLE	IF	CITATIONS
2770	GLT-1 transporter: An effective pharmacological target for various neurological disorders. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 127, 70-81.	1.3	66
2771	Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 183.	1.0	76
2772	Sustained and "Sleeper" Effects of Group Metacognitive Training for Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 1103.	6.0	136
2773	Neurocognitive Functioning of Individuals With Schizophrenia: Using and Not Using Drugs. <i>Schizophrenia Bulletin</i> , 2014, 40, 856-867.	2.3	26
2774	Maintenance Treatment With Long-Acting Injectable Antipsychotics. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1973.	3.8	6
2775	Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1978.	3.8	129
2776	A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. <i>Current Medical Research and Opinion</i> , 2014, 30, 1629-1641.	0.9	34
2777	Long-Term Risperidone Treatment Induces Visceral Adiposity Associated with Hepatic Steatosis in Mice: A Magnetic Resonance Approach. <i>Schizophrenia Research and Treatment</i> , 2014, 2014, 1-11.	0.7	8
2778	The BEHAVE-AD Assessment System: A Perspective, A Commentary on New Findings, and A Historical Review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 89-146.	0.7	34
2779	Ethanol extracts of <i>Alstonia Scholaris</i> and <i>Bacopa Monniera</i> possess neuroleptic activity due to anti-dopaminergic effect. <i>Pharmacognosy Research (discontinued)</i> , 2014, 6, 46.	0.3	11
2780	Integrating Psychosocial Concepts into Psychopharmacology Training: A Survey Study of Program Directors and Chief Residents. <i>Psychodynamic Psychiatry</i> , 2014, 42, 243-254.	0.1	5
2781	Curing the Disobedient Patient: Medication Adherence Programs as Pharmaceutical Marketing Tools. <i>Journal of Law, Medicine and Ethics</i> , 2014, 42, 492-500.	0.4	4
2782	Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy. <i>BMC Psychiatry</i> , 2014, 14, 341.	1.1	30
2783	Another Look at Outcomes and Outcome Measures in Psychiatry: Cui bono?. <i>Psychotherapy and Psychosomatics</i> , 2014, 83, 6-9.	4.0	7
2784	International Consensus Study of Antipsychotic Dosing. <i>Focus (American Psychiatric Publishing)</i> , 2014, 12, 235-243.	0.4	6
2785	Negative Impact of Self-Stigmatization on Attitude Toward Medication Adherence in Patients with Psychosis. <i>Journal of Psychiatric Practice</i> , 2014, 20, 405-410.	0.3	27
2786	Hospitalization Resource Utilization and Costs Among Medicaid Insured Patients With Schizophrenia With Different Treatment Durations of Long-Acting Injectable Antipsychotic Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 30-35.	0.7	3
2787	Interrater reliability of the Observer Rating of Medication Taking scale in an inpatient mental health facility. <i>International Journal of Mental Health Nursing</i> , 2014, 23, 498-505.	2.1	1

#	ARTICLE	IF	CITATIONS
2788	Experiencing antipsychotic discontinuation: results from a survey of <scp>A</scp>ustralian consumers. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2014, 21, 917-923.	1.2	23
2789	A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia. <i>International Psychogeriatrics</i> , 2014, 26, 19-37.	0.6	16
2790	Treatment resistance and other complicating factors in the management of schizophrenia. <i>CNS Spectrums</i> , 2014, 19, 13-24.	0.7	7
2791	Factors influencing weight gain in an Asian population of psychiatric inpatients: A retrospective study in Taiwan. <i>Asia-Pacific Psychiatry</i> , 2014, 6, 226-234.	1.2	3
2792	Treatment adherence and quality of sleep in schizophrenia outpatients. <i>International Journal of Psychiatry in Clinical Practice</i> , 2014, 18, 70-76.	1.2	30
2793	Weight control in schizophrenic patients through Sakata's Charting of Daily Weight Pattern and its associations with temperament and character. <i>Asian Journal of Psychiatry</i> , 2014, 7, 52-57.	0.9	6
2794	A cross-national factor analytic comparison of three models of PANSS symptoms in schizophrenia. <i>Psychiatry Research</i> , 2014, 219, 283-289.	1.7	43
2795	How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses. <i>European Neuropsychopharmacology</i> , 2014, 24, 1279-1288.	0.3	13
2796	Tardive dyskinesia syndromes: current concepts. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S113-S117.	1.1	81
2797	Factors associated with length of psychiatric hospitalization. <i>Comprehensive Psychiatry</i> , 2014, 55, 681-687.	1.5	43
2798	The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. <i>Psychiatry Research</i> , 2014, 218, 201-208.	1.7	11
2800	Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia. <i>Asian Journal of Psychiatry</i> , 2014, 9, 31-35.	0.9	18
2801	Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 185-195.	1.4	11
2802	The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum. <i>Clinical Epigenetics</i> , 2014, 6, 1.	1.8	62
2803	Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2014, 53, 133-140.	1.5	84
2804	Identification of Candidate Single-Nucleotide Polymorphisms in NRXN1 Related to Antipsychotic Treatment Response in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2014, 39, 2170-2178.	2.8	22
2805	Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. <i>BMC Psychiatry</i> , 2014, 14, 53.	1.1	6
2806	Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly. <i>Drugs and Aging</i> , 2014, 31, 159-184.	1.3	14

#	ARTICLE	IF	CITATIONS
2807	Comorbid Personality Disorders and Violent Behavior in Psychotic Patients. <i>Psychiatric Quarterly</i> , 2014, 85, 65-78.	1.1	34
2808	CTOs: what is the state of the evidence?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 1861-1871.	1.6	40
2809	Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. <i>European Journal of Health Economics</i> , 2014, 15, 133-142.	1.4	11
2810	Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 1063-1070.	1.6	26
2811	Mobile phone text message reminders of antipsychotic medication: is it time and who should receive them? A cross-sectional trust-wide survey of psychiatric inpatients. <i>BMC Psychiatry</i> , 2014, 14, 15.	1.1	22
2812	Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada. <i>BMC Psychiatry</i> , 2014, 14, 16.	1.1	10
2813	Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 654-672.	1.1	42
2814	Prior Antipsychotic Drug Treatment Prevents Response to Novel Antipsychotic Agent in the Methylazoxymethanol Acetate Model of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 341-350.	2.3	62
2815	Toward a more parsimonious assessment of neurocognition in schizophrenia: A 10-minute assessment tool. <i>Journal of Psychiatric Research</i> , 2014, 52, 50-56.	1.5	25
2816	Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD006569.	1.5	70
2817	↑FosB Induction in Prefrontal Cortex by Antipsychotic Drugs is Associated with Negative Behavioral Outcomes. <i>Neuropsychopharmacology</i> , 2014, 39, 538-544.	2.8	23
2819	How evidence-based medicine is failing due to biased trials and selective publication. <i>Journal of Evaluation in Clinical Practice</i> , 2014, 20, 908-914.	0.9	143
2820	Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary. <i>Schizophrenia Research</i> , 2014, 152, 246-254.	1.1	59
2821	Revitalizing Psychiatric Therapeutics. <i>Neuropsychopharmacology</i> , 2014, 39, 220-229.	2.8	76
2822	Pyrroloquinoline quinone prevents MK-801-induced stereotypical behavior and cognitive deficits in mice. <i>Behavioural Brain Research</i> , 2014, 258, 153-159.	1.2	15
2823	±2-Adrenoceptors are targets for antipsychotic drugs. <i>Psychopharmacology</i> , 2014, 231, 801-812.	1.5	39
2824	Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 416-427.	0.7	22
2825	Antipsychotics Activate mTORC1-Dependent Translation to Enhance Neuronal Morphological Complexity. <i>Science Signaling</i> , 2014, 7, ra4.	1.6	62

#	ARTICLE	IF	CITATIONS
2826	Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9578-9597.	2.9	46
2827	Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. <i>Evidence-Based Mental Health</i> , 2014, 17, 33-37.	2.2	89
2828	Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD009369.	1.5	7
2829	The metabolic syndrome and risk of coronary artery disease in patients with chronic schizophrenia or schizoaffective disorder in a chronic mental institute. <i>Kaohsiung Journal of Medical Sciences</i> , 2014, 30, 579-586.	0.8	7
2831	Association of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2014, 55, 1914-1919.	1.5	4
2832	Evaluating aripiprazole as a potential bipolar disorder therapy for adults. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1713-1730.	1.9	7
2833	Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 30-39.	2.2	53
2834	New developments in diagnosis and treatment update: Schizophrenia/first episode psychosis in children and adolescents. <i>Journal of Child and Adolescent Mental Health</i> , 2014, 26, 109-124.	1.7	17
2835	Molecular pathophysiology of metabolic effects of antipsychotic medications. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 593-600.	3.1	95
2836	Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia. <i>Health Policy and Technology</i> , 2014, 3, 314-324.	1.3	6
2837	Developing tomorrow's antipsychotics: the need for a more personalised approach. <i>Advances in Psychiatric Treatment</i> , 2014, 20, 3-12.	0.6	3
2839	Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. <i>The Cochrane Library</i> , 2014, 2014, CD001470.	1.5	9
2840	A review of self-report medication side effect questionnaires for mental health patients. <i>Psychiatry Research</i> , 2014, 219, 664-673.	1.7	12
2841	Neurophysiological Biomarkers Informing the Clinical Neuroscience of Schizophrenia: Mismatch Negativity and Prepulse Inhibition of Startle. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 21, 293-314.	0.8	34
2842	Daytime sleepiness and EEG abnormalities in patients treated with second generation antipsychotic agents. <i>Pharmacological Reports</i> , 2014, 66, 1077-1082.	1.5	7
2845	Pharmacogenetics of second-generation antipsychotics. <i>Pharmacogenomics</i> , 2014, 15, 869-884.	0.6	29
2846	Antipsychotic treatment of schizophrenia: An update. <i>Asian Journal of Psychiatry</i> , 2014, 11, 3-7.	0.9	69
2847	Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE dataset. <i>European Neuropsychopharmacology</i> , 2014, 24, 1615-1621.	0.3	5

#	ARTICLE	IF	CITATIONS
2848	Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 37-49.	1.0	74
2849	Biological insights from 108 schizophrenia-associated genetic loci. <i>Nature</i> , 2014, 511, 421-427.	13.7	6,934
2850	Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. <i>Current Medical Research and Opinion</i> , 2014, 30, 1643-1655.	0.9	47
2851	Decisions on WHO's essential medicines need more scrutiny. <i>BMJ, The</i> , 2014, 349, g4798-g4798.	3.0	19
2852	Cognitive therapy for patients with schizophrenia. <i>Lancet, The</i> , 2014, 384, 401.	6.3	2
2853	Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD009396.	1.5	12
2854	Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 605-624.	1.0	41
2855	PCP-induced deficits in murine nest building activity: Employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia. <i>Behavioural Brain Research</i> , 2014, 273, 63-72.	1.2	46
2856	Psychiatric Care of the Older Adult. <i>Medical Clinics of North America</i> , 2014, 98, 1145-1168.	1.1	6
2857	A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs. <i>Human and Experimental Toxicology</i> , 2014, 33, 473-487.	1.1	4
2858	Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4196-4212.	2.9	36
2859	Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar disorder, depression: An integrated analysis. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 498-505.	1.0	6
2861	Linear model-based estimation of blood pressure and cardiac output for Normal and Paranoid cases. <i>Neural Computing and Applications</i> , 2014, 25, 1223-1240.	3.2	11
2862	Predictors of Medication Non-adherence in Bulgarian Outpatients with Schizophrenia. <i>Community Mental Health Journal</i> , 2014, 50, 854-861.	1.1	16
2863	State investments in psychiatric innovation: investigating unmeasured state factors. <i>Health Services and Outcomes Research Methodology</i> , 2014, 14, 34-53.	0.8	0
2864	Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. <i>Journal of Autism and Developmental Disorders</i> , 2014, 44, 948-957.	1.7	62
2865	The Earlier the Better: Alzheimer's Prevention, Early Detection, and the Quest for Pharmacological Interventions. <i>Culture, Medicine and Psychiatry</i> , 2014, 38, 217-236.	0.7	23
2866	Tetrahydronaphthyrine and Dihydronaphthyrinone Ethers As Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 5 (mGlu ₅). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5620-5637.	2.9	13

#	ARTICLE	IF	CITATIONS
2867	A Novel Aminotetralin-Type Serotonin (5-HT) _{2C} Receptor-Specific Agonist and 5-HT _{2A} Competitive Antagonist/5-HT _{2B} Inverse Agonist with Preclinical Efficacy for Psychoses. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 310-318.	1.3	20
2868	Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. <i>Bipolar Disorders</i> , 2014, 16, 410-421.	1.1	99
2869	Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. <i>Current Medical Research and Opinion</i> , 2014, 30, 695-709.	0.9	6
2870	Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 593-603.	0.9	8
2871	Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research. <i>Translational Behavioral Medicine</i> , 2014, 4, 260-274.	1.2	306
2872	Atypical Antipsychotics Olanzapine, Quetiapine, and Risperidone and Risk of Acute Major Cardiovascular Events in Young and Middle-Aged Adults: A Nationwide Register-Based Cohort Study in Denmark. <i>CNS Drugs</i> , 2014, 28, 963-973.	2.7	12
2873	Epigenetic Dysregulation in the Schizophrenic Brain. <i>Current Behavioral Neuroscience Reports</i> , 2014, 1, 86-93.	0.6	3
2874	Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 107-120.	0.7	15
2875	Clozapine: a review of clinical practice guidelines and prescribing trends. <i>BMC Psychiatry</i> , 2014, 14, 102.	1.1	174
2876	Towards the clinical implementation of pharmacogenetics in bipolar disorder. <i>BMC Medicine</i> , 2014, 12, 90.	2.3	23
2877	Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice. <i>Annals of General Psychiatry</i> , 2014, 13, 10.	1.2	11
2878	Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2014, 40, 1385-1403.	2.3	166
2879	Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 800-814.	1.1	15
2880	Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. <i>Schizophrenia Research</i> , 2014, 159, 90-94.	1.1	34
2881	Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 228-239.	1.2	18
2882	The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity. <i>European Journal of Clinical Nutrition</i> , 2014, 68, 146-152.	1.3	55
2883	P.3.d.032 Therapeutic strategies to potentiate refractory schizophrenia. <i>European Neuropsychopharmacology</i> , 2014, 24, S540.	0.3	0
2885	A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. <i>Schizophrenia Research</i> , 2014, 153, 160-168.	1.1	15

#	ARTICLE	IF	CITATIONS
2886	Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs. <i>European Neuropsychopharmacology</i> , 2014, 24, 1046-1055.	0.3	22
2887	Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: Analysis of amisulpride vs placebo in three clinical trials. <i>Schizophrenia Research</i> , 2014, 156, 107-114.	1.1	18
2888	Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 299-308.	0.9	10
2889	The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland. <i>Pharmacological Reports</i> , 2014, 66, 613-617.	1.5	15
2890	Promoting positive behavioral health: A non-pharmacologic Toolkit for senior living communities. <i>Geriatric Nursing</i> , 2014, 35, 7-8.	0.9	3
2891	Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study. <i>European Neuropsychopharmacology</i> , 2014, 24, 1078-1085.	0.3	21
2893	Impact of primary negative symptoms on functional outcomes in schizophrenia. <i>European Psychiatry</i> , 2014, 29, 449-455.	0.1	153
2894	Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans. <i>European Neuropsychopharmacology</i> , 2014, 24, 822-835.	0.3	105
2895	An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. <i>Schizophrenia Research</i> , 2014, 152, 450-457.	1.1	155
2896	Combining efficacy and completion rates with no data imputation: A composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trials. <i>European Neuropsychopharmacology</i> , 2014, 24, 357-368.	0.3	2
2897	Abbreviated quality of life scales for schizophrenia: Comparison and utility of two brief community functioning measures. <i>Schizophrenia Research</i> , 2014, 154, 89-92.	1.1	15
2898	Symptom structure and severity: A comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia. <i>Comprehensive Psychiatry</i> , 2014, 55, 887-895.	1.5	6
2899	Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia. <i>Value in Health</i> , 2014, 17, 310-319.	0.1	16
2900	Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: Assessment of a new, commercially available, semi-automated instrument. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 120, 109-116.	1.3	10
2901	Controversies in the use of second generation antipsychotics as sleep agent. <i>Pharmacological Research</i> , 2014, 79, 1-8.	3.1	18
2902	Dissecting psychiatric spectrum disorders by generative embedding. <i>NeuroImage: Clinical</i> , 2014, 4, 98-111.	1.4	150
2903	Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. <i>Lancet, The</i> , 2014, 383, 1395-1403.	6.3	196
2904	Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR). <i>Current Medical Research and Opinion</i> , 2014, 30, 1279-1289.	0.9	7

#	ARTICLE	IF	CITATIONS
2905	Antipsychotics use in children and adolescents: An on-going challenge in clinical practice. <i>Journal of Psychopharmacology</i> , 2014, 28, 615-623.	2.0	32
2906	Different effects of Bifeprunox, Aripiprazole, and Haloperidol on body weight gain, food and water intake, and locomotor activity in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 124, 167-173.	1.3	14
2907	Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazine. <i>Psychiatry Research</i> , 2014, 219, 261-267.	1.7	21
2908	Presynaptic Dopaminergic Function: Implications for Understanding Treatment Response in Psychosis. <i>CNS Drugs</i> , 2014, 28, 649-663.	2.7	5
2909	Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis?. <i>Pharmacoeconomics</i> , 2014, 32, 521-523.	1.7	4
2910	Antipsychotic induced metabolic changes & treatment response: A prospective study. <i>Asian Journal of Psychiatry</i> , 2014, 11, 39-44.	0.9	7
2911	Cognitive therapy: at last an alternative to antipsychotics?. <i>Lancet, The</i> , 2014, 383, 1364-1366.	6.3	13
2912	Sowing the seeds of doubt: a narrative review on metacognitive training in schizophrenia. <i>Clinical Psychology Review</i> , 2014, 34, 358-366.	6.0	268
2913	Risk genes for schizophrenia: Translational opportunities for drug discovery. , 2014, 143, 34-50.		26
2914	Immune system and glucose metabolism interaction in schizophrenia: A chickenâ€“egg dilemma. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 48, 287-294.	2.5	66
2915	Pharmacogenetics of Antipsychotics. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 76-88.	0.9	83
2916	Prescribing Antipsychotics in Montenegro: a Focus Group Analysis. <i>Serbian Journal of Experimental and Clinical Research</i> , 2014, 15, 39-42.	0.2	1
2918	Can student mental health nurses be prepared for medicines management?. <i>NursePrescribing</i> , 2014, 12, 614-620.	0.1	0
2919	Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. <i>The Cochrane Library</i> , 0, , .	1.5	1
2920	Community Violence Perpetration and Victimization Among Adults With Mental Illnesses. <i>American Journal of Public Health</i> , 2014, 104, 2342-2349.	1.5	142
2921	Directions for Future Patient-Centered and Comparative Effectiveness Research for People With Serious Mental Illness. <i>Schizophrenia Bulletin</i> , 2014, 40, i-S94.	2.3	23
2922	SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells. <i>International Journal of Molecular Medicine</i> , 2014, 33, 1364-1370.	1.8	21
2923	Flexible-dose oral paliperidone ER in non-acute schizophrenia previously unsuccessfully treated with oral risperidone. <i>Clinical Practice (London, England)</i> , 2014, 11, 573-583.	0.1	1

#	ARTICLE	IF	CITATIONS
2924	Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, 2014, CD009230.	1.5	17
2925	Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, , CD009227.	1.5	5
2926	Functional Magnetic Resonance Imaging of Impaired Sensory Prediction in Schizophrenia. JAMA Psychiatry, 2014, 71, 28.	6.0	138
2927	The impact of a change in prescribing policy on antipsychotic prescribing in a general adult psychiatric hospital. Irish Journal of Psychological Medicine, 2014, 31, 167-173.	0.7	4
2928	Letter to the Editor: Concepts and methods when considering negative symptom course: a reply. Psychological Medicine, 2015, 45, 2459-2460.	2.7	1
2929	Motivation and Social Cognition in Patients with Schizophrenia. Journal of the International Neuropsychological Society, 2015, 21, 436-443.	1.2	16
2930	Akathisia with Erythromycin: Induced or precipitated?. Saudi Pharmaceutical Journal, 2015, 23, 541-543.	1.2	6
2931	P.3.d.008 Nor-clozapine plasma concentration/daily clozapine dose ratio: an index of response to clozapine treatment. European Neuropsychopharmacology, 2015, 25, S484-S485.	0.3	0
2932	Cost-Utility and Budget Impact Analyses Comparing Lurasidone with Aripiprazole in Adults with Schizophrenia in Scotland. Value in Health, 2015, 18, A408-A409.	0.1	1
2933	Perphenazine for schizophrenia. The Cochrane Library, 2015, 2015, CD003443.	1.5	15
2934	Treatments for delusional disorder. The Cochrane Library, 2015, 2015, CD009785.	1.5	24
2935	Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry, 2015, 14, 56-63.	4.8	82
2936	Evaluating subjective domains of antipsychotic-induced adverse effects using heart rate variability. Psychiatry and Clinical Neurosciences, 2015, 69, 283-291.	1.0	1
2937	Practical pharmacotherapy for acute schizophrenia patients. Psychiatry and Clinical Neurosciences, 2015, 69, 674-685.	1.0	2
2938	Administration of Olanzapine as an Antiemetic Agent Changes Glucose Homeostasis in Cisplatin-Treated Rats. Biological and Pharmaceutical Bulletin, 2015, 38, 587-593.	0.6	5
2939	The proteome of schizophrenia. NPJ Schizophrenia, 2015, 1, 14003.	2.0	96
2940	WSKY, a traditional Chinese decoction, rescues cognitive impairment associated with NMDA receptor antagonism by enhancing BDNF/ERK/CREB signaling. Molecular Medicine Reports, 2015, 11, 2927-2934.	1.1	13
2942	Schizophrenia. Nature Reviews Disease Primers, 2015, 1, 15067.	18.1	724

#	ARTICLE	IF	CITATIONS
2946	Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study. <i>Scientific Reports</i> , 2015, 5, 10793.	1.6	25
2947	Protocol for a systematic review of telephone delivered psychosocial interventions on relapse prevention, adherence to psychiatric medication and health risk behaviours in adults with a psychotic disorder. <i>BMJ Open</i> , 2015, 5, e009985.	0.8	1
2948	Association between antipsychotic/antidepressant drug treatments and hospital admissions in schizophrenia assessed using a mental health case register. <i>NPJ Schizophrenia</i> , 2015, 1, 15035.	2.0	8
2949	Acute akathisia. , 0, , 3-19.		4
2950	Animal Models of Deficient Sensorimotor Gating in Schizophrenia: Are They Still Relevant?. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 28, 305-325.	0.8	45
2951	Preventing crime in cooperation with the mental health care profession. <i>Crime, Law and Social Change</i> , 2015, 64, 263-275.	0.7	2
2952	Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 583-591.	0.9	25
2953	Increasing antipsychotic dose for non response in schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	2
2954	Effectiveness and Predictors of Continuation of Paliperidone Palmitate Long-Acting Injection Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 591-595.	0.7	26
2955	Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 97-108.	2.2	216
2956	Recovery from psychosis: physical health, antipsychotic medication and the daily dilemmas for mental health nurses. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2015, 22, 549-557.	1.2	12
2957	Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. <i>Psychiatry and Clinical Neurosciences</i> , 2015, 69, 497-503.	1.0	9
2958	Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice. <i>Trials</i> , 2015, 16, 179.	0.7	27
2959	Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2015, 1, 15.	0.4	28
2960	Living with antipsychotic medication side-effects: The experience of Australian mental health consumers. <i>International Journal of Mental Health Nursing</i> , 2015, 24, 253-261.	2.1	48
2961	New Targets for the Management of Schizophrenia. <i>Journal of Microbiology and Biotechnology</i> , 2015, 25, 407-428.	0.9	4
2962	Weight change during long-term treatment with lurasidone. <i>International Clinical Psychopharmacology</i> , 2015, 30, 342-350.	0.9	30
2963	A pharmacogenomic study revealed an association between <i>SLC6A4</i> and risperidone-induced weight gain in Chinese Han population. <i>Pharmacogenomics</i> , 2015, 16, 1943-1949.	0.6	8

#	ARTICLE	IF	CITATIONS
2964	Switching antipsychotic for non response in schizophrenia. The Cochrane Library, 2015, , .	1.5	0
2965	Persistence of racial disparities in prescription of first-generation antipsychotics in the USA. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1197-1206.	0.9	29
2966	Equivalence of kernel machine regression and kernel distance covariance for multidimensional phenotype association studies. <i>Biometrics</i> , 2015, 71, 812-820.	0.8	26
2967	Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 630-634.	0.7	14
2968	Urine testing for antipsychotics: a pilot trial for a method to determine detection levels. <i>Human Psychopharmacology</i> , 2015, 30, 350-355.	0.7	4
2969	Australian case managers' views about the impact of antipsychotic medication on mental health consumers. <i>International Journal of Mental Health Nursing</i> , 2015, 24, 547-553.	2.1	12
2970	Microwave-assisted copper powder-catalyzed coupling and cyclization of α -bromo- β -unsaturated amides with amidine hydrochlorides leading to pyrimidinones. <i>Applied Organometallic Chemistry</i> , 2015, 29, 372-375.	1.7	6
2971	Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 728-730.	0.7	0
2972	Antipsychotic drugs on maternal behavior in rats. <i>Behavioural Pharmacology</i> , 2015, 26, 616-626.	0.8	18
2973	Effects of Mirtazapine on Patients Undergoing Naturalistic Diabetes Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 730-731.	0.7	10
2974	Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 486-492.	0.5	16
2975	Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. <i>International Clinical Psychopharmacology</i> , 2015, 30, 320-328.	0.9	15
2976	Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 109-121.	2.2	87
2977	Cost-effectiveness analysis of paliperidone palmitate versus long-acting risperidone as maintenance treatment in schizophrenia patients in Italy. <i>Global & Regional Health Technology Assessment</i> , 2015, 2, GRHTA.5000186.	0.2	2
2978	Solving Global Mental Health as a Delivery Problem. , 2015, , 544-574.		7
2979	Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition. <i>International Heart Journal</i> , 2015, 56, 395-399.	0.5	9
2980	Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study. <i>Journal of Pragmatic and Observational Research</i> , 2015, 6, 39.	1.1	8
2981	Antipsicóticos en esquizofrenia: revisión de guías internacionales actuales. <i>Revista De La Asociación Española De Neuropsiquiatría</i> , 2015, 35, 79-91.	0.1	0

#	ARTICLE	IF	CITATIONS
2982	How Effective Are Antipsychotic Medications?. Ethical Human Psychology and Psychiatry, 2015, 17, 176-184.	0.5	2
2983	Aspectos conceptuales sobre el proceso de decisi3n compartida en salud mental. Revista De La Asociaci3n Espa±ola De NeuropsiquiatrAa, 2015, 35, 455-472.	0.1	3
2984	Quo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context. International Journal of Molecular Sciences, 2015, 16, 23012-23034.	1.8	17
2985	The Drug Adherence and Treatment Effect of the Paliperidone Long Acting Injection. Journal of Korean Neuropsychiatric Association, 2015, 54, 69.	0.2	3
2986	Family Support and Adherence to Treatment in Patients Diagnosed with Schizophrenia in Tabasco, Mexico: A Case- Series Study. Journal of Psychiatry, 2015, 18, .	0.1	3
2987	The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia. Neuropsychiatric Disease and Treatment, 2015, 11, 1511.	1.0	8
2988	Validation of an analytical method for the determination in serum of psychotropic drugs by High-Performance Liquid Chromatography with Diode Array Detection. Rwanda Journal, 2015, 2, 13.	0.3	3
2989	Measurement of Metabolic Monitoring in Youth and Adult Medicaid Recipients Prescribed Antipsychotics. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 769-777.	0.5	13
2990	Validation of an analytical method for the determination in serum of psychotropic drugs by High-Performance Liquid Chromatography with Diode Array Detection. Rwanda Journal, 2015, 2, 13.	0.3	0
2991	Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Frontiers in Neuroscience, 2015, 9, 297.	1.4	82
2992	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. The Cochrane Library, 2015, , .	1.5	2
2993	Treatment of Schizophrenia: Past, Present and Future. Journal of Microbiology and Biotechnology, 2015, 25, 95-99.	0.9	1
2995	Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group. Neuropsychiatric Disease and Treatment, 2015, 11, 1265.	1.0	13
2996	Olanzapine-induced neutropenia. Mental Illness, 2015, 7, 5871.	0.8	8
2997	Association of Histamine N-Methyltransferase Thr105Ile Polymorphism with Parkinsonâ€™s Disease and Schizophrenia in Han Chinese: A Case-Control Study. PLoS ONE, 2015, 10, e0119692.	1.1	19
2998	Synergy of Omeprazole and Praziquantel In Vitro Treatment against Schistosoma mansoni Adult Worms. PLoS Neglected Tropical Diseases, 2015, 9, e0004086.	1.3	17
2999	A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona. PLoS ONE, 2015, 10, e0139403.	1.1	20
3000	Metacognitive therapy (MCT+) in patients with psychosis not receiving antipsychotic medication: A case study. Frontiers in Psychology, 2015, 6, 967.	1.1	11

#	ARTICLE	IF	CITATIONS
3001	Preferences for different insomnia treatment options in people with schizophrenia and related psychoses: a qualitative study. <i>Frontiers in Psychology</i> , 2015, 6, 990.	1.1	41
3002	Reducing Delusional Conviction through a Cognitive-Based Group Training Game: A Multicentre Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2015, 6, 66.	1.3	26
3003	Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 754-769.	0.5	173
3004	A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model. <i>International Journal of Medicinal Chemistry</i> , 2015, 2015, 1-54.	2.2	37
3006	Olanzapine-induced neutropenia. <i>Mental Illness</i> , 2015, 7, 18-20.	0.8	0
3007	The quality of reporting of phase II and III trials for new antipsychotics: a systematic review. <i>Psychological Medicine</i> , 2015, 45, 467-479.	2.7	9
3008	Loxapine Add-on for Adolescents and Adults with Autism Spectrum Disorders and Irritability. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 150-159.	0.7	19
3009	A Typology of Community Violence Perpetration and Victimization Among Adults With Mental Illnesses. <i>Journal of Interpersonal Violence</i> , 2015, 30, 522-540.	1.3	17
3010	Motivational deficits in early schizophrenia: Prevalent, persistent, and key determinants of functional outcome. <i>Schizophrenia Research</i> , 2015, 166, 9-16.	1.1	120
3011	Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 685.	1.0	19
3012	Racial Disparities in Community Outcomes Among Individuals with Schizophrenia and Cooccurring Substance Use Disorders. <i>Journal of Social Work Practice in the Addictions</i> , 2015, 15, 165-184.	0.4	2
3013	Acetylcholinesterase and Cognitive Enhancement. , 2015, , 11-18.		0
3014	Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis. <i>Drug Safety</i> , 2015, 38, 641-650.	1.4	33
3015	The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: An analysis of the CATIE Schizophrenia Trial. <i>Schizophrenia Research</i> , 2015, 166, 110-114.	1.1	11
3016	Cardiovascular Risk Prediction Models for People With Severe Mental Illness. <i>JAMA Psychiatry</i> , 2015, 72, 143.	6.0	127
3018	A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome. <i>Schizophrenia Research</i> , 2015, 166, 178-186.	1.1	11
3019	New treatments for psychotic disorders. <i>Lancet Psychiatry</i> , the, 2015, 2, 282-283.	3.7	0
3020	Methodological Comments: McFarlane et al. <i>Schizophrenia Bulletin</i> , 2015, 41, 20-21.	2.3	0

#	ARTICLE	IF	CITATIONS
3021	Excitation-Inhibition Discoordination in Rodent Models of Mental Disorders. <i>Biological Psychiatry</i> , 2015, 77, 1079-1088.	0.7	54
3022	Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. <i>Journal of Neurosciences in Rural Practice</i> , 2015, 6, 017-022.	0.3	28
3023	Recovery Model of Mental Illness: A Complementary Approach to Psychiatric Care. <i>Indian Journal of Psychological Medicine</i> , 2015, 37, 117-119.	0.6	178
3024	Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Schizophrenia Research</i> , 2015, 169, 30-35.	1.1	27
3025	Social and Clinical Descriptors of Antipsychotic Prescription. <i>International Journal of Psychiatry in Medicine</i> , 2015, 49, 45-62.	0.8	5
3026	Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. <i>European Heart Journal</i> , 2015, 36, 984-992.	1.0	36
3027	Is It Time to Call It Quits on Low-Dose Quetiapine?. <i>The Consultant Pharmacist</i> , 2015, 30, 287-290.	0.4	2
3028	Pharmacogenetics and Antipsychotic Treatment Response/ $\text{D}^{\circ}\text{N}\text{E}^{\text{1/4}}\text{D}^{\circ}\text{D}^{\text{3/4}}\text{D}^{\text{3}}\text{D}^{\text{1/2}}\text{D}^{\text{1}}\text{N}^{\text{1}}\text{D}^{\circ}\text{D}$, $\text{D}^{\text{C}}\text{D}^{\text{1}}\text{N}^{\text{1}}\text{D}$, $\text{N}^{\text{1}}\text{E}^{\text{D}^{\circ}}\text{N}^{\text{1}}\text{S}^{\text{D}^{\circ}}$ D^{\sim} $\text{D}^{\text{z}}\text{D}^{\text{3}}\text{D}^{\text{3}}$	0.3	8
3029	Psychiatry Reconsidered. , 2015, , .		8
3030	Effects of high-intensity aerobic exercise on psychotic symptoms and neurocognition in outpatients with schizophrenia: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 557.	0.7	22
3031	Psychotropic drugs. , 2015, , 293-339.		2
3032	Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. <i>Psychopharmacology</i> , 2015, 232, 605-621.	1.5	243
3033	Investigation of <i>TSPO</i> variants in schizophrenia and antipsychotic treatment outcomes. <i>Pharmacogenomics</i> , 2015, 16, 5-22.	0.6	15
3035	Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2015, 161, 351-356.	1.1	32
3036	Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. <i>European Neuropsychopharmacology</i> , 2015, 25, 599-656.	0.3	113
3037	Bioequivalence and therapeutic equivalence of psychotropic drugs. <i>Postepy Psychiatrii I Neurologii</i> , 2015, 24, 8-17.	0.2	0
3038	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. <i>Schizophrenia Research</i> , 2015, 161, 429-433.	1.1	22
3039	The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics. <i>Journal of Health Economics</i> , 2015, 40, 26-39.	1.3	30

#	ARTICLE	IF	CITATIONS
3040	Indications of atypical antipsychotics in the elderly. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 5-7.	1.3	21
3041	Australian case managers' perceptions of mental health consumers use of antipsychotic medications and associated side effects. <i>International Journal of Mental Health Nursing</i> , 2015, 24, 104-111.	2.1	21
3042	Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: An introduction to this Special Issue of schizophrenia research. <i>Schizophrenia Research</i> , 2015, 163, 9-16.	1.1	47
3043	Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. <i>European Neuropsychopharmacology</i> , 2015, 25, 295-302.	0.3	8
3044	Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 149-174.	1.5	14
3045	The role of genetic variation across IL-1 β , IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 45-56.	1.3	28
3046	Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. <i>The Cochrane Library</i> , 2015, 2015, CD009831.	1.5	52
3047	Antipsychotics and Amotivation. <i>Neuropsychopharmacology</i> , 2015, 40, 1539-1548.	2.8	45
3048	The Bidirectional Relation Between Psychiatric Disorders With Selected Cardiovascular and Endocrinal Diseases: An Egyptian Perspective. <i>Current Psychiatry Reports</i> , 2015, 17, 528.	2.1	6
3049	Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 342-362.	1.8	891
3050	Antipsychotic Use and Risk of Nursing Home Admission Among Dual-Eligible Medicare Beneficiaries: A Propensity-Matched Study. <i>Drugs - Real World Outcomes</i> , 2015, 2, 61-71.	0.7	0
3051	Electroconductive smart polyacrylamide-polypyrrole (PAC-PPY) hydrogel: a device for controlled release of risperidone. <i>RSC Advances</i> , 2015, 5, 27665-27673.	1.7	19
3052	The Cost of Inpatient Care of Schizophrenia in the Polish and Ukrainian Academic Centers—Poznan and Lviv. <i>Academic Psychiatry</i> , 2015, 39, 165-173.	0.4	9
3053	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 718-727.e3.	0.3	32
3054	Bioequivalence and Therapeutic Equivalence of Psychotropic Drugs.. <i>European Psychiatry</i> , 2015, 30, 1594.	0.1	0
3055	Neuromodulation Treatments for Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 339-348.	0.7	8
3056	Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. <i>European Neuropsychopharmacology</i> , 2015, 25, 1158-1166.	0.3	84
3057	Identification and management of tardive dyskinesia: A case series and literature review. <i>Postgraduate Medicine</i> , 2015, 127, 726-737.	0.9	18

#	ARTICLE	IF	CITATIONS
3058	Pragmatic design in randomized controlled trials. <i>Psychological Medicine</i> , 2015, 45, 225-230.	2.7	11
3059	Schizophrenia: Metabolic Consequences. , 2015, , 21-27.		0
3060	Epigenetic signaling in schizophrenia. <i>Cellular Signalling</i> , 2015, 27, 2131-2136.	1.7	49
3061	<i>GIPR</i> Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 162-164.	0.9	9
3062	The Other 23 Hours: A Qualitative Study of Fitness Provider Perspectives on Social Support for Health Promotion for Adults with Mental Illness. <i>Health and Social Work</i> , 2015, 40, 91-99.	0.5	6
3063	Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 125-139.	2.5	15
3064	Insight and subjective measures of quality of life in chronic schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 127-132.	0.7	47
3065	Prevalence and predictors of medication non-adherence among Chinese patients with first-episode psychosis. <i>Psychiatry Research</i> , 2015, 228, 680-687.	1.7	12
3067	The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization. <i>Schizophrenia Research</i> , 2015, 166, 69-79.	1.1	20
3068	Clinical management of negative symptoms of schizophrenia: An update. , 2015, 153, 135-147.		55
3069	â€œLong-actingâ€•olanzapine in maintenance therapy of schizophrenia: A study with plasma levels. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 99-105.	1.2	15
3070	Neuroleptics and enrichment environment treatment in memory disorders and other central nervous system function observed in prenatally stressed rats. <i>Human and Experimental Toxicology</i> , 2015, 34, 526-537.	1.1	6
3071	Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. <i>Annals of the New York Academy of Sciences</i> , 2015, 1344, 105-119.	1.8	119
3073	Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function. <i>Neuropharmacology</i> , 2015, 99, 715-725.	2.0	16
3074	Sleep in Schizophrenia. <i>Sleep Medicine Clinics</i> , 2015, 10, 49-55.	1.2	44
3075	Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. <i>Schizophrenia Research</i> , 2015, 164, 122-126.	1.1	8
3076	Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: A 2year follow-up study. <i>Journal of Psychosomatic Research</i> , 2015, 78, 399-406.	1.2	55
3077	Pharmacogenetics of Antipsychotic-Induced Movement Disorders as a Resource for Better Understanding Parkinson's Disease Modifier Genes. <i>Frontiers in Neurology</i> , 2015, 6, 27.	1.1	7

#	ARTICLE	IF	CITATIONS
3078	Perceived risk of relapse and role of medication: comparison between patients with psychosis and their caregivers. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2015, 50, 307-315.	1.6	15
3080	Drug repurposing and emerging adjunctive treatments for schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1049-1067.	0.9	30
3081	Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study. <i>Annals of General Psychiatry</i> , 2015, 14, 1.	1.2	12
3082	Transcriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophrenia. <i>Schizophrenia Research</i> , 2015, 167, 28-34.	1.1	50
3083	Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics. <i>Current Medical Research and Opinion</i> , 2015, 31, 1437-1448.	0.9	10
3084	Five-year patient outcomes with risperidone long-acting injection or oral aripiprazole. <i>Therapeutic Advances in Psychopharmacology</i> , 2015, 5, 151-157.	1.2	3
3085	A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 493-506.	1.0	10
3086	Person-centered care planning and service engagement: a study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 180.	0.7	27
3088	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Schizophrenia Bulletin</i> , 2015, 41, 549-558.	2.3	47
3089	Pharmacogenomics in practice: a case report of personalized inpatient psychiatric care. <i>Pharmacogenomics</i> , 2015, 16, 433-439.	0.6	12
3090	Antipsychotic medication in schizophrenia: a review. <i>British Medical Bulletin</i> , 2015, 114, 169-179.	2.7	356
3091	Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. <i>Schizophrenia Research</i> , 2015, 165, 157-162.	1.1	40
3092	Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data. <i>Psychological Medicine</i> , 2015, 45, 1613-1627.	2.7	57
3093	Decision-Theoretic Psychiatry. <i>Clinical Psychological Science</i> , 2015, 3, 400-421.	2.4	58
3094	Practical Clinical Trials in Psychopharmacology. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 178-183.	0.7	5
3095	Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study. <i>Human Brain Mapping</i> , 2015, 36, 2558-2579.	1.9	63
3096	CYP1A2*1D and *1F Polymorphisms Have a Significant Impact on Olanzapine Serum Concentrations. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 152-160.	1.0	31
3097	Clinical and Functional Outcomes in People With Schizophrenia With a High Sense of Well-Being. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 187-193.	0.5	10

#	ARTICLE	IF	CITATIONS
3098	Antipsychotic Prescribing. <i>Medical Care</i> , 2015, 53, 338-345.	1.1	9
3099	Relationship Between Symptomatic Improvement and Overall Illness Severity in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 128-133.	0.7	5
3100	Outcomes of Medicaid Beneficiaries With Schizophrenia Receiving Clozapine Only or Antipsychotic Combinations. <i>Psychiatric Services</i> , 2015, 66, 127-133.	1.1	30
3101	Weight Gain on Antipsychotic Medication Is Associated With Sustained Use Among Veterans With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 57-62.	0.7	3
3102	Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment. <i>Psychiatric Services</i> , 2015, 66, 719-726.	1.1	28
3103	Gender differences in antipsychotics prescribed to veterans with serious mental illness. <i>General Hospital Psychiatry</i> , 2015, 37, 347-351.	1.2	7
3104	Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. <i>Schizophrenia Bulletin</i> , 2015, 41, 1397-1402.	2.3	198
3105	Translational Medicine in Psychiatry. , 2015, , 195-213.		0
3106	Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis of randomized-controlled trials. <i>Journal of Psychiatric Research</i> , 2015, 62, 38-47.	1.5	43
3107	Design and inference for the intent-to-treat principle using adaptive treatment. <i>Statistics in Medicine</i> , 2015, 34, 1441-1453.	0.8	5
3108	Regulatory and clinical aspects of psychotropic medicinal products bioequivalence. <i>European Neuropsychopharmacology</i> , 2015, 25, 1027-1034.	0.3	2
3109	Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 138, 14-19.	1.3	7
3110	Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1233.	3.8	3
3111	Olanzapine promotes the accumulation of lipid droplets and the expression of multiple perilipins in human adipocytes. <i>Biochemical and Biophysical Research Communications</i> , 2015, 467, 906-912.	1.0	28
3112	Pharmacological management of antipsychotic-induced akathisia: an update and treatment algorithm. <i>BJ Psych Advances</i> , 2015, 21, 342-344.	0.5	1
3113	Nursing Care for Lifestyle Behavioral Change. <i>Issues in Mental Health Nursing</i> , 2015, 36, 464-473.	0.6	4
3114	Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. <i>Current Medical Research and Opinion</i> , 2015, 31, 1633-1643.	0.9	98
3115	Metabolic abnormalities among people diagnosed with schizophrenia: a literature review and implications for mental health nurses. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2015, 22, 157-170.	1.2	24

#	ARTICLE	IF	CITATIONS
3116	Tackling medication non-adherence in severe mental illness: where are we going wrong?. Journal of Psychiatric and Mental Health Nursing, 2015, 22, 192-198.	1.2	11
3117	Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital. Psychogeriatrics, 2015, 15, 7-13.	0.6	4
3118	Increasing Endocannabinoid Levels in the Ventral Pallidum Restore Aberrant Dopamine Neuron Activity in the Subchronic PCP Rodent Model of Schizophrenia. International Journal of Neuropsychopharmacology, 2015, 18, pyu035-pyu035.	1.0	23
3119	Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia. Journal of Psychiatric Research, 2015, 70, 106-112.	1.5	30
3120	Clotiapine in schizophrenia: a guide to its use. Drugs and Therapy Perspectives, 2015, 31, 365-371.	0.3	3
3121	Suicidality in Schizophrenia Spectrum Disorders: The Relationship to Hallucinations and Persecutory Delusions. European Psychiatry, 2015, 30, 830-836.	0.1	77
3122	The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. CNS Drugs, 2015, 29, 637-658.	2.7	69
3123	Psychotherapy and Psychosocial Treatment. Psychiatric Clinics of North America, 2015, 38, 405-418.	0.7	11
3124	End of Life Care in Frailty. Interdisciplinary Topics in Gerontology and Geriatrics, 2015, 41, 151-160.	2.6	8
3125	Schizophrenia in children and adolescents. BJ Psych Advances, 2015, 21, 333-341.	0.5	7
3126	The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research, 2015, 229, 760-770.	1.7	20
3127	Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. International Journal of Neuropsychopharmacology, 2015, 18, pyv047.	1.0	83
3128	Association of a Schizophrenia Risk Variant at the <i>DRD2</i> Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophrenia Bulletin, 2015, 41, 1248-1255.	2.3	64
3129	Detection and treatment of at-risk mental state for developing a first psychosis: making up the balance. Lancet Psychiatry, the, 2015, 2, 825-834.	3.7	42
3130	The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert Review of Neurotherapeutics, 2015, 15, 969-981.	1.4	9
3131	Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial. European Psychiatry, 2015, 30, 975-982.	0.1	24
3133	P.3.d.010 Effectiveness, tolerability and treatment adherence of high doses of paliperidone palmitate in patients with severe schizophrenia. European Neuropsychopharmacology, 2015, 25, S485-S486.	0.3	1
3134	<i>CHRNA7</i> and <i>CHRFAM7A</i> : Psychosis and Smoking? Blame the Neighbors!. American Journal of Psychiatry, 2015, 172, 1054-1056.	4.0	6

#	ARTICLE	IF	CITATIONS
3135	Sleep Disturbances in Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2015, 38, 777-792.	0.7	32
3136	A catalytic route to dibenzodiazepines involving Buchwald-Hartwig coupling: reaction scope and mechanistic consideration. <i>RSC Advances</i> , 2015, 5, 99990-99999.	1.7	12
3137	The impact of missing data on the results of a schizophrenia study. <i>Pharmaceutical Statistics</i> , 2015, 14, 4-10.	0.7	4
3138	Psychosis (Schizophrenia Spectrum and Other Psychotic Disorders). , 2015, , 265-278.		0
3139	Searching human brain for mechanisms of psychiatric disorders. Implications for studies on schizophrenia. <i>Schizophrenia Research</i> , 2015, 167, 91-97.	1.1	14
3140	Oscillations and Neuronal Dynamics in Schizophrenia: The Search for Basic Symptoms and Translational Opportunities. <i>Biological Psychiatry</i> , 2015, 77, 1001-1009.	0.7	198
3141	Effects of risperidone treatment on the expression of hypothalamic neuropeptide in appetite regulation in Wistar rats. <i>Brain Research</i> , 2015, 1596, 146-155.	1.1	19
3142	In search of innovative therapeutics for neuropsychiatric disorders: The case of neurodegenerative diseases. <i>Annales Pharmaceutiques Francaises</i> , 2015, 73, 3-12.	0.4	9
3143	Handbook of Consultation-Liaison Psychiatry. , 2015, , .		12
3144	Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 22-30.	1.3	20
3146	A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats. <i>Human and Experimental Toxicology</i> , 2015, 34, 205-223.	1.1	2
3147	Drug models of schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2015, 5, 43-58.	1.2	108
3148	Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach. <i>Psychiatric Quarterly</i> , 2015, 86, 107-121.	1.1	1
3149	Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: A randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. <i>Journal of Psychopharmacology</i> , 2015, 29, 69-79.	2.0	5
3150	Weight gain and antipsychotics: a drug safety review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 73-96.	1.0	155
3152	Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 627-636.	2.3	44
3153	Serotonin in antipsychotic drugs action. <i>Behavioural Brain Research</i> , 2015, 277, 125-135.	1.2	46
3154	Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D2 but not 5-HT2A/2C bindings in rat brains. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 56, 75-80.	2.5	13

#	ARTICLE	IF	CITATIONS
3155	A molecular pathway analysis of the glutamatergic-“monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment. <i>Journal of Neural Transmission</i> , 2015, 122, 465-475.	1.4	3
3156	8. Antipsychotics. , 2016, , 183-198.		0
3157	Reason for Clozapine Discontinuation. <i>Korean Journal of Schizophrenia Research</i> , 2016, 19, 17.	0.3	2
3158	Acceptance and Commitment Therapy Compared to Treatment as Usual in Psychosis: A Systematic Review and Meta-Analysis. <i>Journal of Psychiatry</i> , 2016, 19, .	0.1	17
3159	Epigenetic Approaches to Define the Molecular and Genetic Risk Architectures of Schizophrenia. , 2016, , 61-82.		1
3160	COMBIMOD, un programme int�gratif de r�habilitation et de rem�diation cognitive pour la schizophr�nie. , 2016, , 99-117.		1
3161	Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 502	2.0	68
3162	Prevencci�n e intervenciones tempranas en salud mental: una perspectiva internacional. <i>Acta Bioethica</i> , 2016, 22, 37-50.	0.1	11
3163	Metabolic effects of Olanzapine versus loperidone: A 24 weeks randomized, prospective, interventional study. <i>Internet Journal of Medical Update</i> , 2016, 11, 17.	0.2	1
3164	The Neurobiology of Comorbid Drug Abuse in Schizophrenia and Psychotic Disorders. , 2016, , 82-88.		59
3165	Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2587-2594.	1.0	58
3166	Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. <i>PLoS ONE</i> , 2016, 11, e0148539.	1.1	19
3167	Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia. <i>PLoS ONE</i> , 2016, 11, e0149518.	1.1	11
3168	Chronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin Resistance. <i>PLoS ONE</i> , 2016, 11, e0167930.	1.1	8
3169	Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. <i>Current Topics in Medicinal Chemistry</i> , 2016, 16, 3385-3403.	1.0	193
3170	Editorial: Non-pharmacological Interventions for Schizophrenia: How Much Can Be Achieved and How?. <i>Frontiers in Psychology</i> , 2016, 7, 1289.	1.1	9
3171	Orthostatic Hypotension. , 2016, , 81-101.		1
3172	Experimental treatment of antipsychotic-induced movement disorders. <i>Journal of Experimental Pharmacology</i> , 2016, Volume 8, 1-10.	1.5	18

#	ARTICLE	IF	CITATIONS
3173	Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 917.	1.0	25
3174	Brain-derived neurotrophic factor and schizophrenia. <i>Mental Health Clinician</i> , 2016, 6, 285-288.	0.5	26
3175	Studying medication adherence in patients with schizophrenia. <i>Middle East Current Psychiatry</i> , 2016, 23, 27-34.	0.5	5
3176	Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 130-140.	0.7	37
3177	Drug-Induced Extrapyrarnidal Syndromes. <i>Psychiatric Clinics of North America</i> , 2016, 39, 391-411.	0.7	58
3178	A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 163-168.	0.7	21
3179	Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management. <i>CNS Drugs</i> , 2016, 30, 845-867.	2.7	58
3180	Adaptive Interventions in Child and Adolescent Mental Health. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2016, 45, 383-395.	2.2	61
3181	A regulatory perspective on missing data in the aftermath of the NRC report. <i>Statistics in Medicine</i> , 2016, 35, 2853-2864.	0.8	34
3182	Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. <i>Addiction</i> , 2016, 111, 599-612.	1.7	92
3183	Exploring the presence of narcolepsy in patients with schizophrenia. <i>BMC Psychiatry</i> , 2016, 16, 177.	1.1	22
3184	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2016, 72, 1-10.	1.3	31
3185	Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study. <i>Psychological Medicine</i> , 2016, 46, 2179-2188.	2.7	14
3186	Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. <i>Biomedical Chromatography</i> , 2016, 30, 263-268.	0.8	10
3187	PANSS: a brief rating scale for the measurement of severity in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 436-444.	2.2	79
3188	The prevalence and risk factors of the metabolic syndrome in inpatients with intellectual disability. <i>Journal of Intellectual Disability Research</i> , 2016, 60, 594-605.	1.2	8
3189	Different mechanisms of risperidone result in improved interpersonal trust, social engagement and cooperative behavior in patients with schizophrenia compared to trifluoperazine. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 218-226.	1.0	4
3190	Trends in Off-Label Use of Second-Generation Antipsychotics in the Medicare Population From 2006 to 2012. <i>Psychiatric Services</i> , 2016, 67, 898-903.	1.1	23

#	ARTICLE	IF	CITATIONS
3191	Genetics of Common Antipsychotic-Induced Adverse Effects. <i>Molecular Neuropsychiatry</i> , 2016, 2, 61-78.	3.0	47
3192	Body mass index and blood glucose in psychiatric and general practice populations. <i>BJPsych Bulletin</i> , 2016, 40, 127-131.	0.7	1
3193	Waterborne aripiprazole blunts the stress response in zebrafish. <i>Scientific Reports</i> , 2016, 6, 37612.	1.6	21
3194	Perceptions of strategies for successful weight loss in persons with serious mental illness participating in a behavioral weight loss intervention: A qualitative study.. <i>Psychiatric Rehabilitation Journal</i> , 2016, 39, 137-146.	0.8	22
3195	Nardostachys jatamansi Targets BDNF-TrkB to Alleviate Ketamine-Induced Schizophrenia-Like Symptoms in Rats. <i>Neuropsychobiology</i> , 2016, 74, 104-114.	0.9	10
3196	Risperidone versus placebo for schizophrenia. <i>The Cochrane Library</i> , 2016, 12, CD006918.	1.5	24
3198	Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. <i>Lancet Psychiatry</i> , 2016, 3, 1115-1128.	3.7	59
3199	Targeting the Endocannabinoid System in Psychiatric Illness. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 691-703.	0.7	27
3200	National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. <i>Medicine (United States)</i> , 2016, 95, e3784.	0.4	77
3201	Acute paranoid schizophrenia patients present higher serum S100B protein levels at admission than at discharge. <i>European Neuropsychopharmacology</i> , 2016, 26, S587-S588.	0.3	0
3202	Genome-wide association analysis in schizophrenia. , 0, , 106-122.		0
3203	Clinical manifestations of neuroleptic malignant syndrome. Case report. <i>European Neuropsychopharmacology</i> , 2016, 26, S530-S531.	0.3	1
3209	Obtaining employment as an anchor for estimating the minimum clinically important difference on the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. <i>Psychiatry Research</i> , 2016, 238, 304-309.	1.7	7
3210	Detecting and Managing Adverse Effects of Antipsychotic Medications. <i>Psychiatric Clinics of North America</i> , 2016, 39, 275-311.	0.7	26
3211	Mental Health Issues and Special Care Patients. <i>Dental Clinics of North America</i> , 2016, 60, 551-566.	0.8	2
3212	Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study. <i>Clinical Trials</i> , 2016, 13, 251-259.	0.7	6
3213	Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 70, 260-270.	2.9	93
3214	Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 381-384.	0.7	5

#	ARTICLE	IF	CITATIONS
3215	Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 21-23.	1.8	6
3216	Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia. <i>CNS Drugs</i> , 2016, 30, 589-601.	2.7	13
3217	Three-month paliperidone palmitate - a new treatment option for schizophrenia. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 899-904.	1.3	8
3218	Clinical factors related to schizophrenia relapse. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 54-69.	1.2	31
3220	Association of DNA Methylation Differences With Schizophrenia in an Epigenome-Wide Association Study. <i>JAMA Psychiatry</i> , 2016, 73, 506.	6.0	151
3221	Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. <i>Pharmacoeconomics</i> , 2016, 34, 709-721.	1.7	12
3222	Cariprazine in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2016, 31, 61-68.	0.9	56
3223	First-generation antipsychotics: not gone but forgotten. <i>BJPsych Bulletin</i> , 2016, 40, 93-96.	0.7	6
3224	Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study. <i>Schizophrenia Research</i> , 2016, 174, 137-143.	1.1	14
3225	Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. <i>Journal of Medical Economics</i> , 2016, 19, 913-921.	1.0	15
3226	Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 498-502.	0.7	17
3227	Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 197-202.	1.0	8
3228	Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. <i>Psychopharmacology</i> , 2016, 233, 2441-2450.	1.5	2
3229	A Subgroup Analysis of Chinese Patients Switched to Paliperidone Palmitate One-Month Injectable by Prior Oral Antipsychotic Treatment. <i>Pharmacopsychiatry</i> , 2016, 49, 32-41.	1.7	5
3230	The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study. <i>BJPsych Open</i> , 2016, 2, 139-146.	0.3	25
3231	ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. <i>Biological Psychiatry</i> , 2016, 79, 952-961.	0.7	222
3232	Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 162-171.	1.2	3
3233	<i>Clinical Psychopharmacology</i> , 2016, , 707-780.		2

#	ARTICLE	IF	CITATIONS
3234	Medication adherence in patients with schizophrenia. <i>International Journal of Psychiatry in Medicine</i> , 2016, 51, 211-219.	0.8	76
3235	A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. <i>Psychopharmacology</i> , 2016, 233, 3787-3795.	1.5	12
3236	Epigenetic Mechanisms in Psychiatric Diseases and Epigenetic Therapy. <i>Drug Development Research</i> , 2016, 77, 407-413.	1.4	24
3237	The Need for Quality Improvement in Behavioral Health. , 2016, , 33-54.		3
3238	Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 713-728.	2.6	13
3239	The NMDA Receptor and Schizophrenia. <i>Advances in Pharmacology</i> , 2016, 76, 351-382.	1.2	213
3240	Liberty versus Need " Our Struggle to Care for People with Serious Mental Illness. <i>New England Journal of Medicine</i> , 2016, 375, 1490-1495.	13.9	10
3241	Schizophrenia and neurosurgery: A dark past with hope of a brighter future. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 53-58.	0.8	19
3242	The latent structure of psychiatric symptoms across mental disorders as measured with the PANSS and BPRS-18. <i>Psychiatry Research</i> , 2016, 245, 83-90.	1.7	16
3243	A longitudinal analysis of the overlap between violence and victimization among adults with mental illnesses. <i>Psychiatry Research</i> , 2016, 246, 203-210.	1.7	22
3244	A review of the efficacy and tolerability of antipsychotic long-acting injections. <i>Progress in Neurology and Psychiatry</i> , 2016, 20, 22-28.	0.4	6
3245	A population-based study of the comparative effectiveness of second-generation antipsychotics vs older antimanic agents in bipolar disorder. <i>Bipolar Disorders</i> , 2016, 18, 481-489.	1.1	9
3246	Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample. <i>Pharmacogenomics Journal</i> , 2016, 16, 352-356.	0.9	37
3247	Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 1191-1199.	1.0	30
3248	Core Concepts Involving Adverse Psychotropic Drug Effects. <i>Psychiatric Clinics of North America</i> , 2016, 39, 375-389.	0.7	7
3249	Evaluation of genetic association of neurodevelopment and neuroimmunological genes with antipsychotic treatment response in schizophrenia in Indian populations. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 18-27.	0.6	16
3250	Factors Affecting Medication Adherence Among Adults with Schizophrenia: A Literature Review. <i>Archives of Psychiatric Nursing</i> , 2016, 30, 797-809.	0.7	25
3251	Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. <i>Journal of Psychopharmacology</i> , 2016, 30, 1072-1081.	2.0	159

#	ARTICLE	IF	CITATIONS
3252	Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. The Cochrane Library, 2016, 2016, CD010832.	1.5	4
3253	Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. CNS Drugs, 2016, 30, 1043-1054.	2.7	35
3254	Comparative Physicochemical and Pharmacokinetic Properties of Quetiapine and Its Active Metabolite Norquetiapine. Chemical and Pharmaceutical Bulletin, 2016, 64, 1546-1554.	0.6	12
3256	SZDB: A Database for Schizophrenia Genetic Research. Schizophrenia Bulletin, 2017, 43, sbw102.	2.3	91
3257	Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort: a four-year mirror image study. European Psychiatry, 2016, 37, 43-48.	0.1	35
3258	Proximal Risk Factors for Short-Term Community Violence Among Adults With Mental Illnesses. Psychiatric Services, 2016, 67, 771-778.	1.1	25
3259	Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications. Focus (American Psychiatric Publishing), 2016, 14, 370-377.	0.4	3
3260	Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject. Therapeutic Advances in Psychopharmacology, 2016, 6, 335-342.	1.2	9
3261	Reviewing depot injection efficacy in the treatment of schizophrenia. Nursing Standard (Royal College) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	2
3262	Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectrums, 2016, 21, 393-402.	0.7	28
3263	Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatrica Scandinavica, 2016, 134, 374-384.	2.2	54
3264	Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction. Schizophrenia Research, 2016, 176, 411-416.	1.1	20
3265	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Focus (American) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.5	11
3266	Clinical Update on Nursing Home Medicine: 2016. Journal of the American Medical Directors Association, 2016, 17, 978-993.	1.2	9
3267	Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. Psychopharmacology, 2016, 233, 3113-3124.	1.5	51
3268	Experience of Psychotropic Medication - An Interview Study of Persons with Psychosis. Issues in Mental Health Nursing, 2016, 37, 820-828.	0.6	20
3269	Factors important to psychiatrists when prescribing depot antipsychotics. Progress in Neurology and Psychiatry, 2016, 20, 16-20.	0.4	3
3270	Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. Schizophrenia Bulletin, 2016, 43, sbw148.	2.3	21

#	ARTICLE	IF	CITATIONS
3271	Positive Allosteric Modulation of the Muscarinic M ₁ Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 359, 354-365.	1.3	21
3272	Neuroleptic drugs. , 2016, , 53-119.		0
3274	Rhabdomyolysis With Acute Renal Failure Requiring Dialysis in McArdle Disease. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 406-408.	0.7	6
3275	Incidence of Antipsychotic-Associated Side Effects. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 593-596.	0.7	4
3276	Time-to-First Discontinuation, Adherence and Persistence in New Users of Second-Generation Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 649-657.	0.7	6
3277	Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). <i>International Clinical Psychopharmacology</i> , 2016, 31, 323-331.	0.9	14
3278	Comparison of Treatment Retention Between Risperidone Long-Acting Injection and First-Generation Long-Acting Injections in Patients With Schizophrenia for 5 Years. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 405-406.	0.7	4
3279	Comparative persistence of antiepileptic drugs in patients with epilepsy. <i>Medicine (United States)</i> , 2016, 95, e4481.	0.4	11
3280	Resilience in Patients With Recent Diagnosis of a Schizophrenia Spectrum Disorder. <i>Journal of Nervous and Mental Disease</i> , 2016, 204, 578-584.	0.5	21
3281	Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder. <i>International Clinical Psychopharmacology</i> , 2016, 31, 275-286.	0.9	6
3283	Effectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study. <i>BJPsych Open</i> , 2016, 2, 323-329.	0.3	20
3284	Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. <i>Microbial Biotechnology</i> , 2016, 10, 193-202.	0.9	128
3285	Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. <i>CNS Drugs</i> , 2016, 30, 689-701.	2.7	67
3286	Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia. <i>BMC Psychiatry</i> , 2016, 16, 176.	1.1	4
3288	The public debate on psychotropic medication and changes in attitudes 1990-2011. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 165-172.	1.8	11
3289	Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2016, 67, 1124-1130.	1.1	13
3290	A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD). <i>Journal of Psychiatric Research</i> , 2016, 80, 87-92.	1.5	11
3291	The Business Case for Expanded Clozapine Utilization. <i>Psychiatric Services</i> , 2016, 67, 1197-1205.	1.1	23

#	ARTICLE	IF	CITATIONS
3292	Quality Improvement in Behavioral Health. , 2016, , .		1
3293	Novel Targets for Drug Treatment in Psychiatry. , 2016, , 601-654.		0
3294	The involvement of family members in the treatment of patients with schizophrenia. Current Treatment Options in Psychiatry, 2016, 3, 111-118.	0.7	2
3295	Improving Treatment Adherence in Schizophrenia. Current Treatment Options in Psychiatry, 2016, 3, 119-132.	0.7	1
3296	Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry,the, 2016, 3, 717-729.	3.7	56
3297	Antipsychotic prescribing and its correlates in New Zealand. Australasian Psychiatry, 2016, 24, 360-364.	0.4	10
3298	Commentary on Schulz et al.. Clinical Trials, 2016, 13, 260-261.	0.7	1
3299	Response from the authors. Clinical Trials, 2016, 13, 262-263.	0.7	0
3300	Short term effectiveness of haloperidol versus risperidone in first-episode schizophrenia. Proceedings of Singapore Healthcare, 2016, 25, 72-79.	0.2	2
3301	Psychopharmacology in Primary Care Settings. Primary Care - Clinics in Office Practice, 2016, 43, 327-340.	0.7	3
3302	Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology, 2016, 233, 2663-2674.	1.5	29
3303	Drama therapy to empower patients with schizophrenia: Is justice possible?. Arts in Psychotherapy, 2016, 50, 91-100.	0.6	8
3304	LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model. Behavioural Pharmacology, 2016, 27, 339-349.	0.8	7
3305	Efficacy of ranitidine in olanzapineâ€induced weight gain: a doseâ€response study. Microbial Biotechnology, 2016, 10, 522-527.	0.9	13
3306	Implementation of a Reverse Colocation Model: Lessons from Two Community Behavioral Health Agencies in Rural Pennsylvania. Journal of Behavioral Health Services and Research, 2016, 43, 443-458.	0.6	10
3307	The â€Efficacy-Effectiveness Gapâ€: Historical Background and Current Conceptualization. Value in Health, 2016, 19, 75-81.	0.1	109
3308	The Cost of Inpatient Care of Schizophrenia and Treatment Schedules Used in German Academic Center: Kiel. Psychiatric Quarterly, 2016, 87, 595-603.	1.1	6
3309	Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. Molecular Psychiatry, 2016, 21, 1537-1544.	4.1	68

#	ARTICLE	IF	CITATIONS
3310	Behandlung der Schizophrenie. , 2016, , 41-83.		1
3311	Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients. Journal of Contemporary Psychotherapy, 2016, 46, 1-13.	0.7	14
3312	Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus. Schizophrenia Bulletin, 2016, 42, 703-711.	2.3	14
3313	Adherence to common cardiovascular medications in patients with schizophrenia vs. patients without psychiatric illness. General Hospital Psychiatry, 2016, 38, 9-14.	1.2	23
3314	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv132.	1.0	50
3315	Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI. ACS Medicinal Chemistry Letters, 2016, 7, 312-317.	1.3	8
3316	Brain Biomarkers of Vulnerability and Progression to Psychosis. Schizophrenia Bulletin, 2016, 42, S127-S132.	2.3	32
3317	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. European Psychiatry, 2016, 31, 13-19.	0.1	17
3318	Sexual dysfunction and its impact on quality of life in Chinese patients with schizophrenia treated in primary care. Comprehensive Psychiatry, 2016, 65, 116-121.	1.5	31
3319	Comparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: A nationwide population-based cohort study. Schizophrenia Research, 2016, 173, 37-44.	1.1	9
3320	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2016, 30, 495-553.	2.0	755
3321	Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study. Schizophrenia Bulletin, 2016, 42, S62-S70.	2.3	26
3322	Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain. Clinical Drug Investigation, 2016, 36, 479-490.	1.1	5
3323	Motivational Interviewing in a Patient With Schizophrenia to Achieve Treatment Collaboration: A Case Study. Archives of Psychiatric Nursing, 2016, 30, 150-154.	0.7	5
3324	Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatrica Scandinavica, 2016, 133, 63-75.	2.2	20
3325	Individualization of Treatment and Comparative Effectiveness Research. , 2016, , 255-274.		0
3326	Ameliorating antipsychotic-induced weight gain by betahistidine: Mechanisms and clinical implications. Pharmacological Research, 2016, 106, 51-63.	3.1	47
3327	EPA guidance on improving the image of psychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 139-154.	1.8	27

#	ARTICLE	IF	CITATIONS
3328	The client experience of psychiatric medication: A qualitative study. <i>Social Work in Mental Health</i> , 2016, 14, 61-81.	0.7	9
3329	Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. <i>Lancet Psychiatry</i> , 2016, 3, 350-357.	3.7	107
3330	Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 70, 170-218.	2.5	55
3331	NeuN+ neuronal nuclei in non-human primate prefrontal cortex and subcortical white matter after clozapine exposure. <i>Schizophrenia Research</i> , 2016, 170, 235-244.	1.1	20
3332	Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 449-455.	1.0	11
3333	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 210-220.	1.3	4
3334	Effects of olanzapine on LPS-induced inflammation in rat primary glia cells. <i>Innate Immunity</i> , 2016, 22, 40-50.	1.1	8
3335	Use of haloperidol and risperidone in highly aggressive Swiss Webster mice by applying the model of spontaneous aggression (MSA). <i>Behavioural Brain Research</i> , 2016, 301, 110-118.	1.2	15
3336	Preventing Schizophrenia and Severe Mental Illness. <i>Research on Social Work Practice</i> , 2016, 26, 449-459.	1.1	9
3337	Cardiovascular safety of antipsychotics: a clinical overview. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 679-688.	1.0	44
3338	Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity. <i>Current Gastroenterology Reports</i> , 2016, 18, 2.	1.1	16
3339	Genome-Wide Association Study Suggested the <i>PTPRD</i> Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications. <i>Schizophrenia Bulletin</i> , 2016, 42, 814-823.	2.3	32
3341	Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. <i>Journal of Medical Economics</i> , 2016, 19, 121-130.	1.0	23
3342	Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment. <i>RSC Advances</i> , 2016, 6, 2032-2045.	1.7	86
3343	A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers. <i>Psychoneuroendocrinology</i> , 2016, 66, 101-110.	1.3	12
3344	Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 289-293.	1.3	34
3345	Incident users of antipsychotics: who are they and how do they fare?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2016, 51, 505-512.	1.6	7
3346	Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 221-229.	1.3	24

#	ARTICLE	IF	CITATIONS
3347	The effects in rats of lisdexamfetamine in combination with olanzapine on mesocorticolimbic dopamine efflux, striatal dopamine D 2 receptor occupancy and stimulus generalization to a d-amphetamine cue. <i>Neuropharmacology</i> , 2016, 101, 24-35.	2.0	4
3348	Response-adaptive designs for clinical trials: Simultaneous learning from multiple patients. <i>European Journal of Operational Research</i> , 2016, 248, 619-633.	3.5	32
3349	THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. <i>Journal of Psychopharmacology</i> , 2016, 30, 169-181.	2.0	14
3350	Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. <i>American Journal of Psychiatry</i> , 2016, 173, 166-173.	4.0	134
3351	Differential Response to Risperidone in Schizophrenia Patients by <i>KCNH2</i> Genotype and Drug Metabolizer Status. <i>American Journal of Psychiatry</i> , 2016, 173, 53-59.	4.0	24
3352	Antipsychotic medications and extreme weight gain in two health systems. <i>Obesity Research and Clinical Practice</i> , 2016, 10, 408-423.	0.8	11
3353	Antipsychotic medication side effect assessment tools: A systematic review. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 399-409.	1.3	21
3354	Therapeutic equivalence of antipsychotics and antidepressants – A systematic review. <i>Pharmacological Reports</i> , 2016, 68, 217-223.	1.5	10
3355	Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia. <i>Neuropsychopharmacology</i> , 2016, 41, 1274-1285.	2.8	46
3356	Reduced Sleep Spindles in Schizophrenia: A Treatable Endophenotype That Links Risk Genes to Impaired Cognition?. <i>Biological Psychiatry</i> , 2016, 80, 599-608.	0.7	171
3357	Neurocognitive impairment in the deficit subtype of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 397-407.	1.8	21
3358	Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia. <i>Psychiatric Quarterly</i> , 2016, 87, 265-280.	1.1	6
3359	Hyperglycemia Secondary to Nondiabetic Conditions and Therapies. , 2016, , 737-751.e6.		0
3360	Rational Use of Second-Generation Antipsychotics for the Treatment of ICU Delirium. <i>Journal of Pharmacy Practice</i> , 2017, 30, 121-129.	0.5	10
3361	Editor’s Choice-Clinical impact of delirium and antipsychotic therapy: 10-Year experience from a referral coronary care unit. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 560-568.	0.4	21
3362	A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications. <i>Community Mental Health Journal</i> , 2017, 53, 163-175.	1.1	11
3364	The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. <i>Sleep Medicine Reviews</i> , 2017, 33, 51-57.	3.8	78
3365	Community Health Workers: a Resource to Support Antipsychotic Medication Adherence. <i>Journal of Behavioral Health Services and Research</i> , 2017, 44, 341-346.	0.6	4

#	ARTICLE	IF	CITATIONS
3366	Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis. <i>Qualitative Health Research</i> , 2017, 27, 559-572.	1.0	30
3367	The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. <i>Pharmacogenomics Journal</i> , 2017, 17, 146-154.	0.9	37
3368	Factors associated with complete discontinuation of medication among patients with schizophrenia in the year after hospital discharge. <i>Psychiatry Research</i> , 2017, 250, 129-135.	1.7	16
3369	Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis. <i>Current Medical Research and Opinion</i> , 2017, 33, 813-820.	0.9	12
3370	A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia. <i>Schizophrenia Research</i> , 2017, 185, 80-87.	1.1	12
3371	Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. <i>BMJ Open</i> , 2017, 7, e013881.	0.8	92
3372	Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 113-119.	2.5	3
3373	Course of psychotic symptoms, depression and global functioning in persons at clinical high risk of psychosis: Results of a longitudinal observation study over three years focusing on both converters and non-converters. <i>Schizophrenia Research</i> , 2017, 189, 19-26.	1.1	18
3374	Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. <i>Current Medical Research and Opinion</i> , 2017, 33, 723-731.	0.9	27
3375	The prevalence of diabetes mellitus and abnormal glucose metabolism in the inpatient psychiatric setting: A systematic review and meta-analysis. <i>General Hospital Psychiatry</i> , 2017, 45, 76-84.	1.2	17
3376	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017, 16, 77-89.	4.8	156
3377	Real-world Effectiveness of Antipsychotics for the Treatment of Negative Symptoms in Patients with Schizophrenia with Predominantly Negative Symptoms. <i>Pharmacopsychiatry</i> , 2017, 50, 56-63.	1.7	15
3378	Zebrafish models in neuropsychopharmacology and CNS drug discovery. <i>British Journal of Pharmacology</i> , 2017, 174, 1925-1944.	2.7	137
3379	Effects of clozapine on adipokine secretions/productions and lipid droplets in 3T3-L1 adipocytes. <i>Journal of Pharmacological Sciences</i> , 2017, 133, 79-87.	1.1	8
3380	Olanzapine-induced early cardiovascular effects are mediated by the biological clock and prevented by melatonin. <i>Journal of Pineal Research</i> , 2017, 62, e12402.	3.4	15
3381	Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). <i>Schizophrenia Research</i> , 2017, 190, 74-76.	1.1	11
3382	Switching antipsychotics: Results of 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders. <i>Acta Pharmaceutica</i> , 2017, 67, 99-112.	0.9	3
3383	Neuroleptic (Antipsychotic) Drugs: An Epidemic of Tardive Dyskinesia and Related Brain Injuries Afflicting Tens of Millions. , 2017, , 123-161.		0

#	ARTICLE	IF	CITATIONS
3384	Cost-effectiveness of therapeutic interventions in schizophrenia. <i>European Journal of Psychiatry</i> , 2017, 31, 11-16.	0.7	0
3385	Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium. <i>Journal of Medical Ethics</i> , 2017, 43, 359-363.	1.0	2
3386	Thiol/disulfide homeostasis in untreated schizophrenia patients. <i>Psychiatry Research</i> , 2017, 251, 212-216.	1.7	25
3387	Measurement of agitation and aggression in adult and aged neuropsychiatric patients: review of definitions and frequently used measurement scales. <i>CNS Spectrums</i> , 2017, 22, 407-414.	0.7	19
3388	Practical Use of Pharmacotherapy for Obesity. <i>Gastroenterology</i> , 2017, 152, 1765-1779.	0.6	49
3389	Metabolic Syndrome Prevalence and Reduction in Inmates Prescribed Antipsychotic Medications. <i>Journal of Correctional Health Care</i> , 2017, 23, 203-213.	0.2	7
3390	A cost analysis of implementing a behavioral weight loss intervention in community mental health settings: Results from the ACHIEVE trial. <i>Obesity</i> , 2017, 25, 1006-1013.	1.5	9
3391	Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2017, 47, 2217-2228.	2.7	80
3392	Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide. <i>Neuropharmacology</i> , 2017, 123, 55-66.	2.0	13
3393	Lipophilic β -Blockers and Suicide in the Elderly. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 381-384.	0.7	4
3394	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 675.	6.0	153
3395	The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. <i>American Journal of Psychiatry</i> , 2017, 174, 840-849.	4.0	155
3396	A molecular pathway analysis stresses the role of inflammation and oxidative stress towards cognition in schizophrenia. <i>Journal of Neural Transmission</i> , 2017, 124, 765-774.	1.4	10
3397	Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?. <i>Clinical Drug Investigation</i> , 2017, 37, 713-727.	1.1	48
3398	The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia. <i>American Journal of Psychiatry</i> , 2017, 174, 421-426.	4.0	30
3399	Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. <i>Molecular Brain</i> , 2017, 10, 15.	1.3	113
3400	Detection and Management of Preexisting Cognitive Impairment in the Critical Care Unit. <i>Critical Care Clinics</i> , 2017, 33, 441-459.	1.0	5
3401	Pdxdc1 modulates prepulse inhibition of acoustic startle in the mouse. <i>Translational Psychiatry</i> , 2017, 7, e1125-e1125.	2.4	12

#	ARTICLE	IF	CITATIONS
3402	Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 639-648.	0.6	29
3403	BDNF rescues prefrontal dysfunction elicited by pyramidal neuron-specific DTNBP1 deletion <i>in vivo</i> . <i>Journal of Molecular Cell Biology</i> , 2017, 9, 117-131.	1.5	13
3404	Use of mobile technologies in patients with psychosis: A systematic review. <i>Revista De PsiquiatrĀa Y Salud Mental (English Edition)</i> , 2017, 10, 168-178.	0.2	20
3405	Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients. <i>Psychopharmacology</i> , 2017, 234, 2657-2671.	1.5	17
3406	LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition. <i>Behavioural Pharmacology</i> , 2017, 28, 48-62.	0.8	12
3407	The MAM-E17 schizophrenia rat model: Comprehensive behavioral analysis of pre-pubertal, pubertal and adult rats. <i>Behavioural Brain Research</i> , 2017, 332, 75-83.	1.2	15
3408	Classics in Chemical Neuroscience: Aripiprazole. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1135-1146.	1.7	80
3409	Treatment retention of risperidone long-acting injection in patients with early-onset schizophrenia in Japan. <i>Asian Journal of Psychiatry</i> , 2017, 27, 137-138.	0.9	4
3410	Utilizaci3n de tecnologĀas m3viles en pacientes con psicosis: una revisi3n sistemĀtica. <i>Revista De PsiquiatrĀa Y Salud Mental</i> , 2017, 10, 168-178.	1.0	30
3411	TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese. <i>Scientific Reports</i> , 2017, 7, 45203.	1.6	13
3412	Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 581-588.	0.9	28
3413	Caveolin-1 regulation of <i>disrupted-in-schizophrenia-1</i> as a potential therapeutic target for schizophrenia. <i>Journal of Neurophysiology</i> , 2017, 117, 436-444.	0.9	27
3414	rs 7968606 polymorphism of ANKS1B is associated with improvement in the PANSS general score of schizophrenia caused by amisulpride. <i>Human Psychopharmacology</i> , 2017, 32, e2562.	0.7	8
3415	Is Ondansetron Augmentation Effective in Obsessive-Compulsive Disorder?. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 380-381.	0.7	3
3416	Motivation deficits and use of alcohol and illicit drugs among individuals with schizophrenia. <i>Psychiatry Research</i> , 2017, 253, 391-397.	1.7	7
3417	Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions. <i>Neuropsychopharmacology</i> , 2017, 42, 2232-2241.	2.8	19
3418	Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. <i>Advances in Therapy</i> , 2017, 34, 1036-1048.	1.3	40
3419	Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 296-301.	0.7	4

#	ARTICLE	IF	CITATIONS
3420	Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 103-111.	1.2	15
3421	Paliperidone Long-Acting Plasma Level Monitoring and a New Method of Evaluation of Clinical Stability. <i>Pharmacopsychiatry</i> , 2017, 50, 145-151.	1.7	10
3422	Peripheral blood nerve growth factor levels in major psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2017, 86, 39-45.	1.5	25
3423	Leading indicators of community-based violent events among adults with mental illness. <i>Psychological Medicine</i> , 2017, 47, 1179-1191.	2.7	17
3424	Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. <i>Pharmacotherapy</i> , 2017, 37, 261-267.	1.2	207
3425	Individualized metacognitive therapy for delusions: A randomized controlled rater-blind study. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2017, 56, 144-151.	0.6	34
3426	Sedative effect of Clozapine is a function of 5-HT2A and environmental novelty. <i>European Neuropsychopharmacology</i> , 2017, 27, 70-81.	0.3	7
3427	Computational approaches to schizophrenia: A perspective on negative symptoms. <i>Schizophrenia Research</i> , 2017, 186, 46-54.	1.1	27
3428	Service Business Model Innovation in Healthcare and Hospital Management. , 2017, , .		11
3429	Fine-mapping of antipsychotic response genome-wide association studies reveals novel regulatory mechanisms. <i>Pharmacogenomics</i> , 2017, 18, 105-120.	0.6	14
3430	Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. <i>Psychiatry Research</i> , 2017, 247, 257-264.	1.7	32
3431	Psychiatric Care in Severe Obesity. , 2017, , .		3
3432	Outcomes in Child Psychiatry. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 535-537.	0.7	1
3433	Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. <i>Journal of Psychiatric Research</i> , 2017, 95, 299-307.	1.5	5
3434	Misleading Guidance From Pharmacogenomic Testing. <i>American Journal of Psychiatry</i> , 2017, 174, 922-924.	4.0	23
3435	Student pharmacist experiences as inpatient psychiatry medication education group leaders during an early immersion program. <i>Currents in Pharmacy Teaching and Learning</i> , 2017, 9, 856-861.	0.4	3
3436	Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 657-663.	0.7	18
3437	Individual Factors Affecting Self-esteem, and Relationships Among Self-esteem, Body Mass Index, and Body Image in Patients With Schizophrenia. <i>Archives of Psychiatric Nursing</i> , 2017, 31, 588-595.	0.7	15

#	ARTICLE	IF	CITATIONS
3438	Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychotherapy and Psychosomatics, 2017, 86, 189-219.	4.0	199
3439	Why do individuals with schizophrenia drop out of observational clinical trials?. Psychiatry Research, 2017, 256, 1-5.	1.7	9
3440	Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology, 2017, 234, 3279-3297.	1.5	81
3442	Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents. Clinical Drug Investigation, 2017, 37, 947-956.	1.1	17
3443	Discontinuing Psychiatric Medications: A Survey of Long-Term Users. Psychiatric Services, 2017, 68, 1232-1238.	1.1	40
3444	Physical Health and Drug Safety in Individuals with Schizophrenia. Canadian Journal of Psychiatry, 2017, 62, 673-683.	0.9	22
3445	The epigenomics of schizophrenia, in the mouse. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 631-640.	1.1	12
3446	Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation. L'Encephale, 2017, 43, 303-310.	0.3	3
3448	Special Populations: Agitation in Elderly Patients. , 0, , 74-87.		0
3449	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane Library, 2017, 2017, CD009377.	1.5	73
3450	Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. Journal of Medical Economics, 2017, 20, 1187-1199.	1.0	17
3451	Yoga for Schizophrenia: a Review of Efficacy and Neurobiology. Current Behavioral Neuroscience Reports, 2017, 4, 209-220.	0.6	4
3452	Reconstructing Identity. , 2017, , .		2
3453	Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia. Journal of Clinical Psychopharmacology, 2017, 37, 13-20.	0.7	16
3454	Targets for the Treatment of Insomnia in Veterans With Serious Mental Illness. Journal of Psychiatric Practice, 2017, 23, 270-280.	0.3	4
3455	Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia. Journal of Medical Economics, 2017, 20, 1252-1260.	1.0	12
3456	Extrapyramidal Symptoms Probably Related to Risperidone Treatment: A Case Series. Annals of Neurosciences, 2017, 24, 155-163.	0.9	12
3457	Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety. Expert Opinion on Pharmacotherapy, 2017, 18, 1799-1809.	0.9	9

#	ARTICLE	IF	CITATIONS
3458	The Treatment of Refractory Generalized Anxiety Disorder. <i>Current Treatment Options in Psychiatry</i> , 2017, 4, 404-417.	0.7	2
3459	A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events. <i>Drugs in R and D</i> , 2017, 17, 631-643.	1.1	9
3461	Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 132.	3.8	101
3462	Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2017, 37, 861-871.	1.1	6
3463	A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain. <i>Schizophrenia Research</i> , 2017, 187, 67-73.	1.1	18
3464	Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study. <i>Journal of Technology in Behavioral Science</i> , 2017, 2, 84-87.	1.3	25
3465	Schizophrenia: Basic and Clinical. <i>Advances in Neurobiology</i> , 2017, 15, 255-280.	1.3	28
3466	Electroconvulsive therapy-induced brain functional connectivity predicts therapeutic efficacy in patients with schizophrenia: a multivariate pattern recognition study. <i>NPJ Schizophrenia</i> , 2017, 3, 21.	2.0	27
3467	Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. <i>New England Journal of Medicine</i> , 2017, 377, 62-70.	13.9	684
3468	Serious mental illness and medical comorbidities: Findings from an integrated health care system. <i>Journal of Psychosomatic Research</i> , 2017, 100, 35-45.	1.2	64
3470	The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 8-12.	0.7	8
3471	Provision of peer specialist services in VA patient aligned care teams: protocol for testing a cluster randomized implementation trial. <i>Implementation Science</i> , 2017, 12, 57.	2.5	23
3472	The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 165.	0.7	11
3473	Interventions to Improve Pharmacological Adherence Among Adults With Psychotic Spectrum Disorders and Bipolar Disorder: A Systematic Review. <i>Psychosomatics</i> , 2017, 58, 101-112.	2.5	21
3474	The Harms of Antipsychotic Drugs: Evidence from Key Studies. <i>Drug Safety</i> , 2017, 40, 3-14.	1.4	7
3475	Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 76, 317-335.	2.9	31
3476	Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials. <i>Statistics in Medicine</i> , 2017, 36, 403-415.	0.8	6
3477	A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. <i>Clinical Psychology Review</i> , 2017, 51, 75-95.	6.0	51

#	ARTICLE	IF	CITATIONS
3478	Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study. <i>Psychopharmacology</i> , 2017, 234, 3-13.	1.5	12
3479	Unbiased Metabolite Profiling of Schizophrenia Fibroblasts under Stressful Perturbations Reveals Dysregulation of Plasmalogens and Phosphatidylcholines. <i>Journal of Proteome Research</i> , 2017, 16, 481-493.	1.8	18
3480	Crosstalk between insulin and dopamine signaling: A basis for the metabolic effects of antipsychotic drugs. <i>Journal of Chemical Neuroanatomy</i> , 2017, 83-84, 59-68.	1.0	32
3481	Treating refractory mental illness with closed-loop brain stimulation: Progress towards a patient-specific transdiagnostic approach. <i>Experimental Neurology</i> , 2017, 287, 461-472.	2.0	94
3482	New drug developments in psychosis: Challenges, opportunities and strategies. <i>Progress in Neurobiology</i> , 2017, 152, 3-20.	2.8	57
3483	Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income. <i>Schizophrenia Research</i> , 2017, 182, 120-128.	1.1	74
3486	An original pharmacoepidemiologicalâ€“pharmacodynamic method: application to antipsychoticâ€“induced movement disorders. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 612-622.	1.1	29
3487	Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. <i>Schizophrenia Research</i> , 2017, 179, 64-69.	1.1	10
3488	-759C>T Polymorphism of the HTR2C Gene is Associated with Second Generation Antipsychotic-Induced Weight Gain in Female Patients with Schizophrenia. <i>Pharmacopsychiatry</i> , 2017, 50, 14-18.	1.7	10
3489	Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. <i>Schizophrenia Research</i> , 2017, 183, 10-21.	1.1	66
3490	Association between antipsychotic drug use and cataracts in patients with bipolar disorder: A population-based, nested case-control study. <i>Journal of Affective Disorders</i> , 2017, 209, 86-92.	2.0	12
3491	The real-life effectiveness of psychosocial therapies on social autonomy in schizophrenia patients: Results from a nationwide cohort study in France. <i>Psychiatry Research</i> , 2017, 247, 97-104.	1.7	6
3492	Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine. <i>Schizophrenia Research</i> , 2017, 183, 116-123.	1.1	8
3493	Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis. <i>CNS Spectrums</i> , 2017, 22, 315-324.	0.7	33
3494	Aripiprazole augmentation in highly treatment-resistant obsessiveâ€“compulsive disorder â€“ experience from a specialty clinic in India. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 67-69.	1.2	7
3495	The validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. <i>European Neuropsychopharmacology</i> , 2017, 27, S940-S941.	0.3	0
3496	Impact of once-monthly paliperidone palmitate treatment on hospitalisation risk in patients with schizophrenia switching from oral antipsychotics. <i>European Neuropsychopharmacology</i> , 2017, 27, S941.	0.3	0
3497	The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1233-e1241.	1.1	39

#	ARTICLE	IF	CITATIONS
3498	Effective and underprescribed: what about clozapine?. <i>Mental Illness</i> , 2017, 9, 65-65.	0.8	0
3499	A Study on Discontinuation Rate on Maintenance Treatment of Antipsychotic Agents in Schizophrenic Patients. <i>Korean Journal of Schizophrenia Research</i> , 2017, 20, 69.	0.3	1
3500	Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. <i>Frontiers in Pharmacology</i> , 2017, 8, 399.	1.6	25
3501	Commentary: A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated with Initiation of Atypical Antipsychotic Therapy in Children and Adolescents. <i>Frontiers in Psychiatry</i> , 2017, 8, 59.	1.3	2
3502	Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review. <i>Frontiers in Psychiatry</i> , 2017, 8, 238.	1.3	114
3503	In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 424-431.	1.4	26
3504	Reducing Off-Label Antipsychotic Use in Older Community-Dwelling Adults With Dementia: A Narrative Review. <i>Journal of Osteopathic Medicine</i> , 2017, 117, 441-450.	0.4	6
3505	Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2231-2241.	1.0	196
3506	Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2193-2207.	1.0	11
3507	Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2045-2056.	1.0	10
3508	Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine. <i>Internal Medicine</i> , 2017, 56, 335-339.	0.3	7
3509	Prospects for Modeling Abnormal Neuronal Function in Schizophrenia Using Human Induced Pluripotent Stem Cells. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 360.	1.8	18
3510	ASENAPINE MALEATE LOADED SOLID LIPID NANOPARTICLES FOR ORAL DELIVERY. <i>International Research Journal of Pharmacy</i> , 2017, 8, 45-53.	0.0	9
3511	Electroconvulsive Therapy in the Treatment of Mood Disorders: One-Year Follow-up. <i>Noropsikiyatri Arsivi</i> , 2017, 54, 196-201.	0.2	7
3512	Prefrontal Cortical Abnormalities in Cognitive Deficits of Schizophrenia. , 2017, , 277-287.		1
3513	Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 979-987.	1.0	18
3514	Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. <i>Annals of General Psychiatry</i> , 2017, 16, 36.	1.2	13
3515	The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial. <i>Annals of General Psychiatry</i> , 2017, 16, 47.	1.2	18

#	ARTICLE	IF	CITATIONS
3516	Internet use, eHealth literacy and attitudes toward computer/internet among people with schizophrenia spectrum disorders: a cross-sectional study in two distant European regions. BMC Medical Informatics and Decision Making, 2017, 17, 136.	1.5	40
3517	Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N -(1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzopyridin-4-one (TAK-915), for the Treatment of Cognitive Disorders. Chemical and Pharmaceutical Bulletin, 2017, 65, 1058-1077.	0.2	1
3518	Treatment outcomes in schizophrenia: qualitative study of the views of family carers. BMC Psychiatry, 2017, 17, 266.	1.1	13
3519	The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry, 2017, 17, 305.	1.1	49
3520	Achievement of Adequate Glycemic Control in Patients With Type 2 Diabetes and Comorbid Mental Health Conditions Treated in a Primary Care Setting. Diabetes Spectrum, 2017, 30, 277-287.	0.4	5
3521	Coronary Heart Disease Risk in Patients with Schizophrenia: A Lebanese Cross-Sectional Study. Journal of Comorbidity, 2017, 7, 79-88.	3.9	9
3522	Psychiatric Polypharmacy, Etiology and Potential Consequences. Current Psychopharmacology, 2017, 6, 12-26.	0.1	13
3523	Effective and underprescribed: what about clozapine?. Mental Illness, 2017, 9, 7193.	0.8	0
3524	Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1089-1097.	1.0	1
3525	An Instrumental Variable Tree Approach for Detecting Heterogeneous Treatment Effects in Observational Studies. SSRN Electronic Journal, 0, , .	0.4	10
3526	Psychotropic prescriptions for the treatment of schizophrenia in an outpatient clinic. Trends in Psychiatry and Psychotherapy, 2017, 39, 165-172.	0.4	4
3527	Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2767-2779.	1.0	21
3528	Prevalence of Extrapyramidal Side Effects in Patients on Antipsychotics Drugs at a Tertiary Care Center5. Journal of Psychiatry, 2017, 20, .	0.1	3
3529	Antipsychotic use in a resource-limited setting: Findings in an Eastern Cape psychiatric hospital. South African Journal of Psychiatry, 2017, 23, 1093.	0.2	4
3530	Medication nonadherence among South American patients with schizophrenia. Patient Preference and Adherence, 2017, Volume 11, 1737-1744.	0.8	10
3531	Neuroprotection in Schizophrenia and Its Therapeutic Implications. Psychiatry Investigation, 2017, 14, 383.	0.7	18
3533	Crosstalk Between 5-HT _{2A} and mGlu ₂ Receptors: Implications in Schizophrenia and Its Treatment. , 2018, , 147-189.		1
3534	Schizophrenia: Practical prescribing of antipsychotics. NursePrescribing, 2018, 16, 64-70.	0.1	0

#	ARTICLE	IF	CITATIONS
3535	Acting on delusions: the role of negative affect in the pathway towards serious violence. <i>Journal of Forensic Psychiatry and Psychology</i> , 2018, 29, 691-704.	0.6	13
3536	Decomposition of the Total Effect in the Presence of Multiple Mediators and Interactions. <i>American Journal of Epidemiology</i> , 2018, 187, 1311-1318.	1.6	37
3537	A Review Essay on <i>Social Neuroscience</i> : Can Research on the Social Brain and Economics Inform Each Other?. <i>Journal of Economic Literature</i> , 2018, 56, 234-264.	4.5	25
3538	Early treatment resistance in a Latin-American cohort of patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 199, 380-385.	1.1	12
3539	Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics. <i>Drugs - Real World Outcomes</i> , 2018, 5, 81-90.	0.7	10
3540	Complex Polypharmacy in Patients With Schizophrenia-Spectrum Disorders Before a Psychiatric Hospitalization. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 180-187.	0.7	8
3541	Progressive symptom-associated prefrontal volume loss occurs in first-episode schizophrenia but not in affective psychosis. <i>Brain Structure and Function</i> , 2018, 223, 2879-2892.	1.2	16
3542	Diabetes and Mental Health. <i>Canadian Journal of Diabetes</i> , 2018, 42, S130-S141.	0.4	98
3543	Effects of the monoamine stabilizer (âˆ“)OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 761-768.	1.4	4
3544	Anhedonia in depression and schizophrenia: A transdiagnostic challenge. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 615-623.	1.9	92
3545	Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. <i>Biostatistics</i> , 2018, 19, 199-215.	0.9	19
3546	Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge. <i>Schizophrenia Research</i> , 2018, 199, 285-291.	1.1	33
3547	No differences in olanzapineâ€•and risperidoneâ€•related weight gain between women and men: a metaâ€•analysis of shortâ€•and middleâ€•term treatment. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 110-122.	2.2	8
3548	Tardive dyskinesia: Epidemiology. <i>Journal of the Neurological Sciences</i> , 2018, 389, 17-20.	0.3	35
3549	Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. <i>Current Medical Research and Opinion</i> , 2018, 34, 1377-1388.	0.9	6
3550	Protective effects of stigmasterol against ketamineâ€•induced psychotic symptoms: Possible behavioral, biochemical and histopathological changes in mice. <i>Pharmacological Reports</i> , 2018, 70, 591-599.	1.5	35
3551	Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: A meta-analysis of randomized controlled trials. <i>European Psychiatry</i> , 2018, 49, 69-77.	0.1	94
3552	Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders. <i>International Clinical Psychopharmacology</i> , 2018, 33, 147-154.	0.9	1

#	ARTICLE	IF	CITATIONS
3553	Diagnostic value of structural and diffusion imaging measures in schizophrenia. <i>NeuroImage: Clinical</i> , 2018, 18, 467-474.	1.4	27
3554	A prospective year-long follow-up of lurasidone use in clinical practice: factors predicting treatment persistence. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 117-125.	1.2	7
3555	QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 383-390.	1.8	22
3556	Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. <i>The Cochrane Library</i> , 2018, 2018, CD011057.	1.5	15
3557	Gaps in Psychiatric Training Could Challenge Delivery of Optimal Schizophrenia Pharmacotherapy. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 146-147.	0.9	0
3558	Substantia nigra ultrastructural pathology in schizophrenia. <i>Schizophrenia Research</i> , 2018, 197, 209-218.	1.1	24
3559	Effectiveness of an Interprofessional Glycemic Optimization Clinic on Preoperative Glycated Hemoglobin Levels for Adult Patients With Type 2 Diabetes Undergoing Bariatric Surgery. <i>Canadian Journal of Diabetes</i> , 2018, 42, 514-519.	0.4	12
3560	A Patient-Centered Antipsychotic Medication Adherence Intervention. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 142-148.	0.5	4
3561	Cardiometabolic effects of psychotropic medications. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2018, 36, .	0.3	72
3562	Inference on phenotype-specific effects of genes using multivariate kernel machine regression. <i>Genetic Epidemiology</i> , 2018, 42, 64-79.	0.6	1
3563	Functional Changes of Orexinergic Reaction to Psychoactive Substances. <i>Molecular Neurobiology</i> , 2018, 55, 6362-6368.	1.9	29
3564	Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 474-485.	1.2	51
3565	Risk factors for relapse in patients with first-episode schizophrenia: Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015. <i>International Journal of Mental Health Systems</i> , 2018, 12, 9.	1.1	6
3566	Attempting to stop antipsychotic medication: success, supports, and efforts to cope. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2018, 53, 745-756.	1.6	18
3567	A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales. <i>JRSM Open</i> , 2018, 9, 205427041875857.	0.2	23
3568	Clozapine use in old age psychiatry. <i>BJ Psych Advances</i> , 2018, 24, 204-211.	0.5	5
3569	Predictors of "all-cause discontinuation" of initial oral antipsychotic medication in first episode psychosis. <i>Schizophrenia Research</i> , 2018, 201, 287-293.	1.1	15
3570	Mental health multimorbidity and poor quality of life in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 201, 39-45.	1.1	28

#	ARTICLE	IF	CITATIONS
3571	Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 737-748.	0.6	10
3572	Recent Progress in Pharmacogenomics of Antipsychotic Drug Response. <i>Current Psychiatry Reports</i> , 2018, 20, 24.	2.1	22
3573	Psychodynamic Psychiatry, the Biopsychosocial Model, and the Difficult Patient. <i>Psychiatric Clinics of North America</i> , 2018, 41, 237-248.	0.7	15
3574	Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis. <i>BMJ Open</i> , 2018, 8, e018359.	0.8	17
3575	Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. <i>European Journal of Endocrinology</i> , 2018, 178, R245-R258.	1.9	33
3576	Psychosis in Children and Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 308-312.	0.3	28
3577	New findings in pharmacogenetics of schizophrenia. <i>Current Opinion in Psychiatry</i> , 2018, 31, 200-212.	3.1	36
3578	Outcomes and feasibility of the short transitional intervention in psychiatry in improving the transition from inpatient treatment to the community: A pilot study. <i>International Journal of Mental Health Nursing</i> , 2018, 27, 571-580.	2.1	9
3579	Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. <i>Schizophrenia Research</i> , 2018, 192, 194-204.	1.1	64
3580	Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. <i>CNS Spectrums</i> , 2018, 23, 39-50.	0.7	48
3581	A computational algorithm for personalized medicine in schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 131-136.	1.1	17
3582	MEF2C transcription factor is associated with the genetic and epigenetic risk architecture of schizophrenia and improves cognition in mice. <i>Molecular Psychiatry</i> , 2018, 23, 123-132.	4.1	70
3583	The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. <i>Schizophrenia Bulletin</i> , 2018, 44, 453-462.	2.3	25
3584	Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan. <i>Schizophrenia Research</i> , 2018, 193, 107-113.	1.1	11
3585	Psychopharmacologic treatment of in-patients with schizophrenia: comparing forensic and general psychiatry. <i>Journal of Forensic Psychiatry and Psychology</i> , 2018, 29, 1-15.	0.6	9
3586	Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMSÂ®): A six-month post-discharge prospective study. <i>Schizophrenia Research</i> , 2018, 193, 114-118.	1.1	16
3587	A Powerful Test for SNP Effects on Multivariate Binary Outcomes Using Kernel Machine Regression. <i>Statistics in Biosciences</i> , 2018, 10, 117-138.	0.6	7
3588	Application of plasma levels of olanzapine and N -desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 193, 139-145.	1.1	22

#	ARTICLE	IF	CITATIONS
3589	Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia. <i>Schizophrenia Research</i> , 2018, 193, 83-90.	1.1	13
3590	Delusions, Harmful Dysfunctions, and Treatable Conditions. <i>Neuroethics</i> , 2018, 11, 167-181.	1.7	1
3591	Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: A retrospective cohort study. <i>Schizophrenia Research</i> , 2018, 195, 237-244.	1.1	13
3592	Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. <i>Psychopharmacology</i> , 2018, 235, 245-255.	1.5	30
3593	Engineered D2R Variants Reveal the Balanced and Biased Contributions of G-Protein and β -Arrestin to Dopamine-Dependent Functions. <i>Neuropsychopharmacology</i> , 2018, 43, 1164-1173.	2.8	24
3594	Impairment of neural coordination in hippocampal neuronal ensembles after a psychotomimetic dose of dizocilpine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 275-283.	2.5	8
3595	Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 85, 146-159.	2.9	63
3596	Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. <i>Molecular Psychiatry</i> , 2018, 23, 2156-2166.	4.1	148
3597	Prevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India – a cross-sectional study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 101-108.	1.2	6
3598	Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Schizophrenia Research</i> , 2018, 195, 275-282.	1.1	24
3599	How Psychiatrists Recommend Treatment and Its Relationship with Patient Uptake. <i>Health Communication</i> , 2018, 33, 1345-1354.	1.8	30
3600	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018, 51, 9-62.	1.7	787
3601	A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. <i>Schizophrenia Research</i> , 2018, 195, 245-251.	1.1	42
3602	Prenatal exposure to ketamine in rats: Implications on animal models of schizophrenia. <i>Developmental Psychobiology</i> , 2018, 60, 30-42.	0.9	24
3603	Decision-making Capacity for Treatment of Psychotic Patients on Long Acting Injectable Antipsychotic Treatment. <i>Archives of Psychiatric Nursing</i> , 2018, 32, 300-304.	0.7	6
3604	A synopsis of anti-psychotic medicinal plants in Nigeria. <i>Transactions of the Royal Society of South Africa</i> , 2018, 73, 33-41.	0.8	14
3605	Prevalence, correlates and outcomes of insomnia in patients with first episode psychosis from a tertiary psychiatric institution in Singapore. <i>General Hospital Psychiatry</i> , 2018, 51, 15-21.	1.2	21
3606	Causal beliefs in people experiencing psychosis: The relationship to treatment accessed and the perceived helpfulness of treatment. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2018, 91, 332-344.	1.3	12

#	ARTICLE	IF	CITATIONS
3607	Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia. <i>Psychiatric Services</i> , 2018, 69, 12-14.	1.1	10
3608	Insights on insight. <i>Schizophrenia Research</i> , 2018, 197, 61-62.	1.1	2
3609	Side effect burden of antipsychotic drugs in real life – Impact of gender and polypharmacy. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 82, 263-271.	2.5	77
3610	Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders. <i>JAMA Psychiatry</i> , 2018, 75, 11.	6.0	88
3611	A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment. <i>International Clinical Psychopharmacology</i> , 2018, 33, 1-14.	0.9	12
3612	Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules. <i>Biometrics</i> , 2018, 74, 18-26.	0.8	24
3613	Calcium as a Trojan horse in mental diseases – The role of PMCA and PMCA-interacting proteins in bipolar disorder and schizophrenia. <i>Neuroscience Letters</i> , 2018, 663, 48-54.	1.0	7
3614	Carers’ Perspectives on Mental Health Consumers’ Use of Antipsychotic Medication: A Multidimensional Scalogram Analysis. <i>Contemporary Family Therapy</i> , 2018, 40, 99-109.	0.6	7
3615	Involved, inputting or informing: – Shared decision making in adult mental health care. <i>Health Expectations</i> , 2018, 21, 192-200.	1.1	28
3616	Safety and Efficacy of Acceptance and Commitment Therapy (ACT) in Schizophrenia Spectrum and Other Psychotic Disorders: Protocol for a Systematic Review and Meta-Analysis. <i>Methods and Protocols</i> , 2018, 1, 38.	0.9	4
3617	Clinician perspectives on supporting adults with psychosis who wish to discontinue neuroleptic medication: qualitative analysis. <i>Psychosis</i> , 2018, 10, 239-250.	0.4	2
3618	Analysis of Clozapine Use and Safety by Using Comprehensive National Data From the Japanese Clozapine Patient Monitoring Service. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 302-306.	0.7	18
3619	The development of antipsychotic drugs. <i>Brain and Neuroscience Advances</i> , 2018, 2, 239821281881749.	1.8	15
3620	Fat Distribution in Schizophrenia Patients. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 68-71.	0.7	4
3621	Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning. <i>Yonago Acta Medica</i> , 2018, 61, 091-102.	0.3	46
3622	Negative Symptoms of Schizophrenia: Constructs, Burden, and Management. , 2018, , .		1
3623	COMT, 5-HTR2A, and SLC6A4 mRNA Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association With Treatment Outcomes. <i>Frontiers in Psychiatry</i> , 2018, 9, 577.	1.3	9
3624	Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia. <i>Translational Psychiatry</i> , 2018, 8, 252.	2.4	73

#	ARTICLE	IF	CITATIONS
3625	Attitudes to antipsychotics: a multi-site survey of Canadian psychiatry residents. <i>Journal of Mental Health Training, Education and Practice</i> , 2018, 13, 318-338.	0.3	1
3626	Effects of Crocins in the Management of Neurodegenerative Pathologies: A Review. <i>Neurophysiology</i> , 2018, 50, 302-308.	0.2	7
3627	Change in Cognitive Function after Antipsychotics Treatment : A Pilot Study of Long-Acting Injectable versus Oral Form. <i>Korean Journal of Schizophrenia Research</i> , 2018, 21, 74.	0.3	0
3628	Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome. <i>Frontiers in Psychiatry</i> , 2018, 9, 647.	1.3	17
3629	EVALUATION OF NEUROLEPTIC ACTIVITY OF PIPERINE ON PSYCHOSIS INDUCED SWISS ALBINO MICE. <i>International Research Journal of Pharmacy</i> , 2018, 9, 110-114.	0.0	0
3630	Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia. <i>Clinical Therapeutics</i> , 2018, 40, 1845-1854.e2.	1.1	32
3631	Epigenetic Alterations in Prenatal Stress Mice as an Endophenotype Model for Schizophrenia: Role of Metabotropic Glutamate 2/3 Receptors. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 423.	1.4	16
3632	Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. <i>BMC Psychiatry</i> , 2018, 18, 292.	1.1	25
3633	Qualitative systematic review of barriers and facilitators to patient-involved antipsychotic prescribing. <i>BJPsych Open</i> , 2018, 4, 5-14.	0.3	16
3634	Translation and cultural adaptation of Glasgow Antipsychotic Side-effects Scale (GASS) in Arabic. <i>PLoS ONE</i> , 2018, 13, e0201225.	1.1	7
3635	ABCB1 1199G>A Polymorphism Affects the Intracellular Accumulation of Antidepressants in LLC-PK1 Recombinant Cell Lines. <i>DNA and Cell Biology</i> , 2018, 37, 1055-1060.	0.9	4
3636	The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1623-1629.	0.9	10
3637	Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801. <i>Psychopharmacology</i> , 2018, 235, 3339-3350.	1.5	5
3638	Attempting to discontinue antipsychotic medication: Withdrawal methods, relapse and success. <i>Psychiatry Research</i> , 2018, 270, 365-374.	1.7	11
3639	Effects of Long-Term Multimodal Psychosocial Treatment on Antipsychotic-Induced Metabolic Changes in Patients With First Episode Psychosis. <i>Frontiers in Psychiatry</i> , 2018, 9, 488.	1.3	0
3640	Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia. <i>BMJ Open</i> , 2018, 8, e020070.	0.8	9
3641	Predicting program success for adult offenders with serious mental illness in a court ordered diversion program. <i>Social Work in Mental Health</i> , 2018, 16, 665-681.	0.7	0
3642	Psychotropic drug therapy in patients in the intensive care unit - usage, adverse effects and drug interactions: a review. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1799-1812.	0.9	14

#	ARTICLE	IF	CITATIONS
3643	Does the Time of Drug Administration Alter the Metabolic Risk of Aripiprazole?. <i>Frontiers in Psychiatry</i> , 2018, 9, 494.	1.3	12
3644	Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 1090-1101.	1.0	16
3645	Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i> , 2018, 17, 341-356.	4.8	294
3646	A thematic analysis assessing clinical decision-making in antipsychotic prescribing for schizophrenia. <i>BMC Psychiatry</i> , 2018, 18, 290.	1.1	6
3647	The validity and sensitivity of PANSS in treatment-resistant schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 420-431.	2.2	17
3648	Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 443-456.	0.7	13
3649	Precise treatments for schizophrenia: where is the way forward?. <i>Annals of General Psychiatry</i> , 2018, 31, e000002.	1.1	5
3650	PRESCRIPTION PATTERNS OF SEDATIVE DRUGS, EFFICACY AND DAYTIME SEDATION IN VARIOUS PSYCHIATRIC PATIENTS IN A TEACHING HOSPITAL. <i>International Research Journal of Pharmacy</i> , 2018, 9, 187-192.	0.0	0
3651	Innovative Add-On Treatments for Schizophrenia. <i>Psychiatric Annals</i> , 2018, 48, 208-209.	0.1	0
3652	Iron overload prevents oxidative damage to rat brain after chlorpromazine administration. <i>BioMetals</i> , 2018, 31, 561-570.	1.8	6
3653	TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 271-285.	1.2	5
3655	Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. <i>Schizophrenia Research</i> , 2018, 201, 324-328.	1.1	10
3656	Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case-control study. <i>BMJ Open</i> , 2018, 8, e019868.	0.8	12
3657	Increase Adherence to Psychotropic Medication Through Motivational Adherence Therapy: A Quality Improvement Project. <i>Issues in Mental Health Nursing</i> , 2018, 39, 709-713.	0.6	4
3658	Exploration of illness perception among patients with mental illness in a multi-ethnic Asian sample. <i>Psychiatry Research</i> , 2018, 267, 516-527.	1.7	10
3659	Changes in antipsychotic drug usage and factors affecting the use of typical drugs based on nationwide health insurance data in South Korea. <i>BMJ Open</i> , 2018, 8, e020280.	0.8	7
3660	Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis. <i>Schizophrenia Research and Treatment</i> , 2018, 2018, 1-9.	0.7	15
3661	Chromosomal Conformations and Epigenomic Regulation in Schizophrenia. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 157, 21-40.	0.9	16

#	ARTICLE	IF	CITATIONS
3662	Sub-circuit alterations in dorsal hippocampus structure and function after global neurodevelopmental insult. <i>Brain Structure and Function</i> , 2018, 223, 3543-3556.	1.2	4
3663	Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. , 2018, 192, 20-41.		140
3664	Interventions for the management of obesity in people with bipolar disorder. <i>The Cochrane Library</i> , 2018, , .	1.5	3
3665	What can we learn about brain donors? Use of clinical information in human postmortem brain research. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 150, 181-196.	1.0	8
3666	Risk of weight gain for specific antipsychotic drugs: a meta-analysis. <i>NPJ Schizophrenia</i> , 2018, 4, 12.	2.0	60
3667	Unique Effects of Clozapine: A Pharmacological Perspective. <i>Advances in Pharmacology</i> , 2018, 82, 137-162.	1.2	100
3668	Ketogenic diet for schizophrenia: Nutritional approach to antipsychotic treatment. <i>Medical Hypotheses</i> , 2018, 118, 74-77.	0.8	21
3669	Recent Advancements in Treating Sleep Disorders in Co-Occurring PTSD. <i>Current Psychiatry Reports</i> , 2018, 20, 48.	2.1	80
3670	Revisiting the canons of psychiatry: Teaching the fundamentals of CATIE, STAR*D, and STEP-BD to family medicine residents. <i>International Journal of Psychiatry in Medicine</i> , 2018, 53, 455-463.	0.8	1
3671	Sleep profiles and CBT-I response in schizophrenia and related psychoses. <i>Psychiatry Research</i> , 2018, 268, 279-287.	1.7	41
3672	Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-term psychosis. <i>BMC Psychiatry</i> , 2018, 18, 142.	1.1	31
3673	Prescription and Underprescription of Clozapine in Dutch Ambulatory Care. <i>Frontiers in Psychiatry</i> , 2018, 9, 231.	1.3	5
3674	Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. <i>Epilepsia</i> , 2018, 59, 1727-1739.	2.6	67
3675	Experimental Designs for Research on Adaptive Interventions: Singly and Sequentially Randomized Trials. <i>Statistics for Social and Behavioral Sciences</i> , 2018, , 89-120.	0.3	19
3676	Metabolic Side Effects in Patients Using Atypical Antipsychotic Medications During Hospitalization. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2018, 56, 28-37.	0.3	10
3677	The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. <i>Frontiers in Neuroscience</i> , 2017, 11, 741.	1.4	78
3678	High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. <i>BMC Psychiatry</i> , 2018, 18, 180.	1.1	14
3679	Pharmacological Treatment for Long-Term Patients with Schizophrenia and Its Effects on Sleep in Daily Clinical Practice: A Pilot Study. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 44.	0.7	7

#	ARTICLE	IF	CITATIONS
3680	fMRI correlates of jumping-to-conclusions in patients with delusions: Connectivity patterns and effects of metacognitive training. <i>NeuroImage: Clinical</i> , 2018, 20, 119-127.	1.4	10
3681	Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. <i>Current Medical Research and Opinion</i> , 2018, 34, 2197-2205.	0.9	14
3682	Efficacy of PRIME, a Mobile App Intervention Designed to Improve Motivation in Young People With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 1010-1020.	2.3	143
3683	HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice. <i>Neuroscience</i> , 2018, 388, 102-117.	1.1	31
3684	Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis. <i>BMC Health Services Research</i> , 2018, 18, 243.	0.9	6
3685	Miscommunication in Doctor-Patient Communication. <i>Topics in Cognitive Science</i> , 2018, 10, 409-424.	1.1	89
3686	Increasing antipsychotic dose for non response in schizophrenia. <i>The Cochrane Library</i> , 2018, 5, CD011883.	1.5	8
3687	Treat the Patient, Not the Rule Book. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 380-382.	0.5	0
3688	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. <i>The Cochrane Library</i> , 2018, 5, CD011884.	1.5	4
3689	“Will I need to take these medications for the rest of my life?” <i>World Psychiatry</i> , 2018, 17, 165-166.	4.8	8
3690	The Role of Cannabis within an Emerging Perspective on Schizophrenia. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 86.	0.7	4
3691	Pharmacogenomics and Psychiatric Clinical Care. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2018, 56, 22-31.	0.3	4
3692	Short-term feeding of a ketogenic diet induces more severe hepatic insulin resistance than an obesogenic high-fat diet. <i>Journal of Physiology</i> , 2018, 596, 4597-4609.	1.3	64
3693	Medication adherence in patients with schizophrenia: a qualitative study of the patient process in motivational interviewing. <i>BMC Psychiatry</i> , 2018, 18, 135.	1.1	31
3694	Evaluating the Feasibility of a Pilot Exercise Intervention Implemented Within a Residential Rehabilitation Unit for People With Severe Mental Illness: GO HEART: (Group Occupational Health) Tj ETQq0 0 0 rgB/Overlook 10 Tf 50		
3695	Neuropharmacology of attention. <i>European Journal of Pharmacology</i> , 2018, 835, 162-168.	1.7	18
3696	Use of antipsychotic drugs in dermatology. <i>Clinics in Dermatology</i> , 2018, 36, 765-773.	0.8	19
3697	Trajectories of depressive symptoms in the acute phase of psychosis: Implications for treatment. <i>Journal of Psychiatric Research</i> , 2018, 103, 219-228.	1.5	6

#	ARTICLE	IF	CITATIONS
3698	Effectiveness of psychotherapies that engage with the voices of Voice Hearers. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 1373-1380.	1.7	0
3699	Pharmacogenetics in Psychiatry. <i>Advances in Pharmacology</i> , 2018, 83, 297-331.	1.2	31
3700	Twenty years of adverse drug reactions: a look back – part 2. <i>Adverse Drug Reaction Bulletin</i> , 2018, 310, 1199-1202.	0.6	0
3701	Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective. <i>World Psychiatry</i> , 2018, 17, 163-165.	4.8	4
3702	Association analysis of CHRNA3 polymorphisms with schizophrenia in a Chinese Han population. <i>Medicine (United States)</i> , 2018, 97, e10863.	0.4	3
3703	Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. <i>Nature Communications</i> , 2018, 9, 2265.	5.8	38
3704	Antidepressant and antipsychotic medication errors reported to United States poison control centers. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 902-911.	0.9	3
3705	Telephone-delivered psychosocial interventions targeting key health priorities in adults with a psychotic disorder: systematic review. <i>Psychological Medicine</i> , 2018, 48, 2637-2657.	2.7	18
3706	Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 474-484.	0.7	21
3707	Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale. <i>Angiology</i> , 2019, 70, 103-129.	0.8	20
3708	Factors associated with poor satisfaction with treatment and trial discontinuation in chronic schizophrenia. <i>CNS Spectrums</i> , 2019, 24, 380-389.	0.7	3
3709	Pharmacotherapy of schizophrenia: toward a metabolomic-based approach. <i>CNS Spectrums</i> , 2019, 24, 281-286.	0.7	11
3710	Medication, hospitalizations and mortality in 5 years after first-episode psychosis in a Swedish nationwide cohort. <i>Microbial Biotechnology</i> , 2019, 13, 902-907.	0.9	10
3711	Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Only Tablets: Results From a Randomized, Crossover Relative Bioavailability Study. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 459-466.	0.8	19
3712	Treatment Options for Insomnia in Schizophrenia: A Systematic Review. <i>Pharmacopsychiatry</i> , 2019, 52, 165-169.	1.7	9
3713	The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. <i>Journal of Psychiatric Research</i> , 2019, 108, 57-83.	1.5	54
3714	Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity. <i>Neuropsychopharmacology</i> , 2019, 44, 443-454.	2.8	30
3715	Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment. <i>Medicinal Research Reviews</i> , 2019, 39, 386-403.	5.0	36

#	ARTICLE	IF	CITATIONS
3716	Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia. <i>Schizophrenia Research</i> , 2019, 204, 262-270.	1.1	21
3717	Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 94-104.	1.2	16
3718	Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. <i>Current Medical Research and Opinion</i> , 2019, 35, 41-49.	0.9	5
3719	Rediscovery of penicillin of psychiatry: haloperidol decanoate. <i>Journal of Theoretical Social Psychology</i> , 2019, 29, 264-275.	1.2	2
3720	Predictors of treatment satisfaction in antipsychotic-naïve and previously medicated patients with acute-phase psychosis. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 349-356.	0.7	3
3721	The <i>ANKK1</i> gene and its associated phenotypes: focus on CNS drug response. <i>Pharmacogenomics</i> , 2019, 20, 669-684.	0.6	13
3722	SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D ₂ Receptor Mechanism of Action. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 1-14.	1.3	118
3723	A systematic review of sex-based differences in effectiveness and adverse effects of clozapine. <i>Psychiatry Research</i> , 2019, 280, 112506.	1.7	28
3724	Group cognitive behavioural therapy for psychosis in the Asian context: a review of the recent studies. <i>International Review of Psychiatry</i> , 2019, 31, 460-470.	1.4	1
3725	Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1611-1620.	2.8	6
3726	Effectiveness of a community-based nurse-led lifestyle modification intervention for people with serious mental illness and metabolic syndrome. <i>International Journal of Mental Health Nursing</i> , 2019, 28, 1328-1337.	2.1	16
3727	Establishing an effective dose for chronic intracerebroventricular administration of clozapine in mice. <i>Acta Neuropsychiatrica</i> , 2019, 31, 305-315.	1.0	2
3728	Sexual dysfunction in Chinese rural patients with schizophrenia. <i>BMC Psychiatry</i> , 2019, 19, 218.	1.1	14
3729	Site-Selective Interaction of Human Serum Albumin with 4-Chloro-7-nitro-1,2,3-benzoxadiazole Modified Olanzapine Derivative and Effect of β -Cyclodextrin on Binding: In the Light of Spectroscopy and Molecular Docking. <i>ACS Applied Bio Materials</i> , 2019, 2, 3551-3561.	2.3	14
3730	Mental health professionals' views and experiences of antipsychotic reduction and discontinuation. <i>PLoS ONE</i> , 2019, 14, e0218711.	1.1	22
3731	Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 541-547.	1.0	23
3733	The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population. <i>Medicina (Lithuania)</i> , 2019, 55, 320.	0.8	4
3734	Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia—a systematic review of the literature. <i>Psychopharmacology</i> , 2019, 236, 3081-3092.	1.5	11

#	ARTICLE	IF	CITATIONS
3735	Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. <i>Journal of Psychopharmacology</i> , 2019, 33, 1303-1316.	2.0	23
3736	Coprescription of QT interval-prolonging antipsychotics with potentially interacting medications in Thailand. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861985488.	1.0	1
3737	<p>Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1037-1050.	0.8	5
3738	Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. <i>Lancet</i> , The, 2019, 394, 939-951.	6.3	1,050
3739	Does Change over Time in Delusional Beliefs as Measured with PDI Predict Change over Time in Belief Flexibility Measured with MADS?. <i>Psychiatric Quarterly</i> , 2019, 90, 693-702.	1.1	3
3740	Comorbid brain disorders associated with diabetes: therapeutic potentials of prebiotics, probiotics and herbal drugs. <i>Translational Medicine Communications</i> , 2019, 4, .	0.5	12
3741	Regulatory Considerations for the Use of Biomarkers and Personalized Medicine in CNS Drug Development: A European Perspective. <i>Handbook of Behavioral Neuroscience</i> , 2019, , 259-275.	0.7	1
3742	Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 560-573.	1.0	32
3743	Examination of heterogeneity in treatment response to antipsychotic medications. <i>Schizophrenia Research</i> , 2019, 211, 100-102.	1.1	0
3744	The Management of Obesity in People with Severe Mental Illness: An Unresolved Conundrum. <i>Psychotherapy and Psychosomatics</i> , 2019, 88, 327-332.	4.0	20
3745	Does the Beck Cognitive Insight Scale predict change in delusional beliefs?. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2020, 93, 690-704.	1.3	4
3746	The role of the brainâ€™gutâ€™microbiota axis in psychology: The importance of considering gut microbiota in the development, perpetuation, and treatment of psychological disorders. <i>Brain and Behavior</i> , 2019, 9, e01408.	1.0	30
3747	Brexipiprazole has a low risk of dopamine D₂ receptor sensitization and inhibits rebound phenomena related to D₂ and serotonin 5â€™HT_{2A} receptors in rats. <i>Neuropsychopharmacology Reports</i> , 2019, 39, 279-288.	1.1	19
3748	The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 165, 415-428.	1.0	18
3749	S3-Leitlinie Schizophrenie. , 2019, , .		29
3750	<p>Clozapine As Transformative Treatment In Bipolar Patients</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2901-2905.	1.0	11
3751	Reduced Brain Activity in the Right Putamen as an Early Predictor for Treatment Response in Drug-Naive, First-Episode Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 741.	1.3	20
3753	Antipsychotics and schizophrenia, and their relationship to diabetes. <i>Practical Diabetes</i> , 2019, 36, 147.	0.1	1

#	ARTICLE	IF	CITATIONS
3754	Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. <i>CNS Spectrums</i> , 2019, 24, 38-69.	0.7	87
3755	In Search of a New Paradigm for Research on Violence and Schizophrenia. <i>American Journal of Psychiatry</i> , 2019, 176, 677-679.	4.0	11
3756	Stratified medicine in schizophrenia: how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life?. <i>European Journal of Health Economics</i> , 2019, 20, 1425-1435.	1.4	12
3757	SLC39A8 is a risk factor for schizophrenia in Uygur Chinese: a case-control study. <i>BMC Psychiatry</i> , 2019, 19, 293.	1.1	7
3758	<p>>A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future</p>>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2559-2569.	1.0	42
3759	How do we select an antipsychotic for those with schizophrenia?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2195-2199.	0.9	6
3760	Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. <i>Schizophrenia Research</i> , 2019, 212, 204-212.	1.1	15
3761	Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects. <i>Frontiers in Pharmacology</i> , 2019, 10, 1045.	1.6	39
3762	Obesity in Adolescents with Psychiatric Disorders. <i>Current Psychiatry Reports</i> , 2019, 21, 3.	2.1	49
3763	The association of mental health disease with perioperative outcomes following femoral neck fractures. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2019, 10, S77-S83.	0.6	13
3764	Integrating Genomics into Psychiatric Practice: Ethical and Legal Challenges for Clinicians. <i>Harvard Review of Psychiatry</i> , 2019, 27, 53-64.	0.9	19
3765	Correlation Between Violence and Antipsychotic Dosage in Schizophrenia: A Secondary Analysis of The Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) Dataset. <i>Pharmacopsychiatry</i> , 2019, 52, 217-221.	1.7	4
3766	Association of First- vs. Second-Generation Antipsychotics with Lipid Abnormalities in Individuals with Severe Mental Illness: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2019, 39, 253-273.	1.1	17
3767	Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. <i>Health Policy and Technology</i> , 2019, 8, 84-91.	1.3	7
3768	Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2019, 176, 449-456.	4.0	116
3769	Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Schizophrenia Research</i> , 2019, 209, 193-197.	1.1	16
3770	Effects of haloperidol on cognitive function and behavioural flexibility in the IntelliCage social home cage environment. <i>Behavioural Brain Research</i> , 2019, 371, 111976.	1.2	12
3771	The influence of substance use on the effectiveness of antipsychotic medication: a prospective, pragmatic study. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 281-287.	0.7	6

#	ARTICLE	IF	CITATIONS
3772	Amelioration of cerebellar hemorrhage-associated intractable vomiting by perphenazine: a report of two cases. <i>Nosotchu</i> , 2019, 41, 115-119.	0.0	0
3773	Eating Behavior and the Evolutionary Perspective on Anorexia Nervosa. <i>Frontiers in Neuroscience</i> , 2019, 13, 596.	1.4	10
3774	A Critical Period for the Development of Schizophrenia-Like Pathology by Aberrant Postnatal Neurogenesis. <i>Frontiers in Neuroscience</i> , 2019, 13, 635.	1.4	19
3776	Consistency checks to improve measurement with the Montgomery-Asberg Depression Rating Scale (MADRS). <i>Journal of Affective Disorders</i> , 2019, 256, 143-147.	2.0	12
3777	Developing Novel Psychopharmacological Strategies and Therapeutics. <i>American Journal of Psychiatry</i> , 2019, 176, 419-421.	4.0	0
3778	Speaking-Induced Suppression of the Auditory Cortex in Humans and Its Relevance to Schizophrenia. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 791-804.	1.1	19
3779	A Sociodemographic Profile of Asian Americans Served in Community Mental Health Centers for a Diagnosis of Schizophrenia Spectrum Disorder. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2019, 46, 555-567.	1.2	2
3780	Food craving and consumption evolution in patients starting treatment with clozapine. <i>Psychopharmacology</i> , 2019, 236, 3317-3327.	1.5	7
3781	In vitro effects of antipsychotics on mitochondrial respiration. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 1209-1223.	1.4	27
3782	Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. <i>World Psychiatry</i> , 2019, 18, 208-224.	4.8	93
3783	Monotherapy vs. combination therapy for post mania maintenance treatment: A population based cohort study. <i>European Neuropsychopharmacology</i> , 2019, 29, 691-700.	0.3	16
3784	Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. <i>Neurology and Therapy</i> , 2019, 8, 215-230.	1.4	16
3785	Reporting of Multi-Arm Parallel-Group Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1610.	3.8	158
3786	Correlates of Future Violence in People Being Treated for Schizophrenia. <i>American Journal of Psychiatry</i> , 2019, 176, 694-701.	4.0	53
3787	Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 314.	1.3	36
3788	A Structured Preapproval and Postapproval Comparative Study Design Framework to Generate Valid and Transparent Real-World Evidence for Regulatory Decisions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 103-115.	2.3	36
3789	<p>Overcoming barriers to effective management of tardive dyskinesia</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 785-794.	1.0	22
3790	Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia. <i>Psychiatry Research</i> , 2019, 275, 149-154.	1.7	30

#	ARTICLE	IF	CITATIONS
3791	A systematic review of genome-wide association studies of antipsychotic response. <i>Pharmacogenomics</i> , 2019, 20, 291-306.	0.6	27
3792	The Long-Acting Injectable Antipsychotics in Clinical Practice. <i>Journal of Korean Neuropsychiatric Association</i> , 2019, 58, 29.	0.2	1
3793	Evaluation of Risk Factors for Antipsychotic Polypharmacy in Inpatient Psychiatry Units of a Community Hospital: A Retrospective Analysis. <i>Community Mental Health Journal</i> , 2019, 55, 750-754.	1.1	4
3794	Patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. <i>Psychiatry Research</i> , 2019, 274, 409-413.	1.7	1
3796	<p>Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 587-602.	1.0	4
3797	Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1917-1924.	2.8	24
3798	Effects of olanzapine on cytokine profile and brain-derived neurotrophic factor in drug-naive subjects with first-episode psychosis. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 3071-3076.	0.8	10
3799	Insulin Resistance in Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1134, 1-16.	0.8	19
3800	Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2019, 176, 457-467.	4.0	59
3801	Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets. <i>Frontiers in Pharmacology</i> , 2019, 10, 186.	1.6	12
3802	Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress. <i>Frontiers in Psychiatry</i> , 2019, 10, 93.	1.3	51
3804	<p>Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 731-737.	1.0	7
3805	Neuroprotective effects of the second generation antipsychotics. <i>Schizophrenia Research</i> , 2019, 208, 1-7.	1.1	69
3806	Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 509-527.	1.3	20
3807	Disparate effects of first and second generation antipsychotics on cognition in schizophrenia â€“ Findings from the randomized NeSSy trial. <i>European Neuropsychopharmacology</i> , 2019, 29, 720-739.	0.3	29
3808	Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and Samidorphan. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 503-510.	0.8	11
3809	Bridging the Efficacy-Effectiveness Gap in the Antipsychotic Treatment of Schizophrenia: Back to the Basics. <i>Asian Journal of Psychiatry</i> , 2019, 40, A1-A2.	0.9	2
3811	Biological Changes in Older People with Schizophrenia. , 2019, , 55-68.		0

#	ARTICLE	IF	CITATIONS
3812	Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Non-affective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2019, 10, 210.	1.3	40
3813	Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres. <i>PLoS ONE</i> , 2019, 14, e0211938.	1.1	3
3814	Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. <i>Schizophrenia Research</i> , 2019, 208, 44-48.	1.1	5
3816	Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 179, 55-62.	1.3	5
3817	Exploring the barriers to the implementation of cognitive behavioural therapy for psychosis (CBTp). <i>Mental Health Review Journal</i> , 2019, 24, 30-43.	0.3	1
3818	Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, â€œreal worldâ€-clinical trial. <i>Psychiatry Research</i> , 2019, 273, 631-640.	1.7	11
3819	Pathology of white matter integrity in three major white matter fasciculi: A post-mortem study of schizophrenia and treatment status. <i>British Journal of Pharmacology</i> , 2019, 176, 1143-1155.	2.7	16
3820	Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 177.	1.6	13
3821	Methodological limitations in the measurement and statistical modeling of violence among adults with mental illness. <i>International Journal of Methods in Psychiatric Research</i> , 2019, 28, e1776.	1.1	5
3822	History of Psychopharmacology. <i>Annual Review of Clinical Psychology</i> , 2019, 15, 25-50.	6.3	51
3823	Dietary intake of people with severe mental illness: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2019, 214, 251-259.	1.7	160
3824	The Association Between Psychotropic Drug Use and Fertility Problems Among Male Subjects. <i>Journal of Psychiatric Practice</i> , 2019, 25, 22-33.	0.3	6
3825	The Psychological Management of the Poor: Prescribing Psychoactive Drugs in the Age of Neoliberalism. <i>Journal of Social Issues</i> , 2019, 75, 217-237.	1.9	7
3826	The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study. <i>L'Encephale</i> , 2019, 45, 459-467.	0.3	6
3827	Staff perceptions of PRN medication in a residential care setting. <i>Journal of Mental Health Training, Education and Practice</i> , 2019, 14, 469-479.	0.3	1
3828	Evaluation of Antipsychotic Activity of Ethanolic Extract of Dhatriyadi Ghrita on Wistar Rats. <i>Current Psychopharmacology</i> , 2019, 8, 213-237.	0.1	0
3829	Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis. <i>BMJ Open</i> , 2019, 9, e025952.	0.8	10
3830	Dying Too Soon: Excess Mortality in Severe Mental Illness. <i>Frontiers in Psychiatry</i> , 2019, 10, 855.	1.3	56

#	ARTICLE	IF	CITATIONS
3831	Prescribing Pattern of Clozapine and Clinical Factors associated with Discontinuation of Clozapine. Korean Journal of Schizophrenia Research, 2019, 22, 1.	0.3	3
3832	Functional recovery in schizophrenia. Revista Colombiana De Psiquiatr�a (English Ed), 2019, 48, 252-260.	0.1	8
3833	Les cris�: prendre soin en situation de complexit� et d'incertitude. NPG Neurologie - Psychiatrie - Geriatrie, 2019, 19, 209-214.	0.1	1
3834	Biological and practical implications of genome-wide association study of schizophrenia using Bayesian variable selection. NPJ Schizophrenia, 2019, 5, 19.	2.0	0
3835	Clozapine-associated neutropenia in Latin America. International Clinical Psychopharmacology, 2019, 34, 257-263.	0.9	6
3836	Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology, 2019, 39, 428-433.	0.7	14
3837	Commentary on Braga et al. Journal of ECT, 2019, 35, 153-155.	0.3	1
3840	PT-31, a putative β -adrenoceptor agonist, is effective in schizophrenia cognitive symptoms in mice. Behavioural Pharmacology, 2019, 30, 574-587.	0.8	8
3841	Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy. Journal of Clinical Psychopharmacology, 2019, 39, 336-343.	0.7	14
3842	Zinc finger proteins in psychiatric disorders and response to psychotropic medications. Psychiatric Genetics, 2019, 29, 132-141.	0.6	13
3843	Effects of chronic physical illness on treatment outcomes among patients with schizophrenia. Current Opinion in Psychiatry, 2019, 32, 451-460.	3.1	5
3844	Retrospective Accounts of the Process of Using and Discontinuing Psychiatric Medication. Qualitative Health Research, 2019, 29, 198-210.	1.0	15
3845	Audit clinique cibl� des prescriptions d'anticholinergiques correcteurs des troubles neurologiques lors d'un traitement antipsychotique. Annales Medico-Psychologiques, 2019, 177, 408-412.	0.2	0
3846	BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis. Pharmacogenomics Journal, 2019, 19, 269-276.	0.9	11
3847	Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics. International Journal of Neuropsychopharmacology, 2019, 22, 28-36.	1.0	22
3848	The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial. Schizophrenia Research, 2019, 206, 96-102.	1.1	10
3849	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. World Journal of Biological Psychiatry, 2019, 20, 2-16.	1.3	26
3850	Drugs for Neuropsychiatric Disorders. , 2019, , 241-269.		0

#	ARTICLE	IF	CITATIONS
3852	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2019, 176, 21-28.	4.0	127
3853	Comorbid Sleep and Wake Problems in Treatment-Resistant Psychiatric Conditions. , 2019, , 261-270.		0
3854	Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1753-1764.	1.7	17
3855	Resistance is not futile: treatment-refractory schizophrenia “ overview, evaluation and treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 11-24.	0.9	23
3856	Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2019, 29, 32-45.	0.3	59
3857	Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 598-605.	2.8	207
3858	Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 183-198.	1.0	33
3859	Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice. <i>Psychiatry Research</i> , 2019, 272, 698-706.	1.7	8
3860	Effects of Medication Nonadherence and Comorbidity on Health Resource Utilization in Schizophrenia. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 37-46.	0.5	20
3861	Reinforcement attenuation as a behavioral technique to suppress conditioned avoidance response in rats: A comparative study with olanzapine. <i>Journal of Psychopharmacology</i> , 2019, 33, 86-100.	2.0	1
3862	Tardive dyskinesia update: treatment and management. <i>BJ Psych Advances</i> , 2019, 25, 78-89.	0.5	4
3863	Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia. <i>Psychiatric Quarterly</i> , 2019, 90, 101-110.	1.1	6
3864	Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. <i>Clinical Drug Investigation</i> , 2019, 39, 169-178.	1.1	11
3865	Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa. <i>CNS Drugs</i> , 2019, 33, 31-46.	2.7	33
3866	Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects. <i>Frontiers in Psychiatry</i> , 2019, 9, 702.	1.3	43
3868	Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. <i>Psychopharmacology</i> , 2019, 236, 545-559.	1.5	33
3869	The Dynamic Duo: Combining noninvasive brain stimulation with cognitive interventions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 347-360.	2.5	114
3870	Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain. <i>Journal of Neural Transmission</i> , 2019, 126, 27-33.	1.4	13

#	ARTICLE	IF	CITATIONS
3871	Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate. <i>Pharmacoeconomics - Open</i> , 2019, 3, 177-188.	0.9	13
3872	Treating depressive episodes or symptoms in patients with schizophrenia. <i>CNS Spectrums</i> , 2019, 24, 239-248.	0.7	19
3873	Recuperación funcional en la esquizofrenia. <i>Revista Colombiana De Psiquiatría</i> , 2019, 48, 252-260.	0.1	12
3874	Nonlinear single-input single-output model-based estimation of cardiac output for normal and depressed cases. <i>Neural Computing and Applications</i> , 2019, 31, 2955-2978.	3.2	12
3875	Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure. <i>Schizophrenia Bulletin</i> , 2019, 45, 69-79.	2.3	47
3876	Medication adherence in first-episode psychosis patients in Singapore. <i>Microbial Biotechnology</i> , 2019, 13, 780-788.	0.9	15
3877	Preventing discrimination based on psychiatric risk biomarkers. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2019, 180, 159-171.	1.1	10
3878	BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia. <i>Neuroscience Letters</i> , 2020, 726, 133870.	1.0	28
3879	Examining patient outcomes of receiving long-acting injectable antipsychotics. <i>Perspectives in Psychiatric Care</i> , 2020, 56, 14-19.	0.9	1
3880	Metabolic Syndrome Screening in People With Severe Mental Illness: Results From Two Spanish Community Mental Health Centers. <i>Journal of the American Psychiatric Nurses Association</i> , 2020, 26, 162-171.	0.4	7
3881	Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia. <i>Neuropharmacology</i> , 2020, 163, 107632.	2.0	22
3882	A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. <i>Molecular Psychiatry</i> , 2020, 25, 2101-2118.	4.1	59
3883	Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice. <i>Molecular Neurobiology</i> , 2020, 57, 135-138.	1.9	9
3884	Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naïve, first-episode schizophrenia: A global-brain functional connectivity analysis. <i>Schizophrenia Research</i> , 2020, 215, 337-343.	1.1	24
3885	Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 121.	6.0	72
3886	Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain. <i>Acta Neuropsychiatrica</i> , 2020, 32, 72-83.	1.0	13
3887	Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. <i>Neuropharmacology</i> , 2020, 172, 107704.	2.0	180
3888	A comprehensive analysis of attempted and fatal suicide cases involving frequently used psychotropic medications. <i>General Hospital Psychiatry</i> , 2020, 63, 16-20.	1.2	25

#	ARTICLE	IF	CITATIONS
3889	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 83-94.	1.8	4
3890	Psychiatric drugs impact mitochondrial function in brain and other tissues. <i>Schizophrenia Research</i> , 2020, 217, 136-147.	1.1	27
3891	A Brief Guide to Medications for Psychosis. , 2020, , 537-560.		1
3892	Genetic variability of serotonin pathway associated with schizophrenia onset, progression, and treatment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020, 183, 113-127.	1.1	10
3893	Perception of Community Pharmacists in Malaysia About Mental Healthcare and Barriers to Providing Pharmaceutical Care Services to Patients with Mental Disorders. <i>Community Mental Health Journal</i> , 2020, 56, 88-98.	1.1	11
3894	Serious Games, Gamification, and Serious Mental Illness: A Scoping Review. <i>Psychiatric Services</i> , 2020, 71, 170-183.	1.1	60
3895	Relationship of SNAP25 variants with schizophrenia and antipsychotic-induced weight change in large-scale schizophrenia patients. <i>Schizophrenia Research</i> , 2020, 215, 250-255.	1.1	30
3896	Metformin addâ€œon vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. <i>World Psychiatry</i> , 2020, 19, 69-80.	4.8	68
3897	Delirium in hospitalized older adults. <i>Hospital Practice (1995)</i> , 2020, 48, 3-16.	0.5	51
3898	Detecting G protein-coupled receptor complexes in postmortem human brain with proximity ligation assay and a Bayesian classifier. <i>BioTechniques</i> , 2020, 68, 122-129.	0.8	9
3899	Telemedicine interventions for medication adherence in mental illness: A systematic review. <i>General Hospital Psychiatry</i> , 2020, 62, 28-36.	1.2	45
3900	Causal Inference and Estimands in Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 54-67.	0.6	41
3901	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020, 34, 3-78.	2.0	259
3902	Integrative network analysis identifies differential regulation of neuroimmune system in Schizophrenia and Bipolar disorder. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 2, 100023.	1.3	9
3903	Cognitive Effects of Combined Amisulpride and Quetiapine Treatment in Patients With Refractory Schizophrenia: A Naturalistic, Prospective Study. <i>American Journal of Therapeutics</i> , 2020, 27, e346-e355.	0.5	3
3904	Predicting response to electroconvulsive therapy combined with antipsychotics in schizophrenia using multi-parametric magnetic resonance imaging. <i>Schizophrenia Research</i> , 2020, 216, 262-271.	1.1	26
3905	Enriched developmental biology molecular pathways impact on antipsychotics-induced weight gain. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 9-20.	0.7	4
3906	Psychotic Disorders. <i>Current Clinical Psychiatry</i> , 2020, , .	0.2	7

#	ARTICLE	IF	CITATIONS
3907	The Gut Microbiome and Treatment-Resistance in Schizophrenia. <i>Psychiatric Quarterly</i> , 2020, 91, 127-136.	1.1	9
3908	Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope?. <i>Schizophrenia Bulletin</i> , 2020, 46, 484-495.	2.3	17
3909	Acceptance- and mindfulness-based interventions for persons with psychosis: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2020, 215, 25-37.	1.1	90
3910	Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [¹¹ C]-(+)-PHNO. <i>Psychopharmacology</i> , 2020, 237, 519-527.	1.5	15
3911	Cross-sectional and within-subject seasonality and regularity of hospitalizations: A population study in mood disorders and schizophrenia. <i>Bipolar Disorders</i> , 2020, 22, 508-516.	1.1	11
3912	Assessment of Real-Life Outcomes in Schizophrenia Patients according to Compliance. <i>Psychiatry Journal</i> , 2020, 2020, 1-10.	0.7	2
3913	Expanding our Understanding of Atypical Antipsychotics: Acute Urinary Retention Secondary to Olanzapine. <i>Case Reports in Psychiatry</i> , 2020, 2020, 1-6.	0.2	3
3914	Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders – A comprehensive systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2020, 90, 364-380.	2.0	66
3915	Mortality risk from long-term treatment with antipsychotic polypharmacy vs monotherapy among adults with serious mental illness: A systematic review and meta-analysis of observational studies. <i>Schizophrenia Research</i> , 2020, 223, 18-28.	1.1	7
3916	Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial. <i>BJPsych Open</i> , 2020, 6, e126.	0.3	3
3917	Opening the curtains for better sleep in psychotic disorders - considerations for improving sleep treatment. <i>Comprehensive Psychiatry</i> , 2020, 103, 152207.	1.5	10
3918	Attitude and preferences towards oral and long-acting injectable antipsychotics in patients with psychosis in KwaZulu-Natal, South Africa. <i>South African Journal of Psychiatry</i> , 2020, 26, 1509.	0.2	5
3919	An 18-month longitudinal study of suicidality in patients diagnosed with schizophrenia. <i>Schizophrenia Research</i> , 2020, 224, 102-107.	1.1	3
3920	Sudden Cardiac Death in Schizophrenia: A Review. <i>Heart Lung and Circulation</i> , 2020, 29, 1427-1432.	0.2	23
3921	Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. <i>Psychiatry Research</i> , 2020, 293, 113380.	1.7	9
3922	The effectiveness of adjunct music therapy for patients with schizophrenia: A meta-analysis. <i>Psychiatry Research</i> , 2020, 293, 113464.	1.7	16
3923	Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. <i>European Psychiatry</i> , 2020, 63, e71.	0.1	27
3924	Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital. <i>Indian Journal of Psychological Medicine</i> , 2020, 42, 162-167.	0.6	0

#	ARTICLE	IF	CITATIONS
3925	Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safetyâ€™Particularities in the Context of COVID-19. <i>Brain Sciences</i> , 2020, 10, 840.	1.1	28
3926	Mindfulness for psychosis groups; description and preliminary evaluation of a novel routine care pathway in Hong Kong. <i>International Journal of Mental Health Systems</i> , 2020, 14, 81.	1.1	4
3927	Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital. <i>NPJ Schizophrenia</i> , 2020, 6, 32.	2.0	8
3928	EEG Microstate Differences in Medicated vs. Medication-NaÃve First-Episode Psychosis Patients. <i>Frontiers in Psychiatry</i> , 2020, 11, 600606.	1.3	15
3929	How Much of an Advance Is the Addition of Samidorphan to Olanzapine?. <i>American Journal of Psychiatry</i> , 2020, 177, 1113-1114.	4.0	8
3930	Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. <i>Schizophrenia Research</i> , 2021, 230, 87-94.	1.1	2
3931	The mGluR2/3 agonist pomaglumedad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus. <i>Neuropsychopharmacology</i> , 2020, 45, 2106-2113.	2.8	10
3932	An update on the efficacy and safety of iloperidone as a schizophrenia therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1793-1798.	0.9	1
3933	Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches. <i>CNS Drugs</i> , 2020, 34, 947-959.	2.7	28
3935	Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs â€™ A study based on blood sample analyses from 24,239 patients. <i>European Neuropsychopharmacology</i> , 2020, 37, 64-69.	0.3	10
3936	The Impact of Mental Illness Stigma on Psychiatric Emergencies. <i>Frontiers in Psychiatry</i> , 2020, 11, 573.	1.3	22
3937	Antipsychotic Behavioral Phenotypes in the Mouse Collaborative Cross Recombinant Inbred Inter-Crosses (RIX). <i>G3: Genes, Genomes, Genetics</i> , 2020, 10, 3165-3177.	0.8	4
3938	Interventions for the management of obesity in people with bipolar disorder. <i>The Cochrane Library</i> , 2020, 2020, CD013006.	1.5	15
3939	Satisfaction with antipsychotics as a medication: the role of therapeutic alliance and patient-perceived participation in decision making in patients with schizophrenia spectrum disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 268-276.	1.2	2
3940	Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. <i>American Journal of Psychiatry</i> , 2020, 177, 1168-1178.	4.0	72
3941	Disease burden of schizophrenia patients visiting a Chinese regional mental health centre. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 469-481.	0.6	3
3943	Longitudinal study of inflammatory markers and psychopathology in schizophrenia. <i>Schizophrenia Research</i> , 2020, 224, 58-66.	1.1	22
3944	What is the â€™best introâ€™ explanatory versus pragmatic antipsychotic drug trials. <i>Lancet Psychiatry</i> , 2020, 7, 1004-1006.	3.7	4

#	ARTICLE	IF	CITATIONS
3945	ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder. American Journal of Health-System Pharmacy, 2020, 77, 2114-2132.	0.5	4
3946	<p>>Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia</p></p>. Patient Preference and Adherence, 2020, Volume 14, 1595-1604.	0.8	8
3947	The onset and accumulation of physical multimorbidity in severe and common mental disorders. Current Opinion in Psychiatry, 2020, Publish Ahead of Print, 484-490.	3.1	16
3948	Factors associated with discontinuation in the drug and placebo groups of trials of second generation antipsychotics for acute schizophrenia: A meta-regression analysis. Journal of Psychiatric Research, 2020, 130, 240-246.	1.5	4
3949	The Inflamed Brain in Schizophrenia: The Convergence of Genetic and Environmental Risk Factors That Lead to Uncontrolled Neuroinflammation. Frontiers in Cellular Neuroscience, 2020, 14, 274.	1.8	114
3950	Effects of Doxycycline in Swiss Mice Predictive Models of Schizophrenia. Neurotoxicity Research, 2020, 38, 1049-1060.	1.3	4
3951	Recurrence of Mania or Depression Among Adult Bipolar Patients Who Continued Using Lithium. Journal of Clinical Psychopharmacology, 2020, 40, 468-474.	0.7	6
3952	The effect of a computerized best practice alert system in an outpatient setting on metabolic monitoring in patients on secondâ€generation antipsychotics. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1398-1404.	0.7	6
3953	Delirium on clozapine: A tale of friend turned foe-A case report. International Journal of Psychiatry in Medicine, 2021, 56, 446-458.	0.8	9
3954	Are CB2 Receptors a New Target for Schizophrenia Treatment?. Frontiers in Psychiatry, 2020, 11, 587154.	1.3	17
3955	<p>>Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey</p></p>. Patient Preference and Adherence, 2020, Volume 14, 2043-2054.	0.8	14
3956	A targeted neurotransmitter quantification and nontargeted metabolic profiling method for pharmacometabolomics analysis of olanzapine by using UPLC-HRMS. RSC Advances, 2020, 10, 18305-18314.	1.7	6
3958	Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists. Drugs, 2020, 80, 871-882.	4.9	20
3959	A Brief History of Psychopharmacology. , 2020, , 1-34.		0
3960	Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychoticâ€like effects without affecting cognitive enhancement and cataleptic effects in rats. Neuropsychopharmacology Reports, 2020, 40, 190-195.	1.1	5
3961	Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients. Frontiers in Pharmacology, 2020, 11, 739.	1.6	25
3962	Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectrums, 2020, 26, 1-10.	0.7	13
3963	Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane. Journal of Nutritional Biochemistry, 2020, 81, 108399.	1.9	24

#	ARTICLE	IF	CITATIONS
3964	Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region. <i>Asia-Pacific Psychiatry</i> , 2020, 12, e12393.	1.2	16
3965	Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients. <i>Journal of Proteomics</i> , 2020, 224, 103813.	1.2	8
3966	Direct C ¹³ H Arylation of Aldehydes by Merging Photocatalyzed Hydrogen Atom Transfer with Palladium Catalysis. <i>ACS Catalysis</i> , 2020, 10, 7543-7551.	5.5	80
3967	The polygenic architecture of schizophrenia " rethinking pathogenesis and nosology. <i>Nature Reviews Neurology</i> , 2020, 16, 366-379.	4.9	122
3969	Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses. <i>Neuropsychopharmacology</i> , 2020, 45, 1637-1644.	2.8	5
3971	A qualitative study of medication adherence amongst people with schizophrenia. <i>Archives of Psychiatric Nursing</i> , 2020, 34, 194-199.	0.7	14
3972	Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacOBOLD in healthy volunteers. <i>Neuropsychopharmacology</i> , 2020, 45, 1842-1850.	2.8	32
3973	Antipsychotics for schizophrenia and substance misuse " Authors' reply. <i>Lancet, The</i> , 2020, 395, 1903.	6.3	1
3974	What is the potential of neurostimulation in the treatment of motor symptoms in schizophrenia?. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 697-706.	1.4	23
3975	<i>New Directions in Psychiatry.</i> , 2020, , .		0
3976	Severe weight gain as an adverse drug reaction of psychotropics: Data from the AMSP project between 2001 and 2016. <i>European Neuropsychopharmacology</i> , 2020, 36, 60-71.	0.3	17
3977	Generating comparative evidence on new drugs and devices after approval. <i>Lancet, The</i> , 2020, 395, 998-1010.	6.3	52
3978	Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors. <i>Pharmacological Research</i> , 2020, 156, 104749.	3.1	50
3979	<i>The Inpatient with Schizophrenia.</i> , 2020, , 1-27.		0
3980	Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics. <i>Schizophrenia Bulletin</i> , 2020, 46, 496-504.	2.3	11
3981	Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. <i>CNS Drugs</i> , 2020, 34, 473-507.	2.7	38
3982	Updating the Comparative Evidence on Second-Generation Antipsychotic Use With Schizophrenia. <i>Psychiatric Research and Clinical Practice</i> , 2020, 2, 76-87.	1.3	2
3983	Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112521.	2.6	5

#	ARTICLE	IF	CITATIONS
3984	Influence of More Than 5 Years of Continuous Exposure to Antipsychotics on Cerebral Functional Connectivity of Chronic Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 463-472.	0.9	4
3985	Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. <i>Neuropsychopharmacology</i> , 2020, 45, 1339-1345.	2.8	30
3986	Estimation of Latent Variable Scores with Multiple Group Item Response Models: Implications for Integrative Data Analysis. <i>Structural Equation Modeling</i> , 2020, 27, 931-941.	2.4	0
3987	Psychometric Properties of the MacArthur Community Violence Screening Instrument. <i>International Journal of Forensic Mental Health</i> , 2020, 19, 253-268.	0.6	0
3988	Measurement based care in schizophreniaâ€”Feasibility in routine clinical practice. <i>Asian Journal of Psychiatry</i> , 2020, 49, 101954.	0.9	6
3989	Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia. <i>JAMA Network Open</i> , 2020, 3, e1921660.	2.8	21
3990	Predicting treatment dropout after antidepressant initiation. <i>Translational Psychiatry</i> , 2020, 10, 60.	2.4	22
3991	Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia. <i>Archives of Medical Research</i> , 2020, 51, 13-20.	1.5	3
3992	Pragmatic trial design of an intervention to reduce cardiovascular risk in people with serious mental illness. <i>Contemporary Clinical Trials</i> , 2020, 91, 105964.	0.8	6
3993	Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring. <i>Scientific Reports</i> , 2020, 10, 1219.	1.6	2
3994	Robust kernel association testing (RobKAT). <i>Genetic Epidemiology</i> , 2020, 44, 272-282.	0.6	2
3995	Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease. <i>Cellular Signalling</i> , 2020, 70, 109592.	1.7	19
3996	Age dependent association of inbreeding with risk for schizophrenia in Egypt. <i>Schizophrenia Research</i> , 2020, 216, 450-459.	1.1	1
3997	Sleep disturbance: a potential target to improve symptoms and quality of life in those living with psychosis. <i>Irish Journal of Psychological Medicine</i> , 2020, , 1-6.	0.7	5
3998	Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 10-17.	1.2	2
3999	Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction. <i>PLoS Biology</i> , 2020, 18, e3000604.	2.6	98
4000	The collaborative management of antipsychotic medication and its obstacles: A qualitative study. <i>Social Science and Medicine</i> , 2020, 247, 112811.	1.8	13
4001	Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia. <i>Annals of General Psychiatry</i> , 2020, 19, 1.	1.2	37

#	ARTICLE	IF	CITATIONS
4002	Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 217-229.	1.0	40
4003	Lights and shadows of schizophrenia therapy research: Lessons from oral risperidone and olanzapine. <i>Journal of Psychopharmacology</i> , 2020, 34, 574-579.	2.0	0
4004	Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 100, 109881.	2.5	9
4005	Economic burden in patients with ALK+ non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. <i>Journal of Medical Economics</i> , 2020, 23, 894-901.	1.0	8
4006	Changing the Drug Delivery System: Does it Add to Non-Compliance Ramifications Control? A Simulation Study on the Pharmacokinetics and Pharmacodynamics of Atypical Antipsychotic Drug. <i>Pharmaceutics</i> , 2020, 12, 297.	2.0	12
4007	Antipsychotics and the microbiota. <i>Current Opinion in Psychiatry</i> , 2020, 33, 225-230.	3.1	20
4008	Saffron and Neurological Disorders. , 2020, , 103-116.		3
4009	Glutamatergic Contribution to Probabilistic Reasoning and Jumping to Conclusions in Schizophrenia: A Double-Blind, Randomized Experimental Trial. <i>Biological Psychiatry</i> , 2020, 88, 687-697.	0.7	12
4010	Functional Neuroimaging in Psychiatry – Aiding in Diagnosis and Guiding Treatment. What the American Psychiatric Association Does Not Know. <i>Frontiers in Psychiatry</i> , 2020, 11, 276.	1.3	30
4011	Actitud de los psiquiatras respecto al uso de olanzapina en la prÁctica clÁnica: una encuesta nacional. <i>Psiquiatría Biológica</i> , 2020, 27, 3-8.	0.0	3
4012	Sexual health of women with schizophrenia: A review. <i>Frontiers in Neuroendocrinology</i> , 2020, 57, 100840.	2.5	18
4013	A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. <i>New England Journal of Medicine</i> , 2020, 382, 1497-1506.	13.9	192
4014	Active Ingredients and Mechanisms of Change in Motivational Interviewing for Medication Adherence. A Mixed Methods Study of Patient-Therapist Interaction in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 78.	1.3	14
4015	Hyperprolactinaemia in the context of psychiatry. <i>BJ Psych Advances</i> , 2021, 27, 26-37.	0.5	0
4016	The Impact of Anticholinergic Burden on Functional Capacity in Persons With Schizophrenia Across the Adult Life Span. <i>Schizophrenia Bulletin</i> , 2021, 47, 249-257.	2.3	14
4017	Psychotic disorders, dopaminergic agents and EEG/MEG resting-state functional connectivity: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 354-371.	2.9	12
4018	Recruitment of Asian Americans with Schizophrenia Spectrum Disorder for Research Participation: Barriers, Strategies, and Outcomes. <i>Community Mental Health Journal</i> , 2021, 57, 490-501.	1.1	2
4019	Clinical effectiveness of metacognitive training as a transdiagnostic program in routine clinical settings: A prospective, multicenter, single-group study. <i>Japan Journal of Nursing Science</i> , 2021, 18, e12389.	0.5	2

#	ARTICLE	IF	CITATIONS
4020	Correlates of preferring a passive role in decision-making among patients with schizophrenia or bipolar disorder. <i>Patient Education and Counseling</i> , 2021, 104, 1125-1131.	1.0	4
4021	Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 15-26.	1.5	14
4022	Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders. <i>Schizophrenia Research</i> , 2021, 228, 590-596.	1.1	12
4023	How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 172-180.	2.2	14
4024	A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. <i>Advances in Pharmacology</i> , 2021, 90, 253-276.	1.2	16
4025	Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia. <i>Journal of Psychiatric Research</i> , 2021, 132, 144-150.	1.5	2
4026	Factors Related to Repeat Forensic Hospital Admissions for Restoration of Competency to Stand Trial. <i>Journal of Forensic Psychology Research and Practice</i> , 2021, 21, 91-117.	0.4	0
4027	Multi-targeted drug design strategies for the treatment of schizophrenia. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 101-114.	2.5	10
4028	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). <i>Schizophrenia Bulletin</i> , 2021, 47, 505-516.	2.3	51
4029	The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans. <i>Molecular Psychiatry</i> , 2021, 26, 1272-1285.	4.1	37
4030	Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments. <i>International Journal of Developmental Disabilities</i> , 2021, 67, 159-167.	1.3	3
4031	Psychiatrist and Psychiatric Pharmacists Beliefs and Preferences for Atypical Antipsychotic Treatments in Patients With Schizophrenia and Bipolar Disorders. <i>Journal of Pharmacy Practice</i> , 2021, 34, 78-88.	0.5	2
4032	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study. <i>Molecular Psychiatry</i> , 2021, 26, 1332-1345.	4.1	23
4033	Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021, 47, 662-671.	2.3	39
4034	Network meta-analysis on the comparative efficacy of family interventions for psychotic disorders: a protocol. <i>BMJ Open</i> , 2021, 11, e039777.	0.8	1
4035	Effect of nurse-led screening linked brief psycho-education for improving adherence to antipsychotic medications among clients with mental illness: A quasi-experimental study. <i>Journal of Mental Health and Human Behaviour</i> , 2021, 26, 28.	0.3	1
4036	The circadian system: From clocks to physiology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 179, 233-247.	1.0	18
4038	Using Virtual Reality as a Tool in the Rehabilitation of Movement Abnormalities in Schizophrenia. <i>Frontiers in Psychology</i> , 2020, 11, 607312.	1.1	10

#	ARTICLE	IF	CITATIONS
4039	The effect of lemborexant for insomnia disorder. <i>SAGE Open Medicine</i> , 2021, 9, 205031212110390.	0.7	5
4040	A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotoninâ€‘dopamine receptors. <i>Briefings in Bioinformatics</i> , 2021, 22, 1023-1037.	3.2	14
4041	Understanding the multidimensional phenomenon of medication adherence attitudes in psychosis. <i>Psychiatry Research</i> , 2021, 295, 113601.	1.7	4
4042	Antipsychotics/Neuroleptics: Course and Duration of Therapy, Withdrawal Symptoms, Resistance to Therapy, Side Effects, and Contraindications. , 2021, , 1-21.		0
4043	Psychopharmacology of Williams syndrome: safety, tolerability, and effectiveness. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 293-306.	1.0	9
4044	Olanzapine-Induced Activation of Hypothalamic Astrocytes and Toll-Like Receptor-4 Signaling via Endoplasmic Reticulum Stress Were Related to Olanzapine-Induced Weight Gain. <i>Frontiers in Neuroscience</i> , 2020, 14, 589650.	1.4	10
4045	Psychotropic drug prescription patterns and their predictors among older adult patients with schizophrenia in a tertiary-referral psychiatric hospital. <i>Taiwanese Journal of Psychiatry</i> , 2021, 35, 70.	0.1	0
4046	Contrasting Typical and Atypical Antipsychotic Drugs. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 3-13.	0.4	16
4047	Use of pragmatic clinical trials in reimbursement decisions. , 2021, , 455-460.		0
4048	Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: A Randomized Controlled Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4049	Efficacy and durability of cognitive behavior therapy in managing hallucination in patients with schizophrenia. <i>Industrial Psychiatry</i> , 2021, 30, 255.	0.3	5
4050	Optimizing and Individualizing the Pharmacological Treatment of First-Episode Schizophrenic Patients: Study Protocol for a Multicenter Clinical Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 611070.	1.3	8
4051	Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders. <i>Psychological Medicine</i> , 2022, 52, 2681-2691.	2.7	17
4052	Safety and tolerability of lumateperone 42Âµg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 198-205.	1.1	16
4054	Sex-specific Association of Antipsychotic-induced Weight Gain and Treatment Response for Antipsychotic-Naive First Episode Schizophrenia Patients: A Prospective 8-week Longitudinal Study. <i>Pharmacopsychiatry</i> , 2021, 54, 68-74.	1.7	6
4055	Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulationsâ€‘an observational study using blood samples from 1223 patients. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1201-1208.	0.8	5
4056	Deprescribing in mental health: pragmatic steps for a better quality of life. <i>Journal of Prescribing Practice</i> , 2021, 3, 60-66.	0.1	1
4057	Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone. <i>BMC Psychiatry</i> , 2021, 21, 70.	1.1	12

#	ARTICLE	IF	CITATIONS
4058	Guidelines to understand and compute the number needed to treat. Evidence-Based Mental Health, 2021, 24, 131-136.	2.2	10
4059	The efficacy of real-time functional magnetic resonance imaging neurofeedback for psychiatric illness: A meta-analysis of brain and behavioral outcomes. Neuroscience and Biobehavioral Reviews, 2021, 121, 291-306.	2.9	22
4060	Effect of 5-HT _{2C} receptor gene polymorphism (HTR2C âˆ’ 759C /T) on metabolic adverse effects in Thai psychiatric patients treated with risperidone. Pharmacoepidemiology and Drug Safety, 2021, 30, 806-813.	0.9	1
4061	Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress. European Journal of Medicinal Chemistry, 2021, 214, 113155.	2.6	5
4062	Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Pharmaceuticals, 2021, 14, 238.	1.7	80
4063	Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia. Brain and Behavior, 2021, 11, e02109.	1.0	5
4064	Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study. Neurotherapeutics, 2021, 18, 1316-1324.	2.1	15
4065	Demonstration of automated non-adherence and service disengagement risk monitoring with active follow-up for severe mental illness. Australian and New Zealand Journal of Psychiatry, 2021, 55, 976-982.	1.3	7
4066	A network meta-analysis of the doseâ€“response effects of lurasidone on acute schizophrenia. Scientific Reports, 2021, 11, 5571.	1.6	5
4067	The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children. Frontiers in Psychiatry, 2021, 12, 623681.	1.3	44
4068	The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol. American Journal of Psychiatry, 2021, 178, 266-274.	4.0	23
4069	Minding metabolism: targeted interventions to improve cardio-metabolic monitoring across early and chronic psychosis. Irish Journal of Medical Science, 2022, 191, 337-346.	0.8	3
4070	The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study. CNS Drugs, 2021, 35, 451-460.	2.7	2
4071	Making a case for the inclusion of refractory and severe mental illness as a sole criterion for Canadians requesting medical assistance in dying (MAiD): a review. Journal of Medical Ethics, 2022, 48, 929-934.	1.0	5
4072	Prevalence of Circadian Rhythm Sleep-Wake Disorder in Outpatients with Schizophrenia and Its Association with Psychopathological Characteristics and Psychosocial Functioning. Journal of Clinical Medicine, 2021, 10, 1513.	1.0	5
4073	Pharmacogenetic markers of antipsychotic-induced weight gain: leptin and neuropeptide Y. V M Bekhterev Review of Psychiatry and Medical Psychology, 2021, , 3-10.	0.1	2
4074	Evidence of an interaction between <i>FXR1</i> and <i>GSK3Î²</i> polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics. European Psychiatry, 2021, 64, e39.	0.1	6
4075	Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856. International Journal of Molecular Sciences, 2021, 22, 4119.	1.8	26

#	ARTICLE	IF	CITATIONS
4076	Pharmacotherapy of schizophrenia: Mechanisms of antipsychotic accumulation, therapeutic action and failure. <i>Behavioural Brain Research</i> , 2021, 403, 113144.	1.2	14
4077	Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4467.	1.8	27
4078	Change of Prescribing Pattern after Clozapine Discontinuation: A Retrospective Chart Review. <i>Korean Journal of Schizophrenia Research</i> , 2021, 24, 36-43.	0.3	0
4079	Drug-induced hypersomnia. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2021, 13, 117-122.	0.2	0
4080	Effects of khat use on response to antipsychotic medications in patients with newly diagnosed schizophrenia: a retrospective study. <i>Eastern Mediterranean Health Journal</i> , 2021, 27, 353-360.	0.3	8
4081	Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia. <i>Frontiers in Neuroscience</i> , 2021, 15, 641047.	1.4	11
4082	Scientific Advances Supporting New and Improved Treatment Strategies in Psychiatry. <i>American Journal of Psychiatry</i> , 2021, 178, 365-368.	4.0	1
4083	A practical overview and decision tool for analyzing recurrent events in mental illness: A review. <i>Journal of Psychiatric Research</i> , 2021, 137, 7-13.	1.5	6
4084	Collaborative Care in the Identification and Management of Psychosis in Adolescents and Young Adults. <i>Pediatrics</i> , 2021, 147, .	1.0	5
4085	Prescription Pattern of Antidepressants and the Potential for Personalized Medicine in the Qatari Population. <i>Journal of Personalized Medicine</i> , 2021, 11, 406.	1.1	4
4086	Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials. <i>Clinical and Translational Science</i> , 2021, 14, 1864-1874.	1.5	5
4087	Digital aripiprazole as a human technology. <i>Economy and Society</i> , 2021, 50, 359-373.	1.3	0
4088	Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. <i>International Clinical Psychopharmacology</i> , 2021, 36, 244-250.	0.9	16
4089	Brexiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1267-1279.	2.8	5
4090	The relationship between brain-derived neurotrophic factor and metabolic syndrome in patients with chronic schizophrenia: A systematic review. <i>Neuropeptides</i> , 2021, 87, 102135.	0.9	1
4091	Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment. <i>Schizophrenia Research</i> , 2021, 232, 112-124.	1.1	28
4092	Systematic review and meta analysis of differential attrition between active and control arms in randomized controlled trials of lifestyle interventions in chronic disease. <i>BMC Medical Research Methodology</i> , 2021, 21, 122.	1.4	4
4094	American psychiatry in the new millennium: a critical appraisal. <i>Psychological Medicine</i> , 2021, 51, 2762-2770.	2.7	28

#	ARTICLE	IF	CITATIONS
4095	Demographic Equality of Access to Cognitive Behavioural Treatment for Early Psychosis in Community Mental Healthcare in Greater London. <i>Athens Journal of Health & Medical Sciences</i> , 2022, 8, 149-170.	0.1	1
4096	Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia. <i>Health Psychology Research</i> , 2021, 9, 24932.	0.6	5
4097	Atypical dyskinesias under treatment with antipsychotic drugs: Report from the AMSP multicenter drug safety project. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 151-164.	1.3	1
4098	Cognitive insight is correlated with cognitive impairments and contributes to medication adherence in schizophrenia patients. <i>Asian Journal of Psychiatry</i> , 2021, 60, 102644.	0.9	7
4099	Genome wide study of tardive dyskinesia in schizophrenia. <i>Translational Psychiatry</i> , 2021, 11, 351.	2.4	13
4100	A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension. <i>Schizophrenia Research</i> , 2021, 232, 45-53.	1.1	25
4101	Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case-control study. <i>Scientific Reports</i> , 2021, 11, 15304.	1.6	0
4102	Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. <i>Frontiers in Pharmacology</i> , 2021, 12, 711940.	1.6	24
4103	"I don't have a problem, you're the ones who are crazy!" How to communicate with a patient who is unaware of a mental health disorder. <i>Psychiatrie Pro Praxi</i> , 2021, 22, e27-e32.	0.0	0
4104	The use of first-generation long-acting injectable antipsychotics in children and adolescents: A retrospective audit from India. <i>Asian Journal of Psychiatry</i> , 2021, 61, 102663.	0.9	5
4105	Hidden Role of Gut Microbiome Dysbiosis in Schizophrenia: Antipsychotics or Psychobiotics as Therapeutics?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7671.	1.8	37
4106	Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life". <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110250.	2.5	18
4107	Selective serotonin reuptake inhibitors and risk reduction for cardiovascular disease in patients with schizophrenia: A controversial but promising approach. <i>World Journal of Psychiatry</i> , 2021, 11, 316-324.	1.3	6
4108	Melatonin: From Neurobiology to Treatment. <i>Brain Sciences</i> , 2021, 11, 1121.	1.1	24
4109	Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. <i>CNS Drugs</i> , 2021, 35, 999-1008.	2.7	6
4110	The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis. <i>Substance Use and Misuse</i> , 2021, 56, 1880-1891.	0.7	0
4111	Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity. <i>Molecular Psychiatry</i> , 2021, 26, 6159-6169.	4.1	19
4112	The familiar dialectic between overclaiming and moral outrage over brain biology: disconnected from what matters. <i>Psychological Medicine</i> , 2021, 51, 2776-2777.	2.7	0

#	ARTICLE	IF	CITATIONS
4113	Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1245-1254.	1.3	18
4114	A Naturalistic Study of Time to Recovery in Adults with Treatment-refractory Disorders. <i>Psychiatry (New York)</i> , 2021, 84, 260-275.	0.3	4
4115	Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2021, 140, 409-415.	1.5	12
4116	Global Scientific Outputs of Schizophrenia Publications From 1975 to 2020: a Bibliometric Analysis. <i>Psychiatric Quarterly</i> , 2021, 92, 1725-1744.	1.1	36
4117	Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1430-1441.	1.0	6
4118	Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1225.	0.8	3
4119	Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 632-637.	0.7	7
4120	Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. <i>Asian Journal of Psychiatry</i> , 2021, 62, 102732.	0.9	29
4121	Pharmacogenetics—Guided Advances in Antipsychotic Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 582-588.	2.3	12
4122	Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 266-324.	1.1	48
4123	Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 583-590.	1.8	5
4124	An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2885-2904.	1.0	9
4125	Antipsychotic drug Cariprazine synthesis: An improved and commercially viable synthetic approach. <i>Letters in Organic Chemistry</i> , 2021, 18, .	0.2	0
4126	Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies. <i>Annals of General Psychiatry</i> , 2021, 20, 41.	1.2	4
4127	Current findings and perspectives on aberrant neural oscillations in schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 358-368.	1.0	46
4128	The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naïve first episode schizophrenia patients: a 12-week prospective study. <i>Translational Psychiatry</i> , 2021, 11, 458.	2.4	4
4129	Should “typical”™, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1411-1413.	1.8	6
4130	Safety profile of clozapine: Analysis using national registry data in Japan. <i>Journal of Psychiatric Research</i> , 2021, 141, 116-123.	1.5	6

#	ARTICLE	IF	CITATIONS
4131	Antioxidant Enzymes and Weight Gain in Drug-naïve First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study. <i>Current Neuropharmacology</i> , 2022, 20, 1774-1782.	1.4	11
4132	The facilitators' perspectives of delivering a 'Coping with Voices' group (Part 1). <i>Psychosis</i> , 0, , 1-11.	0.4	1
4133	An Instrumental Variable Forest Approach for Detecting Heterogeneous Treatment Effects in Observational Studies. <i>Management Science</i> , 0, , .	2.4	8
4134	Comparative outcomes in electroconvulsive therapy (ECT): A naturalistic comparison between outcomes in psychosis, mania, depression, psychotic depression and catatonia. <i>European Neuropsychopharmacology</i> , 2021, 51, 43-54.	0.3	19
4135	Deprescribing anticholinergic medication in the community mental health setting: A quality improvement initiative. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1841-1846.	1.5	5
4136	Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs. <i>American Journal of Psychiatry</i> , 2021, 178, 932-940.	4.0	13
4137	Apocynin-tandospirone derivatives demonstrate antioxidant properties in the animal model of schizophrenia. <i>Advances in Redox Research</i> , 2021, 3, 100013.	0.9	1
4138	Translational medicine in psychiatry: challenges and imaging biomarkers. , 2021, , 203-223.		0
4139	Depot/Long Acting Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder. <i>Noropsikiyatri Arsivi</i> , 2021, 58, S47-S52.	0.2	5
4140	COGNITIVE BEHAVIORAL THERAPY FOR SCHIZOPHRENIA. <i>Noropsikiyatri Arsivi</i> , 2021, 58, S61-S65.	0.2	2
4141	Exploring the structural basis and atomistic binding mechanistic of the selective antagonist blockade at D_{3} dopamine receptor over D_{2} dopamine receptor. <i>Journal of Molecular Recognition</i> , 2021, 34, e2885.	1.1	3
4142	Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. <i>Harvard Review of Psychiatry</i> , 2021, 29, 20-34.	0.9	11
4143	Progress in mechanistically novel treatments for schizophrenia. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1459-1475.	1.7	5
4144	EPA guidance on assessment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e23.	0.1	94
4145	Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia. <i>JAMA Network Open</i> , 2020, 3, e2027909.	2.8	14
4161	The Dialysis and Kidney Transplant Patient. , 2007, , 205-220.		2
4162	Antipsychotic Medications, Schizophrenia and the Issue of Quality of Life. , 2007, , 307-319.		6
4163	The Data: Observational Studies and Sequentially Randomized Trials. <i>Statistics in the Health Sciences</i> , 2013, , 9-30.	0.2	1

#	ARTICLE	IF	CITATIONS
4164	Management of Medication-Related Adverse Effects. , 2014, , 225-262.		1
4165	Pharmacogenomics Applications in Psychiatric Disorders. Methods in Pharmacology and Toxicology, 2008, , 369-394.	0.1	1
4166	Dopamine Receptors and the Treatment of Schizophrenia. Receptors, 2010, , 431-477.	0.2	7
4167	Antipsychotic Side-Effect Rating Scales in Schizophrenia. , 2012, , 45-53.		1
4168	Factors of Competitive Employment for People with Severe Mental Illness, from Acquisition to Tenure. , 2020, , 525-550.		1
4169	Antipsychotics: Nonmotor Side Effects. Current Clinical Psychiatry, 2020, , 201-214.	0.2	2
4170	Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells. Advances in Neurobiology, 2020, 25, 155-206.	1.3	11
4171	Pharmacogenetics of the Efficacy of Antipsychotic Drugs in Schizophrenia. , 2016, , 1-20.		3
4172	Choosing Psychiatric Medications for Patients with Severe Obesity and Pharmacological Treatments for Severe Obesity in Patients with Psychiatric Disorders: A Case Study. , 2017, , 297-311.		1
4173	Psychiatry Under the Influence. , 2017, , 163-188.		4
4174	Methodik empirischer Forschung. , 2008, , 345-367.		2
4175	Psychopharmaka. , 2007, , 819-868.		4
4176	Schizophrene Störungen. , 2008, , 847-872.		1
4177	Psychopharmaka. , 2008, , 773-817.		4
4178	Wahn " Psychologie. , 2008, , 456-467.		7
4179	Psychopharmaka. , 2008, , 775-819.		1
4180	Psychopharmaka. , 2009, , 767-810.		2
4181	Schizophrene Psychosen. , 2011, , 1420-1529.		4

#	ARTICLE	IF	CITATIONS
4182	Psychopharmaka. , 2010, , 797-842.		4
4183	Targeting Type 2 Diabetes. Handbook of Experimental Pharmacology, 2011, , 1-33.	0.9	8
4184	Cognitive Remediation for Inpatients with Schizophrenia or Schizoaffective Disorder Using "Smart" Technology in a Simulated Apartment: A Feasibility and Exploratory Study. Lecture Notes in Computer Science, 2011, , 286-289.	1.0	2
4186	Psychopharmaka. , 2012, , 833-879.		1
4187	Treatment-Refractory Schizophrenia: Definition and Assessment. , 2014, , 1-19.		7
4188	Psychopharmaka. , 2016, , 663-690.		5
4189	Psychopharmaka. , 2018, , 733-761.		3
4190	Psychopharmaka. , 2019, , 927-959.		3
4191	Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors. , 2014, , 1-84.		1
4192	Is a Neuroprotective Therapy Suitable for Schizophrenia Patients?. , 2010, , 343-395.		2
4193	Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia. , 2011, , 33-74.		1
4194	Clozapine Combinations in Treatment-Resistant Schizophrenia Patients. , 2013, , 109-143.		1
4195	Tricyclic antipsychotics promote adipogenic gene expression to potentiate preadipocyte differentiation in vitro. Human Cell, 2020, 33, 502-511.	1.2	7
4196	Genetic Rat Models for Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 303-324.	0.7	4
4197	Psychosis and Schizophrenia. , 2008, , 371-389.		1
4198	Schizophrenia and related disorders. , 2012, , 259-286.		1
4199	Antipsychotic Drugs. , 2009, , 487-492.		4
4200	PSYCHOSIS AND SCHIZOPHRENIA. , 2009, , 797-815.		1

#	ARTICLE	IF	CITATIONS
4201	Depression and Psychosis in Neurological Practice. , 2012, , 92-116.		10
4202	Neuropsychiatric Complications and Psychopharmacology of End-Stage Renal Disease. , 2008, , 795-817.		1
4203	Behandlungsresistenz. , 2016, , 157-176.		2
4205	Essential CNS Drug Development. , 2012, , .		3
4207	Reducing the risk of violence among people with serious mental illness: A critical analysis of treatment approaches.. , 2009, , 351-376.		3
4208	The cognitive-behavioral treatment of schizophrenia: The state of the art and the evidence.. International Journal of Behavioral and Consultation Therapy, 2006, 2, 1-11.	0.4	6
4209	Neurocognitive functions in schizophrenia: A systematic review of the effects of typical and atypical antipsychotic drugs.. Psychology and Neuroscience, 2016, 9, 12-31.	0.5	4
4210	Dynamic changes of self-stigma, quality of life, somatic complaints, and depression among people with schizophrenia: A pilot study applying kernel smoothers.. Stigma and Health, 2016, 1, 29-43.	1.2	38
4211	Performance and clinical utility of a short violence risk screening tool in U.S. adults with mental illness.. Psychological Services, 2018, 15, 398-408.	0.9	5
4213	Global Mental Health and Psychopharmacology in Precarious Ecologies: Anthropological Considerations for Engagement and Efficacy. , 2017, , 151-168.		30
4214	Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications. Expert Review of Clinical Pharmacology, 2021, 14, 269-279.	1.3	7
4216	Treatment and management of schizophrenia. , 2012, , 578-595.		1
4217	Metacognitive Training in Schizophrenia. , 2013, , 358-383.		15
4218	Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics. Journal of Clinical Psychopharmacology, 2021, 41, 5-12.	0.7	9
4221	Using Mobile Technology to Enhance Psychotherapy for Treatment of Schizophrenia: A Feasibility Study. International Journal of Virtual Worlds and Human Computer Interaction, 0, , .	0.0	1
4222	Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. Journal of Clinical Investigation, 2009, 119, 706-716.	3.9	202
4223	Practical treatment information for schizophrenia. American Journal of Psychiatry, 2006, 163, 563-5.	4.0	16
4224	Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry, 2006, 163, 600-10.	4.0	513

#	ARTICLE	IF	CITATIONS
4225	Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611-22.	4.0	221
4226	Guideline Watch: Practice Guideline for the Treatment of Patients With Bipolar Disorder, 2nd Edition. , O, , .		13
4227	Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. <i>Focus (American J</i>	0.0	0
4228	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression. <i>Focus (American Psychiatric Publishing)</i> , 2011, 9, 500.	0.4	20
4231	Public-Academic Partnerships: Improving Care for Older Persons With Schizophrenia Through an Academic-Community Partnership. <i>Psychiatric Services</i> , 2008, 59, 236-239.	1.1	13
4232	Who Are the New Users of Antipsychotic Medications?. <i>Psychiatric Services</i> , 2008, 59, 507-514.	1.1	76
4233	Implications of CATIE for Mental Health Services Researchers. <i>Psychiatric Services</i> , 2008, 59, 526-529.	1.1	4
4236	Dropout From Outpatient Mental Health Care in the United States. <i>Psychiatric Services</i> , 2009, 60, 898-907.	1.1	105
4237	Management of Psychosis Associated With a Prolactinoma: Case Report and Review of the Literature. <i>Psychosomatics</i> , 2010, 51, 370-376.	2.5	12
4238	Hyponatremia with Olanzapine - A Suspected Association. <i>Shanghai Archives of Psychiatry</i> , 2017, 29, 177-179.	0.7	1
4239	Losing participants before the trial ends erodes credibility of findings. <i>Psychiatric Bulletin</i> , 2009, 33, 254-257.	0.3	361
4241	CIHI Survey: Hospital Readmissions for Patients with Mental Illness in Canada. <i>Healthcare Quarterly</i> , 2007, 10, 30-32.	0.7	35
4242	A Review of the Psychiatric Care Provided to Patients who Subsequently Offended. <i>International Journal of Clinical Psychiatry and Mental Health</i> , 2015, 3, 31-35.	0.3	4
4243	Biomarker Development for Brain-Based Disorders: Recent Progress in Psychiatry. <i>Journal of Neurology and Psychology</i> , 2013, 01, 7.	2.0	11
4244	Strategies for pharmacotherapy of schizophrenia. <i>Drugs of the Future</i> , 2008, 33, 0777.	0.0	17
4245	Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use. <i>PLoS ONE</i> , 2008, 3, e3150.	1.1	55
4246	Long-Stay Psychiatric Patients: A Prospective Study Revealing Persistent Antipsychotic-Induced Movement Disorder. <i>PLoS ONE</i> , 2011, 6, e25588.	1.1	44
4247	Propensity Score Estimation to Address Calendar Time-Specific Channeling in Comparative Effectiveness Research of Second Generation Antipsychotics. <i>PLoS ONE</i> , 2013, 8, e63973.	1.1	7

#	ARTICLE	IF	CITATIONS
4248	Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe. PLoS ONE, 2013, 8, e81208.	1.1	45
4249	Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. PLoS ONE, 2014, 9, e94112.	1.1	382
4250	Influencia de la administración de psicofármacos en el aumento del peso corporal. Revista Espanola De Nutricion Humana Y Dietetica, 2013, 17, 17.	0.1	3
4251	Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. Journal of Psychiatry and Neuroscience, 2012, 37, 407-415.	1.4	52
4252	Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. European Journal of Endocrinology, 2020, 183, 221-231.	1.9	8
4253	Review of serum prolactin levels as an antipsychotic response biomarker. Open Access Journal of Translational Medicine & Research, 2018, 2, 84-91.	0.1	7
4254	Current clinical research environment: focus on psychiatry. Revista Brasileira De Psiquiatria, 2007, 29, 283-290.	0.9	5
4256	Remisión sintomática y recuperación funcional en pacientes que padecen esquizofrenia. Salud Mental, 2014, 37, 59.	0.3	11
4257	The Other Side of Psychopharmacology: A Review of the Literature. Journal of Mental Health Counseling, 2006, 28, 309-337.	0.6	9
4258	Place of piracetam in the modern practice of medicine. Reviews on Clinical Pharmacology and Drug Therapy, 2017, 15, 14-25.	0.2	6
4259	Association analysis of <i>ANKK3</i> gene variants with schizophrenia in a northern Chinese Han population. Oncotarget, 2016, 7, 85888-85894.	0.8	9
4260	Long-term management of people with psychotic disorders in the community. Australian Prescriber, 2007, 30, 44-46.	0.5	4
4261	White Paper: Efficacy of Psychiatric Drugs. Ethical Human Psychology and Psychiatry, 2016, 18, 20-28.	0.5	3
4262	A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatric Disease and Treatment, 2006, 2, 427-443.	1.0	54
4263	Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia. Neuropsychiatric Disease and Treatment, 2006, 2, 521-529.	1.0	6
4264	Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics. Neuropsychiatric Disease and Treatment, 2006, 2, 583-585.	1.0	12
4265	Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatric Disease and Treatment, 2007, 3, 13-39.	1.0	28
4266	Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease and Treatment, 2007, 3, 219-235.	1.0	56

#	ARTICLE	IF	CITATIONS
4267	An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 277-284.	1.0	3
4268	Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. <i>Patient Preference and Adherence</i> , 2012, 6, 109.	0.8	21
4269	Human Disease and Drug Pharmacology, Complex as Real Life. <i>Current Medicinal Chemistry</i> , 2013, 20, 1623-1634.	1.2	33
4270	Davunetide: Peptide Therapeutic in Neurological Disorders. <i>Current Medicinal Chemistry</i> , 2014, 21, 2591-2598.	1.2	39
4271	Targeting Functional Biomarkers in Schizophrenia with Neuroimaging. <i>Current Pharmaceutical Design</i> , 2016, 22, 2117-2123.	0.9	10
4272	A New Regulatory Road-Map for Alzheimer's Disease Drug Development. <i>Current Alzheimer Research</i> , 2014, 11, 215-220.	0.7	18
4273	Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 2364-2385.	1.0	6
4274	Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges. <i>Current Neuropharmacology</i> , 2017, 15, 789-798.	1.4	65
4275	Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review. <i>Current Clinical Pharmacology</i> , 2013, 8, 256-264.	0.2	25
4276	Positive and Negative Effects of Antipsychotic Medication: An International Online Survey of 832 Recipients. <i>Current Drug Safety</i> , 2019, 14, 173-181.	0.3	28
4277	Neuropeptide Systems and Schizophrenia. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 619-632.	0.8	36
4278	Improving the Treatment of Schizophrenia: Role of 5-HT Receptors in Modulating Cognitive and Extrapyrimal Motor Functions. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 861-869.	0.8	36
4279	Clinical and Cost Consequences of Metabolic Effects of Lurasidone Versus Other Atypical Antipsychotics in Schizophrenia. <i>Open Medicine Journal</i> , 2014, 1, 1-9.	0.5	3
4280	Feasibility, Acceptability, and Preliminary Impacts of Web-Based Patient Education on Patients With Schizophrenia Spectrum Disorder: Quasi-Experimental Cluster Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e13073.	2.1	9
4281	Can Online Consumers Contribute to Drug Knowledge? A Mixed-Methods Comparison of Consumer-Generated and Professionally Controlled Psychotropic Medication Information on the Internet. <i>Journal of Medical Internet Research</i> , 2011, 13, e53.	2.1	53
4282	Short Text Messages to Encourage Adherence to Medication and Follow-up for People With Psychosis (Mobile.Net): Randomized Controlled Trial in Finland. <i>Journal of Medical Internet Research</i> , 2017, 19, e245.	2.1	26
4283	Defining Treatment Response, Remission, Relapse, and Recovery in First-Episode Psychosis: A Survey among Korean Experts. <i>Psychiatry Investigation</i> , 2020, 17, 163-174.	0.7	12
4284	Physical Comorbidity in Bipolar Disorder. <i>Medical Psychiatry</i> , 2007, , 387-400.	0.2	1

#	ARTICLE	IF	CITATIONS
4285	Economic evaluation and schizophrenia. <i>Medical Psychiatry</i> , 2009, , 347-361.	0.2	1
4286	Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. <i>Dialogues in Clinical Neuroscience</i> , 2006, 8, 85-94.	1.8	25
4287	Schizophrenia in late life: emerging issues. <i>Dialogues in Clinical Neuroscience</i> , 2006, 8, 45-52.	1.8	57
4288	The NIMH-MATRICES project for developing cognition-enhancing agents for schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2006, 8, 109-113.	1.8	62
4289	Shared decision making in mental health: prospects for personalized medicine. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 455-463.	1.8	107
4290	Pharmacogenetics of antipsychotic-induced side effects. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 405-415.	1.8	50
4291	Nature and nurture in neuropsychiatric genetics: where do we stand?. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 7-23.	1.8	38
4292	Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 359-382.	1.8	62
4293	Pharmacologic treatment of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 345-357.	1.8	86
4294	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. <i>Dialogues in Clinical Neuroscience</i> , 2011, 13, 155-172.	1.8	38
4295	Pragmatic vs explanatory trials: the pragmascope tool to help measure differences in protocols of mental health randomized controlled trials. <i>Dialogues in Clinical Neuroscience</i> , 2011, 13, 209-215.	1.8	64
4296	Effectiveness studies: advantages and disadvantages. <i>Dialogues in Clinical Neuroscience</i> , 2011, 13, 199-207.	1.8	52
4297	Epigenetic mechanisms in schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 405-417.	1.8	74
4298	Pharmacogenetics and outcome with antipsychotic drugs. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 555-566.	1.8	72
4299	Clinical predictors of therapeutic response to antipsychotics in schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 505-524.	1.8	186
4300	Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. <i>Dialogues in Clinical Neuroscience</i> , 2016, 18, 323-337.	1.8	38
4301	The Use of Rapid Tranquilization in Aggressive Behavior. <i>Deutsches A&#x0308;rzteblatt International</i> , 2019, 116, 445-452.	0.6	14
4302	Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID). <i>Health Technology Assessment</i> , 2009, 13, iii-iv, ix-xi, 1-54.	1.3	39

#	ARTICLE	IF	CITATIONS
4303	The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2010, 14, 1-157, iii.	1.3	46
4304	Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. <i>Health Technology Assessment</i> , 2016, 20, 1-46.	1.3	25
4305	Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-144.	1.3	16
4306	Coercion in mental health: a trial of the effectiveness of community treatment orders and an investigation of informal coercion in community mental health care. <i>Programme Grants for Applied Research</i> , 2016, 4, 1-354.	0.4	13
4307	Two-year Rehospitalization Rates of Patients with Newly Diagnosed or Chronic Schizophrenia on Atypical or Typical Antipsychotic Drugs: Retrospective Cohort Study. <i>Croatian Medical Journal</i> , 2008, 49, 215-223.	0.2	22
4308	A Review of the Impact of Exclusion Criteria on the Generalizability of Schizophrenia Treatment Research. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, 11, 49-57.	1.4	11
4309	The Efficacy and Safety of Conventional and Atypical Antipsychotics in First-Episode Schizophrenia: A Review of the Literature. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 27-42.	1.4	3
4310	Why Not Clozapine?. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 92-95.	1.4	15
4311	Clinical Pharmacology and Medication-Associated Side Effects: A Review of Second-Generation Antipsychotics for Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 135-146.	1.4	3
4312	Factors Associated with Dropout and Noncompliance in Patients with Schizophrenia: Results of a One-Year Follow-Up. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 161-167.	1.4	3
4313	Dual Diagnosis of Substance Abuse and Schizophrenia: Improving Compliance with Pharmacotherapy. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 259-269.	1.4	1
4314	Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008, 2, 136-146.	1.4	4
4315	Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008, 2, 226-234.	1.4	5
4316	A Pilot Study to Determine a Prolactin Threshold that Identifies Improved Sexual Functioning when Switching from a Prolactin-Elevating to a Prolactin-Neutral Antipsychotic. <i>Clinical Schizophrenia and Related Psychoses</i> , 2010, 3, 209-216.	1.4	4
4317	Concomitant Psychotropic Medication Use During Treatment of Schizophrenia Patients: Longitudinal Results from the CATIE Study. <i>Clinical Schizophrenia and Related Psychoses</i> , 2011, 5, 124-134.	1.4	19
4318	Ziprasidone's Effect on Metabolic Markers in Patients with Diabetes and Chronic Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 5, 185-192.	1.4	5
4319	Monitoring Metabolic Side Effects when Initiating Treatment with Second-Generation Antipsychotic Medication. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 5, 201-207.	1.4	10
4320	One-Year Treatment Continuation in Patients Prescribed Risperidone Long-Acting Injection in New Zealand: A Retrospective Study. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 6, 61-68.	1.4	6

#	ARTICLE	IF	CITATIONS
4321	New Serotonin/Dopamine Antagonists for the Treatment of Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 6, 122-133.	1.4	17
4322	Clozapine. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 6, 134-144.	1.4	183
4323	Topiramate in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 6, 186-196.	1.4	21
4324	A review of the impact of exclusion criteria on the generalizability of schizophrenia treatment research. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, , 1-25.	1.4	5
4325	Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report. <i>Clinical Schizophrenia and Related Psychoses</i> , 2015, 9, 141-144.	1.4	2
4326	Interventions in the Early Stages of Psychosis. <i>Psychiatric Annals</i> , 2008, 38, .	0.1	5
4327	Comorbidities of Obesity in Serious Mental Illness. <i>Psychiatric Annals</i> , 2011, 41, 469-472.	0.1	2
4328	Epidemiology of Obesity. <i>Psychiatric Annals</i> , 2011, 41, 484-488.	0.1	7
4329	Psychotropic Medications, Associated QTc Prolongation, and Sudden Cardiac Death: A Review for Clinicians. <i>Psychiatric Annals</i> , 2013, 43, 58-65.	0.1	4
4330	Sleep and Schizophrenia. <i>Psychiatric Annals</i> , 2016, 46, 192-196.	0.1	3
4331	The Integral Role of Psychoeducation in Clinical Care. <i>Psychiatric Annals</i> , 2016, 46, 286-292.	0.1	2
4332	Building a Better Mental Health Workforce: 8 Core Elements. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2007, 45, 24-34.	0.3	12
4333	Unawareness as a Barrier to Treatment in Patients with Schizophrenia: A Conceptual Analysis. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2010, 48, 30-36.	0.3	1
4335	Psykiatriens indre konflikter eksponert. <i>Tidsskrift for Den Norske Laegeforening</i> , 2017, 137, 421-421.	0.2	3
4336	A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 487-499.	1.1	49
4337	Risperidone Long-Acting Injection. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 196-200.	1.1	48
4338	Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 75-80.	1.1	29
4339	Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 295-303.	1.1	57

#	ARTICLE	IF	CITATIONS
4340	Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 669-675.	1.1	46
4341	Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). <i>Journal of Clinical Psychiatry</i> , 2012, 73, 526-532.	1.1	78
4342	A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 803-810.	1.1	111
4343	Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 349-356.	1.1	128
4344	Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 10-18.	1.1	46
4345	Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. <i>Journal of Clinical Psychiatry</i> , 2018, 80, .	1.1	3
4346	Sexual Function and Gonadal Hormones in Patients Taking Antipsychotic Treatment for Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 361-367.	1.1	77
4347	Patterns of Atypical Antipsychotic Subtherapeutic Dosing Among Oregon Medicaid Patients. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1540-1547.	1.1	27
4348	Treating Bipolar Disorder in the Primary Care Setting. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2009, 11, 245-257.	0.6	2
4349	The Effect of Antipsychotic Medication on Neuromotor Abnormalities in Neuroleptic-Naive Non-affective Psychotic Patients. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010, 12, .	0.6	26
4350	Sulfotransferase 4A1 Haplotype 1 (SULT4A1-1) Is Associated With Decreased Hospitalization Events in Antipsychotic-Treated Patients With Schizophrenia. <i>primary care companion for CNS disorders, The</i> , 2012, 14, .	0.2	3
4351	Antipsychotic Adherence and Its Correlation to Health Outcomes for Chronic Comorbid Conditions. <i>primary care companion for CNS disorders, The</i> , 2012, 14, .	0.2	13
4352	Olanzapine-Induced Weight Gain in Patients With Bipolar I Disorder. <i>primary care companion for CNS disorders, The</i> , 2011, 13, .	0.2	3
4353	Pharmacologic Treatment of First-Episode Schizophrenia. <i>primary care companion for CNS disorders, The</i> , 2012, 14, .	0.2	8
4354	Review of the Safety of Second-Generation Antipsychotics. <i>primary care companion for CNS disorders, The</i> , 2012, 14, .	0.2	16
4355	Change in Framingham Risk Score in Patients With Schizophrenia. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2006, 8, 329-33.	0.6	9
4356	Metabolic Adverse Events in Patients With Mental Illness Treated With Antipsychotics. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2008, 10, 15-24.	0.6	29
4357	Coverage of Atypical Antipsychotics Among Medicare Drug Plans in the State of Washington for Fiscal Year 2007. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2008, 10, 313-317.	0.6	3

#	ARTICLE	IF	CITATIONS
4358	Adolescent Onset Psychosis: A 2-year retrospective study of adolescents admitted to a general psychiatric unit. <i>South African Journal of Psychiatry</i> , 2009, 15, 7.	0.2	11
4359	Olanzapine-induced oculogyric crisis in a patient with schizophrenia. <i>Indian Journal of Medical Sciences</i> , 2008, 62, 238.	0.1	5
4360	Clinical Practice Guidelines for Management of Schizophrenia. <i>Indian Journal of Psychiatry</i> , 2017, 59, 19.	0.4	33
4361	Clozapine: Current perspective. <i>Indian Journal of Psychiatry</i> , 2007, 49, 271.	0.4	12
4362	Are we over-dependent on pharmacotherapy?. <i>Indian Journal of Psychiatry</i> , 2008, 50, 7.	0.4	6
4363	Early intervention in psychotic disorders: Challenges and relevance in the Indian context. <i>Indian Journal of Psychiatry</i> , 2010, 52, 153.	0.4	19
4364	Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. <i>Indian Journal of Psychiatry</i> , 2011, 53, 128.	0.4	43
4365	Regional brain metabolism in schizophrenia. <i>Journal of Postgraduate Medicine</i> , 2007, 53, 241-246.	0.2	4
4366	Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: A randomized, double-blind, multicentric trial. <i>Industrial Psychiatry</i> , 2011, 20, 25.	0.3	10
4367	Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis. <i>Journal of Research in Pharmacy Practice</i> , 2013, 2, 138.	0.2	8
4368	A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia. <i>Indian Journal of Psychiatry</i> , 2018, 60, 10.	0.4	4
4369	Exploring the Economic Implications of a Group-Based Lifestyle Intervention for Middle-Aged Adults with Chronic Schizophrenia and Co-Morbid Type 2 Diabetes. <i>Journal of Diabetes & Metabolism</i> , 2014, 05, .	0.2	3
4370	The Pharmacological Role and Clinical Applications of Antipsychotics's™ Active Metabolites: Paliperidone versus Risperidone. <i>Clinical & Experimental Pharmacology</i> , 2013, 03, .	0.3	23
4371	A Patient Bill of Rights for Psychotropic Prescription: A Call for a Higher Standard of Care. <i>International Journal of Clinical Medicine</i> , 2011, 02, 353-359.	0.1	1
4373	Innovations in Clinical Research Design and Conduct in Psychiatry: Shifting to Pragmatic Approaches. <i>Psychiatry Investigation</i> , 2009, 6, 1.	0.7	12
4374	The Pharmacogenetics of Symptom Response to Antipsychotic Drugs. <i>Psychiatry Investigation</i> , 2012, 9, 1.	0.7	28
4375	The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 459.	0.7	1
4376	Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data. <i>Psychiatry Investigation</i> , 2015, 12, 46.	0.7	15

#	ARTICLE	IF	CITATIONS
4377	Outpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based Study. <i>Psychiatry Investigation</i> , 2015, 12, 425.	0.7	23
4378	Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study. <i>Psychiatry Investigation</i> , 2016, 13, 458.	0.7	2
4379	Aspects of sexual self-perception in schizophrenic patients. <i>European Journal of Psychiatry</i> , 2009, 23, .	0.7	3
4380	Characteristics of Outpatients Initiated on Olanzapine versus Risperidone in the Treatment of Schizophrenia in Japan: A Healthcare Database Analysis. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , 2011, 2, 1-8.	0.3	3
4381	Whatâ€™s in a name? Compliance, adherence and concordance in chronic psychiatric disorders. <i>World Journal of Psychiatry</i> , 2014, 4, 30.	1.3	137
4382	PSYCHOEDUCATION FOR PSYCHOTIC PATIENTS. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2011, 155, 385-395.	0.2	9
4383	Does lack of improvement in the first two weeks predict treatment resistance in recent-onset psychosis?. <i>Clinics</i> , 2012, 67, 1479-1482.	0.6	9
4384	Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. <i>Drugs in Context</i> , 2015, 4, 1-12.	1.0	15
4385	Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. <i>Drugs in Context</i> , 2016, 5, 1-10.	1.0	4
4386	The association between a free medicine program and functioning in people with schizophrenia: a cross-sectional study in Liuyang, China. <i>PeerJ</i> , 2020, 8, e8929.	0.9	6
4387	Ethnic and Age Disparities in Patients Taking Long-acting Injectable Atypical Antipsychotics. <i>Cureus</i> , 2017, 9, e1772.	0.2	4
4388	Excessive Daytime Sleepiness in Schizophrenia: A Naturalistic Clinical Study. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, VC06-VC08.	0.8	10
4389	Re-implementation of a pharmacist-managed metabolic syndrome clinic in an outpatient mental health clinic setting. <i>Mental Health Clinician</i> , 2015, 5, 57-62.	0.5	2
4390	Antipsychotics Prescribing Patterns of Patients with Schizophrenia Admitted to Korean General Hospital Psychiatric Unit: 2001 to 2008. <i>Clinical Psychopharmacology and Neuroscience</i> , 2011, 9, 17-22.	0.9	10
4391	Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2011, 9, 45-53.	0.9	25
4392	Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012, 10, 71-77.	0.9	49
4393	Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2014, 12, 1-7.	0.9	4
4394	Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017, 15, 132-137.	0.9	11

#	ARTICLE	IF	CITATIONS
4395	Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018, 16, 235-245.	0.9	17
4396	Biological Aspects of Aggression and Violence in Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 475-486.	0.9	31
4397	Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 386-394.	0.9	19
4398	A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 587-598.	0.9	1
4399	Olanzapine and Olanzapine Pamoate. , 2021, , 296-317.		0
4400	Important Concepts about First-Generation Antipsychotics. , 2021, , 147-156.		0
4401	Perphenazine and Perphenazine Decanoate. , 2021, , 190-200.		0
4402	The Therapeutic Threshold and the Point of Futility. , 2021, , 34-59.		0
4403	Effect of high-endurance exercise intervention on sleep-dependent procedural memory consolidation in individuals with schizophrenia: a randomized controlled trial. <i>Psychological Medicine</i> , 2023, 53, 1708-1720.	2.7	9
4405	Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 22-31.	1.0	4
4406	Association of the First Antipsychotic Treatment Duration With the Re-Initiation of Treatment in Schizophrenia: A National Health Insurance Data-Based Study. <i>Korean Journal of Schizophrenia Research</i> , 2021, 24, 60-67.	0.3	0
4407	Pharmacogenomics: A road ahead for precision medicine in psychiatry. <i>Neuron</i> , 2021, 109, 3914-3929.	3.8	25
4408	Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions. <i>CNS Drugs</i> , 2021, 35, 1153-1161.	2.7	9
4409	Antipsychotic Medications and Metabolic Syndrome. , 2021, , 19-30.		0
4410	Efficacité des antipsychotiques atypiques dans la schizophrénie : les données de l'étude CATIE. <i>Perspectives Psy</i> , 2005, 44, 324-326.	0.0	1
4411	INCREASED RISK OF DEATH WITH ANTIPSYCHOTICS FOR DEMENTED ELDERLY. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2006, 6, 18.	0.0	0
4412	Langzeittherapie schizophrener und schizoaffektiver Psychosen. , 2006, , 289-297.		0
4413	Welk risico bestaat er op ontwikkeling van diabetes mellitus bij toepassing van atypische antipsychotica?. , 2006, , 1909-1911.		0

#	ARTICLE	IF	CITATIONS
4414	A Review of: "The \$800 Million Pill. The Truth Behind the Cost of New Drugs. By Merrill Goozner;" Annals of Clinical Psychiatry, 2006, 18, 72-73.	0.6	0
4415	ON FDA POLICY ON ANTIPSYCHOTICS AND OTHER DRUGS, EXPERTS SAY "SHOW US THE DATA" TM . Neurology, 2006, 6, 20-21.	1.5	1
4416	Tipo de antipsicótico y correlatos de la interrupción del tratamiento de antipsicóticos en el tratamiento ambulatorio de la esquizofrenia. European Psychiatry (Ed Española), 2006, 13, 236-243.	0.0	0
4419	An Evidence-Based Approach to Optimizing the Management of Psychotic Disorders in the Long-Term Care Setting. The Consultant Pharmacist, 2006, 21, 1-28.	0.4	0
4420	Brain, Body, and Self. , 2006, , 13-44.		0
4422	Pharmacological and Psychological Interventions. , 2006, , 76-115.		0
4423	Neurosurgery, Psychosurgery, and Neurostimulation. , 2006, , 116-147.		0
4425	Clinical use of aripiprazole in patients with schizophrenia: A real-life setting results from the German Postmarketing Surveillance Study. World Journal of Biological Psychiatry, 2010, 11, 1-8.	1.3	4
4426	Psychiatric Disorders. , 2007, , 1249-1288.		2
4427	Antipsychotic Drugs and Stress. , 2007, , 226-231.		0
4428	Involuntary Movement Disorders. , 2007, , 401-464.		0
4429	Schizophrenie "Pharmakotherapie (ICD-10 F2). , 2007, , 55-78.		0
4430	Kapitel 8 Literaturverzeichnis. , 2007, , 167-196.		0
4431	Monoamine-Based Treatments in Schizophrenia: Time to Change the Paradigm?. , 2007, , 299-312.		0
4432	Natural History of Obesity. , 2007, , 93-119.		0
4433	Antipsychotic drug prescription in postgraduate psychiatry training programs in India: Time to reflect. Indian Journal of Psychiatry, 2007, 49, 225.	0.4	5
4434	Psychopharmacologic treatment of psychiatric disorders in patients with diabetes mellitus. , 2007, , 153-177.		1
4435	Clinical Endophenotypes: Implications for Genetic and Clinical Research. Medical Psychiatry, 2007, , 153-172.	0.2	0

#	ARTICLE	IF	CITATIONS
4436	Electroconvulsive Therapy—An Outdated Treatment, or One Whose Time Has Come?. Southern Medical Journal, 2007, 100, 462-463.	0.3	0
4437	Clinical Endophenotypes: Implications for Genetic and Clinical Research. , 2007, , 165-184.		0
4438	Costs of New Atypical Antipsychotic Agents for Schizophrenia: Does Unrestricted Access Reduce Hospital Utilization?. Healthcare Policy, 2007, 3, 58-79.	0.3	0
4439	Evidence-based Psychiatry: Outcomes and Decisions. Southern Medical Journal, 2007, 100, 861-862.	0.3	1
4440	Eficacia de los antipsicóticos: relación con la ocupación óptima de los receptores D2. European Psychiatry (Ed Española), 2007, 14, 325-334.	0.0	0
4441	Observaciones y percepciones del médico sobre los síntomas positivos y negativos de la esquizofrenia: encuesta multinacional transversal. European Psychiatry (Ed Española), 2007, 14, 383-392.	0.0	0
4443	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie. , 2008, , 971-983.		0
4444	DNA Biomarkers for Pharmacogenomics and Personalized Medicine. , 2008, , 445-471.		0
4446	Do Clinical Trials Always Benefit Patients?. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2008, 13, 95-109.	0.0	0
4447	17 Psychotische stoornissen. , 2008, , 531-545.		0
4449	Psychopharmacological Management of Schizophrenia. , 2008, , 1-21.		0
4450	Competing Risks Model in the Analysis of Survival Data. Japanese Journal of Biometrics, 2008, 29, 141-170.	0.0	1
4451	Antipsychotic Drugs. , 2008, , 577-594.		1
4452	Schizophrene Psychosen. , 2008, , 1255-1358.		0
4454	Trastornos de movimientos involuntarios. , 2008, , 407-452.		1
4455	Ensayo multicéntrico, aleatorio, naturalista y abierto de comparación entre aripiprazol y el estándar óptimo de tratamiento de pacientes esquizofrénicos de la comunidad Ensayo de Aripiprazol en la Esquizofrenia: estudio STAR. European Psychiatry (Ed Española), 2008, 15, 31-42.	0.0	0
4456	Estudio SOHO (Variables Relacionadas con la Salud en Pacientes Ambulatorios con Esquizofrenia): resultados a los 3 años de la suspensión del tratamiento antipsicótico y factores clínicos relacionados con ella en España. European Psychiatry (Ed Española), 2008, 15, 137-144.	0.0	0
4457	Schizophrenia and Other Psychoses. , 0, , 1201-1282.		6

#	ARTICLE	IF	CITATIONS
4459	CATIE and CUtLASS (UK): Is it time psychiatrists start changing their practice?- The debate goes on!. Indian Journal of Psychiatry, 2009, 51, 161.	0.4	2
4461	Pharmakotherapie der Schizophrenie (ICD-10 F2): Akut-, Notfall- und Langzeitbehandlung. , 2009, , 55-94.		0
4463	Les effets indésirables des antipsychotiques et leur gestion. , 2009, , 29-48.		0
4465	Schizophrenien und andere psychotische Störungen. , 2009, , 411-490.		1
4466	Factores farmacológicos y no farmacológicos que afectan la adherencia al tratamiento de los pacientes esquizofrénicos dados de alta en la Unidad de Salud Mental del Hospital Universitario de Neiva entre enero y junio del 2008. RFS Revista Facultad De Salud, 2009, 1, 25-30.	0.0	0
4467	Comparative Efficacy and Safety of First - and Second-Generation Antipsychotics in the Treatment of Schizophrenia: Facts and Fiction. , 2010, , 389-401.		0
4468	Prediction of Psychosis Through the Prodromal Syndrome. , 2010, , 251-266.		0
4469	Evaluation and medication therapy for treatment resistance in schizophrenia. Medical Psychiatry, 2009, , 185-200.	0.2	0
4470	Life Care Planning for the Amputee. , 2009, , 355-382.		0
4472	An update of meta-analyses on second-generation antipsychotic drugs for schizophrenia. Medical Psychiatry, 2009, , 164-173.	0.2	2
4473	Long-Acting Antipsychotic Medication and the Outcome of Schizophrenia. , 2010, , 403-415.		0
4475	Genetic Dissection of Dopamine-Mediated Prefrontal-Striatal Mechanisms and Its Relationship to Schizophrenia. , 2009, , 187-200.		0
4476	10.3 How Antipsychotics Work: Linking Receptors to Response. , 2009, , 540-557.		0
4477	Hyperglycemia Secondary to Nondiabetic Conditions and Therapies. , 2010, , 808-821.		1
4480	Inhibition of Glycine Transporter-1 Improves the Functional Outcome of Schizophrenia. , 2010, , 577-610.		1
4481	Obesity and Metabolic Dysfunction in the Child with a Major Behavioral Disorder: Atypical Antipsychotics. , 2010, , 369-376.		0
4482	Troubles schizophréniques. , 2010, , 148-155.		0
4483	Schizophrenia and Acute Psychosis. , 2010, , 985-994.e1.		0

#	ARTICLE	IF	CITATIONS
4484	Clinical psychopharmacology. , 2010, , 227-294.		1
4485	Schizophrenia and related disorders. , 2010, , 48-63.		0
4486	Antipsychotiques. , 2010, , 25-38.		0
4487	Farmacogenética de los trastornos psiquiátricos. , 2010, , 137-153.		0
4488	A survey of antipsychotic polypharmacy in outpatients at Nagoya University Hospital. Clinical Neuropsychopharmacology and Therapeutics, 2010, 1, 43-49.	0.3	0
4490	Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients. , 2012, , 3-17.		0
4491	Comparative Effectiveness Research in the Era of Health Reform. North Carolina Medical Journal, 2010, 71, 263-267.	0.1	0
4493	Don't forget preclinical science. BMJ: British Medical Journal, 2010, 341, c6324-c6324.	2.4	0
4494	Genetic Studies of Schizophrenia. Advances in Neurobiology, 2011, , 333-380.	1.3	0
4495	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie. , 2011, , 1177-1191.		0
4496	Effects of Combined Use of Antiretroviral Agents and Atypical Antipsychotics on Lipid Parameters. Journal of Antivirals & Antiretrovirals, 2011, 03, .	0.1	4
4497	Pharmacologic Approaches to Medication-Resistant Anxiety in Children and Adolescents. , 2011, , 355-370.		0
4498	Schizophrenia and Comorbid Substance Abuse – Pathophysiological and Therapeutic Approaches. , 2011, , 321-363.		0
4499	Methodik empirischer Forschung. , 2011, , 429-452.		0
4500	Antipsicóticos en neurología: farmacología, indicaciones y utilización clínica. , 2011, , 43-69.		0
4501	Clinical and functional outcomes for patients with schizophrenia treated with olanzapine: One-year naturalistic outcomes for inpatients and outpatients in Japan. Clinical Neuropsychopharmacology and Therapeutics, 2011, 2, 45-55.	0.3	0
4508	The patient's subjective dimension within a Psychiatry for the Person. International Journal of Person Centered Medicine, 2011, , .	0.2	0
4510	Psychiatric Disorders - Worldwide Advances. , 2011, , .		1

#	ARTICLE	IF	CITATIONS
4511	Neurocognitive Expression of Hypofrontality in Long Term Schizophrenia. , 0, , .		0
4512	Mental Health and Behavioral Disorders in Pregnancy. , 2012, , 1156-1187.		1
4513	Antipsychotika. , 2012, , 659-693.		1
4514	Schizophrenien und andere psychotische Störungen. , 2012, , 347-419.		2
4517	Psychopharmaka bei neurologischen Erkrankungen. , 2012, , 1163-1172.		1
4518	Psychiatric comorbidity in patients with dizziness. Equilibrium Research, 2012, 71, 96-102.	0.2	1
4520	Mentalizing Skills Deficits in Schizophrenia as a Clue for Drug Choice: Clozapine Versus Other Antipsychotics on Keeping Outpatients Stable. , 0, , .		0
4521	Regional disease characteristics and comorbidities of patients with schizophrenia in the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from an international large simple trial. Open Journal of Psychiatry, 2012, 02, 423-432.	0.2	0
4523	The Efficacy of Yokukansan to Treat the Behavioral and Psychological Symptoms of Dementia Patients. Kyushu Neuropsychiatry, 2012, 58, 133-141.	0.1	0
4524	The evaluation of physical treatments. , 2012, , 1151-1158.		0
4526	Antipsychotic and anticholinergic drugs. , 2012, , 1208-1231.		0
4527	Schizophrenia and paranoid disorders in late life. , 2012, , 1546-1550.		0
4528	Schizophrenia and folate pharmacogenetics: Review of the literature regarding folic acid and its pharmacogenetically regulated metabolism in relation to schizophrenia treatments. Mental Health Clinician, 2012, 1, 225-229.	0.5	1
4529	Treatment-resistant schizophrenia. , 2012, , 252-268.		0
4530	The general health of people with schizophrenia. , 2012, , 91-106.		0
4531	Depression and anxiety in schizophrenia. , 2012, , 72-90.		0
4532	Psychopharmacological management of schizophrenia. , 2012, , 1-31.		0
4535	Systematic Review and Meta-analysis of Anticholinergic Side Effects of Long-acting Antipsychotics. The Open Conference Proceedings Journal, 2012, 3, 18-34.	0.6	1

#	ARTICLE	IF	CITATIONS
4539	Beware the cost-benefit analysis. <i>BMJ, The</i> , 2012, 345, e5040-e5040.	3.0	0
4541	Treatment-resistant schizophrenia. , 2012, , 252-268.		0
4542	Depression and anxiety in schizophrenia. , 2012, , 72-90.		0
4543	Consider pharmacotherapy for antipsychotic-induced orthostatic hypotension only if nonpharmacological measures fail. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 19-23.	0.3	0
4544	The general health of people with schizophrenia. , 2012, , 91-106.		0
4545	Psychopharmacological management of schizophrenia. , 2012, , 1-31.		0
4547	Teaching patients how to effectively solve medication-related problems in an acute inpatient psychiatric setting. <i>Mental Health Clinician</i> , 2012, 2, 80-82.	0.5	1
4548	Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice?. , 2013, , 81-107.		0
4549	Antipsychotic Polypharmacy and Associated Phenomena in Patients with Schizophrenia: Rational or Irrational?. , 2013, , 61-80.		0
4550	Antipsychotic Treatment Within a Naturalistic Trialâ€”How Are We Treating Schizophrenia Patients in the â€œReal-Worldâ€?. , 2013, , 137-156.		0
4551	Antipsychotic Medication: Future Prospects. , 2013, , 1-5.		0
4552	Psychiatric comorbidity in patients with dizziness. <i>Equilibrium Research</i> , 2013, 72, 51-67.	0.2	0
4553	Registro ElectrÃ³nico de Adherencia al Tratamiento de Esquizofrenia en LatinoamÃ©rica (e-STAR): Resultados clÃ­nicos del uso de risperidona inyectable de liberaciÃ³n prolongada a dos aÃ±os de seguimiento. <i>Salud Mental</i> , 2013, 36, 19.	0.3	1
4554	A General Treatment Approach. , 2013, , 14-19.		0
4555	UmsatzverÃ¤nderungen in einzelnen Indikationsgruppen. , 2013, , 43-376.		0
4556	Farmacoterapia antipsicÃ³tica e disturbi cognitivi. , 2013, , 37-45.		0
4558	A Genetic Dissection of Antipsychotic Induced Movement Disorders. <i>Current Medicinal Chemistry</i> , 2013, 20, 312-330.	1.2	2
4559	Schizophrenie und Diabetes. , 2013, , 225-231.		0

#	ARTICLE	IF	CITATIONS
4560	Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients. , 2013, , 3-17.		0
4562	Comparison of Post Hoc Multiple Pairwise Testing Procedures as Applied to Small k-Group Logrank Tests. International Journal of Statistics in Medical Research, 2013, 2, 104-116.	0.5	0
4563	UmsatzverÄnderungen in einzelnen Indikationsgruppen. , 2013, , 47-373.		0
4564	Ethische Probleme in der Schizophrenieforschung. , 2013, , 169-184.		0
4565	Adherence: The Great Masquerader of Treatment-Resistance. , 2013, , 20-28.		0
4566	Psychopharmaka. , 2013, , 821-864.		0
4568	The Medical Treatment of Autism Disorders. , 0, , .		1
4569	The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication. Journal of Health Economics and Outcomes Research, 2013, 1, 54-61.	0.6	0
4571	Antipsychotics: A General View of Therapeutic and Adverse Effects. , 2013, , 23-65.		0
4572	Implementation of antipsychotic selection recommendations at a veterans affairs facility. Mental Health Clinician, 2013, 3, 188-192.	0.5	1
4573	Dynamics of drug evaluation: Formulary placement of antipsychotics. Mental Health Clinician, 2013, 3, 185-187.	0.5	0
4575	Observational Studies in a Learning Health System. , 2013, , .		4
4576	Management of Comorbid Medical Conditions in Schizophrenia. , 2014, , 175-204.		0
4577	Auswirkungen von Äkonomisierungsprozessen auf die Versorgungsqualität von Arzneimitteln. , 2014, , 115-139.		0
4578	Troubles schizophrÄoniques. , 2014, , 251-259.		0
4579	Observance, insight etÄrgles de prescription desÄpsychotropes. , 2014, , 189-194.		0
4581	Predictors of Discontinuation of Antipsychotic Therapy in Patients with Acute Schizophrenia: A 1-Year Observational Study with More Than 1000 Patients. Open Journal of Psychiatry, 2014, 04, 364-371.	0.2	0
4583	Psychopharmaka. , 2014, , 921-965.		0

#	ARTICLE	IF	CITATIONS
4584	Intérêt de la pharmacogénétique en psychiatrie. , 2014, , 35-53.		0
4585	Antipsychotiques. , 2014, , 31-65.		0
4587	Umsatzveränderungen in einzelnen Indikationsgruppen. , 2014, , 49-376.		0
4588	Religion, Pluralism and the Secular State: Commentary on Marriage Equality and Disability Rights. SSRN Electronic Journal, 0, , .	0.4	0
4589	Future Directions in Genetics of Psychiatric Disorders. , 2014, , 311-337.		1
4594	Clinical Applications of Neuromodulation in Psychiatry. , 2015, , 171-185.		0
4595	N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder. Current Psychiatry Reviews, 2014, 10, 308-316.	0.9	0
4597	mHealth and Pharmacy in Health Care. , 2014, , 613-630.		0
4598	Arzneimitteltherapiesicherheit und besondere Verfahren. , 2015, , 863-966.		0
4599	Prinzipien der Methodik empirischer Forschung in der Psychiatrie. , 2015, , 1-28.		0
4600	The Role of Noninferiority Designs in Bipolar Disorder Clinical Trials. , 2015, , 49-57.		0
4602	Chapter 29. Psychiatry. , 2015, , .		0
4603	Schizophrenien und andere psychotische Störungen. , 2015, , 349-412.		0
4605	Zentrales Nervensystem. , 2015, , 229-415.		0
4606	Individualization of Treatment and Comparative Effectiveness Research. , 2015, , 1-21.		0
4607	Informational Shocks and the Effects of Physician Detailing. SSRN Electronic Journal, 0, , .	0.4	2
4608	FACTORS FOR NON - COMPLIANCE OF MEDICATION IN PATIENTS WITH PSYCHOTIC ILLNESS. Journal of Evolution of Medical and Dental Sciences, 2015, 4, 8084-8091.	0.1	0
4609	Assessment and Treatment of Early-Stage Schizophrenia. Psychiatric Annals, 2015, 45, 542-544.	0.1	0

#	ARTICLE	IF	CITATIONS
4610	Rethinking the Concept of Psychosis and the Link Between Autism and Schizophrenia. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 2016, 4, 4-11.	0.3	0
4611	Is Metabolic Syndrome On the Radar?. primary care companion for CNS disorders, The, 2016, 18, .	0.2	5
4612	Psychopharmacology for Children and Adolescents: A Paradigm Shift. , 2016, , 285-301.		0
4613	Treatment Persistence Associated with Typical versus Atypical Antipsychotics among Out-patients with Schizophrenia. British Journal of Pharmaceutical Research, 2016, 10, 1-8.	0.4	0
4615	Quality of Life and Health Costs: The Feasibility of Cost-Utility Analysis in Schizophrenia. , 2016, , 175-183.		0
4616	Dysregulation of Dopamine Systems in a Developmental Disruption Model of Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 107-124.	0.7	3
4617	Synaptic Abnormalities and Neuroplasticity. Handbook of Behavioral Neuroscience, 2016, , 375-390.	0.7	0
4618	Conoscenze e cultura dell'uso degli psicofarmaci: che cosa si deposita nelle strategie di utilizzo degli psicofarmaci nei servizi di salute mentale?. Rivista Sperimentale Di Freniatria, 2016, , 9-22.	0.1	0
4619	Ricerca e impiego degli psicofarmaci. Rivista Sperimentale Di Freniatria, 2016, , 23-42.	0.1	0
4620	Perils of Pragmatic Psychiatry: How We Can Do Better. Psychiatry Depression & Anxiety, 2016, 2, 1-1.	0.1	0
4621	Geriatric Psychiatry: Perceptions, Presentations, and Treatments. , 2017, , 179-199.		0
4622	Psychopharmacology in Bariatric Surgery Patients. , 2017, , 313-333.		2
4623	Patient Driven Service Delivery Models in Mental Health Care. , 2017, , 111-135.		0
4626	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. , 2017, , 1-111.		0
4627	Identity and Psychiatric Disorders. , 2017, , 41-59.		0
4628	Prinzipien der Methodik empirischer Forschung in der Psychiatrie. , 2017, , 463-490.		0
4629	Schizophrenie. , 2017, , 7-37.		0
4630	Psychopharmaka. , 2017, , 681-708.		0

#	ARTICLE	IF	CITATIONS
4631	DOES OLANZAPINE HAVE ADVANTAGE OVER ILOPERIDONE IN EARLY AMELIORATION OF SYMPTOMS IN SCHIZOPHRENIA? A RANDOMISED PARALLEL GROUP TRIAL. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2017, 4, 1990-1995.	0.0	0
4632	Chapter 14: Comparative Effectiveness. , 2017, , .		0
4634	Pharmacodynamic gene polymorphism and adverse drug reactionsthen applying antipsychotic drugs. <i>World Journal of Personalized Medicine</i> , 2017, 1, 5-12.	0.3	1
4635	A STUDY OF FACTORS RELATED TO NON-COMPLIANCE OF PSYCHOTROPIC DRUGS AMONG THE PATIENTS WITH PSYCHOTIC ILLNESS. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2017, 6, 6322-6324.	0.1	0
4636	Zentrales Nervensystem. , 2018, , 253-445.		0
4637	Arzneimitteltherapiesicherheit und besondere Verfahren. , 2018, , 971-1009.		0
4638	COMPARATIVE STUDY OF OLANZAPINE AND QUETIAPINE IN PSYCHOTIC DISORDERS. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2018, 5, 205-213.	0.0	0
4639	Psychosis: Schizophrenia and Related Disorders. , 2018, , 335-372.		0
4641	Psychosis and Suicide. , 2018, , 53-69.		0
4642	Is there an evidence for the efficacy of high-dose olanzapine?. <i>Psychiatrie Pro Praxi</i> , 2018, 19, 22-23.	0.0	0
4643	Supplemental Use of Complementary Alternative Medicine for the Treatment of Schizophrenia. <i>Psychiatric Annals</i> , 2018, 48, 211-213.	0.1	0
4644	Sleep Disturbances Among Patients in Primary Care: <i>Psychiatric Practice</i> . , 2019, , 373-381.		0
4645	Identifying the "Therapy Targets" for Treating the Negative Symptoms of Psychosis Using Cognitive Behavioral Therapy. <i>Journal of Cognitive Psychotherapy</i> , 2018, 32, 203-220.	0.2	1
4646	Antipsychotic Drug Therapies: Matching primary care practice to clinical challenges. <i>Archives of Community Medicine and Public Health</i> , 0, , 047-050.	0.1	0
4648	The Effect of Metformin on Antipsychotic-induced Weight Gain in Patients with Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. <i>Korean Journal of Clinical Pharmacy</i> , 2018, 28, 204-215.	0.0	1
4649	Antipsychotic Medication-Induced Weight Gain. , 2019, , 61-67.		0
4651	Effects of local guidelines on prescribing practice and treatment outcomes in a long-stay psychiatric facility. <i>Hospital Pharmacology</i> , 2019, 6, 756-764.	0.1	0
4652	Antipsychotics and Cardiac Side Effects. , 2019, , 1-10.		0

#	ARTICLE	IF	CITATIONS
4653	Schizophrenien und andere psychotische Störungen. , 2019, , 301-362.e7.		1
4654	The Case of Ramona Williams: Losing Touch. , 2019, , 35-43.		0
4655	Investigation of Emotional Expression Processing Following Cognitive Behavioural Therapy for Patients with Schizophrenia: An Event-Related Potentials Study. Neuropsychologie Clinique Et Appliquée, 2019, 3, 146-164.	0.1	0
4656	Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a). , 2019, , 51-137.		0
4657	Antipsychotic Drugs. , 2019, , .		0
4658	Antipsychotic Drugs. , 2019, , .		0
4661	Influencia del sexo en el tratamiento con olanzapina: una revisión sistemática. Psiquiatria Biologica, 2019, 26, 45-51.	0.0	0
4662	Management of schizophrenia and bipolar disorder in pediatric practice. Ukrain Kyi Visnyk Psykhonevrolohi, 2019, 27, 38-47.	0.0	0
4666	Treatment-Resistant Schizophrenia. Current Clinical Psychiatry, 2020, , 157-170.	0.2	0
4667	Antipsychotics: Overview. Current Clinical Psychiatry, 2020, , 171-184.	0.2	2
4668	Antipsychotics: Clinical Effectiveness. Current Clinical Psychiatry, 2020, , 215-230.	0.2	0
4669	Gut Microbiota and Antipsychotics Induced Metabolic Alteration. Global Clinical and Translational Research, 2019, , 131-143.	0.4	0
4670	Comorbid Psychiatric and Physical Disorders. , 2020, , 205-228.		0
4671	Unmet Needs in Patients with Schizophrenia. , 2020, , 15-25.		0
4672	Antipsychotics and Cardiac Side Effects. , 2020, , 721-729.		0
4673	Sleep Disorders in Veterans: Prevalence, Consequences, and Treatment. , 2020, , 315-340.		1
4674	Culture and family-based intervention for schizophrenia, bipolar, and other psychotic-related spectrum disorders. , 2020, , 645-674.		0
4675	Psychotische Erkrankungen (Schizophrenie). , 2020, , 275-296.		0

#	ARTICLE	IF	CITATIONS
4676	Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics. Zhurnal Nevrologii i Psikhiatrii Imeni S S Korsakova, 2020, 120, 134.	0.1	3
4677	Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics. Clinical and Translational Science, 2020, 13, 1170-1177.	1.5	6
4678	Iatrogenic Obesity. Endocrinology and Metabolism Clinics of North America, 2020, 49, 265-273.	1.2	1
4681	Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia. RSC Drug Discovery Series, 2020, , 175-197.	0.2	1
4682	Tackling myths of common prescribing patterns in schizophrenia amongst Egyptian psychiatrists. Middle East Current Psychiatry, 2020, 27, .	0.5	2
4683	Is There Evidence That Stimulus Parameters and Electrode Placement Affect the Cognitive Side Effects of Electroconvulsive Therapy in Patients With Schizophrenia and Schizoaffective Disorder?. Journal of ECT, 2021, 37, 133-139.	0.3	3
4684	Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination. Clinical Pharmacokinetics, 2021, 60, 637-647.	1.6	7
4685	Dopamine and Response to Antipsychotic Medication. , 2021, , 481-524.		0
4686	Obesity and schizophrenia: New drugs, new hopes. Psihijatrija Danas, 2020, 52, 113-130.	0.1	0
4687	A UPLC-MS/MS Assay for Simultaneous Determination of Two Antipsychotics and Two Antidepressants in Human Plasma and Its Application in Clinic. Current Pharmaceutical Biotechnology, 2020, 21, 60-69.	0.9	1
4688	Psychopharmaka. , 2020, , 781-814.		4
4689	Polytherapy in schizophrenia in light of the literature data. Pharmacotherapy in Psychiatry and Neurology, 2020, 35, 193-199.	0.1	0
4690	Factors of Competitive Employment for People with Severe Mental Illness, from Acquisition to Tenure. , 2020, , 1-26.		2
4691	Association of selected antipsychotics on the triglyceride levels in patients with schizophrenia in inpatient and outpatient settings. Clinical Neuropsychopharmacology and Therapeutics, 2020, 11, 15-22.	0.3	0
4692	The relation of integrated psychological therapy to resting state functional brain connectivity networks in patients with schizophrenia. Psychiatry Research, 2021, 306, 114270.	1.7	6
4693	Weight change, cardio-metabolic risk factors and cardiovascular incidence in people with serious mental illness: protocol of a population-based cohort study in the UK from 1998 to 2020. BMJ Open, 2021, 11, e053427.	0.8	1
4694	Promoting Medication Adherence Among Psychiatric Patients With a History of Nonadherence: A Clinical Practice Improvement Program. Journal of Psychiatric Practice, 2020, 26, 284-293.	0.3	6
4695	Treatment of Children and Adolescents with Obesity and Comorbid Psychiatric Conditions. Issues in Clinical Child Psychology, 2008, , 425-443.	0.2	0

#	ARTICLE	IF	CITATIONS
4696	Novel Mechanisms of Drug Treatment in Psychiatry. , 2008, , 519-534.		0
4697	Clinical Psychopharmacology and Other Somatic Therapies. , 2008, , 577-634.		0
4701	Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders. Drug Safety, 2012, 35, 819-836.	1.4	4
4702	In the Aftermath of CATIE: How Should Administrators Value Atypical Antipsychotic Medications?. Administration and Policy in Mental Health and Mental Health Services Research, 2006, 33, 541.	1.2	0
4703	Pseudo-Resistant Schizophrenia: Non-Adherence to Treatment. Korean Journal of Schizophrenia Research, 2020, 23, 51-57.	0.3	0
4706	Schizofreniespectrum- en andere psychotische stoornissen. , 2021, , 165-196.		0
4707	The science of well-being: an integrated approach to mental health and its disorders. World Psychiatry, 2006, 5, 71-6.	4.8	158
4708	Caveats for psychiatric rehabilitation. World Psychiatry, 2006, 5, 158-9.	4.8	3
4709	The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacks. Journal of Psychiatry and Neuroscience, 2007, 32, 232-3.	1.4	0
4710	Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2006, 15, 27-39.	0.7	84
4711	Developing and testing adaptive treatment strategies using substance-induced psychosis as an example. Psychopharmacology Bulletin, 2008, 41, 51-67.	0.0	4
4712	Costs of new atypical antipsychotic agents for schizophrenia: does unrestricted access reduce hospital utilization?. Healthcare Policy, 2007, 3, 58-79.	0.3	2
4713	Fifty years chlorpromazine: a historical perspective. Neuropsychiatric Disease and Treatment, 2007, 3, 495-500.	1.0	119
4714	Obstructive sleep apnea, hypoxia, and metabolic syndrome in psychiatric and nonpsychiatric settings. Psychiatry, 2008, 5, 48-50.	0.3	2
4715	Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. Patient Preference and Adherence, 2007, 1, 9-17.	0.8	11
4716	Cognitive behavior therapy for people with schizophrenia. Psychiatry, 2009, 6, 32-9.	0.3	4
4717	Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T. Psychiatry, 2007, 4, 23-9.	0.3	2
4718	Cognitive Outcomes in the CATIE Schizophrenia Trial: Why do they seem different from previous results?. Psychiatry, 2007, 4, 20-3.	0.3	4

#	ARTICLE	IF	CITATIONS
4719	Schizophrenia (maintenance treatment). <i>Clinical Evidence</i> , 2009, 2009, .	0.2	1
4720	Real-world Data on Atypical Antipsychotic Medication Side Effects. <i>Psychiatry</i> , 2010, 7, 9-12.	0.3	4
4721	Physical healthcare of people with severe mental illness: everybody's business!. <i>Mental Health in Family Medicine</i> , 2010, 7, 115-22.	0.2	13
4722	Paliperidone: the evidence of its therapeutic value in schizophrenia. <i>Core Evidence</i> , 2008, 2, 261-71.	4.7	12
4724	Mental health and the global agenda: core conceptual issues. <i>Mental Health in Family Medicine</i> , 2011, 8, 69-82.	0.2	19
4725	International and national policy challenges in mental health. <i>Mental Health in Family Medicine</i> , 2011, 8, 101-14.	0.2	22
4726	Health system challenges and solutions to improving mental health outcomes. <i>Mental Health in Family Medicine</i> , 2011, 8, 119-27.	0.2	29
4727	Newer oral atypical antipsychotic agents: a review. <i>P and T</i> , 2011, 36, 832-8.	1.0	4
4728	Effect of Early Intervention with Omega-3 on Insulin Resistance in Patients Initiated on Olanzapine with either Sodium Valproate or Lithium: A randomized, Double-blind, Placebo-Controlled Trial. <i>Iranian Journal of Psychiatry</i> , 2010, 5, 18-22.	0.4	4
4729	A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report. <i>Innovations in Clinical Neuroscience</i> , 2012, 9, 21-4.	0.1	6
4730	Olanzapine as a cause of urinary incontinence: a case report. <i>Iranian Journal of Psychiatry</i> , 2012, 7, 146-8.	0.4	2
4731	Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluation. <i>P and T</i> , 2013, 38, 109-15.	1.0	11
4735	Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. <i>Discovery Medicine</i> , 2012, 14, 413-20.	0.5	36
4736	Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. <i>Discovery Medicine</i> , 2012, 14, 335-43.	0.5	31
4737	Quantitative Methods for Valuing Comparative Effectiveness Information. , 2010, 17, 2-10.		2
4738	Risk factors for medication-induced amenorrhea in first-episode female Chinese patients with schizophrenia treated with risperidone. <i>Shanghai Archives of Psychiatry</i> , 2013, 25, 40-7.	0.7	0
4740	Use pattern and off-label use of atypical antipsychotics in bipolar disorder, 1998-2002. <i>American Health and Drug Benefits</i> , 2009, 2, 184-91.	0.5	1
4741	Schizophrenia: current concepts and approaches to patient care. <i>American Health and Drug Benefits</i> , 2008, 1, 13-22.	0.5	2

#	ARTICLE	IF	CITATIONS
4742	Schizophrenia: overview and treatment options. P and T, 2014, 39, 638-45.	1.0	165
4743	What does schizophrenia teach us about antipsychotics?. Canadian Journal of Psychiatry, 2015, 60, S14-8.	0.9	5
4744	Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. Journal of Research in Medical Sciences, 2015, 20, 364-71.	0.4	9
4745	Rapid adipose deposition with mood disorders. Annals of Clinical Psychiatry, 2015, 27, 283-8.	0.6	5
4747	Patient, Physician and Organizational Influences on Variation in Antipsychotic Prescribing Behavior. Journal of Mental Health Policy and Economics, 2016, 19, 45-59.	0.6	11
4749	Polymorphic Variations in 5-HT2A, 5-HTT and DISC 1 in First Episode Schizophrenia Patients. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2009, 19, 185-92.	0.7	0
4750	Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures. Journal of Mental Health Policy and Economics, 2016, 19, 69-78.	0.6	3
4752	The Black Book of Psychotropic Dosing and Monitoring. Psychopharmacology Bulletin, 2018, 48, 64-153.	0.0	1
4753	Sensitivity of the Positive and Negative Syndrome Scale (PANSS) in Detecting Treatment Effects via Network Analysis. Innovations in Clinical Neuroscience, 2017, 14, 59-67.	0.1	15
4754	Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI). Innovations in Clinical Neuroscience, 2017, 14, 68-72.	0.1	12
4755	The protective effects of crocin in the management of neurodegenerative diseases: a review. American Journal of Neurodegenerative Disease, 2018, 7, 1-10.	0.1	15
4756	Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations. Discovery Medicine, 2013, 16, 113-22.	0.5	19
4757	Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2018, 18, 1-141.	3.0	4
4758	Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia. Shanghai Archives of Psychiatry, 2018, 30, 178-187.	0.7	3
4759	Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications. Psychopharmacology Bulletin, 2021, 51, 131-148.	0.0	1
4760	Frontal neural metabolite changes in schizophrenia and their association with cognitive control: A systematic review. Neuroscience and Biobehavioral Reviews, 2022, 132, 224-247.	2.9	11
4761	Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clinical Drug Investigation, 2021, 41, 1067-1073.	1.1	18
4762	Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders. Journal of Personalized Medicine, 2021, 11, 1189.	1.1	5

#	ARTICLE	IF	CITATIONS
4763	Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities. <i>Frontiers in Public Health</i> , 2021, 9, 770276.	1.3	5
4764	The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing. <i>Frontiers in Public Health</i> , 2021, 9, 779563.	1.3	1
4765	Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study. <i>Current Neuropharmacology</i> , 2022, 20, 1793-1803.	1.4	10
4766	Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 226-234.	0.9	4
4767	Medicinal Plants Used in the Management of Psychosis. , 0, , .		2
4768	Inflammation and JNK's Role in Niacin-GPR109A Diminished Flushed Effect in Microglial and Neuronal Cells With Relevance to Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 771144.	1.3	1
4770	Deprescribing to Resolve Oversedation and Confusion in an Older Person Treated for Auditory Hallucinations and Poststroke Seizure Prophylaxis. , 2021, 36, 645-651.		0
4771	Effects of Antipsychotics on Triglyceride Trajectories and Its Implications in CVD: A Longitudinal Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4773	Sex difference in association between insomnia and cognitive impairment in patients with chronic schizophrenia. <i>Schizophrenia Research</i> , 2022, 240, 143-149.	1.1	9
4774	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. <i>European Neuropsychopharmacology</i> , 2022, 55, 112-157.	0.3	7
4775	Psychosis in Children and Youth: Focus on Early-Onset Schizophrenia. <i>Pediatrics in Review</i> , 2013, 34, 296-306.	0.2	2
4776	Antipsicóticos de longa ação como facilitadores da adesão no tratamento da esquizofrenia: relato de caso. <i>Revista Debates Em Psiquiatria</i> , 2014, 4, 32-34.	0.3	0
4777	A Review on Current Effective Medications in the Treatment of Schizophrenia. <i>International Journal of Advances in Pharmacy and Biotechnology</i> , 2020, 6, 1-4.	0.3	3
4877	Inflammation Subtypes and Translating Inflammation-Related Genetic Findings in Schizophrenia and Related Psychoses: A Perspective on Pathways for Treatment Stratification and Novel Therapies. <i>Harvard Review of Psychiatry</i> , 2022, 30, 59-70.	0.9	45
4878	New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment. <i>Schizophrenia Research</i> , 2022, 239, 192-199.	1.1	2
4879	Antipsychotic Use in Pregnancy: Patient Mental Health Challenges, Teratogenicity, Pregnancy Complications, and Postnatal Risks. <i>Neurology International</i> , 2022, 14, 62-74.	1.3	10
4880	Treating Refractory Mental Illness With Closed-Loop Brain Stimulation: Progress Towards a Patient-Specific Transdiagnostic Approach. <i>Focus (American Psychiatric Publishing)</i> , 2022, 20, 137-151.	0.4	2
4881	Sleep in Psychotic Disorders: Results From Nationwide SUPER Finland Study. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	2

#	ARTICLE	IF	CITATIONS
4882	CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis. <i>Frontiers in Psychology</i> , 2021, 12, 768748.	1.1	7
4883	Effects of Aerobic, Resistance, and Combined Exercise Training on Psychiatric Symptom Severity and Related Health Measures in Adults Living With Schizophrenia: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 753117.	1.1	13
4884	A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China. <i>BMC Psychiatry</i> , 2022, 22, 95.	1.1	5
4885	Analgesic Effects of Oxycodone in Combination With Risperidone or Ziprasidone: Results From a Pilot Randomized Controlled Trial in Healthy Volunteers. <i>Frontiers in Pain Research</i> , 2022, 3, 752256.	0.9	0
4886	The combined effect of psychodynamic psychotherapy and pharmacotherapy on healthcare cost. <i>Psychotherapy Research</i> , 2022, 32, 874-885.	1.1	0
4887	Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders. <i>Biomedicines</i> , 2022, 10, 398.	1.4	17
4889	Criminal Recidivism in Inmates with Mental Illness and Substance Use Disorders. <i>Journal of the American Academy of Psychiatry and the Law</i> , 2020, 48, 209-215.	0.2	16
4892	Zentrales Nervensystem. , 2022, , 301-510.		0
4893	Arzneimitteltherapiesicherheit und besondere Verfahren. , 2022, , 1071-1113.		0
4894	Pharmacogenomics and antipsychotics: efficacy and adverse drug reactions. , 2022, , 161-188.		1
4895	Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections?. <i>CNS Drugs</i> , 2022, 36, 315-325.	2.7	1
4896	Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. <i>BMC Psychiatry</i> , 2022, 22, 114.	1.1	10
4898	Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a New CYP2D6 Genotype. <i>Frontiers in Psychiatry</i> , 2021, 12, 830608.	1.3	2
4899	Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 625-639.	1.0	8
4900	Ká³¼T QUá²c CHÄ,M SÄ“C, Äá»EU TRá»Š Bá»†NH NHÄ,N TÄ,M THá² N PHÄ,N LIá»†T Äá»EU TRá»Š Ná»†I TRÄŠ Tá²Vlá»†N Sá²C KHOá² NÄ,M 2020 ä€“ 2021. <i>Y Hoc Viet Nam</i> , 2022, 510, .	0.0	0
4901	Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness. <i>World Journal of Psychiatry</i> , 2022, 12, 521-532.	1.3	1
4902	Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine. <i>CNS Spectrums</i> , 2023, 28, 288-299.	0.7	4
4903	Effect of Clinical Decision Support on Cardiovascular Risk Among Adults With Bipolar Disorder, Schizoaffective Disorder, or Schizophrenia. <i>JAMA Network Open</i> , 2022, 5, e220202.	2.8	11

#	ARTICLE	IF	CITATIONS
4904	A Complex Combination Therapy for a Complex Disease—Neuroimaging Evidence for the Effect of Music Therapy in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2022, 13, 795344.	1.3	2
4905	Healthcare costs and resource use associated with negative symptoms of schizophrenia: A systematic literature review. <i>Schizophrenia Research</i> , 2022, 241, 251-259.	1.1	14
4906	Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 456-468.	2.2	4
4907	Olanzapine-samidorphane combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?. <i>Expert Review of Neurotherapeutics</i> , 2022, , .	1.4	3
4908	Clinical characteristics and treatment outcomes of patients with newly diagnosed schizophrenia: A 4-year single-center experience in Saudi Arabia. <i>Neuropsychopharmacology Reports</i> , 2022, 42, 199-204.	1.1	2
4909	Early Markers in Resistant Schizophrenia: Effect of the First Antipsychotic Drug. <i>Diagnostics</i> , 2022, 12, 803.	1.3	5
4910	The D2R-DISC1 protein complex and associated proteins are altered in schizophrenia and normalized with antipsychotic treatment. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E134-E147.	1.4	7
4912	Biased Profile of Xanomeline at the Recombinant Human M ₄ Muscarinic Acetylcholine Receptor. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1206-1218.	1.7	6
4913	Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRI±/PCSK9 pathway. <i>Scientific Reports</i> , 2022, 12, 5639.	1.6	10
4914	Gold nanoclusters eliminate obesity induced by antipsychotics. <i>Scientific Reports</i> , 2022, 12, 5502.	1.6	3
4915	Perampanel add-on therapy for drug-refractory epilepsy: A single-center retrospective study based on 6-month treatment outcomes in Central China. <i>Epilepsy and Behavior</i> , 2022, 129, 108617.	0.9	6
4916	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104608.	2.9	67
4917	The experiences of 585 people when they tried to withdraw from antipsychotic drugs. <i>Addictive Behaviors Reports</i> , 2022, 15, 100421.	1.0	3
4918	Resistance to depth inversion illusions: A biosignature of psychosis with potential utility for monitoring positive symptom emergence and remission in schizophrenia. <i>Biomarkers in Neuropsychiatry</i> , 2022, 6, 100050.	0.7	0
4919	HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110553.	2.5	6
4920	Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13185.	1.8	44
4921	Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. <i>NPJ Schizophrenia</i> , 2021, 7, 63.	2.0	39
4922	The Effect of Atypical Anti-psychotic Agents on Obesity and Glucose Metabolism. <i>Journal of Medicine and Life Science</i> , 2021, 18, 49-55.	0.1	0

#	ARTICLE	IF	CITATIONS
4923	Assessing Outcomes Between Risperidone Microspheres and Paliperidone Palmitate Long-Acting Injectable Antipsychotics Among Veterans. , 2021, 38, 586-591.		1
4924	Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. <i>Neuropsychopharmacology</i> , 2022, 47, 696-703.	2.8	6
4926	Efficacy of Vesicular Monoamine Transporter 2 Inhibition and Synergy with Antipsychotics in Animal Models of Schizophrenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 381, 79-95.	1.3	5
4927	How do US military veterans with serious mental illness manage insomnia? A phenomenological analysis. <i>Journal of Sleep Research</i> , 2022, 31, e13570.	1.7	0
4928	Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e055454.	0.8	1
4931	Anesthetic considerations in psychiatric diseases. , 0, , 83-87.		0
4933	Dyslipidemia. , 0, , 31-38.		0
4934	Extrapyramidal symptoms. , 0, , 39-52.		0
4935	Obesity and weight gain. , 0, , 62-68.		0
4936	Prolactin effects. , 0, , 74-79.		0
4937	QTc prolongation, arrhythmias, and sudden cardiac death. , 0, , 80-88.		0
4938	Sedation and sleep disturbances. , 0, , 89-97.		0
4940	The inpatient with schizophrenia. , 0, , 1-20.		0
4968	Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine. <i>Evidence-Based Mental Health</i> , 2010, 13, 84-84.	2.2	0
4970	The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia. <i>Current Health Sciences Journal</i> , 2021, 47, 237-248.	0.2	0
4971	The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: results from a budget impact model. <i>Acta Clinica Belgica</i> , 2012, 67, 108-119.	0.5	2
4973	The Impact of Electroconvulsive Therapy on Negative Symptoms in Schizophrenia and Their Association with Clinical Outcomes. <i>Brain Sciences</i> , 2022, 12, 545.	1.1	2
4974	Applying a Fast-Scan Cyclic Voltammetry to Explore Dopamine Dynamics in Animal Models of Neuropsychiatric Disorders. <i>Cells</i> , 2022, 11, 1533.	1.8	10

#	ARTICLE	IF	CITATIONS
4975	A 10-year mirror-image study of effectiveness and cost of long-acting paliperidone palmitate injectable in patients with schizophrenia or schizoaffective disorder. <i>Psychiatry Research</i> , 2022, 312, 114581.	1.7	0
4976	Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications. <i>Psychiatry Research</i> , 2022, 313, 114590.	1.7	1
4977	Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. <i>Translational Psychiatry</i> , 2022, 12, 173.	2.4	9
4978	Mental Health and Behavioral Disorders in Pregnancy. , 2017, , 1147-1172.e5.		1
4979	METABOLIC SYNDROME IN PATIENTS WITH PSYCHOSIS USING SECOND-GENERATION ANTIPSYCHOTICS. , 2022, , 33-35.		0
4980	Metabolism of the antipsychotic drug olanzapine by CYP3A43. <i>Xenobiotica</i> , 2022, , 1-29.	0.5	2
4981	Relapse prevention through health technology program reduces hospitalization in schizophrenia. <i>Psychological Medicine</i> , 2023, 53, 4114-4120.	2.7	3
4982	Long-term metabolic and inflammatory effects of second-generation antipsychotics: A study in mentally disordered offenders. , 2022, 2, .		0
4983	Prospective Five-Year Follow-Up of Patients with Schizophrenia Suspected with Parkinson's Disease. <i>Parkinson's Disease</i> , 2022, 2022, 1-8.	0.6	0
4984	Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 1057-1067.	1.0	0
4986	New Paradigms of Old Psychedelics in Schizophrenia. <i>Pharmaceuticals</i> , 2022, 15, 640.	1.7	22
4987	National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States. <i>Journal of Medical Economics</i> , 2022, 25, 792-807.	1.0	9
4988	Olanzapine/Samidorphane: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain. <i>CNS Drugs</i> , 2022, 36, 605-616.	2.7	6
4989	Symptomatic versus disease-modifying effects of psychiatric drugs. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 251-257.	2.2	6
4990	Drug-drug interactions involving antipsychotics and antihypertensives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 285-298.	1.5	4
4991	Psychotropic drugs. , 2007, , 288-320.		0
4992	Involuntary Movement Disorders. , 2007, , 401-464.		18
4997	Positive Allosteric Modulation of α 5-GABAA Receptors Reverses Stress-Induced Alterations in Dopamine System Function and Prepulse Inhibition of Startle. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 688-698.	1.0	5

#	ARTICLE	IF	CITATIONS
4998	Efficacy of Integrated Social Cognitive Remediation vs. Neurocognitive Remediation in Improving Functional Outcome in Schizophrenia: Concept and Design of a Multicenter, Single-Blind RCT (The ISST) Tj ETQq0 0.9 rgt / Overlock 10	0.9	0
4999	Sustained specialized and family treatment in first-episode schizophrenia or related disorders: a 5-year randomized controlled trial. <i>Psychological Medicine</i> , 2023, 53, 4316-4323.	2.7	1
5000	Long-Term Antipsychotic Effectiveness and Comparison of the Efficacy of Monotherapy and Polypharmacy in Schizophrenia: A 3-Years Follow-Up "Real World" Study in China. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
5001	Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease. <i>Pharmacological Reviews</i> , 2022, 74, 630-661.	7.1	9
5002	Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 383-390.	0.7	2
5003	Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	4
5004	Cardiometabolic Comorbidity Risk in Pediatric Patients With Psychiatric Illnesses: A Case-Control Inpatient Study. <i>Cureus</i> , 2022, , .	0.2	0
5005	Antipsychotic factors related to time to competency for forensic inpatients in a state psychiatric facility. <i>Mental Health Clinician</i> , 2022, 12, 175-180.	0.5	1
5006	The influence of polymorphisms in <i>ANKK1</i> gene on risperidone response in a Chinese Han population. <i>Pharmacogenomics</i> , 0, , .	0.6	0
5007	BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling "Negative-Like" Symptoms of Schizophrenia. <i>Biomedicines</i> , 2022, 10, 1462.	1.4	4
5008	Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study. <i>Psychiatry Research</i> , 2022, 314, 114680.	1.7	3
5010	Trust but verify: An analysis of redundant publications from two major psychiatry journals in India. <i>Indian Journal of Psychiatry</i> , 2022, 64, 342.	0.4	3
5012	Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study. <i>CNS Neuroscience and Therapeutics</i> , 0, , .	1.9	2
5013	Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States. <i>Advances in Therapy</i> , 2022, 39, 3933-3956.	1.3	7
5014	Olanzapine Promotes the Occurrence of Metabolic Disorders in Conditional TCF7L2-Knockout Mice. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
5015	Sudden Cardiac Death in Schizophrenia During Hospitalization: An Autopsy-Based Study. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
5016	Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis. <i>Pharmacopsychiatry</i> , 0, , .	1.7	0
5017	Effects of antipsychotics on triglyceride trajectories and its implications in CVD: A longitudinal cohort study. <i>EBioMedicine</i> , 2022, 81, 104123.	2.7	4

#	ARTICLE	IF	CITATIONS
5018	Probing the molecular and cellular pathological mechanisms of schizophrenia using human induced pluripotent stem cell models. <i>Schizophrenia Research</i> , 2022, , .	1.1	5
5019	Drug Discovery in Psychiatry: Rethinking Conventional Wisdom D'couverte de m'dicaments en psychiatrie: Repenser les id'es conventionnelles. <i>Canadian Journal of Psychiatry</i> , 0, , 070674372211129.	0.9	1
5020	Retrospective Comparison of Weight Gain between Olanzapine- and Risperidone-Treated Patients. <i>Zanco Journal of Medical Sciences</i> , 2010, 14, 35-41.	0.0	0
5027	Index by Drug Name. , 2020, , 895-910.		0
5031	Index by Class. , 2020, , 919-922.		0
5035	Index by Use. , 2020, , 911-918.		0
5078	Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	3
5079	The future of antipsychotics studies: How innovative designs may benefit patients with psychotic disorders. <i>European Neuropsychopharmacology</i> , 2022, 62, 46-48.	0.3	3
5084	Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years' experience at a UK high-secure hospital. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532211130.	1.2	1
5085	Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study. <i>Advances in Therapy</i> , 2022, 39, 4299-4314.	1.3	1
5086	Olanzapine/Samidorphane: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder. <i>Journal of Pharmacy Technology</i> , 2022, 38, 304-313.	0.5	0
5087	Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia. <i>JAMA Network Open</i> , 2022, 5, e2224163.	2.8	8
5088	Second-Generation Antipsychotics' Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders. <i>Journal of Clinical Medicine</i> , 2022, 11, 4530.	1.0	13
5089	Effects of Chronic Diseases on All-Cause Mortality in People with Mental Illness: A Retrospective Cohort Study Using the Korean National Health Insurance Service-Health Screening. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 9989.	1.2	0
5090	Predicting symptom response and engagement in a digital intervention among individuals with schizophrenia and related psychoses. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
5091	Effect of quetiapine on inflammation and immunity: a systematic review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 196-207.	1.2	2
5092	Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
5093	Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review. <i>Mental Health Clinician</i> , 2022, 12, 254-262.	0.5	3

#	ARTICLE	IF	CITATIONS
5094	Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1011-1016.	1.3	1
5095	Dynamics between insight and medication adherence in first-episode psychosis: Study of 3-year trajectories. <i>European Psychiatry</i> , 2022, 65, .	0.1	4
5096	Identification of novel proteins associated with movement-related adverse antipsychotic effects by integrating GWAS data and human brain proteomes. <i>Psychiatry Research</i> , 2022, 317, 114791.	1.7	3
5097	Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study. <i>Schizophrenia Research</i> , 2022, 248, 279-286.	1.1	2
5098	National trends in metabolic risk of psychiatric inpatients in the United States during the atypical antipsychotic era. <i>Schizophrenia Research</i> , 2022, 248, 320-328.	1.1	0
5099	Modulating Specific Pathways In Vitro to Understand the Synaptic Dysfunction of Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 121-127.	0.8	0
5100	Genetic Influences on Cognitive Dysfunction in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 291-314.	0.8	1
5101	The effect of lansoprazole on MK-801-induced schizophrenia-like behaviors in mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2023, 120, 110646.	2.5	6
5102	Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	6
5103	Olanzapine enhances adipogenesis and suppresses lipolysis in 3T3L1 adipocytes under low glucose and weak differentiation/maturation conditions. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	0
5104	Clinical profile of patients with lupus psychosis in a Colombian cohort. <i>Reumatismo</i> , 2022, 74, .	0.4	0
5105	Sleep-related Memory Consolidation in Schizophrenia. <i>Journal of Turkish Sleep Medicine</i> , 2022, 9, 186-189.	0.2	0
5106	Cerebral, Psychosocial, Family Functioning and Disability of Persons with Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 2069-2082.	1.0	2
5107	A New Treatment Paradigm. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, S1-S13.	0.7	11
5108	Treatment persistence with aripiprazole once monthly: a 4-year follow-up. <i>Annals of General Psychiatry</i> , 2022, 21, .	1.2	0
5109	Pharmacokinetics and Safety of Sodium Benzoate, a d-Amino Acid Oxidase (DAAO) Inhibitor, in Healthy Subjects: A Phase I, Open-label Study. <i>Clinical Therapeutics</i> , 2022, 44, 1326-1335.	1.1	2
5111	Repetitive transcranial magnetic stimulation for psychiatric symptoms in long-term hospitalized veterans with schizophrenia: A randomized double-blind controlled trial. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
5112	Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 591-593.	0.7	1

#	ARTICLE	IF	CITATIONS
5114	Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting. <i>Psychiatry Research</i> , 2022, 317, 114878.	1.7	3
5115	Discovery and In Vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)-N-(3,5-dimethylphenyl)piperidine-1-carboxamide Hydrochloride (AP163) for the Treatment of Psychotic Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11579.	1.8	1
5116	Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study. <i>Schizophrenia Bulletin</i> , 2023, 49, 454-463.	2.3	9
5117	Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101711.	2.2	2
5118	Switching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 5965.	1.0	0
5119	Efficacy of Olanzapine for Symptom Relief in Cancer Patients. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 0, , 1-7.	0.5	0
5120	Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. <i>Molecular Psychiatry</i> , 2023, 28, 44-58.	4.1	23
5121	A new era in the diagnosis and treatment of tardive dyskinesia. <i>CNS Spectrums</i> , 0, , 4-14.	0.7	1
5122	Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients. <i>CNS Spectrums</i> , 0, , 1-4.	0.7	2
5123	“I found hundreds of other people but I still wasn’t believed” An exploratory study on lived experiences of antipsychotic withdrawal. <i>Psychosis</i> , 2024, 16, 15-27.	0.4	3
5124	Chronic agmatine treatment prevents olanzapine-induced obesity and metabolic dysregulation in female rats. <i>Brain Research Bulletin</i> , 2022, 191, 69-77.	1.4	1
5125	Antipsychotics/Neuroleptics: Course and Duration of Therapy, Withdrawal Symptoms, Resistance to Therapy, Side Effects, and Contraindications. , 2022, , 1709-1729.		0
5126	Funding research to understand mechanisms of commercialized antipsychotic drugs could transform the future of mental health therapeutics. <i>Behavioural Brain Research</i> , 2023, 438, 114214.	1.2	0
5127	Cognitive Dysfunction in Schizophrenia: A Perspective from the Clinic to Genetic Brain Mechanisms. <i>Annals of the Academy of Medicine, Singapore</i> , 2009, 38, 420-424.	0.2	5
5128	Can brain stimulation enhance cognition in clinical populations? A critical review. <i>Restorative Neurology and Neuroscience</i> , 2022, , 1-19.	0.4	0
5129	Discovery of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 2-(5-(4-Chloro-[1,1'-biphenyl]-4-yl)-4H-1,2,4-triazol-3-yl)ethan-1-amine (LK00764) for the Treatment of Psychotic Disorders. <i>Biomolecules</i> , 2022, 12, 1650.	1.8	2
5130	Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation. <i>Advances in Therapy</i> , 0, , .	1.3	1
5131	Treatment of schizophrenia with catatonic symptoms: A narrative review. <i>Schizophrenia Research</i> , 2024, 263, 265-274.	1.1	2

#	ARTICLE	IF	CITATIONS
5133	Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 144, 104979.	2.9	20
5134	Informed Consent and the Ethics of Clinical Research: Reply to Commentaries. <i>Journal of Clinical Ethics</i> , 2005, 16, 376-379.	0.1	0
5135	Increased blood neutrophil extracellular traps (NETs) associated with early life stress: translational findings in recent-onset schizophrenia and rodent model. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	5
5136	Investigating the association between diabetes and mental health: A train-and-test approach. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
5137	Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice. <i>Annals of General Psychiatry</i> , 2022, 21, .	1.2	2
5138	Schizophrenie. <i>Psychotherapie: Manuale</i> , 2023, , 9-57.	0.0	0
5139	Tardive Dyskinesia Following Low-Dose Risperidone. <i>Cureus</i> , 2022, , .	0.2	0
5140	A Brief Review of Quetiapine. <i>The American Journal of Psychiatry Residents' Journal</i> , 2022, 18, 20-22.	0.2	5
5141	Hyperbaric oxygen exposure alleviate metabolic side-effects of olanzapine treatment and is associated with Langerhans islet proliferation in rats. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	0
5142	A 10-Year Observational Study of the Use, Acceptability and Effectiveness of Long-Acting Paliperidone Palmitate: Implications for Clinical Decision Making. <i>CNS Drugs</i> , 2023, 37, 107-116.	2.7	5
5143	Antipsychotic drugâ€™aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms. <i>Pharmacological Reports</i> , 2023, 75, 19-31.	1.5	5
5144	Bayesian Sample Size Calculations for Comparing Two Strategies in SMART Studies. <i>Biometrics</i> , 2023, 79, 2489-2502.	0.8	1
5145	Using Nonhuman Primate Models to Reverse-Engineer Prefrontal Circuit Failure Underlying Cognitive Deficits in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , .	0.8	0
5147	Antipsychotic Drugs Efficacy in Dextromethorphan-Induced Psychosis. <i>Biomedicines</i> , 2023, 11, 123.	1.4	0
5149	Seventy Years of Antipsychotic Development: A Critical Review. <i>Biomedicines</i> , 2023, 11, 130.	1.4	8
5151	Prevention of suicide by clozapine in mental disorders: systematic review. <i>European Neuropsychopharmacology</i> , 2023, 69, 4-23.	0.3	14
5152	Metabolic disturbances during treatment with second generation antipsychotics. <i>Arhivi Na Javnoto Zdravje</i> , 2022, 14, .	0.1	0
5153	Schizophrenia Spectrum and Other Psychotic Disorders. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
5154	Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. <i>Acta Psychiatrica Scandinavica</i> , 2023, 147, 360-372.	2.2	5
5155	Schizophrenia in Japan and cognitive behavioral therapy. , 2023, , 377-385.		0
5156	Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). <i>Lancet Psychiatry</i> , 2023, 10, 197-208.	3.7	14
5157	Metabolic Syndrome in Adults Receiving Clozapine; The Need for Pharmacist Support. <i>Pharmacy (Basel)</i> Tj ETQq1 1,0,784314 rgBT / Qv	0.6	1
5158	Theories and Techniques of Group Therapy. , 2022, , .		0
5160	Psychotherapy With Lesbians. , 2022, , .		0
5161	Neuroscience of Psychotherapy. , 2022, , .		0
5162	Techniques of Psychodynamic Psychotherapy. , 2022, , .		0
5163	Techniques of Individual Interpersonal Psychotherapy. , 2022, , .		0
5164	Efficacy, Indications, and Applications of Individual Interpersonal Psychotherapy. , 2022, , .		0
5165	Supervision and Consultation in Psychotherapy. , 2022, , .		0
5166	How Our Mind Becomes Racialized. , 2022, , .		0
5167	Psychotherapy With Bisexual Patients. , 2022, , .		0
5168	Theoretical Models of Psychodynamic Psychotherapy. , 2022, , .		0
5169	Indications, Applications, and Efficacy of Individual Cognitive-Behavioral Therapy to Specific Psychiatric Disorders. , 2022, , .		0
5170	Applications of Psychodynamic Psychotherapy to Specific Disorders. , 2022, , .		0
5172	The biological paradigm of psychosis in crisis: A Kuhnian analysis. <i>Nursing Philosophy</i> , 2023, 24, .	0.9	1
5173	Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration. <i>Trials</i> , 2023, 24, .	0.7	0

#	ARTICLE	IF	CITATIONS
5174	Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain. <i>Psychopharmacology</i> , 0, , .	1.5	0
5175	Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States. <i>Journal of Medical Economics</i> , 2023, 26, 525-536.	1.0	1
5176	Victimization in schizophrenia and its relation to violence. <i>Schizophrenia Research</i> , 2023, 255, 52-58.	1.1	0
5177	Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5. <i>Neoplasia</i> , 2023, 39, 100894.	2.3	3
5178	Investigating the symptomatic and morphological changes in the brain based on pre and post-treatment: A critical review from clinical to neuroimaging studies on schizophrenia. <i>IBRO Neuroscience Reports</i> , 2023, 14, 366-374.	0.7	3
5179	Dialectical Behavior Therapy. , 2022, , .		0
5180	Treatment Techniques in Dialectical Behavior Therapy. , 2022, , .		0
5181	Transference-Focused Psychotherapy for Levels of Personality Pathology Severity. , 2022, , .		0
5182	South Asian Americans. , 2022, , .		0
5183	Theories of Interpersonal Therapy. , 2022, , .		0
5184	Theories and Techniques of Couple Therapy. , 2022, , .		0
5185	Issues Arising in Psychotherapy With LGBTQ+ Patients. , 2022, , .		0
5186	Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizithyperaktivitätssyndrom. , 2022, , 451-495.		3
5187	Cardiovascular risk factors and metabolic syndrome in patients treated with long-acting injectables antipsychotics: a retrospective study. <i>International Clinical Psychopharmacology</i> , 2023, 38, 160-168.	0.9	4
5188	Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 1269-1276.	1.5	7
5189	Hippocampal Hyperconnectivity to the Visual Cortex Predicts Treatment Response. <i>Schizophrenia Bulletin</i> , 2023, 49, 605-613.	2.3	3
5190	Genome-wide copy number variant screening of Saudi schizophrenia patients reveals larger deletions in cases versus controls. <i>Frontiers in Molecular Neuroscience</i> , 0, 16, .	1.4	1
5191	Nuclear receptor 5A2 regulation of <i>AgRP</i> underlies olanzapine-induced hyperphagia. <i>Molecular Psychiatry</i> , 0, , .	4.1	1

#	ARTICLE	IF	CITATIONS
5192	Shared decision making with schizophrenic patients: a randomized controlled clinical trial with booster sessions (DECIDE Study). <i>Patient Education and Counseling</i> , 2023, 110, 107656.	1.0	4
5193	Vitamin D supplementation is effective for olanzapine-induced dyslipidemia. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
5194	Psychotic Disorders (â€œSchizophreniaâ€). , 2023, , 263-282.		1
5196	Combining Medications and Psychotherapy. , 2022, , .		0
5197	Contextualizing Psychodynamic Psychotherapy With Asian Americans. , 2022, , .		0
5198	Techniques of Individual Supportive Psychotherapy. , 2022, , .		0
5199	Theory of Individual Supportive Psychotherapy. , 2022, , .		0
5200	Techniques of Cognitive-Behavioral Therapy. , 2022, , .		0
5201	Psychotherapy With Gay Men. , 2022, , .		0
5202	African Americans and Psychotherapeutic Treatment. , 2022, , .		0
5203	Cognitive-Behavioral Theories. , 2022, , .		1
5204	Applications of Individual Supportive Psychotherapy to Specific Disorders. , 2022, , .		0
5205	Professional Boundaries and Ethics in Psychotherapy. , 2022, , .		0
5206	Psychotherapy With Trans and Gender Diverse People. , 2022, , .		0
5207	Theory in Dialectical Behavior Therapy. , 2022, , .		0
5208	Theory and Practice of Mentalization-Based Treatment. , 2022, , .		1
5209	Psychotherapy and Cyberspace. , 2022, , .		0
5210	There Is No Such Thing as Latinx. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
5211	Techniques of Brief Psychodynamic Psychotherapy. , 2022, , .		0
5212	Risperidone response in patients with schizophrenia drives DNA methylation changes in immune and neuronal systems. Epigenomics, 2023, 15, 21-38.	1.0	2
5213	The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders. Advances in Neurobiology, 2023, , 37-99.	1.3	1
5214	Oscillatory Deficits in the Sub-Chronic PCP Rat Model for Schizophrenia Are Reversed by mGlu5 Receptor-Positive Allosteric Modulators VU0409551 and VU0360172. Cells, 2023, 12, 919.	1.8	2
5215	Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. Biomedicines, 2023, 11, 921.	1.4	3
5216	Sudden Cardiac Death in People With Schizophrenia. JACC: Clinical Electrophysiology, 2023, , .	1.3	1
5217	An exploratory database study of factors influencing the continuation of brexpiprazole treatment (prescription) in patients with schizophrenia using information from psychiatric electronic medical records processed with natural language processing. Schizophrenia Research, 2023, 255, 122-131.	1.1	0
5218	International rates of receipt of psychological therapy for psychosis and schizophrenia: systematic review and meta-analysis. International Journal of Mental Health Systems, 2023, 17, .	1.1	5
5219	Deep Learning Methods Applied to Drug Concentration Prediction of Olanzapine. Pharmaceutics, 2023, 15, 1139.	2.0	4
5220	Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety. Neuropsychiatric Disease and Treatment, 0, Volume 19, 749-757.	1.0	2
5221	Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups. BMC Psychiatry, 2023, 23, .	1.1	0
5222	Pharmacogenetic application in a patient diagnosed with Schizophrenia and OCD: A case report. International Journal of Radiology and Radiation Oncology, 2023, 9, 008-012.	0.1	0
5223	Un siÃ©cle de Schizophrenie. Information Psychiatrique, 2010, Volume 86, 391-403.	0.1	1
5224	DÃ©veloppement d'un programme psycho-Ã©ducatif ciblÃ© sur l'insight pour les patients souffrant de Schizophrenie. Information Psychiatrique, 2008, Volume 84, 937-939.	0.1	2
5225	Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment. Frontiers in Pharmacology, 0, 14, .	1.6	1
5226	Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders. Journal of Clinical Psychopharmacology, 2023, 43, 246-258.	0.7	2
5227	Eppur si mouve. , 2023, , 23-36.		0
5235	General Principles of Pharmacologic Therapy. , 2023, , 1-18.		0

#	ARTICLE	IF	CITATIONS
5242	Pharmacogenomics in psychiatric diseases. , 2023, , 169-194.		0
5244	Research on the Mental Health Applications of Music Therapy. , 2023, , 772-778.		0
5247	Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 1543-1556.	1.8	10
5251	Psychiatric Epidemiology. , 2023, , 1-41.		0
5254	Neuroscience-Based Nomenclature (NbN): New Pharmacological Driven Classification of Psychotropics. , 2023, , 1-12.		0
5265	Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics). , 2023, , 1-58.		0
5268	The role of pharmacists in supporting service users to optimise antipsychotic medication. International Journal of Clinical Pharmacy, 2023, 45, 1293-1298.	1.0	3
5283	Antipsychotic Drugs: Do They Define Schizophrenia or Do They Blunt All Emotions?. , 2023, , 63-84.		0
5288	Pharmacology-EEG of antipsychotic treatment response: a systematic review. , 2023, 9, .		0
5289	Psychopharmacology in adolescents. , 2023, , .		0
5321	Physical Health of Patients with Schizophrenia. , 2024, , 210-227.		0
5322	Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung. , 2023, , 483-529.		0
5331	Clinical Pharmacokinetics. , 2023, , 151-202.		0